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ABSTRACT 
 
Natural products have long been recognized for their medicinal value in 
traditional medicine and remain an important component of modern drug discovery. 
Known for their immense structural diversity, natural products are secondary metabolites 
that often exhibit unique pharmacological properties. In the marine habitat, alcyonacean 
octocorals are a rich source of diterpenes with promising therapeutic potential. For 
instance, Eunicea fusca contains fuscoside B, a diterpene arabinoside with potent topical 
anti-inflammatory activity. Notably, fuscoside B selectively inhibits 5-lipoxygenase and 
has a negligible effect on prostaglandin (PG) biosynthesis. Pseudopteroxazole, an 
amphilectane diterpene from the octocoral Pseudopterogorgia elisabethae, shows activity 
against Mycobacterium tuberculosis, the etiologic agent of tuberculosis. 
This thesis describes a variety of approaches to discover and develop diterpenes 
from alcyonacean corals. An investigation of E. fusca collected from Hillsboro Ledge, 
Florida has led to the discovery of eunicidiol, a topical anti-inflammatory diterpene. The 
structure of eunicidiol was elucidated by 1D and 2D NMR spectroscopy, while the 
absolute configuration was unambiguously assigned by the Mosher method. The anti-
inflammatory activity of eunicidiol was evaluated by measuring its ability to reduce 
phorbol myristate acetate (PMA)-induced edema in a mouse ear model. Topical 
DSSOLFDWLRQRIDȝJHDUGRVHRIeunicidiol significantly reduced edema with activity 
that was superior to indomethacin, an anti-inflammatory drug serving as an industry 
benchmark. 
vi 
 
A library of novel fuscoside B analogues has been synthesized from fuscol and 
eunicol using a modified Koenigs-Knorr glycosylation approach. This semisynthesis is 
the first successful glycosylation of fuscol and has provided the eunicosides, a novel 
structural class of diterpene glycosides. In addition, glycoside mimics were prepared by 
introducing ethylene glycol (EG)-based substituents in place of the arabinose moiety. The 
library of compounds was evaluated for anti-inflammatory activity in the PMA-induced 
mouse ear edema assay, which demonstrated the remarkable influence of the 
carbohydrate substituent and its configuration on the in vivo efficacy of this glycoside 
class. 
Pseudopteroxazole has shown activity against resistant strains of M. tuberculosis 
as well as in the low-oxygen-recovery assay (LORA), a mycobacterial model of non-
replicating persistence (NRP). To investigate the antitubercular mechanism of action of 
pseudopteroxazole, a collection of semisynthetic probes was prepared to identify putative 
protein targets by affinity chromatography. During the course of this synthesis, structure-
activity relationships (SAR) were assessed in order to maintain high binding affinity to 
the target protein(s). This strategy has led to the identification of several putative targets, 
including (3R)-hydroxyacyl-ACP dehydratase subunit C (HadC). This result suggests that 
pseudopteroxazole may exert its antitubercular activity, at least in part, by inhibiting 
mycolic acid biosynthesis. 
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1.1  The Role of Natural Products in Drug Discovery 
 
Exploration of the natural environment for therapeutic agents is a concept that has 
its roots in traditional medicine, dating back thousands of years. Many ancient societies 
recognized the medicinal benefits of natural products within certain types of vegetation, 
and embarked on a gradual process of trial and error to identify specific varieties of 
plants with medicinal applications.1 Modern drug discovery largely depends on natural 
products to meet current pharmaceutical needs, although the antiquated practice of 
administering crude plant formulations is no longer a customary practice in the developed 
world.2 
A tremendous number of drugs within the current pharmacopeia have natural 
product origins as approximately 50 and 75% of all anticancer and antibacterial agents, 
respectively, are either natural products or derived therefrom.3 Furthermore, a significant 
number of synthetic medicinal agents have been inspired by natural products, as 
demonstrated by structural similarities.3 The ongoing role of natural products in modern 
drug development is underscored by the recent approval of nearly 20 natural product-
based drugs between 2005 and 2010 by regulatory agencies worldwide.4 Indeed, half of 
the approved small molecule drugs in 2010 were either natural products or structural 
mimics thereof.3  
Natural products are secondary metabolites belonging to a unique class of 
biomolecules that are not required for the basic sustenance of life. The secondary 
metabolome includes such compounds as the alkaloids, terpenes, polyketides, and non-
ribosomal peptides, and these are produced by organisms belonging to various taxonomic 
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lineages, including plants, animals, fungi, and bacteria. In the scientific community, 
natural products are renowned for their immense structural diversity and exquisite 
molecular complexity, as well as their unique pharmacological properties.5 Although 
these compounds were once regarded as metabolic waste products with no particular 
function,6 most scientists have now accepted the widely held belief that natural products 
provide a fitness advantage and may be required for ecological viability.7 
 
1.2 Trends in Modern Drug Discovery 
 
1.2.1 Towards combinatorial chemistry: A decline in natural products research 
Despite the paramount role of natural products in modern drug discovery, towards 
the end of the 20th century the pharmaceutical industry scaled back or abandoned their 
efforts in natural product research. As technology progressed, especially in the area of 
automated liquid handling and detection, the throughput of biological assays was 
accelerated; and as a result, supplying sufficient numbers of small molecules to biological 
screening campaigns became a bottleneck in the drug discovery process.8 Natural product 
chemistry struggled to keep up with the intense pace of high-throughput screening. 
Discovering a natural product is a laborious procedure requiring extensive efforts in 
structural determination and dereplication, a lengthy process of ensuring chemical 
novelty.9 Moreover, there remains the enduring challenge of acquiring adequate material 
for clinical evaluation and commercial supply. 
By exploiting solid-phase organic synthesis and split-and-mix techniques, 
combinatorial chemistry promised to deliver a staggering number of compounds for high-
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throughput biological screening.10 In fact, millions of compounds could be synthesized 
by a single chemist within a few weeks by applying these techniques.11 This pace was in 
stark contrast to the laborious procedure of purifying and elucidating the structure of even 
a single natural product.12 Unfortunately, the expectation that combinatorial chemistry 
would accelerate the drug discovery process was greatly exaggerated. Although this 
approach continues to play an important role in lead optimization,13 the anticancer agent 
Sorafenib (Nexavar®) represents the only new molecular entity solely inspired by 
combinatorial chemistry.3, 14 
Synthetic amenability, facile characterization, and compliance with specific rules, 
VXFKDV/LSLQVNL¶V³UXOHRIILYH´RIWHQJRYHUQHGWKHRYHUDOOGHVLJQRIDcombinatorial 
compound library.15 These parameters resulted in a general restraint from incorporating 
chiral centers and encouraged the introduction of many aromatic rings, thus improving 
the overall synthetic tractability.15-16 As a consequence, the vast majority of these 
compounds exhibited molecular topologies that were routinely flat and linear.17 
Furthermore, there was often little emphasis on quality control and the products of these 
syntheses were seldom purified.8 Essentially, the biological relevancy of these 
compounds was neglected.18 
 
1.2.2 Rethinking the role of natural products in drug discovery 
Chemical space describes the theoretical collection of all conceivable small 
molecules, which is commonly estimated at approximately 1030 ± 10200  compounds.19 Its 
vastness is so great that there is insufficient matWHULQWKHNQRZQXQLYHUVHWRVXSSO\ȝJ
of every possible compound.20 Utilizing various molecular descriptors, such as the 
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molecular weight, total number of stereocenters, and hydrophobicity (logP), the 
distribution of a compound collection across chemical space may be computationally 
assessed as a measure of overall structural diversity.21 Employing such algorithms, 
combinatorial libraries were shown to have a confined distribution, emphasizing their low 
structural diversity; meanwhile the distributions of natural products and approved drugs 
were significantly broader, reflecting their greater overall structural diversity.15 
Compared to the biological screening of natural product extracts, combinatorial 
libraries provided disappointing hit rates.12 It has become clear that the structural 
diversity and molecular complexity of a library, not the number of entities, are the recipes 
for achieving higher hit rates.13 Natural products are also more biologically relevant; 
these compounds have undergone a long process of evolutionary selection in order to 
attain optimal binding affinity for a particular biological target in the natural 
environment.22 As a consequence, natural products occupy biologically relevant regions 
of chemical space and are more likely to interact with targets of pharmacological 
significance in humans, especially given the conservative nature of protein structure 
across various taxonomic lineages.9 
 Emerging from the classical ideology of combinatorial chemistry was diversity-
oriented synthesis (DOS), an approach aiming to investigate biologically relevant regions 
of chemical space through the synthesis of molecules that mimic the structural diversity 
of natural products.23 Employing a forward synthetic analysis, DOS typically involves the 
assembly of commercially available chiral building blocks and then pairwise 
combinations of various functional groups to generate products with incredible scaffold 
and stereochemical diversity.24 In drug discovery, there has also been a trend towards 
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libraries based on natural product-like scaffolds.25 These scaffolds should augment the 
drug discovery process as these scaffolds have been evolutionarily pre-validated by 
Nature to interact with biological targets.26 These examples highlight an additional role of 
natural product chemistry; as an inspiration to synthetic chemists in their quest of novel 
drug discovery. 
 
1.3 Marine Natural Products as a Source of Drugs 
 
The diversity of life in the ocean, a habitat covering RYHURIWKH(DUWK¶V
surface, is unparalleled by the terrestrial environment. For instance, of the 33 animal 
phyla, 15 are exclusively marine while five have more than 95% of their species living 
entirely within marine environments.27 The tremendous biological diversity within the 
oceans is a reservoir of immense chemical diversity, and is therefore regarded as a rich 
resource for novel drug discovery.28 Investigation of aquatic habitats was limited until the 
invention of scuba technology and unmanned remotely operated vehicles, and as such, 
marine organisms have only recently had an impact in traditional medicine.29 
Nonetheless, exploration of these untapped marine resources has revealed an exceptional 
number of novel natural products with pharmacological potential.30  
Marine natural products often exhibit unique chemical scaffolds and unusual 
functional groups that have not been observed in terrestrial environments (Figure 1.1). 
Among these scaffolds are the macrocyclic polyketide of muironolide A (1)31 and the  
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Figure 1.1. The structures of muironolide A (1), acremostrictin (2), and barbamide (3) as 
an illustration of the diversity of marine natural products. 
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oxygenated tricyclic lactone of acremostrictin (2).32 The unusual abundance of 
halogenated secondary metabolites is also unique to marine organisms.33 For instance, 
rhodophytes belonging to the genus Laurencia have provided a wealth of brominated 
terpenes and polyketides.34 Barbamide (3) is a molluscicidal natural product containing 
an unusual trichloromethyl functionality.35 Meanwhile, other marine organisms contain 
unusually high amounts of certain metabolites, such as the prostaglandins in the 
alcyonacean coral Plexaura homomalla.36 The presence of such unprecedented chemistry 
has incited further exploration of the marine habitat for novel natural products. 
 
1.3.1 The impact of marine natural product research on drug discovery 
Cytarabine (4) and vidarabine (5) are anticancer pyrimidine and antiviral purine 
nucleosides, respectively, and among the first marine-derived compounds to receive FDA 
approval for the treatment of human disease (Figure 1.2).37 The pioneering work of 
%HUJPDQQHWDOGXULQJWKH¶VRQWKHLVRODWLRQDQGVWUXFWXUDOHOXFLGDWLRQRIQDWXUDO
products from the Caribbean sponge Tethya crypta ultimately led to the development of 
these two drugs,38 inspiring other researchers to explore the marine habitat for 
compounds of pharmacological relevance. 
It was not until approximately 30 years later that another marine-derived natural 
product emerged onto the drug market. Originally isolated from a tropical cone snail, 
ziconotide (6), DȦ-conotoxin that selectively blocks N-type calcium channels,39 has been 
clinically evaluated as an analgesic agent.40 This marine natural product was eventually 
approved by the FDA in 2004 for the treatment of severe chronic pain.41 Ziconotide is 
marketed under the commercial name Prialt® and is primarily administered via  
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Figure 1.2. Marine natural products approved by the FDA, including two anticancer 
drugs, cytarabine (4) and vidarabine (5), and an analgesic agent, ziconotide (6). 
 
. 
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intrathecal injection.42 Since this accomplishment, marine natural products have steadily 
gained momentum in clinical drug development. 
 
1.3.2 Ecteinascidin 743: The first anticancer drug from marine natural products 
Ecteinascidin 743 (7, Figure 1.3) is a tetrahydroisoquinoline alkaloid that was 
discovered from the crude extract of the tunicate Ecteinascidia turbinate.43 Known for its 
exceptional antitumor properties, 7 binds to the minor groove of DNA and undergoes an 
alkylation at the N2 position of guanine nucleotides upon the formation of an iminium 
intermediate, which is generated by dehydration of the carbinolamine moiety.44 Although 
the precise mechanism by which 7 exerts its antiproliferative activity is not yet fully 
understood, 7 has been shown to be involved in the disruption of DNA nucleotide 
excision repair,45 homologous recombination DNA repair,46 as well as transcription.47 
The first enantioselective total synthesis of 7 was completed by Corey et al. in 1996,48 
and then later by Endo et al.49 Although these accomplishments ascertained the absolute 
configuration of 7, a sustainable commercial supply had remained elusive. 
The eventual development of a semisynthetic process beginning with 
cyanosafracin B, an antibiotic produced by fermentation of Pseudomonas fluorescens,50 
proved to be an economically feasible method of supplying 7.51 This achievement 
expedited clinical development, where 7 showed encouraging results in the treatment of 
various tumors, particularly soft tissue sarcoma, osteosarcoma, and ovarian cancer.52 On 
the basis of its efficacy in clinical trials, 7 became the first marine-derived anticancer 
drug, gaining approval from the European Medicines Agency in 2007 for the treatment of 
advanced soft tissue sarcoma, and then in 2009 for relapsed ovarian cancer.53 Currently  
11 
 
 
 
Figure 1.3. Chemical structure of ecteinascidin 743 (7), an anticancer marine natural 
product.  
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marketed by Pharmamar under the product name Yondelis®, this drug is also undergoing 
Phase II clinical evaluation against breast, prostate, and pediatric sarcomas.54 
 
1.3.3 Eribulin mesylate: Inspiration from marine natural product chemistry 
Originally isolated from the sponge Halichondria okadai by Uemura et al., the 
halichondrins are a family of polyether macrolides known for their remarkable anticancer 
properties.55 Halichondrin B (8) exhibits potent cell growth inhibitory activities at 
nanomolar concentrations in vitro and in vivo.56 Nearly seven years after the discovery of 
8, an elegant 90 step total synthesis was accomplished by Aicher et al., establishing the 
relative configuration of 8.57 Although the issue of supply had not been resolved, these 
synthetic efforts permitted the remarkable discovery of a truncated analogue with a 
similar biological profile as 8.58 Further synthetic investigation, focusing on this 
molecular fragment, yielded a halichondrin B mimic called eribulin mesylate (9, Figure 
1.4).59  
An investigation of the mechanism of action of 9, utilizing an affinity 
chromatography approach with a biotinylated analogue, identified tubulin as a target 
protein of 9.60 Subsequent biochemical experiments later confirmed that 9 does indeed 
exert its anticancer activity via tubulin depolymerization. Clinical evaluation of 9 as a 
monotherapy for breast cancer showed that it significantly improved overall patient 
survival.61 As a result, 9 received marketing authorization by the FDA for the treatment 
of metastatic breast cancer, and is currently marketed by Eisai Co. with the product name 
Halaven®.62 
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Figure 1.4. Halichondrin B (8) as an inspiration for the development of eribulin mesylate 
(9) by total synthesis.63 
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From the perspective of preclinical and clinical pipelines, the prospect for future 
drug development from marine natural products appears to be very exciting. An 
assessment of natural products in the clinical pipeline has indicated that 11 marine-
derived compounds are in one of the three Phases of clinical development.64 The 
pharmaceutical preclinical pipeline, during the period 1998 ± 2008, consisted of 592 
marine-derived compounds with antitumor and cytotoxic activities and an additional 666 
marine-derived compounds exhibiting other pharmacological properties, such as 
antimicrobial and anti-inflammatory activities.65 The exceptional wealth of candidates in 
these drug development phases suggests that marine natural products will be a significant 
contributor to the future pharmacopeia. 
  
1.3.4 Marine diterpenes: A family of structurally diverse compounds 
Terpenes are an extraordinarily diverse class of natural products with promising 
therapeutic and industrial potential.66 More than 40,000 different compounds belonging 
to this class have been identified,67 including the anticancer agent paclitaxel,68 the 
antimalarial artemisinin,69 and many other important pharmaceuticals. The biosynthesis 
of terpenes follows either the mevalonate or 2-C-methyl-D-erythritol 4-phosphate (MEP) 
pathway, both of which yield five-carbon isoprene subunits, isopentenyl pyrophosphate 
(IPP) and dimethylallyl pyrophosphate (DMAPP).67 The origin of these precursors may 
be delineated through stable isotope labeling as the mevalonate pathway derives the 
carbon atoms from acetyl-CoA, while the latter utilizes glyceraldehyde-3-phosphate and 
pyruvate.70  
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Terpenes are categorized according to the number of isoprene units they carry in 
their structure. Diterpenes are compounds originating from geranylgeranyl pyrophosphate 
(GGPP), a precursor containing four isoprene units that are assembled through the 
iterative condensation of DMAPP with IPP.67 In addition to varying numbers of isoprene 
units, the enormous skeletal diversity of terpenes is achieved by the catalytic diversity of 
terpene cyclases, a family of enzymes that catalyzes the cyclization of open-chain (C5)n 
precursors.66, 71 Octocorals belonging to the phylogenetic order of Alcyonacea72 are a rich 
source of structurally diverse diterpenes, comprising a total of 40 skeletal classes.73   
  
1.4 Fuscosides: A Family of Anti-Inflammatory Glycosides 
 
The Caribbean alcyonacean Eunicea fusca is a source of the anti-inflammatory 
fuscosides (Figure 1.5), diterpene arabinosides that reduce phorbol 12-myristate 13 
acetate (PMA)-induced mouse ear edema with activities comparable to indomethacin.74 
Topical application of a ȝJdose of fuscosides A (10) and B (11) reduced PMA-
induced edema by 85 and 52%, respectively, compared to 38 and 80% by manoalide and 
indomethacin.75 Although 10 displayed greater potency, 11 was distinguished by its 
selective inhibition of 5-lipoxygenase (5-LO) and negligible effect on cyclooxygenase 
(COX) and their ability to biosynthesize the PGs.76,77 Fuscoside E (12), which has 
recently been reported by Reina et al., is structurally related to 11 and exhibited similar 
anti-inflammatory activity as 11 in the mouse ear edema assay.78 Fuscosides C (13) and 
D (14), despite their structural resemblance to 11, have no reported anti-inflammatory 
activity. 
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Figure 1.5. The collection of all known diterpene arabinosides isolated from Eunicea 
fusca. 
 
  
17 
 
Originally characterized by Shin et al. in 1991,74 the fuscosides are among the few 
classes of marine diterpene glycosides that have been described to date.79 While 
fuscoside B-D (11, 13, 14) belong to the lobane class of diterpenes, fuscosides A (10) and 
E (12) are diterpenoid acetylarabinosides with a unique eremophilane-type framework. 
Fuscosides C (13) and D (14) are a diastereomeric pair of 11,12-epoxide derivatives of 
11, adopting either the RR or SS configurations at the epoxide position. Analysis of NMR 
spectroscopic data revealed that the arabinoses are DWWDFKHGYLDȕ-glycosidic linkages.80 
Although the absolute configuration of the arabinose moiety of 10, 11, 13, and 14 has not 
been unequivocally assigned, the D-configuration was predicted on the basis of 
polarimetric measurements.74 During the recent characterization of 12, the presence of a 
D-arabinose substituent was ascertained by circular dichroism spectroscopy for this 
particular member of the fuscoside class.78  
Fuscol (15, Figure 1.6), the aglycone precursor of fuscoside B (11), was first 
isolated from a crude extract of E. fusca in 1978 by Gopichand et al.81 Possessing a 
lobane carbon skeleton, 15 was the first non-cembranoid diterpene isolated from a 
Caribbean alcyonacean. This diterpene subsequently became an intriguing target for 
synthetic chemists such as Iwashima et al., who accomplished the total synthesis of 15 in 
20 steps with an overall yield of 4.8%.82 This enantioselective synthesis firmly 
established the absolute configuration of 15 as 2R, 7R, 10S, considering the identical 
spectroscopic properties between the synthetic and naturally occurring 15. An alternative 
and more efficient synthesis was later achieved by Kosugi et al.,83 who developed a 10-
step procedure that afforded 15 with a 20% overall yield. Although 11 had served as the  
 
18 
 
 
 
Figure 1.6. Fuscol (15), the aglycone of fuscoside B (11), and other diterpenes isolated 
from Eunicea fusca. 
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inspiration for undertaking this research,82,83 neither group reported any attempt to 
glycosylate 15. 
Originally discovered from the eggs of the alcyonacean soft coral Lobophytum 
microlobulatum,84 eunicol (16) is a dilophol diterpene that is commonly isolated from E. 
fusca as a mixture with fuscol (15).85 While the structural elucidation of 16 was formally 
described by Saleh, et al., the absolute configuration had not yet been assigned.85 Saleh et 
al. also examined the metabolism of tritium labeled GGPP by E. fusca cell-free extracts, 
which showed that 16 and eunicene A (17) were biosynthetic precursors of 15 and 
fuscoside A (10). No glycosides containing the eunicol aglycone have been reported. 
However, the structure of such glycosides first appeared in the literature as the proposed 
structures of calyculaglycoside A-C;86 a later revision revealed that these compounds 
instead belonged to a family of cembrane glycosides.87 Neither the total synthesis nor any 
anti-inflammatory evaluation of 15-17 has been reported. 
 
1.5 The Role of 5-Lipoxygenase in Inflammation 
 
Inflammation is a complex physiological response of the immune system towards 
a harmful stimulus such as microbial infection or physical damage, and is essential for 
eliminating the distressing stimulus and promoting tissue repair.88 Failure to revert the 
inflammatory response once this stimulus has been eradicated may result in a chronic 
state of inflammation that is detrimental towards the tissues of the host and an underlying 
cause of various diseases, such as rheumatoid arthritis, atherosclerosis, and cancer.88a The 
inflammatory response is regulated, to some extent, through the production of 
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leukotrienes (LTs) and prostaglandins (PGs), eicosanoid chemical mediators 
biosynthesized by 5-LO and COX, respectively.89 
The non-steroidal anti-inflammatory drugs (NSAIDs), and particularly the 
selective COX-2 inhibitors known as coxibs90, have recently received much scrutiny over 
their serious cardiovascular side effects.91 Generally speaking, an NSAID is a non-
selective inhibitor of COX, which are enzymes responsible for the biosynthesis of pro-
inflammatory PGs.92 The PGs produced by the housekeeping COX-1, however, also 
contribute to other physiological processes such as the maintenance of gastrointestinal 
mucosa;93 hence the rationale for developing selective inhibitors of COX-2, an isoform 
whose catalytic activity is more relevant to inflammation.91a, 94 Unfortunately, the coxibs 
elevated the risk of severe cardiovascular events by tipping the physiologic balance 
towards thrombogenic PGs.91b, 95 Selective COX-2 inhibition also poses a significant risk 
of ischemic acute renal failure due to the role of PGs in maintaining renal blood supply.96 
With the exception of celecoxib (Celebrex®), all of the coxibs have been withdrawn from 
the market. The backlash towards selective COX-2 inhibitors has encouraged the 
pharmaceutical industry to develop alternative anti-inflammatory drugs, especially 
selective 5-LO inhibitors such as fuscoside B (11). 
 
1.5.1 The 5-lipoxygenase biosynthetic pathway 
5-LO belongs to a family of lipoxygenases that catalyze the addition of molecular 
oxygen to a 1,4-cis,cis-pentadiene.97 Prior to the initial stages of LT biosynthesis, 
cytosolic phospholipase A2 (PLA2) releases arachidonic acid (18) from the nuclear 
envelope while 5-lipoxygenase activating protein (FLAP) aids in the transfer of 18 to  
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Figure 1.7. The biosynthetic pathway of LTs from arachidonic acid (18). The following 
enzymes catalyze the above transformations: (a) 5-lipoxygenase (oxygenase), (b) 5-
lipoxygenase (dehydrase), (c) LTA4 hydrolase, (d) glutathione-S-transferase, (e) Ȗ-
glutamyl transpeptidase, (f) dipeptidase. 
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5-LO.98 The function of 5-LO is two-fold: it catalyzes the oxygenation of arachidonic 
acid to 5(S)-hydroperoxyeicosatetraenoic acid (19, 5-HPETE) and its subsequent 
dehydration to the allylic epoxide LTA4 (21, Figure 1.7).99 The hydroperoxide 
intermediate may also be reduced to 5(S)-hydroxyeicosatetraenoic acid (20, 5-HETE) by 
means of a glutathione peroxidase.100 The unstable epoxide 21 is converted either by 
LTA4 hydrolase to LTB4 (22) or by glutathione-S-transferase to LTC4 (23).101 
Meanwhile, the other cysteinyl-containing LTs, LTD4 (24) and LTE4 (25), are generated 
via the hydrolytic UHPRYDORIWKHȖ-glutamate and glycine appendages of 23, which are 
FDWDO\]HGE\Ȗ-glutamyl transpeptidase and a dipeptidase, in that order.99c 
LTB4 plays a role in leukocyte recruitment by triggering the adhesion of immune 
cells to the luminal surface of blood vessel epithelial cells, a process that promotes their 
migration from the blood into the interstitial fluid.102 Moreover, 22 is a potent 
chemotactic agent that directs the migration of leukocytes to the site of inflammation.103 
The cysteinyl-containing LTs (23-25) are potent broncho- and vasoconstrictors and 
primarily associated with the pathogenesis of asthma.104 The pathophysiological role of 
LTs in atherosclerosis and other chronic illnesses has also been well-documented in the 
literature;105 and thus inhibiting the biosynthesis of LTs has become recognized as an 
effective therapeutic strategy. 
 
1.5.2 Classes of 5-LO inhibitors 
The oxygenase activity of 5-LO is coupled to the redox cycling of its prosthetic, 
non-heme iron.106 As activation of 5-LO requires oxidation of iron from the ferrous to 
ferric state, lipophilic reducing agents, such as nordihydroguaiaretic acid, are potent 
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inhibitors of 5-LO. These redox-type inhibitors, however, non-selectively perturb other 
physiological redox processes causing undesirable side effects.107 As a result, redox-type 
5-LO inhibitors have failed to reach the market. The iron chelating inhibitors, comprised 
of the hydroxamic acids, are more selective and have been successful as anti-
inflammatory drugs. The FDA approved zileuton (Zyflo®) is an iron chelator and the 
only 5-LO inhibitor on the market to date.108 
Non-redox 5-LO inhibitors, such as ZD-2138109 and L-739,010,110 have even 
more appeal because of their greater specificity. The non-redox inhibitors do not undergo 
iron chelation but instead compete for the arachidonic acid binding site. It is anticipated 
that fuscoside B (11) exerts its 5-LO inhibition through a non-redox mechanism as it 
lacks any functional group poised for iron chelation or redox chemistry.77 As a result, 11 
may be a valuable compound for inspiring the future development of novel 5-LO 
inhibitors.  
 
1.5.3 Pharmacological properties of fuscoside B 
In 1992, Jacobson and Jacobs conducted a biological and biochemical evaluation 
of fuscoside B (11) in human neutrophils and a murine model of inflammation.76,77 
According to their autoradiographic experiments, 11 specifically inhibited the LTA4 
synthase function of 5-LO with high potency, as indicated by the relative increase in 5-
HETE biosynthesis.77 Intraperitoneal administration of 11 in a mouse model was 
ineffective against PMA-induced swelling of the mouse ear, presumably due to the 
hydrophobicity of the compound.76 Topical application of 11 at the site of PMA 
administration was required for the desired anti-inflammatory effect. While indomethacin 
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exacerbated the inflammatory response at 24 h post-PMA exposure, 11 showed long-term 
efficacy through its ability to prevent the early recruitment and activation of leukocytes.76 
Fuscoside B (11) also represents the first marine natural product to exhibit selective 5-LO 
inhibition. 
 
1.6 Glycosylation Chemistry 
 
1.6.1  The biological significance of carbohydrate substituents 
Carbohydrates belong to a class of biomolecules having the characteristic 
empirical formula of (CH2O)n. These molecules are well known for their role in energy 
storage and are also indispensible as structural components for a number of biopolymers, 
including cellulose, peptidoglycan, and chitin. In addition, carbohydrates constitute the 
backbone of DNA and RNA, and are also present in over half of all human proteins.111 
Considering how ubiquitous these molecules are in nature, it is perhaps not at all 
surprising that an impressive number of natural products are glycosylated.112 
The remarkable structural diversity displayed by saccharides stems from the 
various stereochemical and substitutional patterns displayed by the basic monosaccharide 
subunit.113 Likewise, the saccharide moieties of glycoside natural products are also 
important contributors to the structural and stereochemical diversity of these compounds. 
Gaining access to new regions of chemical space can be enabled by attaching 
carbohydrate substituents to synthetic compounds or secondary metabolites lacking any 
natural glycosylation.114 The glycan portion itself is often crucial for the biological 
activity of a glycoside, particularly in cases where the aglycone alone fails to elicit the 
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desired biological effect.115 Moreover, the carbohydrate moiety may enhance the 
bioavailability of the compound by improving its water solubility.116  
 
1.6.2  Mechanisms of glycoside bond formation 
Probing the pharmacological significance of a carbohydrate moiety is one of the 
primary aims of glycosylation chemistry, a branch of organic chemistry that was 
developed to generate libraries of compounds with differential glycosylation. The SAR 
obtained from such libraries may lead to the development of analogues with greater 
potency117 or reduced toxicity.118 To establish the glycosidic linkage, glycosylation 
chemistry has traditionally relied on the concept of a glycosyl donor (26), which is a 
protected monosaccharide with a leaving group attached to the anomeric position (Figure 
1.8).119 Initiation of the SN1 reaction begins with the removal of the anomeric leaving 
group. This process is facilitated by an appropriate activating reagent, frequently a Lewis 
acid, resulting in the transient formation of the glycosyl cation (27), which undergoes 
rapid rearrangement to an oxocarbenium ion (28). A hydroxyl group, belonging to the 
glycosyl acceptor, subsequently undergoes a nucleophilic attack at the oxocarbenium ion 
to generate the glycosidic linkage. 
A challenge in glycosylation chemistry is controlling the stereochemical outcome 
of glycoside bond formation, which often results in a mixture of anomers.119 The 
anomeric effect directs the anomeric substituent to the axial position of the ring, although 
there is a steric preference for the equatorial position.120 The nature of this effect is 
widely believed to be a result of hyperconjugation between the annular oxygen lone pair 
and the vacant antibonding orbital of the anomeric C-O bond (n-ıinteractions),121 but  
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Figure 1.8. General glycosylation mechanism and the effect of neighbouring group 
participation on the anomeric configuration. P: protecting group; LG: leaving group; LA: 
Lewis acid; R: aglycone; R1: neighbouring protecting group. Mechanism A: R1 = Bn 
(anomeric effect); Mechanism B: R1 = Ac (neighbouring group participation). Activation 
of the glycosyl donor (26) results in transient formation of the glycosyl cation (27), which 
readily rearranges to the oxocarbenium ion (28). Further rearrangement may occur with 
the participation of a neighbouring acetate protecting group, generating the acyloxonium 
ion (29). 
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intramolecular dipolar interactions are thought to play an important role as well.122 As a 
result, axial-oriented glycosidic linkages are thermodynamically preferred. However, the 
anomeric configuration is also dependent on the protecting groups of the glycosyl donor. 
Neighbouring group participation is defined as the interaction of a lone pair of 
electrons of a nearby nucleophilic substituent with a reaction center during a substitution 
process.123 This  phenomenon may oppose the anomeric effect and direct the formation of 
1,2-trans glycosidic linkages.124 Upon formation of the oxocarbenium ion (28), a 
rearrangement with a neighbouring participating group such as an ester functionality may 
occur to form a cyclic acyloxonium ion (29), which limits the subsequent nucleophilic 
attack to one side of the anomeric center. As a result, neighbouring group participation 
provides some degree of stereocontrol and is commonly exploited for this purpose by 
employing ester protecting groups, as shown in mechanism B in Figure 1.8.125 However, 
various 1,2-cis glycosidic linkages, which are found in many natural compounds,126 
remain elusive.127 
The protecting group also has an impact on glycosyl donor reactivity by 
influencing the activation energy barrier to oxocarbenium ion (28) formation.128 In this 
regard, protecting groups have been divided into WZRFODVVHV³DUPLQJ´DQG
³GLVDUPLQJ´129 Electron donating protecting groups, such as benzyl ethers or acetonides, 
arm the glycosyl donor by lowering the energy of the oxocarbenium ion and thus increase 
the relative rate of glycosyl donor activation. Such glycosyl donors are less stable and 
have higher rates of activation. Meanwhile, electron withdrawing ester protecting groups, 
such as acetates and benzoates, are disarming as they invoke the destabilization of 
28 
 
oxocarbenium ions. These disparities in reactivity rates have recently been exploited by 
Zhang et al. in the development of a strategy for one-pot oligosaccharide synthesis.130  
 
1.6.3  The Koenig-Knorr glycosylation method 
The first chemical glycosylation was accomplished in 1901 by Koenigs and Knorr 
who recognized the potential of glycosyl halides as carbohydrate donors when activated 
by Ag2CO3 or Ag2O.131 Glycosyl bromides are typically favoured as their reactivity and 
hydrolytic stability is intermediate between their glycosyl chloride and iodide 
counterparts.132 Since the discovery of the Koenigs-Knorr method, modifications of the 
procedure have improved glycosylation yields. For instance, the addition of AgOTf, a 
soluble silver salt with a weakly coordinating anion, increases the relative rate of glycosyl 
donor activation and tends to provide higher glycosylation yields.133 In this co-promotion 
system, only a sub-stoichiometric amount of AgOTf is necessary as it is regenerated in 
situ when the glycosylation by-product TfOH reacts with Ag2CO3, which serves as an 
acid scavenger.134 Variations of the Koenigs-Knorr method continue to be applied in the 
glycosylation of steroids,135 natural products,136 and many other glycoconjugates.135 
The modified Koenigs-Knorr method has also found utility in the glycosylation of 
tertiary alcohols.137 Owing to steric interactions, the tertiary hydroxyl group is a weaker 
nucleophile and notoriously difficult to glycosylate. Their relative intractability towards 
glycosylation is demonstrated by the fact that these functionalities are often left 
unprotected while glycosylating other moieties.138 Nonetheless, Harmatha and coworkers 
reported a glycosylation of the tertiary alcohol 20-hydroxyecdysone in nearly 70% 
yield.139 Schneider et al. also managed to introduce a carbohydrate functionality to the 
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tertiary hydroxyl group of the steroidal hormone gibberellin A20 in 40% yield.140 More 
recently, the Koenigs-Knorr approach was carried out to glycosylate tertiary alcohol 
derivatives of an amino acid using a glycosyl bromide.141 Multiple equivalents of 
glycosyl donor and long reaction times were employed in these reactions to achieve 
satisfactory glycosylation yields.  
 
1.6.4  The Schmidt glycosylation method 
 Nearly 80 years after the discovery of the Koenigs-Knorr method, the first 
alternative glycosylation approach was proposed by Schmidt et al.142 This approach 
utilizes glycosyl trichloroacetimidates, whose activation may be carried out with catalytic 
amounts of Lewis acid, usually BF3(W2O or TMSOTf.143 The Schmidt glycosylation has 
since gained wide popularity due to its versatility and reliability.136, 144 Glycosylation of 
natural products,145 cholesteryl glycosides,135 and oligosaccharides146 are among the 
applications of this approach. Tertiary allylic hydroxyl groups, similar to that of fuscol 
(15) and eunicol (16), have also been glycosylated with satisfactory yields.144 A notable 
advantage of the Schmidt method is the relative hydrolytic stability of the 
trichloroacetimidate and the capability of activating these glycosyl donors with reagents 
that are less expensive and easier to handle than heavy metal salts.143 
 
1.6.5  Modern strategies in glycosylation chemistry: Glycorandomization 
Efforts to improve our understanding of the biological significance of 
carbohydrate substituents has unfortunately been curbed by the limited availability of 
robust glycosylation methodology.147 Glycosylation chemistry often suffers from tedious 
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protecting group manipulations and variable reaction yields.148 Polysaccharide synthesis 
via iterative glycoside bond formation is a formidable task requiring the tedious 
manipulation of protecting groups.149 Furthermore, unlike polypeptide and polynucleotide 
synthesis, every glycosylation has stereochemical consequences and may result in a 
mixture of products.119-120 Despite recent progress based on neighbouring group 
participation,125a, 150 stereocontrol remains an issue, as exemplified by the challenge of 
accessing 1,2-cis glycosidic linkages of mannosides.127  
In recent years, there has been considerable progress towards a more universal 
glycosylation approach. Chemoenzymatic glycorandomization is a biocatalytic approach 
that exploits the broad substrate specificity of various glycosyltransferases.151 These 
enzymes accommodate a structurally diverse range of nucleoside diphosphate sugars in 
their catalysis. These activated carbohydrates are meanwhile generated in situ by an 
anomeric kinase and a sugar nucleotidyltransferase, a pair of enzymes also exhibiting 
substrate promiscuity.151 Combining these biocatalytic syntheses greatly enhances the 
pace of glycoside library development. Neoglycorandomization, on the other hand, is a 
novel glycosylation tool that has also accelerated glycoconjugate synthesis.152 This 
strategy exploits the chemoselective condensation between secondary alkoxyamines and 
the reducing end of unprotected and non-activated carbohydrates.153 Although the 
introduction of the alkoxyamine handle to the aglycone represents a potential obstacle,115a 
this method is not restricted by the extent of enzyme flexibility. 
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1.7 Pseudopteroxazole: A Unique Antitubercular Diterpene 
 
Pseudopteroxazole (30) is an antitubercular amphilectane diterpene first isolated 
by Rodríguez et al. from the alcyonacean coral Pseudopterogorgia elisabethae.154 This 
compound was reported alongside seco-pseudopteroxazole (31), a diterpene possessing 
the serrulatane scaffold, while homopseudopteroxazole (32) was discovered at a later 
date.155 The benzoxazole moiety is a characteristic feature of these compounds and 
exceedingly rare in marine natural product chemistry with only a few representatives in 
the literature.156 After completing the enantiospecific synthesis of the proposed structure 
of pseudopteroxazole, Corey et al. recommended a stereochemical revision.157 The same 
group later achieved the first enantiospecific synthesis of 30, establishing its absolute 
configuration as shown in Figure 1.9.158 A concise synthesis of 30 using a tricyclic 
benzothiazine was later reported by Harmata et al.159 Diterpenes 30-32 were shown to 
inhibit the growth of Mycobacterium tuberculosis H37Rv by 97, 66, and 80%, 
UHVSHFWLYHO\DWDGRVHRIȝJP/DQGshowed no signs of cytotoxicity towards the 
NCI-60 cell line panel.154-155 
Although the natural abundance of pseudopteroxazole (30) is low, the 
pseudopterosins are available in multigram quantities, constituting as much as 5% of the 
dry weight of P. elisabethae.160 Considering the availability of pseudopterosins G-J (33-
36), as well as their structural homology to 30, a potential semisynthetic route to 30 was 
realized. Hydrolysis of the carbohydrate in 33-36 followed by facile insertion of the 
oxazole ring could achieve a supply of 30. This opportunity culminated in a 
semisynthesis of 30 and a library of novel analogues.160 This work represented the first  
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Figure 1.9. The structures of pseudopteroxazoles 30-32, antitubercular diterpenes 
isolated from Pseudopterogorgia elisabethae. 
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Figure 1.10. A semisynthetic route to pseudopteroxazole analogues, such as PtxHis (37), 
from a pseudopterosins G-J (33-36) mixture isolated from Pseudopterogorgia 
elisabethae.161 
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insight into SAR for this class of compounds (Figure 1.10). Within this compound 
collection was a histidine-derived analogue, 21-((1H-imidazol-5-yl)methyl)-
pseudopteroxazole (PtxHis, 37), which displayed greater potency than 30 against 
vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus 
(MRSA), and a model of M. tuberculosis in a state of non-replicating persistence 
(NRP).161 
 
1.8 Trends in Antimicrobial Drug Discovery 
 
The serendipitous discovery of penicillin by Alexander Fleming in 1928 is 
arguably the most important medical discovery in the 20th century as it ushered in the 
modern era of antimicrobial drug discovery. After this breakthrough, a remarkable 
decrease in mortality rates from infections was achievedFRQYLQFLQJPDQ\WKDW³LWZDV
time to close the book on inIHFWLRXVGLVHDVHV´.162 Following this notion, many 
governmental agencies and pharmaceutical companies began diverting their resources 
away from antibiotic research during the early 1980s.163 However, extensive clinical and 
industrial use of antibiotics imposed a selective pressure, and as a consequence, clinically 
relevant antibiotic resistance ensued.164 
The mechanism of antibiotic resistance may involve altering the amino acid 
sequence of a protein target to vitiate drug binding interactions.165 For instance, 
Staphylococcus aureus has acquired methicillin resistance by altering a penicillin binding 
protein, which lRZHUHGLWVELQGLQJDIILQLW\WRZDUGȕ-lactam antibiotics.166 Obtaining 
resistance-associated genetic material from other organisms or the surrounding 
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environment may also confer antibiotic resistance.165b The development of vancomycin 
resistance in enterococci was due to the acquisition of the vanHAX gene cassette,167 
which has been thought to originate in soil-dwelling bacteria.168 The expression of 
vanHAX encodes enzymes that are responsible for reinforcing the peptidoglycan layer by 
replacing D-Ala-D-Ala dipeptide residues with D-Ala-D-Lac.167, 169 This alteration 
removes a key hydrogen bonding interaction between vancomycin and the dipeptide and 
thus confers resistance. 
In recent years, nosocomial infections caused by drug-resistant organisms have 
reached epidemic proportions and are responsible for nearly 100,000 deaths per year in 
the United States alone.170 Strains of MRSA possessing intermediate and high-level 
resistance to vancomycin, heralded as WKH³DQWLELRWLFRIODVWUHVRUW´, have recently been 
isolated from clinical cases.171 The emergence of multidrug-resistant (MDR) Gram-
negative pathogens is also alarming.172 Regrettably, antimicrobial drug discovery has 
stagnated and nearly all antimicrobial drugs introduced to the clinical over the last 40 
years are members of an existing class.173 Reinvigorating antimicrobial research has now 
become a matter of urgency and further neglect may have grave consequences on the 
future of human health. 
 
1.8.1 Tuberculosis: A global health crisis 
M. tuberculosis, the etiologic agent of tuberculosis (TB) disease, causes nearly 
one and a half million deaths annually and has established a latent infection in one third 
of the human population.174 Primarily a disease of impoverished regions, especially 
Africa and Asia,175 TB is one of the leading causes of infectious disease-related mortality, 
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second only to HIV/AIDS.176 The HIV/AIDS pandemic has fueled a resurgence of TB as 
HIV-TB co-infection accelerates the progress of both diseases.177 As a result of 
compromised immunity, TB has become the leading cause of death in patients suffering 
from HIV.176 The interaction between anti-HIV and antitubercular drugs may delay the 
initiation of highly active anti-retroviral therapy until the initial phase of antitubercular 
treatment has been completed.178 Characterized as an asymptomatic and non-contagious 
state, a latent infection is the predominant form of TB and progresses to the active state in 
only 10% of all cases, though the risk increases substantially in HIV-positive patients.179 
Pulmonary TB infections, the most common form of active TB, expedite the 
transmission of the disease through the expulsion of aerosolized mycobacteria as a result 
of chronic coughing.180 Along with its high rate of transmission, the success of M. 
tuberculosis as an intracellular pathogen is attributed to its elusiveness. Upon initial 
infection, this obligate aerobe establishes itself within the lung and thereafter invades 
host immune cells, specifically alveolar macrophages.181 After becoming internalized into 
a macrophage by phagocytosis, M. tuberculosis avoids destruction by inhibiting 
phagosome maturation.182 By manipulating various processes within the host cell, 
including inhibition of phagosome-lysosome fusion,183 the mycobacteria create a niche 
within the macrophage.181 To prevent further dissemination of the mycobacteria, cell-
mediated immunity is initiated with the concerted effort of macrophages, lymphocytes, 
and fibroblasts, which together form granulomas around the infected macrophage cells.184  
The majority of TB infections can be cured with a six- to nine-month antibiotic 
treatment, involving rifampin, isoniazid, pyrazinamide, and ethambutol.185 Eliminating 
TB as a major global health issue, however, has proven to be elusive. Waning patient 
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adherence to the lengthy antitubercular therapy has contributed to the spread of TB.186 To 
improve patient compliance, the World Health Organization has recommended directly 
observed therapy, a program in which a health worker supervises the administration of 
antitubercular medication.187 Although the program has proven to be an effective TB 
management strategy, its implementation is expensive compared to the low cost of the 
medication itself.188 The requirement of such prolonged treatments is largely attributed to 
a physiological state of NRP, a quiescent form of M. tuberculosis that is unsusceptible to 
antitubercular treatment.189 As a result, shortening the duration of antitubercular 
chemotherapy by targeting NRP mycobacteria is an important aim of current TB 
research.  
Over the years, low patient compliance has exacerbated the emergence of drug-
resistant strains, including MDR- and extensively-drug resistant (XDR)-TB.190 Such 
cases, which account for approximately 5% of all TB infections, require second-line 
treatments, such as cycloserine, ciprofloxacin, and amikacin.191 These drugs, however, 
are generally less effective, exhibit more serious side effects, or must be administered 
intravenously; factors that further complicate treatment or contribute to patient non-
compliance.191-192 The emergence of MDR- and XDR-TB is a serious threat to TB 
management, and therefore medications that are effective against resistant infections are 
also needed.193 
Despite the ongoing dissemination of TB, it has been approximately 40 years 
since the most recent antitubercular treatment has been approved.194 New classes of 
antitubercular drugs are needed to improve the outcome of TB treatments.195 Preferably, a 
novel drug should shorten the course of treatment by targeting NRP mycobacteria, be 
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compatible with highly active anti-retroviral therapy and other antitubercular treatments, 
have a spectrum of activity focused on TB, and have a novel mechanism of action, such 
that it lacks cross-resistance with other antitubercular drugs.196 Inhibitors of 
mycobacterial proteasomes,197 ATP synthase,198 or proteins associated with the electron 
transport system196 are therefore promising candidates as they possess a unique 
mechanism of action and may potentially achieve the above aims. 
 
1.9 Chemical Proteomics 
 
Small molecules designed by Nature offer an extraordinary opportunity to explore 
new aspects of biological phenomena. Widely acclaimed for their pharmaceutical 
success, natural products also have a long history of employment as chemical tools in 
biological research.199 For instance, improvements in our understanding of cellular 
proliferation,200 macromolecular interactions,201 and other fundamental aspects of biology 
were contingent on natural product probes.202 Furthermore, efforts to pursue the 
biological function of a natural product may also lead to the realization of a novel drug 
target if its function is relevant to a particular disease state.203 Owing to the supply issue, 
however, investigating the mechanism of action of natural products is often unfeasible.204 
Nonetheless, one of the frontiers of natural product drug discovery is the pursuit of the 
biological function of every natural product in order to fully understand their 
pharmacological and ecological significance. 
The use of chemical probes has served as a complement to the more customary 
genetic techniques.205 Genetic techniques, though inexpensive and fairly selective,206 are 
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limited by several issues. For instance, the biological impact of genetic manipulations is 
permanent, which may be inappropriate for genes that are essential for viability.207 The 
chronic loss of a particular gene function may also trigger a compensatory mechanism, 
thus confounding the study.208 The effect of a small molecule, on the other hand, is acute 
and oftentimes reversible, thus enabling a temporal analysis of the biological impact.209 
The dose of a small molecule may also be fine-tuned to precisely control the extent by 
which a biological process is perturbed.209 The high specificity of small molecule tools 
for their cellular targets also accounts for post-translational regulatory control, an aspect 
not captured by gene deletion techniques.210 
 
1.9.1 Chemical proteomics: An approach for novel drug target discovery 
Proteins are by far the most common macromolecular targets in drug discovery.211 
Within the human genome there are a predicted 16,000 protein families, of which only 
four are targeted by more than 50% of FDA-approved drugs.212 Over the past decade, the 
discovery of new drug targets has stagnated at an average of 5.3 per year,212 on par with 
WKHILYHWRVL[³PHFKDQLVWLFDOO\LQQRYDWLYH´QHZPROHFXODUHQWLWLHVDSSURYHGHDFK\HDU213 
Furthermore, the drugs within our current pharmacopeia exploit only approximately 500 
targets.214 $V6LU-DPHV%ODFNIDPRXVO\UHPDUNHG³Whe most fruitful basis for the 
GLVFRYHU\RIDQHZGUXJLVWRVWDUWZLWKDQROGGUXJ´215 But will the pursuit of new drugs 
for old targets provide cures for the most enduring of human illnesses?  
The chemical proteomics approach exploits a small molecule as a chemical tool 
for the identification of its target.216 Frequently, the small molecule is synthetically 
modified to enable its immobilization onto a stationary support, allowing target protein 
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identification by affinity chromatography.217 The compound may otherwise be converted 
to a reagent that specifically labels the target protein through covalent modification. 
Suicide inhibitors (mechanism-based) have an intrinsic protein labeling mechanism, such 
as the mechanism for ȕ-lactam ring opening of penicillin.218 Reversible binders, on the 
other hand, must be modified with an electrophilic or photoreactive functionality to 
facilitate protein labeling.219 In either case, the labeling reagent must also be comprised 
of an identifying tag to expedite the deconvolution of labeled targets.220 
While chemical proteomics is a powerful approach for identifying biological 
targets, the technique is not without limitations.221 Modifying the small molecule into a 
functional probe may abolish the binding activity of interest; therefore an assessment of 
structure-activity relationships (SAR) is a prerequisite.222 Unfortunately, it is difficult to 
accurately assess the binding affinity of small molecules with unknown targets, as cell 
permeability and water-solubility often confound the biological data.217 Chemical 
proteomics is also beset with high background as a result of non-specific binding (NSB), 
which often results from generic hydrophobic or ionic interactions.223 Proteome sample 
preparation by cell lysis may fail to isolate the target protein or there may be issues 
regarding protein stability.221, 224 These issues primarily affect affinity chromatography, 
whereas photoaffinity labeling and activity-based protein profiling techniques are 
conducive to in situ biochemical analysis.204, 225 If these issues can be tackled 
successfully, chemical proteomics is a method of choice for target deconvolution. 
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1.9.2 Affinity chromatography as a tool for identifying protein targets 
Affinity chromatography entails the biochemical isolation of a protein target 
through its binding interaction with a compound immobilized onto an inert stationary 
support.217 The probe acts as small molecule bait for capturing and enriching the target 
protein on the affinity resin. This technique is most successful for probes exhibiting a 
high binding affinity (i.e. Kd ȝ0225 and for protein targets of high abundance.226 
Two strategies are commonly pursued for the preparation of affinity resins: direct 
covalent attachment of the compound to a stationary support or immobilization of a 
biotinylated molecule to a streptavidin-functionalized resin.227 The latter approach 
exploits the binding interaction between biotin and streptavidin, which is the strongest 
non-covalent association known in nature.228  
In both cases, a spacer is frequently placed between the small molecule and the 
stationary support to minimize steric congestion, which can interfere with the desired 
binding interaction.229 Upon binding to streptavidin, biotin is lodged within a deep 
binding pocket of streptavidin such that only the carboxylate protrudes from the protein 
surface.230 As a result, longer spacers are usually required for the streptavidin-biotin 
system.231 These spacers are typically composed of repeating ethylene glycol subunits, an 
alternative to long-chain hydrophobic methylene spacers that tend to increase non-
specific binding.217 A recent study by Sato et al. has also demonstrated the importance of 
spacer rigidity for the binding affinity of target proteins.231 In their approach, a 
polyproline spacer was exploited for its ability to form a stable left-handed helix, which 
prevented folding of the spacer and maintained a stable distance between the small 
molecule and the stationary support.231 
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Deconvolution of drug targets by affinity chromatography is often complicated by 
the interference of NSB.223 Nonetheless, this issue can be mitigated with the 
implementation of a well-designed negative control experiment.204, 217 A competitive 
displacement, in which a target protein is selectively eluted from the resin via 
competition with unbound small molecule, is the epitome of a negative control.232 
Regrettably, the limited solubility of many small molecules in aqueous media often 
precludes their use as competitive ligands.217 A probe lacking the desired activity may 
instead serve as a control, given the similarities in NSB. Such inactive probes are often 
chiral isomers,233 structurally related analogues,234 or may otherwise be prepared by 
attaching the spacer to the pharmacophore of the molecule so as to disrupt its binding 
activity.235 This strategy has recently been demonstrated by Hegde et al., who elucidated 
the molecular basis RIWKLRVWUHSWRQ¶V38) antiproliferative activity using the inactive 
probe 39 (Figure 1.11).227a 
As an alternative to the negative control probe, whose design often requires 
extensive analysis of SAR, the principles of serial affinity chromatography may be 
applied.236 In this approach, a protein preparation is incubated with multiple batches of 
affinity resin in an iterative fashion. During this sequential process, the relative 
abundance of proteins exhibiting NSB remains largely unchanged, owing to their high 
abundance and low binding affinity. In comparison, protein targets with higher affinity 
are predominantly immobilized on the affinity resins, and are therefore depleted from the 
lysate early in the sequence. Analysis of differential band intensities by gel  
43 
 
 
 
 
Figure 1.11. Literature examples of affinity chromatography using immobilized natural 
product-based probes: A biotinylated thiostrepton chemical probe (38) along with the 
inactive control probe (39),227a and bolinaquinone covalently linked to an agarose matrix 
(40).237 
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electrophoresis may allow one to differentiate between NSB and target proteins. Serial 
affinity chromatography was employed during the analysis of bolinaquinone (40, Figure 
1.11), in which clathrin was identified as a molecular target of this anti-inflammatory 
marine natural product.237 
 
1.9.3 Photoaffinity labeling: Target identification for reversible binders 
The popularity of photoaffinity labeling in chemical proteomics has grown 
immensely in recent years, especially for the investigation of natural product mechanism 
of action.238 This approach is commonly employed for target identification of reversible 
binders as these compounds, unlike suicide inhibitors, lack the intrinsic mechanism for 
covalently modifying their protein targets.204 A notable advantage that this technique 
holds over affinity chromatography is the ability to interrogate protein binding within the 
context of a living cell, circumventing any potential issues regarding cell lysate 
preparation.239 Furthermore, photoaffinity labeling is suitable for detecting low affinity 
interactions and protein targets of low abundance.204 Labeling efficiency may be variable 
and depend on factors other than binding affinity.240 For instance, conformational 
flexibility of the photoreactive ligand has been shown to have an impact on the overall 
yield of target labeling.241  
A photoaffinity probe must be comprised of a photoreactive functional group and 
an identifying tag. Benzophenone has become one of the most common photoreactive 
groups because it exhibits excellent stability under ambient light and undergoes 
reversible photoexcitation instead of irreversible photolysis, resulting in higher labeling 
efficiency.242 The longer wavelength of radiation required for benzophenone activation 
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also prevents biological macromolecules from sustaining photochemical damage.242 To 
detect photolabelled targets, the probe must also present an identifying tag, commonly an 
alkyne group. Owing to its steric discreteness, the alkyne tag has a minimal impact on 
cellular uptake yet provides a synthetic handle for attaching a reporter tag, which is 
equipped with fluorescent and/or biotin moieties as provisions for the rapid discernment 
of labeled proteins.243 For this attachment, the reporter tag must also be functionalized 
with an azide group to enable the azide-alkyne Huisgen cycloaddition,244 a 
chemoselective ligation that is compatible with aqueous solutions.245  
One of the preeminent applications of photoaffinity labeling was a study 
conducted by Koteva et al. aiming to resolve the perennial issue of inducible vancomycin 
resistance in enterococci.246 The expression of vanHAX was known to be induced by 
vancomycin, though the exact mechanism provoking this response was the subject of 
much speculation.247 A vancomycin photoaffinity probe (41, Figure 1.12) was prepared 
and found to be a substrate for VanS, a receptor histidine kinase that was shown to 
initiate transcription of vanHAX upon binding to vancomycin.246 This discovery may lead 
to the development of vancomycin analogues with lower VanS binding affinity. 
Combining vancomycin treatment with drugs that inhibit VanS activity may also become 
a future strategy in the struggle against vancomycin resistant infections.246 Using a 
similar protein labeling approach (42), Sieber et al. demonstrated the direct binding of 
vancomycin to other membrane targets; such binding activity may contribute to its 
activity against Gram-positive bacteria.239 
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Figure 1.12. Two literature examples of vancomycin photoaffinity probes designed by 
Koteva et al. (41)246 and Sieber et al. (42).239  
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1.9.4 Activity-based protein profiling: Target identification for suicide inhibitors 
Activity-based protein profiling has become an effective tool for identifying the 
targets of natural products.238 This approach utilizes active-site directed probes, which are 
FRPSRXQGVDUPHGZLWKUHDFWLYHIXQFWLRQDOJURXSVVXFKDVĮ-chloroacetamides or 
Michael acceptors, which enable irreversible covalent binding to protein targets.248 
Similar to the photoaffinity labeling strategy, activity-based probes are commonly 
modified with an alkyne tag to facilitate protein target deconvolution.249 For instance, the 
ȕ-lactam antibiotics, including penicillin and ampicillin, irreversibly attach to serine 
residues within the active sites of penicillin binding proteins.218 This inherent reactivity 
KDVEHHQH[SORLWHGE\6WDXEHWDOLQWKHV\QWKHVLVRIȕ-lactam activity-based probes (43, 
Figure 1.13).218 Within the context of a live cell, thHVHȕ-lactam probes labeled enzymes 
unrelated to penicillin binding proteins, including a lipase acylhydrolase and a virulence-
associated protein.218 Activity-based probes have also been designed for the purpose of 
studying enzymatic function.248b, 250 Wortmannin, a fungal natural product, has been 
designed into a fluorescent activity-based probe (44) for interrogating the biological 
function of phosphoinositide 3-kinase, an intracellular signaling protein with a 
pathophysiologic role in cancer.251 
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Figure 1.13. Ampicillin (43)252 and wortmannin (44)251 activity-based probes possessing 
PHFKDQLVPVIRUSURWHLQODEHOLQJ7KH³5´JURXSUHSUHVHQWVDO\VLQHUHVLGXHEHORQJLQJWR
a target protein. 
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1.10 Research Goals 
 
 The general aim of this research is to investigate the biological properties of 
diterpenes isolated from E. fusca and P. elisabethae. While the anti-inflammatory activity 
of fuscoside B (11) has been well characterized, the biological significance of the 
arabinose moiety is unknown. One of the objectives of this research is to synthesize a 
library of fuscoside B analogues through differential glycosylation of fuscol (15) and 
eunicol (16). During the extraction of 15 and 16 from E. fusca, the coral shall also be 
investigated for diterpenes with potential therapeutic applications. The discovery of novel 
natural products from E. fusca, particularly those of lower abundance, is promising. The 
recent semisynthesis of pseudopteroxazole (30) from pseudopterosins G-J (33-36) in the 
Kerr laboratory represents a tremendous opportunity to investigate its cellular target by 
chemical proteomics. To identify putative targets with this strategy, a collection of 
pseudopteroxazole probes will be prepared for affinity chromatography or photoaffinity 
labeling, techniques commonly used to identify proteins exhibiting specific binding 
interactions. Notably, this approach may reveal a novel drug target for the treatment of 
TB. 
 
Objective 1: To isolate new diterpenes from Eunicea fusca and evaluate their 
biological activity. 
Objective 2: To synthesize a library of fuscoside B analogues and assess 
structure-activity relationships. 
Objective 3: To investigate the antitubercular mechanism of action of 
pseudopteroxazole by chemical proteomics. 
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CHAPTER 2 
 
EUNICIDIOL, AN ANTI-INFLAMMATORY 
DILOPHOL DITERPENE FROM EUNICEA FUSCA 
 
 
 
 
 
 
 
 
 
The contents of this chapter have been published with modification as: 
Marchbank, D.H.; Berrué, F.; Kerr, R.G. J. Nat. Prod. 2012, 75, 1289. 
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2.1 Introduction 
 
Marine corals belonging to the order Alcyonacea have provided a wealth of 
structurally diverse diterpenes with a range of potential therapeutic applications.73, 79 The 
Caribbean alcyonacean Eunicea fusca is a source of the anti-inflammatory fuscosides 
(Figure 2.1), a family of diterpene arabinosides that reduce PMA-induced mouse ear 
edema with activities comparable to indomethacin.74 Although fuscoside A (10) displays 
greater potency, fuscoside B (11) is known for its selective inhibition of 5-LO and 
negligible effect on prostaglandin (PG) biosynthesis.76,77 Fuscosides C (13) and D (14) 
have no reported activity, while fuscoside E (12), a glycoside structurally related to 10, 
has similar anti-inflammatory activity as 11 in the mouse ear edema assay. Although the 
anti-inflammatory potential of the fuscosides is well known, non-glycosidic diterpenes 
from E. fusca have not yet been evaluated for activity in the mouse ear edema assay. 
A preliminary assessment of the anti-inflammatory properties of fuscol (15) was 
conducted by Jacobson and Jacobs in 1991.76,77 Similar to fuscoside B (11), 15 had no 
effect on PLA2 activity up to a concentration of 500 ȝM.76 Fuscol (15) exhibited 
concentration-dependent inhibition of LTB4 biosynthesis in adherent human 
polymorphonuclear leukocytes.77 Notably, 15 [half-maximal inhibitory concentration 
(IC50): 6 ȝM] was slightly more potent than 11 (IC50: 10 ȝM) in this assay.77 This result 
suggests that the carbohydrate portion is not required for in vitro 5-LO inhibition. The 
amount of lactate dehydrogenase (LDH) release by 11 and 15 was assessed as a measure  
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Figure 2.1. The collection of all known diterpenes and diterpene arabinosides isolated 
from Eunicea fusca. 
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of potential toxicity. Fuscoside B (11) showed a concentration-dependent increase in 
LDH release plateauing at approximately 25-30%, whereas 15 showed a maximum of 
5%.77 This result indicates lower in vitro toxicity of 15 towards adherent 
polymorphonuclear leukocytes, although both compounds were comparable at their 
respective IC50 concentrations. Despite a number of shared properties with fuscoside B 
(11), fuscol (15) was not explicitly shown to be a selective 5-LO inhibitor nor was it 
evaluated for in vivo anti-inflammatory activity. 
Eunicol (16) and eunicene A (17), along with fuscol (15), are the only reported 
non-glycosidic diterpenes from E. fusca.85 These diterpenes were investigated for their 
biosynthetic origin but were not reported to have any biological activity.85 Newman and 
Hill have alleged that 15 and 16 reduce PMA-induced edema via selective inhibition of 
leukotriene biosynthesis,253 however, neither compound was directly evaluated for in 
vivo anti-inflammatory activity and there is insufficient biochemical data to support a 
selective 5-LO inhibition mechanism. Other diterpenes isolated from E. fusca include 
fuscoside F (45), eunicene B (46), fuscene A (47), fuscene B (48),254 (+)-germacrene D, 
and a variety of sterols78 that were also isolated from extracts of sponges belonging to the 
order Halichondrida.255 
The low number of literature reports on E. fusca derived secondary metabolites 
suggests that the coral has not yet been thoroughly investigated, thus the discovery of 
novel compounds remains promising. In addition, many of the reported compounds were 
relatively abundant in the E. fusca crude extract, indicating that much of the low-hanging 
fruit has been picked. An investigation of scarce natural products is therefore compelling, 
especially for compounds showing structural homology to fuscol (15) or the fuscosides. 
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This strategy may increase the probability of discovering novel secondary metabolites 
with anti-inflammatory activity. This approach may also provide an opportunity to assess 
the SAR of this family of natural products. 
The aim of this research was to discover new compounds from E. fusca, 
particularly those with potential medicinal applications. The E. fusca extract was 
interrogated by LC-APCIMS for secondary metabolites that are structurally related to 
fuscol (15) and the fuscosides (10-14, 45), as this approach may increase the likelihood of 
discovering novel natural products with anti-inflammatory properties.  
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2.2 Results and Discussion 
 
2.2.1 Identification and isolation of fuscol and eunicol analogues 
To discover novel secondary metabolites that are structurally related to the anti-
inflammatory fuscosides, a chemistry-driven approach was pursued. A crude extract from 
E. fusca initially underwent chromatographic separation by medium pressure liquid 
chromatography (MPLC). This process of separating and enriching the metabolites into 
different chromatographic fractions expedited the subsequent LC-APCIMS analysis. The 
LC-APCIMS data was manually investigated for putative fuscoside and fuscol 
derivatives by searching for ions potentially arising from variations in acetylation, the 
degree of oxygenation, or the index of hydrogen deficiency. Compounds displaying such 
ions were targeted for NMR analysis and further purification. Additional structural 
information was also obtained by analysis of tandem APCIMS spectra. 
A potentially novel diterpene was obtained as an impure sample after separating 
the crude extract of E. fusca by normal phase flash chromatography and RP-MPLC. 
Known diterpenes fuscol (15) and eunicol (16) constituted a significant proportion of the 
crude extract and were also collected. Preliminary analysis of the sample by low 
resolution LC-APCIMS revealed a quasimolecular ion of 289.2 (m/z) and a fragment ion 
of 269.4 (m/z), which suggested a hydroxylated analogue of 15 or 16. Moreover, the 
tandem mass spectrum of this fragment ion revealed a similar fragmentation pattern as 
the 271.3 (m/z) fragment ion of 15 and 16 (Section 2.4), suggesting that the unknown 
compound was structurally related to these diterpenes. $ȝJVDPSOHZDVWHVWHGLQWKH
mouse ear edema assay as a preliminary assessment of the potential anti-inflammatory 
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activity of this unknown diterpene. This sample strongly inhibited PMA-induced swelling 
by 74.5 ± 3.6% (mean ± SEM), and was significantly more potent than a 3.0 mg dose of 
indomethacin (p < 0.05, XQSDLUHG6WXGHQW¶Vt-test), a known anti-inflammatory drug 
employed in this study as an industry benchmark. 
The diterpene was purified by semi-preparative RP-HPLC using a combination of 
phenylhexyl and C18 stationary phases (Figure 2.2). The molecular formula was 
established as C20H32O2 by HRESIMS analysis (m/z 327.2286 [M + Na]+), indicating an 
index of hydrogen deficiency of five. The existence of hydroxyl groups was reflected by 
the IR spectrum (3357 cm-1) and two oxygen-EHDULQJFDUERQUHVRQDQFHVįC 76.2, 70.4) 
in the NMR spectrum. The NMR spectroscopic data was acquired using C6D6 as other 
solvents, including CD3OD, CD2Cl2, and acetone-d6, produced poorly resolved NMR 
spectra with broader and weaker signals. Such signal broadening was also observed in the 
1H and 13C NMR spectra of 16 (Figure A.1), as a consequence of conformational 
isomerism of the cyclodecane ring. Notably, this phenomenon has previously been 
observed for germacrene-type compounds.256 Acquisition of 1H NMR spectra at variable 
temperatures, ranging between -40 and 40 °C using CD3OD or between 10 and 60 °C 
using C6D6, did not improve signal resolution.  
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Figure 2.2. Purification of the novel diterpene by semi-preparative RP-HPLC [UV 
chromatogram (240 nm), phenylhexyl, 77% CH3OH, tR 31 min]. 
  
58 
 
2.2.2 Elucidation of the planar structure of eunicidiol 
The 1H NMR spectrum of the novel diterpene, known as eunicidiol (49), indicated 
a conjugated diene system identical to that of fuscol (15) and eunicol (16), comprising the 
olefinic resonances of H-13 >įH 6.60 (1H, dd, J = 15.1, 10.8 Hz)], H->įH 5.99 (1H, d, J 
= 10.8 Hz)], and H->įH 5.72 (1H, d, J = 15.1 Hz)] (Figure 2.3, Table 2.1). The 
HMBC spectrum showed correlations between H-14 and C-įC 30.2) and C-įC 
70.4), indicating the presence of geminal dimethyl groups and a tertiary hydroxyl group. 
The C-PHWK\OSURWRQVįH 1.24) displayed HMBC correlations with C-19 and C-15 to 
further establish this moiety. The olefinic proton H-12 exhibited HMBC coupling with C-
įC 44.8) and C-įC 13.9), confirming that the side chain of 49 was the same as that 
of 15 and 16. The C-10 methine proton showed COSY correlations with the C-1 
PHWK\OHQHSURWRQVįH 1.60), thus providing partial structure A (Figure 2.4). Owing to 
the lack of unambiguous coupling of partial structure A to other nuclei, additional partial 
structures were elucidated independently. 
The C-įC 150.0) and C-įC 114.7) resonances were assigned by HMBC and 
HSQC coupling with terminal olefinic methylene protons H-DEįH 5.04, 4.94). Long-
range heteronuclear correlations between H-16b and C-įC 25.7) and C-įC 76.2) 
established the 1,1-disubstituted double bond. The incorporation of a secondary hydroxyl 
group at C-ZDVHVWDEOLVKHGRQWKHEDVLVRIWKHGHVKLHOGHGSURWRQįH 3.87) and carbon 
chemical shifts. This analysis provided a 4-carbon segment referred to as partial structure 
B (Figure 2.4). Partial structure C was composed of a trisubstituted double bond 
according to long range HMBC correlations between the remaining olefinic C-17 methyl 
JURXSįH 1.53) and multiple carbon resonances [C-įC 25.8), C-įC 31.2),  
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Figure 2.3. 1H and 13C NMR spectra (600 and 150 MHz, respectively, C6D6) of eunicidiol (49) [įLQSSPrelative to residual solvent 
signal]. 
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Table 2.1. NMR spectroscopic data (600 MHz, C6D6) for eunicidiol (49) [įLQSSP
relative to residual solvent signal].a 
 
Position įC, type įH, multiplicity (J in Hz) COSYb HMBCc NOESYb 
1 36.9,  CH2 1.60, br m 10  2 
2 76.2, CH 3.87, br d (7.7)   1, 10, 12, 16a 
3 150.0, C     
4a 25.7, CH2 2.20, app. td (12.3, 3.9) 4b, 16b  2, 3, 5, 16 16b, 17 
4b   2.05, m 4a, 5a, 16b  16b 
5a 25.8, CH2 2.29, m  4b, 5b, 6   
5b   2.08, m 5a   
6 125.9,  CH 5.45, m 5a  8a, 10 
7 133.5,  C     
8a 40.6,  CH2 1.93, m 9  6 
8b   2.01, m   9 
9 31.2,  CH2 1.29, m 8a, 10  8b 
10 44.8,  CH 1.86, app. t (8.5) 1, 9 2, 8, 9, 11, 12, 18 2, 6, 12 
11 141.9,  C     
12 124.8,  CH 5.99, d (10.8) 13, 18 10, 14, 18 1, 10, 14 
13 123.2,  CH 6.60, dd (15.1, 10.8) 12, 14 11, 15, 19, 20 18, 19, 20 
14 140.1,  CH 5.72, d (15.1) 13 12, 15, 19, 20 12, 19, 20 
15 70.4,  C     
16a 114.7,  CH2 5.04, br s  4a, 16b   2 
16b   4.94, s 4b, 16a 2, 3, 4 4a, 4b 
17 15.7,  CH3 1.53, s  5, 6, 7, 8, 9 4a 
18 13.9,  CH3 1.67, s 12 10, 11, 12 13 
19/20 30.2,  CH3 1.24, s  13, 14, 15, 19, 20 13, 14  
 
a
 See Figures A.2-A.7 for COSY, HSQC, HMBC, TOCSY and NOESY spectra. b COSY 
and NOESY correlations are from proton(s) stated to the indicated proton. c HMBC 
correlations are from proton(s) stated to the indicated carbon.  
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Figure 2.4. Selected HMBC (1H ĺ 13C) and COSY correlations (bold bonds) of partial 
structures A-C as well as the assembled structure of eunicidiol (49). 
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C-įC 125.9), C-įC 133.5), and C-įC 40.6)]. The COSY spectrum indicated a 
vicinal correlation between the C-ROHILQLFPHWKLQHįH 5.45) and C-PHWK\OHQHįH 
1.93) as well as between H-DįH 1.93) and H-įH 1.29).  
The three partial structures must assemble to provide a 10-membered ring to 
satisfy the required index of hydrogen deficiency of five. The HMBC coupling between 
H-10 and C-2 provided the basis for connecting partial structures A and B at C-1 and C-2 
(Figure 2.4). In addition, the C-10 methine proton of partial structure A displayed a 
COSY correlation with the C-9 methylene protons of partial structure C to signify the 
attachment of C-9 and C-10. Moreover, the HMBC correlations between H-10 and C-8 
and C-9 confirmed this assembly. It was not possible to establish the attachment of C-4 
and C-5 via COSY correlations as a result of the inability to discern between cross peaks 
caused by the vicinal correlation between H-4a/H-5b and the geminal correlation between 
H-4a/H-4b. This assignment was instead made on the basis of an HMBC correlation 
between H-4 and C-5. The results of a TOCSY experiment agreed with the assignment of 
the methylene proton resonances to the two separate spin systems of the cyclodecane ring 
(Figure A.6).  
The large vicinal coupling constant (J  +]DFURVVWKHǻ13,14 double bond 
indicated the E FRQILJXUDWLRQ7KHǻ11,12 DQGǻ6,7 double bonds were also assigned E 
configurations given the observed NOESY correlations between H-18/H-13 and H-6/H-
8a. The determination of relative configuration was also enabled by interpretation of 
additional NOESY correlations. The NOESY correlation between H-6 and H-10 
suggested that both protons occupied the same side of the average plane of the ring. 
Meanwhile, the apparent lack of NOESY correlations between H-2/H-4b and H-2/H-6 
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implied the opposite orientation for H-2. This configuration was supported by the 
NOESY correlation between H-2/H-12. The observed NOESY correlations were in 
agreement with the MM2-minimized model of eunicidiol (49) (Figure 2.5). Considering 
their structural similarity, eunicidiol (49) and fuscol (15) likely have a common 
biosynthetic precursor, and therefore have the same configuration at C-10. On this basis, 
the relative configuration of 49 was determined to be 2R*,10S*. 
 
2.2.3 Determining the absolute configuration of eunicidiol 
The absolute configuration of eunicidiol (49) was unambiguously assigned using 
the Mosher method by derivatizing the asymmetric secondary hydroxyl group with (R)- 
and (S)-MPA (Figure 2.6). Although the (R)- and (S)-MPA esters of eunicidiol (50 and 
51) were successfully synthesized using sub-milligram quantities of 49, the tertiary allylic 
hydroxyl group was transformed to its methyl ether during the reaction work-up. The 
scarcity of 49 precluded any effort to synthesize MPA esters without methyl ethers, 
however such efforts were deemed unnecessary as substitution of the achiral tertiary 
hydroxyl group was not expected to affect the Mosher analysis. Isomerization of the 
conjugated diene to introduce the methyl ether at the C-11 position had not occurred 
during this substitution, given the geminal dimethyl signals in the 1H NMR spectra. 
Compared to 51, H-10, H-17, and H-18 of 50 experienced greater shielding from the 
phenyl ring, while H-16a and H-16b were less shielded. As a result, the ǻįR-S values 
indicated the 2R configuration, establishing the absolute configuration of 49 as 2R, 10S. 
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Figure 2.5. The relative configuration of eunicidiol (49) as indicated by key NOESY 
correlations (1H ļ 1H) [ChemBioDraw3D MM2-minimized model]. 
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Figure 2.6. Synthesis of the (R)- and (S)-MPA esters of eunicidiol (50 and 51) and 1H 
NMR chemical shift dLIIHUHQFHVǻįR-S įR ± įS) in ppm. The 1H NMR spectra for 50 and 
51 are shown in Figures A.8-A.9. Reagents and conditions: (a) (i) (R)-MPA, DCC, 
DMAP, CH2Cl2 r.t. (ii) CH3OH. (b) (S)-MPA, DCC, DMAP, CH2Cl2 r.t. (ii) CH3OH. 
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2.2.4 Conformational isomerism of eunicidiol 
As observed for eunicol (16), conformational isomerism of the cyclodecadiene 
ring of eunicidiol (49) resulted in substantial 1H and 13C NMR signal broadening. As a 
result, the NMR data was significantly more complex, and many of the correlations 
between atoms suffered from weak signal-to-noise ratios. This conformational 
phenomenon has been well characterized for germacrene A,256 a structurally related 
sesquiterpene whose 13C NMR spectrum displays 36 separate 13C signals. Notably, the 
NMR data of 16 is remarkably similar to that of germacrene A.256b The proposed 
conformational isomerism of eunicidiol (Figure 2.7) follows that of germacrene A.256 
However, the secondary hydroxyl group may have a significant impact on the overall 
spatial arrangement for each conformer, an effect that may also be solvent dependent. 
Unfortunately, limited amount of sample precluded further NMR characterization of the 
conformational isomerism of 49, which may be an important consideration during the 
analysis of SAR. 
 
2.2.5 Determining the absolute configuration of eunicol 
While the absolute configuration of fuscol (15) has been established,8 the 
configuration of eunicol (16) was assumed to be 10S given its role as a biosynthetic 
precursor to 15.6 Recognizing that 16 may undergo an enantiospecific Cope 
rearrangement to 15, its absolute configuration could be established via spectroscopic 
comparison of the rearranged product to a purified standard of 15. Cope rearrangements 
of germacrenes and germacrenolides to elemenes and elemenolides, respectively, are 
known to proceed with high stereospecificity and retention of the configuration at C-10.7 
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Figure 2.7. Proposed conformational isomerism of the cyclodecadiene moiety of 
eunicidiol (49). 
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Therefore, to unambiguously assign the absolute configuration of 16, an enantiospecific 
Cope rearrangement of the cyclodecadiene moiety of 16 was carried out (Figure 2.8). 
The 1H and 13C NMR spectra of the rearranged product were identical to those of 15 
(Table 2.2, Figures A.10-A.11), indicating the presence of a 2R,7R,10S configuration or 
its enantiomer. The absolute configuration of 2R,7R,10S was ascertained by comparing 
the specific rotation of the rearranged product (>Į@25D = +28.8) with that of 15 (>Į@25D = 
+20.4). This result is in agreement with eunicol having the 10S configuration, and for that 
reason the absolute configuration of eunicol was established as such. 
 
2.2.6 Potential biosynthetic route to eunicidiol 
A previous investigation of the biosynthesis of diterpenes from E. fusca has 
identified eunicene A (17) as the diterpene cyclase product and revealed that its oxidation 
provides eunicol (16).6 Compound 16 subsequently leads to both fuscoside A (10) and 
fuscol (15). Eunicidiol (49) is conceivably derived from an oxidation of 16 as outlined in 
Figure 2.9. Considering the established biosynthetic pathway, the configurations of 10 
and 17 must be consistent with their biosynthetic relatives 15-16, and therefore have the 
absolute configurations displayed in Figure 2.9. A collection of diterpenes previously 
isolated from E. fusca,254 which includes fuscoside F (45), eunicene B (46), fuscene A 
(47), and fuscene B (48), presumably share a common biosynthetic origin and have the 
10S configuration as well. 
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Figure 2.8. Semisynthesis of fuscol (15) by Cope rearrangement of eunicol (16). 
Reagents and conditions: (a) ' toluene, 2.5 hr, 38%. 
 
Table 2.2. Comparison of 1H and 13C NMR spectroscopic data between fuscol (15), 
semisynthetic fuscol, and eunicol (16) [įLQSSPrelative to residual solvent signal]. 
 Fuscol (15)a Semisynthetic Fuscol (15)a Eunicol (16) 
Position įC, type įH, multiplicity (J in Hz) įC, type 
įH, multiplicity (J 
in Hz) įC, type 
įH, multiplicity (J 
in Hz) 
1 33.1, CH2 
1.63, app. q (12.6) 
1.60-1.56, m 33.1, CH2 
1.64, app. q (12.6) 
1.61-1.56, m 35.1, CH2 
2.27-2.22, m 
2.18-2.13, m 
2 53.0, CH 1.93, dd (12.1, 3.9) 53.0, CH 1.93, dd (12.1, 3.9) 131.9, CH 5.20-4.83, m 4.54, app. d (10.3) 
3 147.7, C  147.7, C  128.9, C  
4a 
112.6, CH2 
4.92, br s 
112.6, CH2 
4.92, br s 
39.9, CH2 
2.13-2.08, m 
1.91-1.85, m 4b 4.69, br s 4.69, br s 
5a 
110.1, CH2 
4.95, dd (17.5, 1.1) 
110.1, CH2 
4.95, dd (17.5, 1.1) 
27.1, CH2 
2.21-2.17, m 
2.07-2.02, m 5b 4.94, dd (10.8, 1.1) 4.94, dd (10.8, 1.1) 
6 150.5, CH 5.80, dd 
  (17.5, 10.8) 150.5, CH 
5.80, dd 
  (17.5, 10.8) 126.9, CH 
5.20-4.83, m 
4.77, app. d (11.2) 
7 40.0, C  40.0, C  137.7, C  
8 40.1, CH2 1.41-1.37, m 40.1, CH2 1.41-1.37, m 42.1, CH2 
2.37-2.31, m 
2.09-2.03, m 
9 26.9, CH2 
1.52-1.47, m 
1.44, app. ddd 
   (12.0, 4.0) 
26.9, CH2 
1.52-1.47, m 
1.44, app. ddd 
   (12.0, 4.1) 
33.9, CH2 
1.69-1.62, m 
1.55-1.48, m 
10 48.0, CH 1.90-1.83, m 48.0, CH 1.90-1.83, m 53.7, CH 1.98-1.93, m 
11 142.2, C  142.2, C  145.7, C  
12 123.4, CH 5.99, d (10.8) 123.4, CH 6.00, d (10.8) 122.6, CH 6.07-5.92, m 
13 123.2, CH 6.62, dd 
   (10.8. 15.2) 123.2, CH 
6.62, dd 
   (10.8. 15.2) 123.2, CH 6.62-6.54, m 
14 140.2, CH 5.72, d (15.2) 140.2, CH 5.71, d (15.2) 140.1, CH 5.74-5.67 
15 70.5, C  70.4, C  70.5, C  
16 25.1, CH3 1.71, s 25.1, CH3 1.71, s 16.3, CH3 
1.45, s 
1.35-1.31, br s 
17 16.8, CH3 0.99, s 16.8, CH3 1.00, s 16.8, CH3 1.47-1.41, br s 
18 15.3, CH3 1.68, s 15.3, CH3 1.68, s 14.6, CH3 1.68b, s 
19/20 30.3, CH3 1.22, s 30.3, CH3 1.22, s 30.3, CH3 1.23b, s 
 
a
 See Figures A.10-A.11 for NMR spectra. b Separate signals observed for each 
conformational isomer.  
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Figure 2.9. Biosynthesis of Eunicea fusca diterpenes and the proposed origin of 
eunicidiol (49). 
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2.2.7 Investigating the Eunicea fusca crude extract for fuscoside B 
As fuscoside B (11) is known to exhibit potent anti-inflammatory activity, there 
was an interest to compare fuscol (15), eunicol (16), and eunicidiol (49) to this glycoside. 
Although 11 has been reported as an abundant metabolite in the coral extract,74, 11 was 
not available in sufficient quantities in the E. fusca extract or chromatographic fractions 
therefrom. Several other metabolites were isolated, however, including a significant 
quantity of the acetoxy methyl ester of PGA2 (52, Figure 2.10), a metabolite also found 
in high concentrations in Plexaura homomalla and other alcyonacean species.257 The 
methyl ethers of fuscol and eunicol (53 and 54) were also relatively abundant in a 
CH3OH:CH2Cl2 (1:1) crude extract of E. fusca.258 As substitution of the tertiary hydroxyl 
group with CH3OH is known to proceed rapidly under acidic conditions,259 these methyl 
ethers were likely solvent-derived artifacts. Excluding CH3OH from the solvent during 
future extractions of the coral may be advised to ensure a higher isolation yield of 15 and 
16. To isolate fuscoside B (11) for future studies, it may also be necessary to collect E. 
fusca from a different collection site as there may be geographical variations in the 
amount of 11 present in the crude extract. 
 
2.2.8 Assessment of anti-inflammatory activity and structure-activity relationships 
Diterpenes 15-16 and 49 were evaluated for in vivo anti-inflammatory activity in 
WKHPRXVHHDUHGHPDDVVD\DWDVLQJOHGRVHȝJHDUTable 2.3). Indomethacin, an 
NSAID that non-selectively inhibits COX-1 and -2,260 was also included as a benchmark 
anti-inflammatory agent and administered as a 3 mg/ear dose.261 Topical administration 
of these diterpenes significantly reduced mouse ear edema at 24 hr post-treatment. The  
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Figure 2.10. Compounds isolated from Eunicea fusca during the search for fuscoside B 
(11). 
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Table 2.3. Reduction of PMA-induced mouse ear edema by diterpenes 15-16 and 49. 
 compound dosage (mg/ear) reduction of ear edema (%)a,b 
Indomethacin 3.0 51.4 ± 2.7c 
Eunicidiol (49) 0.1 44.4 ± 3.2c 
Fuscol (15) 0.1 46.3 ± 3.7c 
Eunicol (16) 0.1 53.7 ± 4.9c 
 
a
 Data is presented as the mean ± SEM. b Percent reduction of ear edema is relative to the 
vehicle control group (0.18 mm). c Compared to the vehicle control group, there was a 
statistically significant difference [XQSDLUHG6WXGHQW¶Vt-test (p < 0.05)]. Data for the 
vehicle and indomethacin control groups were obtained from six (n = 6) and four (n = 4) 
replicates, respectively. The diterpenes were tested in triplicate (n = 3).  
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reduction of PMA-induced edema by 15-16 and 49, although comparable to 
indomethacin, was notably achieved with much smaller doses. Eunicol (16) displayed a 
modest increase in potency over fuscol (15) and eunicidiol (49), however, the difference 
between the diterpenes was not statistically significant. In addition, these diterpenes 
displayed no signs of toxicity (i.e. no redness of the ear or mortality) and otherwise 
appeared to be safe at the administered dose. The specified dose of indomethacin, on the 
other hand, may be less tolerable as a single mortality in this test group was observed. 
An evaluation of SAR suggests that the tertiary hydroxyl group and conjugated 
diene moieties could be important for the observed anti-inflammatory activity, as this 
structural feature is present in all three anti-inflammatory diterpenes. The anti-
inflammatory activity appears to tolerate structural variations on the cyclic portion of the 
diterpene scaffold as both lobane (e.g. 15) and dilophol (e.g. 16) diterpenes showed 
activity. Although it appears that the carbohydrate portion of fuscoside B (11) may not be 
necessary for its anti-inflammatory activity, a comparison to 11 could not be carried out 
due to a lack of material. While publishing this study, Reina et al. reported the 
characterization of fuscoside E (12) and a comparison of its in vivo anti-inflammatory 
activity to that of 11 and fuscol (15).78 In their study, the reduction of PMA-induced 
edema by 11 and 12 was 81.5 and 80.5%, respectively, which was significantly greater 
than the 27.3% reduction by 15.78  
A comparison of the anti-inflammatory activity of fuscol (15) between the studies 
may be prohibited due to differences in the experimental protocols.262 For instance, Reina 
HWDODSSOLHGWKHSKORJLVWLFDJHQWDVDȝJGRVHVOLJKWO\JUHDWHUWKDQWKHȝJXVHGLQ
this study. The test samples and PMA were also administered simultaneously by Reina et 
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al., meanwhile in this study, topical application of the test samples preceded the PMA 
challenge by one hour. Furthermore, Reina et al. measured the edema only four hours 
after PMA administration, compared to 24 hours in this study. Regardless, fuscoside B 
(11) and fuscol (15) are nearly equivalent with regards to in vitro LTB4 biosynthesis 
inhibition.77 This result suggests the arabinose moiety may not be required for 5-LO 
inhibition but may instead have an impact on skin penetration and be responsible for 
improving the anti-inflammatory efficacy in vivo.  
 
2.2.9 Assessment of the antimicrobial activity of fuscol and eunicol 
Fuscol (15) and eunicol (16) were also evaluated for antimicrobial activity; 
eunicidiol (49) was not available in sufficient quantities for testing. While 15 and 16 were 
inactive against Candida albicans, Pseudomonas aeruginosa, methicillin-resistant 
Staphylococcus aureus (MRSA), and Staphylococcus warneri, 15 showed moderate 
activity against Mycobacterium smegmatis and M. diernhoferi. (Table 2.4). Fuscol (15) 
also exhibited activity against vancomycin-resistant Enterococcus (VRE), while 16 was 
active against the two mycobacterial species only. In addition, a crude mixture of 15 and 
16 was shown to inhibit the growth of M. tuberculosis H37Rv with an IC50 RIȝJP/
Similar activity was observed in the low-oxygen-recovery assay [LORA, minimum 
LQKLELWRU\FRQFHQWUDWLRQ0,&RIȝJP/@DPRGHORIM. tuberculosis in a state of 
NRP. The diterpene mixture displayed no cytotoxicity towards Vero cells (IC50: >128 
ȝJP/1RWDEO\WKHDQWLPLFURELDOSURSHUWLHVRI15 and 16 have not previously been 
reported. Other members of this diterpene family, including fuscosides A (10) and B (11), 
may also have activity against Gram-positive organisms and, if so, these properties could 
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represent an additional pharmaceutical application of these anti-inflammatory natural 
products. 
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Table 2.4. Antimicrobial susceptibility testing of fuscol (15) and eunicol (16) using the 
microbroth dilution method (n = 3). 
 
 IC50 ȝJP/ 0,&ȝJP/ 
Compound MRSAa VREa S. warneria P. aeruginosaa C. albicansa M. smegmatis M. diernhoferi 
Fuscol (15) 128 (77%)b 13 >128 >128 >128 8 8 
Eunicol (16) >128 >128 >128 >128 >128 8 8 
Vancomycin 0.8 - 0.8 - - - - 
Rifampin - 0.4 - - - 4 4 
Isoniazid - - - - - 1 0.25 
Gentamicin - - - 4.7 - - - 
Nystatin - - - - 4.9 - - 
 
a
 Assay was completed by Martin Lanteigne. b Percent growth inhibition at the indicated 
concentration 
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2.3 Conclusion 
 
In summary, a new analogue of eunicol, hereby known as eunicidiol (49), was 
isolated from Eunicea fusca using a combination of chromatographic techniques. 
Belonging to the dilophol skeletal class, this diterpene is comprised of an uncommon 
cyclodecane ring and an eight-carbon side chain, analogous to the skeleton of eunicol 
(16). The planar structure of this dilophol diterpene was elucidated by 1D and 2D NMR 
spectroscopic analysis, while the absolute configuration was assigned by Mosher analysis 
through the examination of differential shielding effects imposed by (R)- and (S)-MPA 
ester derivatization. Topical administration of a 100 ȝJHDU dose of fuscol (15), 16, and 49 
significantly reduced PMA-induced edema by 44, 46, and 54%, respectively, in the 
mouse ear assay. With regards to the administered dose, these anti-inflammatory 
activities were superior to indomethacin, a benchmark anti-inflammatory drug that was 
administered at 3 mg/ear. It remains to be determined whether diterpenes 15-16 and 49, 
similar to fuscoside B (11), exert their anti-inflammatory activity via selective 5-LO 
inhibition. 
 The absolute configuration of eunicol (16) was unequivocally determined by 
carrying out a stereospecific Cope rearrangement. The product of this semisynthesis was 
spectroscopically identical to fuscol (15), whose absolute configuration has been 
established previously. As a result, the absolute configuration of 16 must be 10S. In 
consideration of the established biosynthetic pathway,85 fuscosides A (10) and B (11), 
eunicene A (17), and other diterpenes belonging to this class (45-48) are proposed to 
have a 10S configuration as well. However, further analysis of each of these diterpenes 
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will be necessary to provide concrete evidence of their absolute configurations. This 
Cope rearrangement may also be employed as an alternative synthetic route to 15, if the 
total synthesis of 16 is accomplished. Given the inherent stereospecificity of the Cope 
rearrangement, and that 16 has only one stereocenter, this may be a more efficient route 
to 15.  
This study represented the first in vivo anti-inflammatory evaluation of fuscol 
(15), eunicol (16), and eunicidiol (49). An analysis of SAR has suggested that the eight-
carbon side chain, consisting of the tertiary hydroxyl group and conjugated diene 
moieties, may be important for the anti-inflammatory activity of these diterpenes, 
considering that it is the common structural feature. Fuscol (15) and 16 also showed good 
activity against M. smegmatis, M. diernhoferi, and M. tuberculosis, while 15 was also 
active against VRE. The antimicrobial activity of 15 and 16 was not previously reported 
and provides impetus for evaluating the fuscosides for such activities as well. Given the 
anti-inflammatory and antimicrobial activities exhibited by these diterpenes, other 
members of this natural product class (45-48) may also have unrealized pharmacological 
potential. 
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2.4 Experimental 
 
General experimental methods as well as procedures for the mouse ear edema assay and 
the microbroth dilution assay are described in Appendix B. 
 
Isolation of fuscol (15) and eunicol (16). E. fusca was collected from Hillsboro Ledge, 
Florida by scuba, air dried at the surface, and kept frozen during transportation. The 
identity of each coral was confirmed by comparing the thin layer chromatography (TLC) 
profile to that of a pure sample of 15. After lyophilization, the gorgonians (124.6 g) were 
exhaustively extracted with CH2Cl2, and the combined extracts were concentrated to 
provide a viscous oil (11.47 g). The crude extract was initially partitioned between 
hexanes and CH3OH:H2O (9:1); afterwards the hexanes layer was evaporated (6.319 g) 
and separated by normal phase flash chromatography using a hexanes:EtOAc stepwise 
gradient elution. The hexanes:EtOAc 4:1 fraction (592.0 mg) contained 15-16 according 
to LC-APCIMS analysis. This fraction was separated by RP-MPLC (C18, H22ĺ
CH3OH) to provide a mixture of 15-16 (289.9 mg, 2.3% of dry coral weight). The 
diterpenes were separated by semi-preparative RP-HPLC using a combination of 
phenylhexyl (87% CH3OH, 3.0 mL/min, 15: tR 24.8 min, 16: tR 26.7 min) and C18 (83% 
CH3OH, 3.0 mL/min, 15: tR 37.6 min, 16: tR 39.6 min) stationary phases. For 15>Į]25D = 
+20.4 (c 0.06 in CHCl3); ,5ȣmax 3379, 3081, 2971, 2930, 2862, 1637, 1577, 1440, 1412, 
1375, 1149, 1004, 967, 907, 890 cm-1. HRESIMS m/z 311.2346 [M + Na]+ (calcd for 
C20H32ONa, 311.2345). APCIMS: m/z 271.3 [M + H - H2O]+; MS/MS spectrum (m/z 
271.3): m/z 243.4, 229.4, 215.3, 201.3, 187.4, 175.3, 161.3, 147.4, 135.4, 119.3, 109.3. 
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For 16: IR ȣmax 3365, 3042, 2969, 2924, 2856, 1652, 1562, 1446, 1384, 1317, 1230, 
1146, 967, 910, 844 cm-1. HRESIMS m/z 311.2346 [M + Na]+ (calcd for C20H32ONa, 
311.2345). APCIMS: m/z 271.3 [M + H - H2O]+. All 1H and 13C NMR spectroscopic data 
were in agreement with the literature (Figures A.1 and A.10-A.11).6,9 
 
Isolation of eunicidiol (49). Eunicidiol (49) was present in the hexanes:EtOAc 4:1 
fraction and collected alongside 15 and 16 during the above mentioned RP-MPLC 
separation. The compound was purified by a semi-preparative RP-HPLC using a 
combination of phenylhexyl (77% CH3OH, 3.0 mL/min, tR 31.1 min) and C18 (80% 
CH3OH, 3.0 mL/min, tR 21.5 min) stationary phases to provide eunicidiol (49, 1.5 mg, 
4.9 ȝmol) as a colorless oil. Eunicidiol (49): clear oil; >Į@25D = -33.4 (c 0.02 in CH3OH); 
IR Qmax 3357, 3064, 3039, 2971, 2925, 2857, 1645, 1450, 1385, 1371, 1149, 1021, 968, 
899. HRESIMS m/z 327.2286 [M + Na]+ (calcd for C20H32O2Na, 327.2295). APCIMS: 
m/z 289.2 [M + H - H2O]+; m/z 269.4 [M + 2H - 2H2O - H]+; MS/MS spectrum (m/z 
269.4): 241.5, 227.4, 213.3, 199.3, 185.3, 173.3, 159.3, 145.2, 133.3, 121.3. All 2D NMR 
spectroscopic data of 49 (Figures A.2-A.7) are summarized in Table 2.1. 
 
Synthesis of (R)- and (S)-MPA esters of eunicidiol (50 and 51). A solution containing 
eunicidiol (49, ȝJȝPRO'0$3PJȝPRO'&&PJ
ȝPRODQGcPROHFXODUVLHYHV(~50 mg) was stirred in freshly distilled CH2Cl2 (3 mL) 
under an N2 atmosphere for 20 min. Subsequently, an excess of (R)- or (S)-MPA (13.8 
PJȝPROZDVDGGHGDQGWKHUHDFWLRQZDVOHIWWRVWLURYHUQLJKWDWURRPWHPSHUDWXUH
The reaction mixture was concentrated under a stream of N2 and eluted through a plug of 
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C18 silica using CH3OH. The filtrate was evaporated in vacuo to provide the reaction 
crude, which was separated by semi-preparative RP-HPLC (C18, 5 min at 90% CH3OH 
increasing linearly to 100% CH3OH at 35 min, 3.0 mL/min, 50/51: tR 15.2 min). For 50: 
HRESIMS m/z 489.2980 [M + Na]+ (calcd for C30H42O4Na, 489.2975). For 51: 
HRESIMS m/z 489.2973 [M + Na]+ (calcd for C30H42O4Na, 489.2975). See Figures A.8-
A.9 for the 1H NMR spectra of 50 and 51. Product yields could not be determined with 
accuracy owing to the small scale of the reactions. 
 
Semisynthesis of fuscol. A purified sample of eunicol (16PJȝPROZDV
heated at reflux in toluene for 2.5 hr and evaporated in vacuo. Analysis of the reaction 
crude by NMR revealed the formation of fuscol (15, 370 ȝJȝPRO 38%), which was 
later purified by semi-preparative RP-HPLC (C18, 88% CH3OH, 3.0 mL/min, tR 25.6 
min).  Semisynthetic fuscol (15>Į@25D = +28.8 (c 0.02 in CHCl3))XVFROOLW>Į@25D = 
+21.0 (c 0.9 in CHCl3).83 See Figures A.10-A.11 for a comparison of 1H and 13C NMR 
spectra. 
 
 
  
83 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
THE SYNTHESIS OF A LIBRARY OF  
NOVEL FUSCOSIDE B ANALOGUES 
 
 
 
 
 
 
 
 
 
The contents of this chapter have been published with modification as: 
Marchbank, D.H.; Kerr, R.G. Tetrahedron 2011, 67, 3053. 
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3.1 Introduction 
 
Glycosylated diterpenes from the marine environment are a rare type of natural 
product whose members are found exclusively in alcyonacean species.79 As explained in 
Chapter 2, Eunicea fusca is a source of the anti-inflammatory fuscosides A (10) and B 
(11),74 which are diterpene arabinosides that reduce PMA-induced mouse ear edema with 
activities comparable to indomethacin (Figure 3.1).75-77 Fuscol (15), the aglycone 
precursor of 11,81 is known to inhibit the biosynthesis of LTB4 in vitro77 and also displays 
in vivo anti-inflammatory activity in the mouse ear edema assay, as shown by work 
described in Chapter 2 as well as a report by Reina et al.78 Considering the greater in vivo 
anti-inflammatory activity observed for 11 and fuscoside E (12),78 the arabinose moiety 
appeared to be important for their in vivo efficacy. The availability of 15 and eunicol (16) 
in the E. fusca crude extract thus provided an opportunity to understand the contribution 
of the arabinose moiety to the observed in vivo anti-inflammatory activity of 11 through a 
medicinal chemistry approach. 
Differential glycosylation of these aglycones could provide a collection of 
fuscoside B analogues, whose anti-inflammatory evaluation may lead to an improved 
understanding of SAR. The stereochemical configuration, ring size, and other structural 
variations of the carbohydrate moiety may be probed for their biological significance. 
Considering the near equivalent activities of fuscol (15) and fuscoside B (11) in vitro, 
replacing the carbohydrate with an alternative chemical moiety may also be permitted. 
An alternative substituent lacking the stereochemical complexity of a carbohydrate may 
confer greater water solubility to the relatively hydrophobic diterpene. As a result, such  
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Figure 3.1. Anti-inflammatory diterpenes and diterpene arabinosides isolated from 
Eunicea fusca. 
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³JO\FRVLGH PLPLFV´PD\KDYHVLPLODUDQWL-inflammatory properties and enable the 
modulation of in vivo efficacy. Synthesizing glycoside mimics may also be less difficult, 
and thus serve as a complement to the glycosylation approach. 
Before pursuing the glycodiversification strategy, a method for glycosylating 
fuscol (15) and eunicol (16) must be established. While the total synthesis of 15 has been 
accomplished by Iwashima et al. and Kosugi et al.,82,83 the glycosylation of 15 was not 
reported. This omission was curious as fuscoside B (11) provided the incentive for 
pursuing this synthetic work. Efforts to synthesize 11 may have been curbed by the 
challenge of glycosylating tertiary hydroxyl groups, owing to their steric hindrance. As 
shown by the total synthesis of erythromycin A, these functionalities often resist 
glycosylation, even when left unprotected.263  
The primary aim of this research was to synthesize a collection of fuscoside B 
analogues via differential glycosylation of fuscol (15) and eunicol (16). To achieve this 
aim, methods for glycosylating these diterpenes and producing fuscoside mimics were 
investigated. Once the library of novel fuscosides was synthesized, the anti-inflammatory 
activity was evaluated using the mouse ear edema assay in an effort to assess SAR and 
determine the biological significance of the carbohydrate moiety. 
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3.2 Results and Discussion 
 
3.2.1 The strategy for synthesizing a fuscoside library 
 A mixture of fuscol (15) and eunicol (16) was isolated from the E. fusca crude 
extract, as previously described in the preceding chapter (Section 2.4) Although the two 
diterpenes could be purified by RP-HPLC using a combination of phenylhexyl and C18 
stationary phases, this approach was far too laborious to achieve a separation on a scale 
that would provide adequate starting material for chemical synthesis. A more realistic 
approach was to instead utilize 15 and 16 as a mixture. These diterpenes are essentially 
identical with regards to the chemical environment of the tertiary hydroxyl groups, and 
therefore neither one would be preferentially glycosylated. Utilizing a diterpene mixture 
would also increase the library by two-fold for every glycosylation reaction.  
As fuscol (15) and eunicol (16) were only available in limited quantities, the 
glycosylation reaction was initially established using a model compound that was 
structurally related and had commercial availability. While 2-methyl-3-buten-2-ol (55) 
provided a suitable model for 15 and 16, preliminary glycosylation attempts were also 
carried out with cholesterol. Tertiary hydroxyl groups are weak nucleophiles as a result of 
steric hindrance, and therefore the introduction of carbohydrate moieties remains a 
formidable challenge. Glycosylation of cholesterol, which contains a secondary hydroxyl 
group, would be facile and thus serve as a control to verify that the basic requirements for 
the reaction have been met; e.g. confirming that the reaction solvent was adequately dry 
and ensuring proper activation of the glycosyl donor by the Lewis acid. 
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3.2.2 Establishing a glycosylation method using a model system 
A review of the glycosylation literature indicated the scope and versatility of the 
method reported by Schmidt,143 which involves mild activation of glycosyl 
trichloroacetimidates by catalytic amounts of BF3(W2O.136, 144 Glycosylation reactions 
were initially carried out with cholesterol using 2,3,4,6-tetra-O-acetyl-Į-D-
galactopyranosyl trichloroacetimidate (56) as a glycosyl donor (Figure 3.2). After 
verifying the formation of the desired cholesteryl glycoside (57, Figure 3.3), the reaction 
was attempted with 2-methyl-3-buten-2-ol (55) but failed as this tertiary alcohol had 
degraded. Fuscol (15) and eunicol (16) also decomposed rapidly under these conditions. 
The BF3(W2O, an oxophilic reagent, presumably cause an elimination by facilitating the 
formation of the tertiar\ʌ-allylic carbocation, an intermediate that is stabilized by 
resonance and may undergo elimination. Further attempts to glycosylate cholesterol or 55 
using other glycosylation methodologies developed by Nicoloau264 and Kahne265 were 
also unsuccessful. For these reactions, the acetylated thioglycoside (58)266 and 
phenylthiosulfoxide (59, Figure 3.2)267 donors were too unreactive to be activated under 
mild conditions, owing to the disarming nature of the acetate protecting groups. 
Further glycosylation efforts focused on the synthetic methodology of Koenigs 
and Knorr.131b This glycosylation may occur under neutral or basic reaction conditions, 
circumventing the need for acidic activating reagents.268 Glycosyl bromides, the most 
common type of glycosyl donor in Koenigs-Knorr glycosylations, are frequently 
protected with ester functionalities, which provide more hydrolytic stability than 
³DUPLQJ´protecting groups, such as acetonides and benzyl ethers.128-129 Ester 
functionalities also undergo neighbouring group participation during the formation of an  
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Figure 3.2. Preparation of various glycosyl donors for the preliminary glycosylation 
reactions. Reagents and conditions: (a) Ac2O (18 eq), pyridine, 92%. (b) N2H4CH3CO2H 
(0.8 eq), DMF, -20 °C, 28%. (c) Cl3CCN (10 eq), DBU (0.03 eq), 1,2-dichloroethane, 
66%. (d) PhSH (1.6 eq), BF3(W2O, 43% over two steps. (e) mCPBA (1.5 eq), CH2Cl2, 
87%. (f) AcBr (3.0 eq), CH3OH (3.3 eq), AcOH, 38% over two steps. 
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Figure 3.3. Synthesis of cholesteryl glycoside (57) during preliminary experimentation 
with glycosylation methods. Reagents and conditions: (a) 56 (2.1 eq), BF3(W2O, CH2Cl2, 
40%. (b) 60 (2.1 eq), AgOTf (0.5 eq), Ag2CO3 (2.1 eq), CH2Cl2, 31%. (c) 60 (2.0 eq), 
Bu4NBr (1.0 eq), DIEA (3.0 eq), DMF, 18%. 
. 
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oxocarbenium ion, DQGWKXVSURYLGH¶¶-trans glycosidic linkages.125 Although this 
DSSURDFKZRXOGIDLOWRSURYLGHWKH¶¶-cis glycoside bond of fuscoside B (11), only 
mild conditions are required for removing ester protecting groups. Acetonides and benzyl 
ethers were not utilized because the conditions required for their deprotection (acid 
hydrolysis and hydrogenolysis, respectively) would not be compatible with the desired 
fuscoside analogues. 
2,3,4,6-Tetra-O-acetyl-Į-D-galactopyranosyl bromide (60) was freshly prepared 
according to known methods (Figure 3.2).269 After successfully glycosylating cholesterol 
(Figure 3.3), the method was attempted with 2-methyl-3-buten-2-ol (55). This 
glycosylation, which employed a combination of AgOTf and Ag2CO3 as activating 
agents, furnished the desired glycoside (61, Figure 3.4), which was purified by normal 
phase MPLC. Increasing the reaction time led to an increase in the glycosylation yield 
(Table 3.1). In an effort to further improve reaction yields, pivaloylated (62) and 
benzoylated (63) glycosyl donors were also prepared for these model reactions (Figure 
3.5). A slight improvement was observed for 62, while 63 was far superior, providing 
glycosylation yields that were comparable to the literature for tertiary alcohols (Table 
3.1).139, 141 Deprotection of 65 was later achieved by treatment with K2CO3/CH3OH to 
afford glycoside 66, showing that the glycosidic linkage withstood these reaction 
conditions.  
 
3.2.3 Analysis of the outcome of the Koenigs-Knorr glycosylation 
The protecting groups of a glycosyl donor are known to have an impact on the 
reactivity of the donor and overall glycosylation yields.130, 270 With regards to the 
glycosylation of 55, the steric bulkiness of the protecting groups was expected to be  
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Figure 3.4. Glycosylation of 2-methyl-3-buten-2-ol (55) with differentially protected 
glycosyl bromides. Reagents and conditions: (a) 55 (1.0 eq), AgOTf (0.4 eq), Ag2CO3 
(4.0 eq), CH2Cl2. (b) K2CO3, CH3OH. 
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Figure 3.5. Synthesis of pivaloylated (62) and benzoylated (63) glycosyl bromides for 
the Koenigs-Knorr glycosylation. Reagents and conditions: (a) (i) PivCl, pyridine. (ii) 
AcBr (3.0 eq), CH3OH (3.3 eq), 26% over two steps. (b) (i) BzCl, pyridine. (ii) AcBr (3.0 
eq), CH3OH (3.3 eq), 36% over two steps. 
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Table 3.1. Reaction conditions employed during the glycosylation of 2-methyl-3-buten-
2-ol (55) with differentially protected glycosyl bromides. 
 
(QWU\ 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significant. Glycosyl donors with pivaloate esters typically lower overall glycosylation 
yields relative to donors containing acetates.271 Contrary to these expectations, glycosyl 
donor 62 provided higher glycosylation yields than 60. Increasing the rate of glycosyl 
donor activation through neighbouring group participation may outweigh steric effects 
and have important consequences on the glycosylation yield.272   
Greater stabilization of the acyloxonium intermediate may be achieved with the 
pivaloate groups via the inductive effect, thus resulting in the higher yields obtained with 
62 compared to 60. Consistent with this trend, the highest glycosylation yields were 
achieved with benzoylated glycosyl donor 63, presumably due to resonance stabilization 
(Figure 3.6). The acyloxonium carbocation (67) may undergo delocalization across the 
phenyl group of the benzoate ester and further increase the rate of donor activation. 
Although further investigation is required to support this finding, Garegg et al. have 
observed a similar trend with this set of protecting groups using thioglycoside donors.273 
 
3.2.4 Degradation of aglycones and deactivation of glycosyl donors: Proposed reaction 
mechanisms 
Glycosylation yields were adversely affected by rearrangement of the glycosyl 
acceptor (55). Isolation of prenyl 2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranoside (68) and 
prenyl-ȕ-D-galactopyranoside (69) from the glycosylation and deprotection crude 
products, respectively, revealed that 2-methyl-3-buten-2-ol (55) underwent an acid-
catalyzed rearrangement to form prenyl alcohol prior to glycosylation (Figure 3.7). This 
finding supported the proposed mechanism for fuscol (15) and eunicol (16) degradation 
under acidic reaction conditions. Furthermore, an acid-catalyzed anomerization of 65 to  
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Figure 3.6. Mechanism of acyloxonium formation by neighbouring group participation 
and proposed resonance stabilization for benzoylated glycosyl donor 63. 
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provide 70 must have occurred as an additional glycoside (71), featuring the 
WKHUPRG\QDPLFDOO\IDYRUHGĮ-glycosidic linkage, was isolated from the deprotection 
crude product (Figure 3.7). 
Deactivation of the glycosyl donor, by way of various side reactions, also 
suppressed glycosylation yields. For instance, formation of a peracylated carbohydrate 
(72) had occurred. This observation indicated that hydrolysis of the anomeric bromide 
installed an equatorial hydroxyl group, which subsequently underwent a 
transesterification to furnish the anomeric pivaloate ester in the observed 1¶,2¶-trans 
configuration (Mechanism A, Figure 3.8). The stereochemical configurations were 
established on the basis of coupling constants in the 1H NMR spectrum and also by 
NOESY correlations. Transesterification, especially of the glycosyl acceptor, is common 
for this type of glycosylation.274 In fact, preliminary work with cholesterol as a glycosyl 
acceptor showed that the aglycone underwent transesterification, which explained the 
presence of cholesteryl acetate in these reactions. 
Isolation of the pivaloylated carbohydrate 73 suggested an alternative route to 
glycosyl donor inactivation. It was postulated that the origin of 73 may be the result of  
C-¶ ester transfer to the anomeric position during neighbouring group participation,275 a 
mechanism involving a molecule of water. This mechanism would furnish 73 with the 
observed 1¶,2¶-cis configuration, by virtue of the axial orientation adopted by the 
acyloxonium ion intermediate at the anomeric position (Mechanism B, Figure 3.8). The 
¶¶-cis configuration may also be conceived by anomerization RID¶¶-trans 
intermediate, the same manner in which WKHĮ-glycoside 70 was formed. However, the  
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Figure 3.7. Mechanisms of prenyl 2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranoside (68) 
and 2-methyl-3-buten-2-yl-Į-D-galactopyranoside (71) formation. The 2-methyl-3-buten-
2-ol (55) underwent rearrangement to provide prenyl alcohol, which was subsequently 
glycosylated with the benzoylated glycosyl donor (63). Reagents and conditions: (a) 
AgOTf (0.4 eq), Ag2CO3 (4.0 eq), CH2Cl2. (b) K2CO3, CH3OH. 
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Figure 3.8. Plausible mechanisms for the formation of deactivated pivaloylated 
carbohydrates 72 and 73 as side products (obtained from reaction entries 3 and 4 in Table 
3.1).276 
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¶¶-trans intermediate was not found in significant amounts in the crude product, 
suggesting that anomerization did not significantly contribute to the formation of 73.  
Considering that Ag2CO3 assumes an acid scavenging role, residual amounts of 
water may form spontaneously by carbonic acid decomposition. As a result, an 
alternative acid scavenger could be explored for future glycosylations. The 
decomposition of 2-methyl-3-buten-2-ol (55), as described earlier (Figure 3.7), may also 
produce water in situ. 
 
3.2.5 Towards the glycosylation of fuscol and eunicol 
Extending this Koenigs-Knorr method to glycosylate fuscol (15) and eunicol (16) 
was initially unsuccessful as it resulted in rapid degradation of the natural products. 
Isolation of fuscene B (48) and eunicene B (46) from the glycosylation crude product 
indicated that elimination had occurred, further demonstrating the inadequacy of Ag2CO3 
as an acid scavenger. Although 15 and 16 continued to degrade in the presence of an 
excess of tetramethylurea, use of the stronger base DIEA proved successful as 
benzoylated glycosides 74 (Figure 3.9) and 75 (Figure 3.10) were synthesized. During 
this preliminary work, a milder glycosylation approach was also attempted, entailing the 
activation of glycosyl bromide with Bu4NBr, a phase-transfer catalyst. Although 
cholesterol was successfully glycosylated using this approach (Figure 3.3), the method 
failed for the model tertiary alcohol (55).  
The glycosylation crude product, containing the benzoylated glycosides 74 and 
75, was subsequently treated with K2CO3/CH3OH to provide fusco-ȕ-D-
galactopyranoside (76) and eunico-ȕ-D-galactopyranoside (77). Deprotecting the crude 
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product without purifying the benzoylated intermediates was advantageous as it 
simplified the product composition by effectively removing all carbohydrate side 
products. Glycoside products lacking the C-¶ester protecting group have also been 
documented as side products of a Koenigs-Knorr glycosylation.277 Therefore, removing 
all protecting groups would simplify the HPLC purification of the desired glycosides. 
Therefore, the fuscoside B anomer (78) and eunico-ȕ-D-arabinopyranoside (79) were 
synthesized by glycosylating fuscol (15) and eunicol (16) with the arabinopyranosyl 
donor (80, Figure C.1), followed by immediate deprotection of the glycosylation crude 
product. Unfortunately, attempts to glycosylate the diterpenes with glucosyl (81, Figure 
C.1) and mannosyl (82, Figure C.1) bromides were unsuccessful. 
All glycosides (74-79) were purified by semi-preparative RP-HPLC and 
characterized by NMR spectroscopy. The glycosidic linkage was indicated by the 
presence of a 3JCH correlation between H-¶DQG&-15 on the HMBC spectrum, while the 
DQWLFLSDWHG¶¶-trans configuration was verified by analyzing vicinal 1H-1H coupling 
constants. In addition, the NOESY spectrum exhibited correlations between H-¶DQGthe 
axially oriented H-¶H-¶for all glycosides. All 1H and 13C assignments of the aglycones 
were consistent with fuscol (15) and eunicol (16). 
 
3.2.6 Is a carbohydrate necessary? A rationale for synthesizing fuscoside mimics 
Considering that fuscoside B (11) and its aglycone (15) are known to inhibit 5-LO 
activity in vitro,77 it was proposed that glycoside mimics of 11 may also exhibit similar 
anti-inflammatory activities. Glycoside mimics with hydrophilic substituents at the 
carbohydrate position were prepared, bearing in mind that the overall polarity and water 
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Figure 3.9. Synthesis of fusco-ȕ-D-galactopyranoside (76) by glycosylation of fuscol and 
deprotection of benzoate esters. Reagents and conditions: (a) 15/16 (1.0 eq), AgOTf (0.4 
eq), Ag2CO3 (4.0 eq), 63 (4.0 eq), DIEA (4.0 eq), CH2Cl2, 15%. (b) K2CO3, CH3OH, 9% 
over two steps. 
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Figure 3.10. Collection of novel galactoside and arabinoside analogues of fuscoside B, 
including the eunicosides (reaction yields shown in parenthesis). 
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solubility of these mimics may be comparable to the glycosides. Moreover, the synthesis 
of these analogs was anticipated to be relatively straightforward, unlike the glycosylation 
chemistry.  
Tri- and tetra-ethylene glycol (EG3 and EG4, respectively) were chosen as 
substitutes of the carbohydrate moiety as they are both hydrophilic and have molecular 
weights comparable to arabinose and galactose moieties. Considering the acid lability of 
the tertiary hydroxyl group, an SN1 reaction was envisioned for preparing the glycoside 
mimics. The mimics were therefore synthesized by dissolving the diterpene mixture in 
either EG3 or EG4 and then adding BF3(W2O to initiate the solvolysis reaction (Figure 
3.11). Indeed, this process was very simple and the reaction proceeded rapidly, as judged 
by thin layer chromatography (TLC) analysis, providing glycoside mimics 80-83. While 
this transformation could also be effected by acetic acid or Amberlyst®, BF3(W2O 
provided the highest yields. Methyl ethers 53 and 54, which were described previously 
(Section 2.2.7), were similarly prepared using CH3OH as the reaction solvent.  
After synthesizing glycoside mimics 80-83, it was anticipated that the 
glycosylation of 15 and 16 could be achieved following a similar mechanism; the 
anomeric hydroxyl group could behave as an ³DJO\FRQHDFFHSWRU´E\XQGHUJRLQJD
nucleophilic attack at the tertiary carbocation as the solvent did in the preceding reactions 
(Figure 3.12). This proposed glycosylation was attempted after synthesizing 2,3,4,6-
tetra-O-benzoyl-ȕ-D-galactopyranose (84) by Ag2CO3-assisted hydrolysis of the 
corresponding glycosyl bromide (Section 3.2.8). This initial glycosylation attempt was  
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Figure 3.11. Synthesis of fuscoside mimics and methyl ether analogues of fuscol and 
eunicol [reaction yields for eunicoside analogues shown in parenthesis]. Reagents and 
conditions: (a) BF3(W2O, THF:HO(C2H4O)3H (1:1), 60% (80). (b) BF3(W2O, 
THF:HO(C2H4O)4H (1:1), 36% (82). (c) BF3(W2O, CH3OH, 54% (53). 
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Figure 3.12. Synthesis of benzylated galactopyranose 85 and proposed mechanism for 
glycosylation using the aglycone acceptor method. Reagents and conditions: (a) (a) BnBr 
(7.3 eq), NaH (7.3 eq), DMF. (b) HOAc:1M H2SO4 ǻF 85, BF3(W2O, 
CH2Cl2. 
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unsuccessful, presumably as a result of the disarming effect of the benzoate esters on the 
anomeric hydroxyl group. As a result, 2,3,4,6-tetra-O-benzyl-ȕ-D-galactopyranose (85, 
Figure 3.12) was synthesized and the reaction was repeated. Once again, no glycoside 
formation was observed. It is possible that the diterpenes must have an appropriate 
activating group, such as a bromide or trichloroacetimidate, to facilitate this reaction. It 
may be worthwhile pursuing this glycosylation ideology, coined as the aglycone acceptor 
method, as it could represent a powerful new approach for introducing carbohydrate 
functionalities to 15, 16, and other aglycones. 
 
3.2.7 Assessment of anti-inflammatory activity of novel fuscoside B analogues 
The new fuscosides (76 and 78), glycoside mimics (80-83) and methyl ethers (53-
54) were assayed for in vivo anti-inflammatory activity using the PMA-induced mouse 
ear edema assay. Indomethacin, a known anti-inflammatory agent, was administered as 
an industry benchmark. As fuscoside B (11) was not available as a positive control, 
fuscol (15) was utilized for comparing anti-inflammatory activities. The results of this 
assay showed that all unnatural glycosides and glycoside mimics were either inactive or 
pro-inflammatory (Table 3.2). The unnatural anomer of 11, fusco-Į-D-arabinopyranoside 
(78), had no effect on PMA-induced swelling, while fusco-ȕ-D-galactopyranoside (76) 
was pro-inflammatory.  All glycoside mimics of fuscol (80 and 82) and of eunicol (81 
and 83) were either inactive or pro-inflammatory. The tertiary hydroxyl group of fuscol 
(15) appeared to be required for activity as the methyl ethers (53-54) were also pro-
inflammatory. 
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Although this library of glycosides and glycoside mimics was limited in size, a 
preliminary analysis of SAR suggested that the ¶¶-cis configuration of the arabinose 
moiety may be important for the in vivo anti-inflammatory activity because the anomer 
of fuscoside B (78) was inactive. However, fuscoside B (11) itself was not available in 
the coral extract for direct comparison. The glycosylation methodology also could not 
provide 11 as LWZDVUHVWULFWHGWR¶¶-trans glycoside analogues. Nonetheless, the 
carbohydrate moiety appeared to modulate the anti-inflammatory efficacy, especially 
considering the pro-inflammatory activity of the galactoside (76), which nearly doubled 
the PMS-induced swelling compared to the vehicle control group. In addition, the 
hydrophilic EG-based substituents were not suitable replacements of the arabinose 
moiety, on the basis of the pro-inflammatory activity of the glycoside mimics (80-82). 
The mouse ear edema assay does not provide a direct indication of 5-LO 
inhibitory activity. Although an in vitro 5-LO assay was attempted using a commercially 
available assay kit and 5-LO enzyme,278 the method was unsuccessful for the fuscoside 
library and fuscol (15). Unfortunately, only the oxygenase function of 5-LO could be 
assessed as the assay was limited to the detection of 5(S)-hydroperoxyeicosatetraenoic 
acid (5-HPETE). Fuscoside B (11), however, is known to be a more potent inhibitor of 
the dehydrase function of 5-LO,77 which may lead to an accumulation of 5-HPETE, 
hence the negative results. In addition, the commercially available 5-LO was non-
mammalian and may not be relevant for assessing the activity of 11 and other types of 
non-redox inhibitors. Future efforts may instead focus on other methods for determining 
5-LO inhibition, such as RP-HPLC analysis of leukotriene biosynthesis in human 
leukocytes. 
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Table 3.2. The effect of fuscoside B analogues on PMA-induced mouse ear edema. 
compound dosage (mg/ear) relative ear edema (%)a,b 
Indomethacin 3.0 60.0 ± 8.8c 
Fuscol (15) 0.1 54.5 ±  6.3c 
Fuscol methyl ether (53) 0.1 196.4 ±  21.8c 
Fuscol-EG3 (80) 0.1 218.2 ±  6.3c 
Fuscol-EG4 (82) 0.1 225.5 ±  13.1c 
Fusco-ȕ-D-galactoside (76) 0.1 192.7 ±  25.5c 
Fusco-Į-D-arabinoside (78) 0.1 112.7 ±  3.6 
Eunicol methyl ether (54) 0.1 138.2 ±  9.6c 
Eunicol-EG3 (81) 0.1 138.2 ±  13.1c 
Eunicol-EG4 (83) 0.1 116.4 ±  13.1 
2-Methyl-3-buten-2-yl-ȕ-D-galactoside (66) 0.1 134.5 ±  3.6c 
 
a
 Data is presented as the mean ± SEM. b Percent ear edema is relative to the vehicle 
control group (0.092 mm). c Compared to the vehicle control group there was a 
statistically significant difference [XQSDLUHG6WXGHQW¶Vt-test (p < 0.05)]. Data for the 
vehicle and indomethacin control groups were obtained from six replicates (n = 6). All 
other samples were assessed in triplicate (n = 3). 
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3.2.8 Preparation of truncated pseudopterosin mimics using glycosylation chemistry 
Originally isolated from Pseudopterogorgia elisabethae by Look et al., the 
pseudopterosins are a family of diterpene glycosides with potent anti-inflammatory and 
antimicrobial activities.279 These compounds possess the amphilectane skeleton and differ 
from one another according to the type and location of the attached carbohydrate moiety 
or the stereochemical configuration of the aglycone.280 A mimic of the pseudopterosin 
aglycone was recently synthesized by Dr. Malcolm McCulloch through the addition of 
prenyl groups to 2,6-dimethoxyphenol (86), a commercially available substance.161 The 
3,4-diprenyl-2,6-dimethoxyphenol (87) showed moderate antimicrobial activity against 
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus 
(VRE), and other Gram-positive organisms. The observed activity for 87 suggested that 
this compound may be a truncated analogue of the pseudopterosin aglycone as it contains 
similar structural features. A glycosylation of 87 was therefore proposed to generate 
pseudopterosin mimics with the aim of improving the antimicrobial and cytotoxicity 
profiles of these synthetic analogues. 
Introducing carbohydrate moieties to phenolic hydroxyl groups may be a 
challenging task, owing to the electron-withdrawing nature of the aromatic ring.281 A 
review of the literature on phenol glycosylation showed the prevalance of the Schmidt 
method using glycosyl trichloroacetimidates.282 Although the preparation of these donors 
is more tedious, they often generate higher glycosylation yields.283 To synthesize the 
glycosyl trichloroacetimidate, 2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranose (84) was first 
prepared by Ag2CO3-assisted hydrolysis of the corresponding glycosyl bromide (63, 
Figure 3.13). The anomeric trichloroacetimidate was then installed by nucleophilic 
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Figure 3.13. Synthesis of glycosyl trichloroacetimidate 88 for the Schmidt glycosylation 
of 2,6-dimethoxyphenol (86) and 3-prenyl-2,6-dimethoxyphenol (89).284 Reagents and 
conditions: (a) Ag2CO3 (1.5 eq), acetone:H2O (19:1), 85%. (b) Cl3CCN (10 eq), K2CO3 
(1.2 eq), CH2Cl2, 36%. (c) 2-methyl-3-buten-2-ol (1.9 eq), TsOH (cat.), ǻ
CH2Cl2/CH3OH (3:1), 27% (89) and 8% (87). (d) 88 (1.2 eq), BF3·Et2O, CH2Cl2, -78 °C, 
71% (90) and 93% (91). (c) K2CO3, CH3OH:TBME (5:1) , 72% (92) and 75% (93). 
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addition of 84 to Cl3CCN in the presence of K2CO3 (88). The phenol glycosylation was 
initially carried out with 2,6-dimethoxyphenol (86) prior to any attempt on 3-prenyl-2,6-
dimethoxyphenol (89) and 3,4-diprenyl-2,6-dimethoxyphenol (87), which were in short 
supply.284 Excellent glycosylation yields were obtained during the synthesis of glycosides 
90 and 91, however, attempts to glycosylate 87 were unsuccessful (Figure 3.13). The 
benzoate esters were then removed by treatment with K2CO3 and CH3OH to provide 
deprotected glycosides 92 and 93. 
Glycoside 93 was evaluated for antimicrobial activity against a variety of 
clinically relevant microorganisms using the microbroth dilution assay (Table 3.3). 
Unfortunately, the glycoside showed no improvement in the antimicrobial activity 
compared to 3-prenyl-2,6-dimethoxyphenol (89), as indicated by the loss of activity 
against Mycobacterium smegmatis and M. diernhoferi. Glycoside 93 also exhibited 
greater toxicity than 3,4-diprenyl-2,6-dimethoxyphenol (87) and 89 in the Vero cell 
cytotoxicity assay. Compared to 89 and 93, the promising activity observed for 87 
indicated that the additional prenyl group at the C-4 position may be important for 
antimicrobial activity. Further attempts to glycosylate 87 were not successful. The limited 
SAR data from this study suggested that the addition of a phenolic carbohydrate moiety 
may not improve the antimicrobial activity nor reduce the cytotoxicity. It is possible that 
the synthetic mimics may exert their antimicrobial activity through a mechanism of 
action that is distinct from the pseudopterosins. Nonetheless, the glycosylation 
methodology using the benzoylated glycosyl donor (63) was effective and may find 
applications in the synthesis of novel pseudopterosin analogues or other phenolic 
glycosides of biological significance. 
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Table 3.3. Antimicrobial susceptibility testing of the truncated pseudopterosin mimic 
using the microbroth dilution method (n = 3).284 
 IC50 ȝJP/ 0,&ȝJP/ IC50 ȝJP/ 
Compound MRSAa VREa M. smegmatis M. diernhoferi M. tuberculosis H37Rv 
Vero cell 
30 2.6 2.9 2 4 - - 
87b >128 >128 128 64 >128 45 
89b 20 3.5 8 8 59 64 
93 >128 >128 >128 >128 >128 82 
Vancomycin 1.2 - - - - - 
Rifampin - 0.9 4 4 0.04 - 
Isoniazid - - 1 0.25 0.03 - 
 
a
 Assay was completed by Martine Lanteigne. b Compound was synthesized and tested 
for antimicrobial activity by Dr. Malcolm McCulloch. 
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3.3 Conclusion 
 
A modification of the Koenigs-Knorr method has enabled the glycosylation of 
fuscol (15) and eunicol (16), providing a collection of novel fuscoside B analogues. This 
glycosylation method was initially established with 2-methyl-3-buten-2-ol (55), a model 
glycosyl acceptor, using differentially protected glycosyl bromides. The glycosylation 
yields provided by these glycosyl donors correlated with apparent acyloxonium stability. 
Glycosyl bromides protected with benzoate esters provided higher yields compared to 
acetylated and pivaloylated variants. The glycosylation method was later adapted for the 
purpose of glycosylating 15 and 16 by employing DIEA as the primary acid scavenger. 
The acid lability of the diterpenes, although a significant hurdle in the glycosylation, was 
later exploited for synthesizing glycoside mimics by introducing EG3 and EG4 as 
substitutes of the arabinose moiety. Attempts to exploit this SN1 mechanism for 
introducing a carbohydrate moiety, a potential glycosylation approach that was coined as 
the aglycone acceptor method, were unsuccessful.  
The fuscoside library was evaluated for anti-inflammatory activity using the 
mouse ear edema assay, which showed the remarkable influence of the carbohydrate 
substituent on the in vivo efficacy of this glycoside class. For instance, the anomer of 
fuscoside B had no anti-inflammatory activity as it was unable to mount a significant 
reduction in PMA-induced swelling. This result suggested that the configuration of the 
glycosidic linkage may be important for the anti-inflammatory activity. Replacing the 
arabinose moiety with galactose or EG-based moieties also failed to emulate the anti-
inflammatory activity of fuscoside B (11). The unsatisfactory performance of this 
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compound collection in the mouse ear edema assay was unforeseen, bearing in mind the 
near equivalent in vitro activities of 11 and fuscol (15). The activity of 15, compared to 
its methyl ether (53), reiterated the significance of the tertiary hydroxyl group, as alluded 
to earlier in Chapter 2 (Section 2.2.8). Regardless, the natural products exhibited anti-
inflammatory activity while all synthetic analogues were inactive. 
The most significant achievement of this research was the glycosylation of fuscol 
(15), a striking omission of previous synthetic efforts. The glycosylation of eunicol (16) 
has also provided the eunicosides, a novel structural class of diterpene glycosides. The 
LQDELOLW\WRLQVWDOO¶¶-cis glycosidic linkages was a limitation of this glycosylation 
methodology, in addition to the low reaction yields that were obtained. A more precise 
examination of the anomeric configuration and its importance was therefore prohibited. 
Future glycosylation efforts should focus on applying this methodology to glycosyl 
donors functionalized with non-participating protecting groups. Although these donors 
ZLOOSURYLGH¶¶-cis glycoside analogues, base-sensitive protecting groups should be 
employed as the fuscoside may not tolerate acidic conditions. Semisynthesis of fuscoside 
B (11E\LQWURGXFLQJD¶¶-cis D-arabinose moiety may provide a rapid route to this 
natural product. Unequivocal determination of the absolute configuration of 11 may also 
be possible by establishing this synthetic method.  
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3.4 Experimental 
 
General experimental methods as well as procedures for the mouse ear edema assay and 
the microbroth dilution assay are described in Appendix B. Also see Appendix B for a 
GHVFULSWLRQRIWKH³VWDQGDUGZRUNXSSURFHGXUH´ 
 
3.4.1 Preparation of glycosyl donors for glycosylation chemistry 
 
2,3,4,6-tetra-O-acetyl-Įȕ-D-galactopyranosyl trichloroacetimidate (56). To a mixture 
of D-galactose (210 mg, 1.17 mmol) in pyridine (4 mL) was added Ac2O (2.0 mL, 21 
mmol). After stirring overnight at room temperature, partially acetylated carbohydrate 
was observed by TLC analysis (EtOAc), and thus additional Ac2O (2.0 mL, 21 mmol) 
was transferred to the mixture. The reaction was stirred for 4 h and then diluted with 
EtOAc. After partitioning the mixture between sat. NaHCO3(aq) and DI H2O, the EtOAc 
phase was recovered and subjected to the standard work up procedure, yielding 1,2,3,4,6-
penta-O-acetyl-Įȕ-D-galactopyranose (418 mg, 1.07 mmol, 92%) as a colorless oil. 
APCIMS: m/z 331.1 [M + H ± CH3CO2H]+. The glycosyl trichloroacetimidate (56) was 
then synthesized according to an established method.285 Without further purification, the 
peracetylated carbohydrate was dissolved in DMF (10 mL) and cooled to -20 °C prior to 
the addition of N2H4CH3CO2H (61.6 mg, 0.669 mmol). The reaction was held at -20 °C 
with stirring and additional N2H4CH3CO2H (total of 77.7 mg, 0.844 mmol) was added as 
long as peracetylated carbohydrate had remained, as judged by TLC analysis (EtOAc). 
The reaction mixture was then diluted with EtOAc and partitioned with DI H2O. The 
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organic layer was recovered, subjected to the standard work up procedure, and separated 
by benchtop flash chromatography (silica, hexanes ĺEtOAc stepwise gradient) to 
provide 2,3,4,6-tetra-O-acetyl-Įȕ-D-galactopyranose (103.9, 0.298 mmol, 28%) as a 
yellow oil. APCIMS: m/z 331.1 [M + H - H2O]+. The anomerically deprotected 
carbohydrate (66.7 mg, 0.192 mmol) was dissolved in anhydrous 1,2-dichloroethane (1 
mL) and stirred with 3Å molecular sieves (~0.1 g) under an N2 atmosphere and cooled to 
0 °C. An aliquot of Cl3&&1ȝ/PPROZDV added, followed by DBU (1.0 ȝ/, 
6.7 ȝmol) approximately 20 min later. The reaction was stirred overnight at room 
temperature, and was later diluted with CH2Cl2 and filtered through Celite®. The filtrate 
was evaporated in vacuo to yield 56 (62.0 mg, 0.126 mmol, 66%) as a yellow amorphous 
solid. All 1H and 13C NMR spectroscopic data for the product were consistent with the 
structure of 56. APCIMS: m/z 331.1 [M + H - Cl3CCONH2]+. 
 
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-ȕ-D-thiogalactopyranoside (58). Glycosyl donor 
58 was prepared according to an established literature protocol.266 A mixture of D-
galactose (1.09 g, 6.03 mmol) was stirred in Ac2O (3 mL) before adding BF3(W2O (1.5 
mL). After confirming the formation of the peracetylated intermediate by TLC analysis 
(EtOAc), PhSH (1 mL, 9.77 mmol) and additional BF3(W2O (1 mL) was added and the 
reaction was stirred for 4 h. At this point, TLC analysis (TBME) indicated partial 
thioglycoside formation. Additional BF3(W2O (1 mL) was then added and the reaction 
was left to stir overnight at room temperature. Afterwards, the reaction mixture was 
diluted with EtOAc and washed successively with NaHCO3(aq) and DI H2O. The EtOAc 
phase was subjected to the standard work up procedure and separated by RP-MPLC (C18, 
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H2O ĺCH3OH) to provide 58 (1.13 g, 2.56 mmol, 43%) as a colorless oil. All 1H and 
13C NMR spectroscopic data for the product were consistent with the structure of 58. 
APCIMS: m/z 463.3 [M + Na]+ ; m/z 331.2 [M + H - PhSH]+. 
 
Phenylsulfenyl 2,3,4,6-tetra-O-acetyl-ȕ-D-galactopyranoside (59). Glycosyl donor 59 
was prepared from thioglycoside 58 following a literature protocol.267 The thioglycoside 
(58, 89.0 mg, 0.202 mmol) was dissolved in CH2Cl2 (5mL) and cooled to 0 °C prior to 
adding mCPBA (41.1 mg, 0.238 mmol). After the reaction was stirred for 4 h, unreacted 
58 had remained, according to TLC analysis (hexanes:EtOAc 1:1), and therefore an 
additional portion of mCPBA (11.7 mg, 0.068 mmol) was added. The reaction was left to 
stir for 2 h and was then diluted with EtOAc and washed successively with DI H2O. The 
EtOAc phase was recovered and subjected to the standard work up procedure to provide a 
diastereomeric mixture of sulfoxide 59 as a colorless oil (80.0 mg, 0.175 mmol, 87%). 
All 1H and 13C NMR spectroscopic data for the product were consistent with the structure 
of 59. APCIMS: m/z 479.2 [M + Na]+ ; m/z 331.1 [M + H - S(OH)Ph]+. 
 
2,3,4,6-tetra-O-acyl-Į-D-glycopyranosyl bromide (60, 62-63, and 81-82) and 2,3,4-
tri-O-benzoyl-ȕ-D-arabinopyranosyl bromide (80). The peracylated carbohydrate 
intermediates and their corresponding glycosyl bromides were synthesized by an 
established method,269b combining AcBr (3.0 eq) and CH3OH (3.3 eq) to generate HBr in 
situ,269a and purified according to the following procedure: After formation of the desired 
glycosyl bromide, as judged by TLC analysis (hexanes:TBME 1:1) the reaction mixture 
was diluted with cold EtOAc and washed successively with cold sat. NaHCO3(aq), until 
119 
 
gas evolution ceased, followed by cold sat. NaCl(aq). The organic extract was subjected to 
the standard work up procedure to provide a crude oil, which was separated by MPLC 
(silica, hexanes ĺTBME) to provide the galactosyl bromide [60 (R = Ac): 38%, 62 (R = 
Piv): 26%, 63 (R = Bz): 36%], arabinosyl bromide [80 (R = Bz): 50%, Figure C.1], 
glucosyl bromide [81 (R = Bz): 13%, Figure C.1], and mannosyl bromide [82 (R = Bz): 
35%, Figure C.1] as white powders. All 1H and 13C NMR spectroscopic data for the 
products were consistent with the structures of 60, 62-63, and 80-82. The following [M - 
Br]+ fragment ions were observed by APCIMS: m/z 331.3 (60); m/z 499.3 (62); m/z 579.2 
(63 and 81-82); m/z 446.3 (80). 
 
2,3,4,6-tetra-O-benzyl-Į/ȕ-D-galactopyranose (85). A stirred mixture of D-galactose 
(1.133 g, 6.289 mmol) in DMF (30 mL) was cooled to 0 °C in an ice bath before slowly 
adding NaH (1.10 g, 45.8 mmol). After the mixture was stirred for 30 min at 0 °C, BnBr 
(5.50 mL, 46.2 mmol) was added, and the reaction was stirred overnight at room 
temperature. Partial product formation was indicated by TLC analysis (hexanes:TBME 
1:1) and additional NaH (377 mg, 15.7 mmol) and BnBr (2.00 mL, 16.8 mmol) was 
added. Upon stirring the reaction for 8 h, the mixture was concentrated under rotary 
evaporation, diluted with EtOAc, and washed successively with NaHCO3(aq) and 
deionized H2O. The organic layer was then recovered and subjected to the standard work 
up procedure yielding 1,2,3,4,6-penta-O-benzyl-Į/ȕ-D-galactopyranose as a crude yellow 
oil, which was used without further purification. APCIMS: m/z 653.4 [M + Na]+ ; m/z 
524.2 [M + H - BnOH]+. The anomeric benzyl group was then hydrolyzed by refluxing in 
HOAc:1M H2SO4 (7:1, 16 mL) for 16 hours, at which point TLC analysis 
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(hexanes:TBME 1:1) indicated product formation. The reaction mixture was then diluted 
with EtOAc and washed successively with NaHCO3(aq) and deionized H2O. After 
recovery of the EtOAc, it was subjected to the standard work up procedure and separated 
by MPLC (silicDKH[DQHVĺ7%0(yielding 85 (857.4 mg, 1.586 mmol, 25%) as a 
viscous yellow oil. All 1H and 13C NMR spectroscopic data for the product were 
consistent with the structure of 85. APCIMS: m/z 524.2 [M + H - H2O]+. 
 
2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranose (84). The anomeric bromide was 
hydrolyzed according to an established method.286 The glycosyl bromide (63, 3.330 g, 
5.049 mmol) was dissolved in acetone:H2O (19:1, 20 mL) and stirred with Ag2CO3 
(2.1389 g, 7.757 mmol) under the exclusion of light. The reaction was left to stir at room 
temperature for 18 h, at which point TLC analysis (hexanes:TBME 1:1) indicated product 
formation. The mixture was then diluted with EtOAc, filtered through Celite®, and 
washed successively with NaHCO3(aq) and DI H2O. The EtOAc phase was recovered, 
subjected to the standard work up procedure, and separated by MPLC (VLOLFDKH[DQHVĺ
TBME) yielding 84 (2.560 g, 4.290 mmol, 85%) as a white solid. All 1H and 13C NMR 
spectroscopic data for the product were consistent with the structure of 84. APCIMS: m/z 
580.3 [M + H - H2O]+. 
 
2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranosyl trichloroacetimidate (88). The glycosyl 
donor was prepared following a literature protocol.286 The benzoylated carbohydrate (84, 
1.893 g, 3.173 mmol) was dissolved in anhydrous CH2Cl2 (30 mL) and stirred with 
K2CO3 (533.7 mg, 3.862 mmol) under a N2 atmosphere. Shortly after, Cl3CCN (3.20 mL, 
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31.9 mmol) was added and the reaction was left to stir for 60 h at room temperature. 
During this time, the reaction was inspected periodically and additional CH2Cl2 was 
added to avoid complete evaporation of the solvent. The reaction was completed at 60 h, 
as judged by TLC analysis (hexanes:acetone 7:3), and was diluted with EtOAc and 
partitioned between DI H2O. The organic layer was recovered and subjected to the 
standard work up procedure before undergoing separation by MPLC (VLOLFDKH[DQHVĺ
acetone), which yielded 88 (855.5 mg, 1.155 mmol, 36%) as a white solid. All 1H and 13C 
NMR spectroscopic data for the product were consistent with the structure of 88. 
APCIMS: m/z 580.2 [M + H - Cl3CCONH2]+. 
 
3.4.2 Model glycosylation reactions and characterization of products 
 
Cholesteryl 2,3,4,6-tetra-O-acetyl-ȕ-D-galactopyranoside (57). The synthesis of the 
cholesteryl galactoside (57) was accomplished with three different glycosylation 
methods. All 1H and 13C NMR spectroscopic data for the product were consistent with 
the structure of 57. APCIMS: m/z 739.4 [M + Na]+ ; m/z 331.2 [M + H - H2O]+. 
 
Schmidt method: &KROHVWHUROPJȝPRO) and glycosyl trichloroacetimidate (56, 
53.8 mg, 0.109 mmol) were dissolved in anhydrous CH2Cl2 (2 mL) and stirred with 3Å 
molecular sieves (~0.2 g) under an atmosphere N2 atmosphere. Upon cooling the reaction 
to -78 °C and stirring for 20 min, BF3(W2O (ȝ/) was added and the mixture was stirred 
for 1 h. Afterwards, the reaction was quenched with Et31ȝ/diluted with EtOAc, 
and washed successively with NaHCO3(aq) and DI H2O. The organic layer was recovered, 
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subjected to the standard work up procedure, and separated by flash chromatography 
(silica, hexanes:EtOAc stepwise gradient) to provide 57 (15.2 mg, 21.2 ȝPRO, 40%) as a 
colorless oil.  
Phase-transfer catalysis method: Cholesterol (137 mg, 0.354 mmol) and glycosyl 
bromide (60, 291 mg, 0.707 mmol) were stirred in anhydrous DMF (10 mL) in the 
presence of 3Å molecular sieves (~1.0 g) under a N2 atmosphere. After approximately 20 
min, the DIEA (185 ȝ/ mmol) was added along with Bu4NBr (125 mg, 0.368 
mmol), and the mixture was stirred for an additional 20 min. The reaction was heated to 
approximately 50 °C and stirred for 8 h. TLC analysis (hexanes:EtOAc 1:1) indicated 
product formation, upon which the reaction mixture was diluted with EtOAc. After 
filtration through Celite®, the mixture was washed successively with NaHCO3(aq) and DI 
H2O. The organic layer was recovered, subjected to the standard work up procedure, and 
separated by flash chromatography (silica, hexanes:TBME stepwise gradient) to provide 
57 PJȝPRO%) as a white solid. Unreacted cholesterol (81.6 mg, 0.211 
mmol, 60% recovery) was also recovered. 
Modified Koenigs-Knorr method: A mixture of cholesterol (61.8 mg, 0.160 mmol), 
Ag2CO3 (94.6 mg, 0.343 mmol), and AgOTf (21.6 mg, 84.1 ȝmol) were stirred in 
anhydrous CH2Cl2 (5 mL) with 3Å molecular sieves (~0.2 g) under an N2 atmosphere and 
exclusion of light. After cooling the reaction mixture to -78 °C and stirring for 20 min, a 
solution of glycosyl bromide (60, 139 mg, 0.338 mmol) in anhydrous CH2Cl2 (5 mL) was 
added. The reaction was stirred overnight at room temperature, after which the desired 
glycoside was observed, as judged by TLC analysis (hexanes:TBME 1:1). Subsequently, 
the mixture was diluted with CH2Cl2, filtered through Celite®, and evaporated in vacuo. 
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The crude product was then separated by flash chromatography (silica, hexanes: TBME 
stepwise gradient), yielding 57 PJȝPRODVDZKLWHVROLG. 
 
General procedure A: Modified Koenigs-Knorr glycosylation of 2-methyl-3-buten-2-
ol. The 2-methyl-3-buten-2-ol (55, ȝ/PPRO) was added to a stirring mixture of 
AgOTf (49 mg, 0.19 mmol), Ag2CO3 (530 mg, 1.92 mmol), and 3Å molecular sieves 
(~0.5 g) in anhydrous CH2Cl2 (5 mL) under a N2 atmosphere and the exclusion of light. 
After stirring for 15 minutes, the mixture was cooled to -78 °C followed by the dropwise 
addition of glycosyl bromide (1.92 mmol) dissolved in anhydrous CH2Cl2 (5 mL). The 
mixture was stirred for 3.5 days and afterward diluted with EtOAc and filtered through 
Celite®. After washing with Na2S2O3(aq) and DI H2O, the organic extract was recovered 
and subjected to the standard work up procedure to provide the glycosylation crude 
product as a colorless oil. 
 
General procedure B: Deprotection of benzoylated glycosides. The glycosylation 
crude product was dissolved in CH3OH (5 mL) and stirred with K2CO3 (53 mg, 0.38 
mmol). The reaction was stirred until TLC analysis indicated the disappearance of 
benzoylated starting materials. The reaction was neutralized by addition of NH4OAc and 
concentrated to 0.5 mL by rotary evaporation in vacuo. This mixture was loaded onto a 
C18 plug and washed with H2O:CH3OH (19:1) to separate the salts from the products. 
Fractions containing the deprotected glycosides, as judged by LC-APCIMS analysis, 
were evaporated and lyophilized to provide a white amorphous solid that was further 
separated by RP-HPLC. 
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2-Methyl-3-buten-2-yl 2,3,4,6-tetra-O-acetyl-ȕ-D-galactopyranoside (61). The 
aglycone 55 was glycosylated using 60 (790 mg, 1.92 mmol) according to general 
procedure A. The glycosylation crude was separated by MPLC (silica, hexanes ĺ
TBME) to yield the desired glycoside (61, 51.8 mg, 0.124 mmol, 26%). 61: >Į@25D = 
+8.98 (c 0.367, CH2Cl2); IR ȣmax 3088, 2982, 1744, 1643, 1216, 1072, 1040 cm-1. 1H 
NMR (600 MHz, C6D6) į 5.86 (1H, dd, J = 17.7, 10.5 Hz, H-3), 5.57 (1H, dd, J = 10.5, 
8.3 Hz, H-¶, 5.41 (1H, dd, J = 3.4, 0.8 Hz, H-¶, 5.12 (1H, dd, J = 10.5, 3.4 Hz, H-¶, 
5.07 (1H, dd, J = 17.7, 1.1 Hz, H-4), 4.99 (1H, dd, J = 10.5, 1.1 Hz, H-4), 4.39 (1H, d, J 
= 8.3 Hz, H-¶, 4.11 (1H, dd, J = 10.9, 6.8 Hz, H-¶, 4.05 (1H, dd, J = 10.9, 6.4 Hz, H-
¶, 3.24 (1H, ddd, J = 6.4, 1.1 Hz, H-¶, 1.75 (3H, s), 1.73 (3H, s), 1.65 (3H, s), 1.53 
(3H, s), 1.24 (3H, s, H-1), 1.18 (3H, s, H-5). 13C NMR (150 MHz, C6D6) į 170.2 (C), 
169.8 (C), 169.5 (C), 168.6 (C), 143.7 (CH, C-3), 113.9 (CH2, C-4), 96.9 (CH, C-¶), 
78.0 (C, C-2), 71.6 (CH, C-¶), 70.6 (CH, C-¶), 69.6 (CH, C-¶), 67.5 (CH, C-¶), 61.6 
(CH2, C-¶), 27.4 (CH3, C-5), 26.2 (CH3, C-1), 20.5 (CH3), 20.3 (CH3), 20.2 (CH3), 19.9 
(CH3). HRESIMS m/z 439.1564 [M + Na]+ (calcd for C19H28O10Na, 439.1575). 
 
2-Methyl-3-buten-2-yl 2,3,4,6-tetra-O-pivaloyl-ȕ-D-galactopyranoside (64). The 
aglycone 55 was glycosylated using 62 (1.11 g, 1.92 mmol) according to general 
procedure A. The glycosylation crude was separated by MPLC (silica, hexanes ĺ
TBME) to yield the desired glycoside (64, 127.4 mg, 0.218 mmol, 46%). 64: >Į@25D = 
+8.56 (c 0.137, CH2Cl2); ,5ȣmax 2975, 2936, 2909, 2874, 1737, 1139, 1073, 1037 cm-1. 
1H NMR (600 MHz, C6D6) į 5.93 (1H, dd, J = 17.7, 10.9 Hz, H-3), 5.56 (1H, dd, J = 
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10.2 Hz, 7.9, H-¶, 5.41 (1H, dd, J = 3.0, 1.1 Hz, H-¶, 5.12 (1H, dd, J = 10.5, 3.4 Hz, 
H-¶, 5.06 (1H, dd, J = 17.7, 1.1 Hz, H-4), 5.00 (1H, dd, J = 10.9, 1.1 Hz, H-4), 4.42 
(1H, d, J = 8.0 Hz, H-¶, 4.12 (1H, dd, J = 10.9, 7.2 Hz, H-¶, 4.06 (1H, dd, J = 10.9, 
6.0 Hz, H-¶, 3.25 (1H, ddd, J = 7.2, 6.4, 1.1 Hz, H-¶, 1.28 (3H, s, H-1), 1.22 (3H, s, 
H-5), 1.21 (9H, s, 9H), 1.17 (9H, s, 9H), 1.17 (9H, s, 9H), 1.10 (9H, s, 9H). 13C NMR 
(150 MHz, C6D6) į 177.1 (C), 177.1 (C), 177.0 (C), 176.0 (C), 143.9 (CH, C-3), 114.1 
(CH2, C-4), 96.9 (CH, C-¶78.0 (C, C-2), 71.8 (CH, C-¶70.8 (CH, C-¶69.5 (CH, 
C-2¶67.4 (CH, C-¶62.0 (CH2, C-¶), 39.0 (C), 38.9 (C), 38.8 (C), 38.7 (C), 28.0 
(CH3, C-5), 27.5 (CH3), 27.3 (CH3), 27.3 (CH3), 27.1 (CH3), 26.2 (CH3, C-1). HRESIMS 
m/z 607.3426 [M + Na]+ (calcd for C31H52O10Na, 607.3453). 
 
2-Methyl-3-buten-2-yl 2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranoside (65). The 
aglycone 55 was glycosylated using 63 (1.27 g, 1.92 mmol) according to general 
procedure A. The glycosylation crude was separated by MPLC (silica, hexanes ĺ
TBME) to yield the desired glycoside (65, 225 mg, 0.339 mmol, 67%). 65: >Į@25D = 
+162.4 (c 0.2833, CH2Cl2); ,5ȣmax 3065, 2980, 1728, 1265, 1108, 710 cm-1. 1H NMR 
(600 MHz, C6D6) į 8.21 (2H, dd), 8.12 (2H, dd), 8.08 (2H, dd), 7.98 (2H, dd), 7.11 (1H, 
tt), 7.06 (2H, tt), 7.03 (1H, tt), 7.00 (1H, tt), 6.95 (2H, tt), 6.87 (2H, tt), 6.83 (1H, tt), 6.71 
(2H, tt), 6.29 (1H, dd, J = 10.5, 8.3 Hz, H-¶, 6.09 (1H, dd, J = 3.8, 1.1 Hz, H-¶, 5.90 
(1H, dd, J = 17.6, 10.8 Hz, H-3), 5.70 (1H, dd, J = 10.2, 3.4 Hz, H-¶, 5.01 (1H, dd, J = 
17.6, 1.1 Hz, H-4), 4.89 (1H, dd, J = 10.8, 1.1 Hz, H-4), 4.70 (1H, d, J = 8.0 Hz, H-¶, 
4.65 (1H, dd, J = 11.3, 7.5 Hz, H-¶, 4.29 (1H, dd, J = 11.3, 5.6 Hz, H-¶, 3.58 (1H, 
ddd, J = 5.6, 1.1 Hz, H-¶, 1.26 (3H, s, H-1), 1.14 (3H, s, H-5). 13C NMR (150 MHz, 
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C6D6) į 165.8 (C), 165.8 (C), 165.7 (C), 165.2 (C), 143.7 (CH, C-3), 133.2 (CH), 133.1 
(CH), 133.1 (CH), 133.0 (CH), 130.5 (C), 130.4 (C), 130.3 (CH), 130.0 (CH), 130.0 
(CH), 129.9 (CH), 129.6 (C), 129.6 (C), 128.8 (CH), 128.6 (CH), 128.6 (CH), 128.4 
(CH), 114.1 (CH2, C-4), 97.1 (CH, C-¶), 78.4 (C, C-2), 72.5 (CH, C-¶), 71.3 (CH, C-
¶), 70.7 (CH, C-¶), 68.8 (CH, C-¶), 62.6 (CH2, C-¶), 27.2 (CH3, C-5), 26.4 (CH3, C-
1). HRESIMS m/z 687.2186 [M + Na]+ (calcd for C39H36O10Na, 687.2201). 
 
2-Methyl-3-buten-2-yl-ȕ-D-galactopyranoside (66). The glycosylation crude from the 
synthesis of 65 was deprotected according to general procedure B. The desired glycoside 
(66) was isolated by RP-HPLC (C18, 30% CH3OH). 66: >Į@25D = -9.29 (c 0.117, CH3OH); 
,5ȣmax 3379, 3090, 2980, 2933, 2881, 1642, 1579, 1059 cm-1. 1H NMR (600 MHz, 
CD3OD) į 6.03 (1H, dd, J = 17.7, 10.9 Hz, H-3), 5.20 (1H, dd, J = 17.7, 1.1 Hz, H-4), 
5.10 (1H, dd, J = 10.9, 1.1 Hz, H-4), 4.28 (1H, d, J = 7.2 Hz, H-¶, 3.83 (1H, dd, J = 3.0, 
0.8 Hz, H-¶, 3.71 (1H, dd, J = 10.9, 5.7 Hz, H-¶, 3.67 (1H, dd, J = 10.9, 6.4 Hz, H-
¶, 3.47 (1H, dd, J = 9.8, 7.2 Hz, H-¶, 3.44 (1H, dd, J = 9.8, 3.4 Hz, H-¶, 3.41 (1H, 
ddd, J = 6.4, 0.8 Hz, H-¶, 1.37 (3H, s, H-1), 1.33 (3H, s, H-5). 13C NMR (150 MHz, 
CD3OD) į 145.6 (CH, C-3), 114.2 (CH2, C-4), 100.2 (CH, C-¶), 79.0 (C, C-2), 76.3 
(CH, C-¶), 75.1 (CH, C-¶), 72.6 (CH, C-¶), 70.2 (CH, C-¶), 62.3 (CH2, C-¶), 27.9 
(CH3, C-5), 26.7 (CH3, C-1). HRESIMS m/z 271.1159 [M + Na]+ (calcd for C11H20O6Na, 
271.1152).  
 
Prenyl 2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranoside (68). Glycoside 68 was isolated 
as a side product from the glycosylation crude reaction mixture of 65 by semi-preparative 
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RP-HPLC (phenylhexyl, 86% CH3OH). 68: ,5ȣmax 3063, 2970, 2931, 1726, 1266, 1108, 
1070, 709 cm-1. 1H NMR (600 MHz, C6D6) į 8.19 (2H, dd), 8.11 (2H, dd), 8.09 (2H, dd), 
7.98 (2H, dd), 7.09 (2H, tt), 7.03 (2H, m), 7.03 (1H, m), 6.97 (2H, tt), 6.91 (1H, tt), 6.89 
(1H, tt), 6.83 (2H, tt), 6.71 (1H, tt), 6.35 (1H, dd, J = 10.5, 7.9 Hz, H-¶, 6.19 (1H, dd, J 
= 3.8, 1.1 Hz, H-¶, 5.76 (1H, dd, J = 10.5, 3.8 Hz, H-¶, 5.29 (1H, m, J = 7.9, 6.4, 1.5 
Hz, H-2), 4.74 (1H, dd, J = 11.3, 7.2 Hz, H-¶, 4.70 (1H, d, J = 8.0 Hz, H-¶, 4.33 (1H, 
dd, J = 11.3, 6.4 Hz, H-¶, 4.29 (1H, dd, J = 12.0, 6.4 Hz, H-1), 4.22 (1H, dd, J = 11.8, 
7.7 Hz, H-1), 3.75 (1H, ddd, J = 6.4, 1.1 Hz, H-¶, 1.45 (3H, s, H-5), 1.39 (3H, s, H-4). 
13C NMR (150 MHz, C6D6) į 165.3 (C), 165.2 (C), 165.2 (C), 165.1 (C), 137.8 (C, C-3), 
132.7 (CH), 132.5 (CH), 132.5 (CH), 132.4 (CH), 130.4 (C), 130.2 (C), 129.8 (C), 129.8 
(C), 129.6 (CH), 129.6 (CH), 129.5 (CH), 129.4 (CH), 128.3 (CH), 128.2 (CH), 128.2 
(CH), 128.0 (CH) 120.4 (CH, C-2), 99.7 (CH, C-¶), 72.2 (CH, C-¶), 71.0 (CH, C-¶), 
70.2 (CH, C-¶), 68.4 (CH, C-¶), 64.9 (CH2, C-1), 62.0 (CH2, C-¶), 25.1 (CH3, C-5), 
17.3 (CH3, C-4). HRESIMS m/z 687.2182 [M + Na]+ (calcd for C39H36O10Na, 687.2201). 
 
Prenyl-ȕ-D-galactopyranoside (69). Glycoside 69 was isolated as a side product from 
the crude product of 66 by RP-HPLC (C18, 30% CH3OH). 69: >Į@25D = -21.4 (c 0.133, 
CH3OH); ,5ȣmax 3384, 3027, 2970, 2915, 2881, 1671, 1646, 1063 cm-1. 1H NMR (600 
MHz, CD3OD) į1H, m, J = 7.9, 6.4, 1.5 Hz, H-2), 4.32 (1H, dd, J = 12.0, 6.4 Hz, 
H-1), 4.24 (1H, d, J = 7.9 Hz, H-¶, 4.22 (1H, dd, J = 12.0, 7.9 Hz, H-1), 3.83 (1H, dd, J 
= 3.2, 1.0 Hz, H-¶, 3.76 (1H, dd, J = 11.3, 6.8 Hz, H-¶, 3.73 (1H, dd, J = 11.3, 5.6 Hz, 
H-¶, 3.51 (1H, dd, J = 9.8, 7.5 Hz, H-¶, 3.48 (1H, ddd, J = 6.8, 1.1 Hz, H-¶, 3.45 
(1H, dd, J = 9.8, 3.4 Hz, H-¶, 1.69 (3H, s, H-4), 1.75 (3H, s, H-5). 13C NMR (150 MHz, 
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CD3OD) į&, C-3), 121.9 (CH2, C-2), 103.5 (CH, C-¶), 76.7 (CH, C-¶), 75.1 
(CH, C-¶), 72.6 (CH, C-¶), 70.4 (CH, C-¶), 66.3 (CH2, C-1), 62.5 (CH2, C-¶), 25.9 
(CH3, C-5), 18.1 (CH3, C-4). HRESIMS m/z 271.1157 [M + Na]+ (calcd for C11H20O6Na, 
271.1152). 
 
2-Methyl-3-buten-2-yl-Į-D-galactopyranoside (71). Glycoside 71 was isolated as a side 
product from the crude product of 66 by RP-HPLC (C18, 30% CH3OH). 71: 1H NMR 
(600 MHz, CD3OD) į 5.93 (1H, dd, J = 17.6, 10.8 Hz, H-3), 5.20 (1H, dd, J = 17.6, 1.1 
Hz, H-4), 5.10 (1H, dd, J = 10.8, 1.1 Hz, H-4), 5.02 (1H, d, J = 2.8 Hz, H-¶+
dd, J = 7.0, 4.8 Hz, H-¶+GGJ = 7.0, 2.8 Hz, H-¶+GGJ = 4.7, 2.8 
Hz, H-¶+GGGJ = 6.8, 5.8, 2.8 Hz, H-¶ (1H, d, 5.8 Hz, H-¶
(1H, d, J = 6.8 Hz, H-¶ 1.37 (3H, s, H-1), 1.33 (3H, s, H-5). 13C NMR (150 MHz, 
CD3OD) į 145.4 (CH, C-3), 114.2 (CH2, C-4), 104.8 (CH, C-¶&+&-¶
(CH, C-¶&&-2), 78.0 (CH, C-¶&+&-¶&+2, C-¶
(CH3, C-5), 26.5 (CH3, C-1). HRESIMS m/z 271.1140 [M + Na]+ (calcd for C11H20O6Na, 
271.1152). 
 
1,2,3,4,6-penta-O-pivaloyl-ȕ-D-galactopyranose (72). Pivaloylated carbohydrate 72 
was isolated as a side product from the crude product of 64 by MPLC (244 mg, 0.406 
mmol, 21% with respect to 62). All 1H and 13C NMR spectroscopic data for 72 were in 
accord with the literature.287 
1,3,4,6-Tetra-O-pivaloyl-Į-D-galactopyranose (73). Pivaloylated carbohydrate 73 was 
isolated as a side product from the crude product of 64 by MPLC (246 mg, 0.476 mmol, 
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25% with respect to 62). 73: (white solid); >Į@25D = +105.5 (c 0.4542, CH2Cl2); IR: 3481, 
2973, 2936, 2910, 2874, 1737, 1137, 1091, 1023 cm-1. 1H NMR (600 MHz, C6D6): į 6.45 
(1H, d, J = 3.8 Hz, H-¶, 5.55 (1H, dd, J = 3.4, 1.1 Hz, H-¶, 5.42 (1H, dd, J = 10.5, 3.4 
Hz, H-¶, 4.28 (1H, ddd, J = 6.4, 7.2, 1.1 Hz, H-¶, 4.16 (1H, dd, J = 11.3, 7.5 Hz, H-
¶, 4.13 (1H, dd, J = 10.2, 3.0 Hz, H-¶+GGJ = 11.3, 6.0 Hz, H-¶+
V¶¶-OPiv+V¶-OPiv+V¶¶-OPiv+V¶-OPiv). 13C 
NMR (150 MHz, C6D6&¶-OC), 177.3 (C, ¶-OC&¶-OC),176.5 (C, 
¶-OC), 92.3 (CH, C-¶&+&-¶&+&-¶&+&-¶&+
C-¶&+2, C-¶&2Piv), 39.1 (C, OPiv), 39.0 (C, OPiv), 38.8 (C, OPiv), 
27.2 (CH3, OPiv), 27.2 (CH3, OPiv), 27.2 (CH3, OPiv), 27.1 (CH3, OPiv). HRESIMS m/z 
539.2809 [M + Na]+ (calcd for C26H44O10Na, 539.2827). 
 
3.4.3 Synthesis and characterization of fuscoside analogues 
 
Fuscene B (48) and Eunicene B (46). Diterpenes 46 and 48 were isolated as a side 
product from the crude product of 76 and 77 by RP-HPLC. All 1H and 13C NMR 
spectroscopic data for 46 and 48 were consistent with previous data.254 
 
Fusco-2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranoside (74) and Eunico-2,3,4,6-tetra-
O-benzoyl-ȕ-D-galactopyranoside (75). Aglycones 15 and 16 PJȝPRO) were 
glycosylated using 63 according to general procedure C. The crude product was separated 
by flash chromatography (silica, hexanes ĺTBME) and the desired glycosides were 
purified by RP-HPLC (C18, 94% CH3OH). 74 (8.6 mgȝPRO, 15%): >Į@25D = +135.1 
(c 0.1192, CH2Cl2); ,5ȣmax 3070, 2975, 2929, 2859, 1729, 1265, 1107, 1069, 709. 1H 
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NMR (600 MHz, CD3OD) į 8.11 (2H, dd), 8.02 (2H, dd), 7.98 (2H, dd), 7.72 (2H, dd), 
7.67 (1H, t), 7.60 (1H, t), 7.57 (1H, t), 7.54 (2H, t), 7.46 (2H, t), 7.45 (1H, t), 7.43 (2H, t), 
7.25 (2H, t), 6.46 (1H, dd, J = 15.5, 10.7 Hz, H-13), 5.95 (1H, dd, J = 3.0 Hz, H-¶, 5.84 
(1H, dd, J = 17.5, 10.8 Hz, H-6), 5.74 (1H, dd, J = 10.2, 3.4 Hz, H-¶, 5.71 (1H, br d, J = 
10.2 Hz, H-12), 5.69 (1H, dd, J = 9.8, 7.5 Hz, H-¶, 5.50 (1H, d, J = 15.5 Hz, H-14), 
5.09 (1H, d, J = 7.2 Hz, H-¶, 4.91 (1H, dd, J = 17.3, 1.4 Hz, H-5), 4.88 (1H, dd, J = 
10.5, 1.5 Hz, H-5), 4.83 (1H, br s, H-4), 4.61 (1H, br s, H-4), 4.54 (1H, dd, J = 10.5, 7.2 
Hz, H-¶, 4.49 (1H, ddd, J = 7.2, 5.0 Hz, H-¶, 4.44 (1H, dd, J = 10.5, 4.9 Hz, H-¶, 
2.03 (1H, app. dd, J = 12.7, 3.0 Hz, H-2), 1.95-1.89 (1H, m, H-10), 1.74 (3H, s, H-18), 
1.72 (3H, s, H-16), 1.63 (1H, app. ddd, J = 12.8 Hz, H-1), 1.56-1.48 (1H, m, H-8), 1.52-
1.47 (2H, m, H-9), 1.46-1.40 (1H, m, H-1), 1.46-1.41 (1H, m, H-8), 1.40 (3H, s, H-19), 
1.26 (3H, s, H-20), 1.02 (3H, s, H-17). 13C NMR (150 MHz, CD3OD) į 166.8 (C), 166.7 
(C), 167.4 (C), 167.3 (C), 151.5 (CH, C-6), 149.0 (C, C-3), 145.3 (C, C-11), 136.8 (CH, 
C-14), 134.9 (CH), 134.7 (CH), 134.6 (CH), 134.5 (CH), 131.0 (CH), 131.0 (C), 130.8 
(C), 130.8 (CH), 130.8 (CH), 130.6 (CH), 130.6 (C), 130.3 (C), 129.9 (CH), 129.7 (CH), 
129.7 (CH), 129.5 (CH), 127.9 (CH), 123.8 (CH, C-12), 112.8 (CH2, C-4), 110.5 (CH2, 
C-5), 97.6 (CH, C-¶), 79.9 (C, C-15), 73.4 (CH, C-¶), 72.2 (CH, C-¶), 71.8 (CH, C-¶), 
70.3 (CH, C-¶), 63.8 (CH2, C-¶), 54.0 (CH, C-2), 49.3 (CH, C-10), 41.1 (CH2, C-8), 
40.8 (C, C-7), 33.9 (CH2, C-1), 28.8 (CH3, C-20), 27.8 (CH2, C-9), 26.7 (CH3, C-19), 
25.4 (CH3, C-16), 17.2 (CH3, C-17), 15.3 (CH3, C-18). HRESIMS m/z 889.3950 [M + 
Na]+ (calcd for C54H58O10Na, 889.3922). 75 (6.9 mgȝPRO, 5%): >Į@25D = +56.3 (c 
0.0167, CH2Cl2); ,5ȣmax 3068, 3034, 2975, 2929, 2860, 1729, 1265, 1107, 1069, 710 cm-
1
. 
1H NMR (600 MHz, C6D6) į 8.23 (2H, dd), 8.19 (2H, dd), 8.08 (2H, dd), 7.97 (2H, dd), 
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7.12 (1H, br tt), 7.08 (1H, br tt), 7.05 (2H, m), 7.05 (2H, m), 7.02 (1H, m), 6.87 (2H, t), 
6.83 (1H, br tt), 6.71 (2H, t), 6.53 (1H, dd, J = 15.8, 10.9 Hz, H-13), 6.33-6.28 (1H, m, 
H-¶, 6.07 (1H, dd, J = 3.0 Hz, H-¶-5.99 (0.5H, br m, H-12), 5.94 (0.5H, br d, J = 
10.5 Hz, H-12), 5.66-5.59 (1H, m, H-¶+GJ = 15.8 Hz, H-14), 5.20-5.03 (1H, 
br m, H-2, H-6), 4.82 (1H, d, J = 7.5 Hz, H-¶, 4.83-4.80 (0.5H, br m, H-6), 4.72-4.67 
(1H, m, H-¶, 4.55 (0.5H, br d, 10.2 Hz, H-¶), 4.32-4.26 (1H, m, H-¶, 2.39-2.33 (1H, 
m, J = 12.8, 7.5 Hz, H-8), 2.28-2.23 (1H, m, H-1), 2.23-2.17 (1H, m, J = 12.8, 4.5 Hz, H-
5), 2.18-2.13 (1H, m, H-1), 2.14-2.09 (1H, m, H-4), 2.10-2.04 (1H, m, H-8), 2.07-2.02 
(1H, m, H-5), 1.95-1.88 (1H, m, H-10), 1.92-1.87 (1H, m, H-4), 1.69 (3H, s, H-18), 1.71-
1.64 (1H, m, H-9), 1.55-1.49 (1H, m, H-9), 1.47 (1.5H, s, H-16), 1.44 (3H, s, H-17), 1.44 
(3H, s, H-19), 1.36-1.32 (1.5H, br s, H-16), 1.28 (3H, br s, H-20). 13C NMR (150 MHz, 
C6D6) į 165.3 (C), 165.3 (C), 165.2 (C), 165.1 (C), 146.9 (C, C-11), 137.8 (C, C-7), 
137.0 (CH, C-14), 133.3 (CH), 133.2 (CH), 133.1 (CH), 133.1 (CH), 132.9 (C), 132.8 
(C), 132.7 (C), 132.7 (C), 131.7 (CH, C-2), 130.4 (CH), 130.1 (CH), 130.1 (CH), 130.0 
(CH), 129.6 (C, C-3), 128.7 (CH), 128.6 (CH), 128.6 (CH), 128.4 (CH), 127.0 (CH, C-6), 
126.6 (CH, C-13), 122.4 (CH, C-12), 97.3 (CH, C-¶), 78.8 (C, C-15), 72.6 (CH, C-¶), 
71.0 (CH, C-¶), 71.0 (CH, C-¶), 68.7 (CH, C-¶), 62.3 (CH2, C-¶), 53.7 (CH, C-10), 
42.0 (CH2, C-8), 39.5 (CH2, C-4), 35.2 (CH2, C-1), 33.9 (CH2, C-9), 28.9 (CH3, C-20), 
27.1 (CH2, C-5), 26.3 (CH3, C-19), 16.8 (CH3, C-16), 16.5 (CH3, C-17), 14.4 (CH3, C-
18). HRESIMS m/z 889.3974 [M + Na]+ (calcd for C54H58O10Na, 889.3922). 
 
Fusco-ȕ-D-galactopyranoside (76) and Eunico-ȕ-D-galactopyranoside (77). 
Aglycones 15 and 16 PJȝPRO) were glycosylated using 63 according to 
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general procedure C and the crude product was deprotected according to general 
procedure D. The desired glycosides were separated by RP-HPLC (phenylhexyl, 81% 
CH3OH). 76 (1.4 mgȝPRO, 9%): >Į@25D = -8.06 (c 0.0500, CH3OH); ,5ȣmax 3381, 
3081, 3046, 2973, 2928, 2860, 1635, 1056 cm-1. 1H NMR (600 MHz, CD3OD) į 6.48 
(1H, dd, J = 15.4, 10.5 Hz, H-13), 5.90 (1H, d, J = 10.5 Hz, H-12), 5.84 (1H, dd, J = 
17.3, 10.8 Hz, H-6), 5.76 (1H, d, J = 15.4 Hz, H-14), 4.90 (1H, dd, J = 17.3, 1.1 Hz, H-
5), 4.87 (1H, dd, J = 10.9, 1.1 Hz, H-5), 4.81 (1H, br s, H-4), 4.60 (1H, br s, H-4), 4.29 
(1H, d, J = 7.5 Hz, H-¶, 3.81 (1H, dd, J = 3.4, 1.1 Hz, H-¶, 3.70 (1H, dd, J = 11.3, 6.0 
Hz, H-¶, 3.68 (1H, dd, J = 11.3, 6.0 Hz, H-¶, 3.48 (1H, dd, J = 9.8, 7.5 Hz, H-¶, 
3.44 (1H, dd, J = 9.8, 3.4 Hz, H-¶+DSSGGJ = 6.0, 1.1 Hz, H-¶+
app. dd, J = 12.8, 3.0 Hz, H-2), 2.03-1.97 (1H, m, H-10), 1.78 (3H, s, H-18), 1.71 (3H, s, 
H-16), 1.66 (1H, app. ddd, J = 12.8 Hz, H-1), 1.57-1.52 (2H, m, H-9), 1.55-1.51 (1H, m, 
H-8), 1.49-1.45 (1H, m, H-1), 1.46-1.42 (1H, m, H-8), 1.41 (3H, s, H-19), 1.36 (3H, s, H-
20), 1.03 (3H, s, H-17). 13C NMR (150 MHz, CD3OD) į 151.6 (CH, C-6), 149.0 (C, C-
3), 144.3 (C, C-11), 138.4 (CH, C-14), 127.1 (CH, C-13), 124.2 (CH, C-12), 112.7 (CH2, 
C-4), 110.4 (CH2, C-5), 100.3 (CH, C-¶), 79.1 (C, C-15), 76.3 (CH, C-¶), 75.1 (CH, C-
¶), 72.7 (CH, C-¶), 70.2 (CH, C-¶), 62.4 (CH2, C-¶), 54.1 (CH, C-2), 49.2 (CH, C-
10), 41.1 (CH2, C-8), 40.8 (C, C-7), 34.1 (CH2, C-1), 28.7 (CH3, C-20), 27.8 (CH2, C-9), 
27.4 (CH3, C-19), 25.3 (CH3, C-16), 17.2 (CH3, C-17), 15.4 (CH3, C-18). HRESIMS m/z 
473.2861 [M + Na]+ (calcd for C26H42O6Na, 473.2874). 77 (1.6 mgȝPRO, 4%): IR 
ȣmax 3373, 3047, 2971, 2923, 2856, 1648, 1591, 1054 cm-1. 1H NMR (600 MHz, CD3OD) 
į 6.43 (1H, dd, J = 15.1, 10.5 Hz, H-13), 5.85 (1H, d, J = 10.2 Hz, H-12), 5.74 (1H, d, J 
= 15.4 Hz, H-14), 5.25-4.95 (1.2H, br m, H-2, H-6), 4.79 (0.4H, br d, J = 11.3 Hz, H-6), 
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4.55 (0.4H, br d, J = 10.2 Hz, H-2), 4.32-4.28 (1H, m, H-¶+EUGGJ = 3.0 Hz, 
H-¶+GGJ = 11.3, 6.0 Hz, H-¶.68 (1H, dd, J = 11.3, 6.4 Hz, H-¶, 3.50-
3.45 (1H, m, H-¶, 3.47-3.43 (1H, m, H-¶, 3.43-3.39 (1H, m, H-¶, 2.40-2.33 (1H, m, 
H-8), 2.33-2.25 (1H, m, J = 12.4, 4.5 Hz, H-5), 2.22-2.17 (1H, m, H-1), 2.20-2.15 (1H, 
m, H-4), 2.10-2.05 (1H, m, H-1), 2.08-2.04 (1H, m, H-5), 2.07-2.05 (1H, m, H-8), 2.01-
1.95 (1H, m, H-10), 1.94-1.88 (1H, m, H-4), 1.77 (1.2H, s, H-18), 1.75 (1.8H, s, H-18), 
1.72-1.63 (2H, m, H-9), 1.59-1.53 (1.2H, br s, H-16), 1.54 (1.8H, s, H-16), 1.53-1.47 
(1.8H, br s, H-17), 1.41 (1.2H, s, H-17), 1.41 (3H, s, H-19), 1.36 (3H, s, H-20). 13C NMR 
(150 MHz, CD3OD) į 147.8 (C, C-11), 138.9 (C, C-7), 138.3 (CH, C-14), 132.6 (CH, C-
2), 130.2 (C, C-3), 127.6 (CH, C-6), 127.0 (CH, C-13), 123.2 (CH, C-12), 100.2 (CH, C-
¶&&-15), 76.3 (CH, C-¶&+&-¶&+&-¶&+&-¶
62.4 (CH2, C-¶ 54.8 (CH, C-10), 42.8 (CH2, C-8), 40.6 (CH2, C-4), 35.8 (CH2, C-1), 
34.8 (CH2, C-9), 28.8 (CH3, C-20), 27.6 (CH2, C-5), 27.4 (CH3, C-19), 17.0 (CH3, C-16), 
16.6 (CH3, C-17), 14.8 (CH3, C-18). HRESIMS m/z 473.2868 [M + Na]+ (calcd for 
C26H42O6Na, 473.2874). 
 
Fusco-Į-D-arabinopyranoside (78) and Eunico-Į-D-arabinopyranoside (79). 
Aglycones 15 and 16 PJȝPRO) were glycosylated using 63 according to 
general procedure C and the crude product was deprotected according to general 
procedure D. The desired glycosides were separated by RP-HPLC (phenylhexyl, 81% 
CH3OH). 78 (1.3 mgȝPRO, 9%): >Į@25D = -6.13 (c 0.0667, CH3OH); ,5ȣmax 3382, 
3081, 2972, 2926, 2856, 1636, 1085 cm-1. 1H NMR (600 MHz, CD3OD) į 6.48 (1H, dd, J 
= 15.8, 10.9 Hz, H-13), 5.89 (1H, d, J = 10.5 Hz, H-12), 5.84 (1H, dd, J = 17.3, 10.9 Hz, 
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H-6), 5.72 (1H, d, J = 15.4 Hz, H-14), 4.90 (1H, dd, J = 17.3, 1.5 Hz, H-5), 4.88 (1H, dd, 
J = 10.9, 1.5 Hz, H-5), 4.81 (1H, br s, H-4), 4.61 (1H, br s, H-4), 4.27 (1H, d, J = 6.8 Hz, 
H-¶, 3.79 (1H, dd, J = 12.4, 2.6 Hz, H-¶, 3.78-3.76 (1H, m, H-¶, 3.51-3.49 (1H, m, 
H-¶, 3.51-3.49 (1H, m, H-¶, 3.47 (1H, dd, J = 12.4, 1.1 Hz, H-¶+DSSGG
J = 12.8, 3.4 Hz, H-2), 2.04-1.98 (1H, m, H-10), 1.79 (3H, s, H-18), 1.71 (3H, s, H-16), 
1.67 (1H, app. ddd, J = 12.8 Hz, H-1), 1.57-1.53 (2H, m, H-9), 1.56-1.52 (1H, m, H-8), 
1.49-1.45 (1H, m, H-1), 1.44 (1H, dd, J = 9.0, 2.6 Hz, H-8), 1.39 (3H, s, H-19), 1.35 (3H, 
s, H-20), 1.03 (3H, s, H-17). 13C NMR (150 MHz, CD3OD) į 151.6 (CH, C-6), 149.0 (C, 
C-3), 144.4 (C, C-11), 138.1 (CH, C-14), 127.1 (CH, C-13), 124.1 (CH, C-12), 112.7 
(CH2, C-4), 110.4 (CH2, C-5), 100.2 (CH, C-¶), 79.1 (C, C-15), 74.4 (CH, C-¶), 72.7 
(CH, C-¶), 69.8 (CH, C-¶), 66.8 (CH, C-¶), 54.0 (CH, C-2), 49.2 (CH, C-10), 41.1 
(CH2, C-8), 40.8 (C, C-7), 34.0 (CH2, C-1), 28.7 (CH3, C-20), 27.9 (CH2, C-9), 27.3 
(CH3, C-19), 25.3 (CH3, C-16), 17.2 (CH3, C-17), 15.3 (CH3, C-18). HRESIMS m/z 
443.2768 [M + Na]+ (calcd for C25H40O5Na, 443.2768). 79 (1.0 mgȝPRO, 3%): 
>Į@25D = -34.4 (c 0.0050, CH3OH); ,5ȣmax 3379, 3081, 3041, 2970, 2924, 2854, 1634, 
1083, 1002 cm-1. 1H NMR (600 MHz, CD3OD) į 6.47-6.40 (1H, m, H-13), 5.85 (1H, d, J 
= 10.5 Hz, H-12), 5.71 (1H, d, J = 15.8 Hz, H-14), 4.95-5.25 (1.2H, br m, H-2, H-6), 4.80 
(0.4H, br d, J = 13.2 Hz, H-6), 4.55 (0.4H, br d, J = 9.8 Hz, H-2), 4.30-4.24 (1H, m, H-
¶, 3.80 (1H, dd, J = 12.4, 2.6 Hz, H-¶, 3.78-3.76 (1H, m, H-¶, 3.52-3.49 (1H, m, H-
¶, 3.51-3.49 (1H, m, H-¶, 3.47 (1H, dd, J = 11.7, 3.8 Hz, H-¶, 2.40-2.34 (1H, m, H-
8), 2.33-2.25 (1H, m, J = 12.8, 4.9 Hz, H-5), 2.22-2.17 (1H, m, H-1), 2.19-2.15 (1H, m, 
H-4), 2.10-2.04 (1H, m, H-1), 2.10-2.04 (1H, m, H-8), 2.07-2.03 (1H, m, H-5), 2.01-1.96 
(1H, m, H-10), 1.94-1.87 (1H, m, J = 12.0, 4.9 Hz, H-4), 1.77 (1.2H, s, H-18), 1.75 
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(1.8H, s, H-18), 1.71-1.63 (2H, m, H-9), 1.60-1.52 (1.2H, br s, H-16), 1.54 (1.8H, s, H-
16), 1.53-1.47 (1.8H, br s, H-17), 1.41 (1.2H, s, H-17), 1.40 (3H, s, H-19), 1.35 (3H, s, H-
20). 13C NMR (150 MHz, CD3OD) į 147.9 (C, C-11), 138.9 (C, C-7), 138.0 (CH, C-14), 
132.6 (CH, C-2), 130.2 (C, C-3), 127.7 (CH, C-6), 127.1 (CH, C-13), 123.1 (CH, C-12), 
100.2 (CH, C-¶), 79.1 (C, C-15), 74.4 (CH, C-¶), 72.7 (CH, C-¶), 69.8 (CH, C-¶), 
66.7 (CH2, C-¶), 54.8 (CH, C-10), 42.8 (CH2, C-8), 40.6 (CH2, C-4), 35.8 (CH2, C-1), 
34.8 (CH2, C-9), 28.9 (CH3, C-20), 27.6 (CH2, C-5), 27.3 (CH3, C-19), 17.0 (CH3, C-16), 
16.6 (CH3, C-17), 14.7 (CH3, C-18). HRESIMS m/z 443.2747 [M + Na]+ (calcd for 
C25H40O5Na, 443.2768). 
 
3.4.4 Synthesis and characterization of fuscoside mimics and methyl ether analogues 
 
EG3-Glycoside Mimics (80 and 81). Solvolysis of 15 and 16 (3.8 mg, 13 ȝmol) was 
performed according to general procedure E using triethylene glycol (EG3) and the 
desired products were separated by RP-HPLC (phenylhexyl, 87% CH3OH). 80 (1.1 mg, 
ȝPRO, 60%): >Į@25D = +5.31 (c 0.0583, CH3OH); ,5ȣmax 3435, 3080, 2972, 2927, 
2864, 1637, 1122, 1082 cm-1. 1H NMR (600 MHz, CD3OD) į 6.45 (1H, dd, J = 15.4, 10.5 
Hz, H-13), 5.90 (1H, d, J = 10.5 Hz, H-12), 5.84 (1H, dd, J = 17.7, 10.9 Hz, H-6), 5.58 
(1H, d, J = 15.4 Hz, H-14), 4.90 (1H, dd, J = 17.7, 1.1 Hz, H-5), 4.88 (1H, dd, J = 10.9, 
1.1 Hz, H-5), 4.81 (1H, br s, H-4), 4.61 (1H, br s, H-4), 3.66 (2H, dd, J = 5.3, 4.2 Hz, H-
¶-3.63 (2H, m, H-¶-3.63 (2H, m, H-¶.59 (2H, dd, J = 5.8, 4.4 Hz, H-
¶, 3.56 (2H, dd, J = 5.5, 4.5 Hz, H-¶3.47 (2H, dd, J = 5.8, 4.4 Hz, H-¶+
app. dd, J = 12.8, 3.0 Hz, H-2), 2.03-1.98 (1H, m, H-10), 1.79 (3H, s, H-18), 1.71 (3H, s, 
H-16), 1.67 (1H, app. ddd, J = 12.8, H-1), 1.57-1.53 (2H, m, H-9), 1.56-1.53 (1H, m, H-
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8), 1.49-1.45 (1H, m, H-1), 1.46-1.43 (1H, m, H-8), 1.30 (6H, s, H-19, H-20), 1.03 (3H, 
s, H-17). 13C NMR (150 MHz, CD3OD) į 151.6 (CH, C-6), 149.0 (C, C-3), 144.3 (C, C-
11), 137.8 (CH, C-14), 127.4 (CH, C-13), 124.0 (CH, C-12), 112.7 (CH2, C-4), 110.4 
(CH2, C-5), 76.7 (C, C-15), 73.7 (CH2, C-¶&+2, C-¶&+2, C-¶
(CH2, C-¶&+2, C-¶&+2, C-¶&+&-2), 49.2 (CH, C-10), 41.1 
(CH2, C-8), 40.8 (C, C-7), 34.1 (CH2, C-1), 27.9 (CH2, C-9), 26.9 (CH3, C-19, C-20), 
25.3 (CH3, C-16), 17.2 (CH3, C-17), 15.3 (CH3, C-18). HRESIMS m/z 443.3124 [M + 
Na]+ (calcd for C26H44O4Na, 443.3132). 81 (1.5 mgȝPRO, 36%): >Į@25D = -14.3 (c 
0.0583, CH3OH); ,5ȣmax 3449, 3040, 2971, 2923, 2860, 1650, 1122, 1081 cm-1. 1H 
NMR (600 MHz, CD3OD) į 6.40 (1H, dd, J = 15.4, 10.9 Hz, H-13), 5.85 (1H, d, J = 10.5 
Hz, H-12), 5.57 (1H, d, J = 15.4 Hz, H-14), 5.25-4.94 (1.2H, br m, H-2, H-6), 4.80 (0.4H, 
br d, J = 13.2 Hz, H-6), 4.56 (0.4H, br d, J = 10.2 Hz, H-2), 3.66 (2H, dd, J = 5.3, 4.5 Hz, 
H-¶, 3.66-3.62 (2H, m, H-¶, 3.66-3.62 (2H, m, H-¶, 3.61-3.58 (2H, m, H-¶, 3.57 
(2H, dd, J = 5.3, 4.5 Hz, H-¶-3.46 (2H, m, H-¶-2.34 (1H, m, H-8), 2.33-
2.25 (1H, m, H-5), 2.21-2.16 (1H, m, H-1), 2.19-2.15 (1H, m, H-4), 2.10-2.04 (1H, m, H-
1), 2.08-2.03 (1H, m, H-8), 2.07-2.02 (1H, m, H-5), 2.02-1.96 (1H, m, H-10), 1.93-1.87 
(1H, m, J = 11.7, 4.9 Hz, H-4), 1.78 (1.2H, s, H-18), 1.75 (1.8H, s, H-18), 1.69-1.64 (2H, 
m, H-9), 1.60-1.54 (1.2H, br s, H-16), 1.54 (1.8H, s, H-16), 1.54-1.46 (1.8H, br s, H-17), 
1.41 (1.2H, s, H-17), 1.31 (6H, s, H-19, H-20). 13C NMR (150 MHz, CD3OD) į 147.8 (C, 
C-11), 138.9 (C, C-7), 137.6 (CH, C-14), 132.6 (CH, C-2), 130.2 (C, C-3), 127.6 (CH, C-
6), 127.3 (CH, C-13), 123.0 (CH, C-12), 76.8 (C, C-15), 73.7 (CH2, C-¶72.1 (CH2, C-
¶71.6 (CH2, C-¶71.4 (CH2, C-¶63.1 (CH2, C-¶62.2 (CH2, C-¶54.8 (CH, C-
10), 42.8 (CH2, C-8), 40.6 (CH2, C-4), 35.8 (CH2, C-1), 34.7 (CH2, C-9), 27.6 (CH2, C-
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5), 26.9 (CH3, C-19, C-20), 17.0 (CH3, C-16), 16.6 (CH3, C-17), 14.8 (CH3, C-18). 
HRESIMS m/z 443.3111 [M + Na]+ (calcd for C26H44O4Na, 443.3132). 
 
EG4-Glycoside Mimics (82 and 83). Solvolysis of 15 and 16 (11.4 mg, 39.5 mmol) was 
performed according to general procedure E using EG4 and the desired products were 
separated by RP-HPLC (phenylhexyl, 86% CH3OH). 82 (2.2 mgȝPRO, 36%): >Į@25D 
= +2.38 (c 0.175, CH3OH); ,5ȣmax 3419, 3080, 2971, 2925, 2864, 1638, 1124, 1081 cm-
1
. 
1H NMR (600 MHz, CD3OD) į 6.44 (1H, dd, J = 15.4, 10.5 Hz, H-13), 5.89 (1H, d, J = 
10.2 Hz, H-12), 5.84 (1H, dd, J = 17.7, 11.3 Hz, H-6), 5.58 (1H, d, J = 15.4 Hz, H-14), 
4.90 (1H, dd, J = 17.3, 1.1 Hz, H-5), 4.88 (1H, dd, J = 10.5, 1.5 Hz, H-5), 4.81 (1H, br s, 
H-4), 4.61 (1H, br s, H-4), 3.66 (2H, dd, J = 5.5, 4.3 Hz, H-¶-3.62 (8H, m, H-¶
H-¶+-¶+-¶+GGJ = 5.8, 4.2, H-¶.56 (2H, dd, J = 5.6, 4.2 Hz, H-¶
3.47 (2H, dd, J = 5.7, 4.1 Hz, H-¶+DSSGGJ = 12.8, 3.4 Hz, H-2), 2.04-1.98 
(1H, m, H-10), 1.79 (3H, s, H-18), 1.71 (3H, s, H-16), 1.67 (1H, app. ddd, J = 12.8 Hz, 
H-1), 1.58-1.54 (2H, m, H-9), 1.56-1.52 (1H, m, H-8), 1.49-1.45 (1H, m, H-1), 1.46-1.41 
(1H, m, H-8), 1.31 (6H, s, H-19, H-20), 1.03 (3H, s, H-17). 13C NMR (150 MHz, 
CD3OD) į 151.6 (CH, C-6), 148.9 (C, C-3), 144.3 (C, C-11), 137.8 (CH, C-14), 127.3 
(CH, C-13), 124.0 (CH, C-12), 112.8 (CH2, C-4), 110.5 (CH2, C-5), 76.8 (C, C-15), 73.7 
(CH2, C-¶&+2, C-¶&+2, C-¶&-¶&-¶&-¶
(CH2, C-¶&+2, C-¶&+&-2), 49.2 (CH, C-10), 41.1 (CH2, C-8), 40.8 
(C, C-7), 34.1 (CH2, C-1), 27.9 (CH2, C-9), 26.9 (CH3, C-19, C-20), 25.4 (CH3, C-16), 
17.2 (CH3, C-17), 15.4 (CH3, C-18). HRESIMS m/z 448.3394 [M + Na]+ (calcd for 
C28H48O5Na, 487.3394). 83 (2.0 mgȝPRO, 15%): >Į@25D = -12.0 (c 0.0158, CH3OH); 
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,5ȣmax 3436, 3040, 2970, 2922, 2860, 1650, 1121, 1079 cm-1. 1H NMR (600 MHz, 
CD3OD) į 6.40 (1H, dd, J = 15.5, 10.9 Hz, H-13), 5.85 (1H, d, J = 9.5 Hz, H-12), 5.57 
(1H, d, J = 15.6 Hz, H-14), 5.26-4.94 (1.2H, br m, H-2, H-6), 4.80 (0.4H, br d, J = 12.1 
Hz, H-6), 4.55 (0.4H, br d, J = 10.4 Hz, H-2), 3.67 (2H, dd, J = 5.3, 4.5 Hz, H-¶-
3.63 (8H, m, H-¶+-¶+-¶+-¶-3.56 (2H, m, H-¶+GGJ = 5.3, 4.1 
Hz, H-¶-3.46 (2H, m, H-¶-2.34 (1H, m, H-8), 2.33-2.25 (1H, m, H-5), 
2.22-2.18 (1H, m, H-1), 2.20-2.15 (1H, m, H-4), 2.10-2.07 (1H, m, H-1), 2.09-2.04 (1H, 
m, H-8), 2.08-2.03 (1H, m, H-5), 2.02-1.96 (1H, m, H-10), 1.94-1.87 (1H, m, J = 12.4, 
5.3 Hz, H-4), 1.78 (1.2H, s, H-18), 1.75 (1.8H, s, H-18), 1.70-1.64 (2H, m, H-9), 1.60-
1.54 (1.2H, br s, H-16), 1.54 (1.8H, s, H-16), 1.54-1.46 (1.8H, br s, H-17), 1.41 (1.2H, s, 
H-17), 1.31 (6H, s, H-19, H-20). 13C NMR (150 MHz, CD3OD) į 147.8 (C, C-11), 138.9 
(C, C-7), 137.7 (CH, C-14), 132.6 (CH, C-2), 130.2 (C, C-3), 127.7 (CH, C-6), 127.3 
(CH, C-13), 123.0 (CH, C-12), 76.8 (C, C-15), 73.7 (CH2, C-¶&+2, C-¶
71.5, 71.5, 71.4 (CH2, C-¶&-¶&-¶&-¶&+2, C-¶ 62.2 (CH2, C-¶
(CH, C-10), 42.8 (CH2, C-8), 40.6 (CH2, C-4), 35.8 (CH2, C-1), 34.8 (CH2, C-9), 27.6 
(CH2, C-5), 26.9 (CH3, C-19, C-20), 17.0 (CH3, C-16), 16.6 (CH3, C-17), 14.8 (CH3, C-
18). HRESIMS m/z 487.3389 [M + Na]+ (calcd for C28H48O5Na, 487.3394). 
 
Methyl Ethers of Fuscol and Eunicol (53 and 54). Solvolysis of 15 and 16 (9.4 mg, 33 
ȝPRO) was performed according to general procedure E (THF not required) using CH3OH 
and separation by RP-HPLC (phenylhexyl, 94% CH3OH). 53 (1.8 mJȝPRO54%): 
>Į@25D = +3.14 (c 0.0833, CH3OH); ,5ȣmax 3080, 2973, 2929, 2860, 1638, 1441, 1376, 
1361, 1254, 1166, 1078, 969, 908, 889, 755 cm-1. 1H NMR (600 MHz, CD3OD) į 6.44 
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(1H, dd, J = 15.5, 10.7 Hz, H-13), 5.90 (1H, d, J = 10.7 Hz, H-12), 5.84 (1H, dd, J = 
17.6, 10.8 Hz, H-6), 5.54 (1H, d, J = 15.5 Hz, H-14), 4.90 (1H, dd, J = 17.6, 1.4 Hz, H-
5), 4.88 (1H, dd, J = 10.8, 1.4 Hz, H-5), 4.81 (1H, br s, H-4), 4.61 (1H, br s, H-4), 3.15 
(3H, s, 15-OCH3), 2.05 (1H, app. dd, J = 12.8, 3.4 Hz, H-2), 2.04-1.98 (1H, m, H-10), 
1.79 (3H, s, H-18), 1.71 (3H, s, H-16), 1.67 (1H, app. ddd, J = 12.8 Hz, H-1), 1.58-1.54 
(2H, m, H-9), 1.56-1.52 (1H, m, H-8), 1.49-1.45 (1H, m, H-1), 1.46-1.41 (1H, m, H-8), 
1.29 (6H, s, H-19, H-20), 1.03 (3H, s, H-17). 13C NMR (150 MHz, CD3OD) į 151.6 (CH, 
C-6), 148.9 (C, C-3), 144.4 (C, C-11), 137.2 (CH, C-14), 127.6 (CH, C-13), 123.9 (CH, 
C-12), 112.7 (CH2, C-4), 110.4 (CH2, C-5), 76.8 (C, C-15), 54.0 (CH, C-2), 50.6 (CH3, 
15-OCH3), 49.2 (CH, C-10), 41.1 (CH2, C-8), 40.8 (C, C-7), 34.0 (CH2, C-1), 27.8 (CH2, 
C-9), 26.4 (CH3, C-19, C-20), 25.3 (CH3, C-16), 17.2 (CH3, C-17), 15.3 (CH3, C-18). 
HRESIMS m/z 325.2512 [M + Na]+ (calcd for C21H34ONa, 325.2502). 54 (0.9 mg, 3 
ȝPRO%): >Į@25D = -9.43 (c 0.0583, CH3OH); ,5ȣmax 3040, 2973, 2857, 1651, 1446, 
1383, 1359, 1253, 1165, 1075, 970, 862, 844, 756 cm-1. 1H NMR (600 MHz, CD3OD) į 
6.39 (1H, dd, J = 15.5, 10.7 Hz, H-13), 5.85 (1H, d, J = 10.7 Hz, H-12), 5.53 (1H, d, J = 
15.5 Hz, H-14), 5.26-4.94 (1.2H, br m, H-2, H-6), 4.79 (0.4H, br d, J = 12.0 Hz, H-6), 
4.56 (0.4H, br d, J = 10.5 Hz, H-2), 3.15 (3H, br s, 15-OCH3), 2.40-2.34 (1H, m, H-8), 
2.33-2.25 (1H, m, H-5), 2.23-2.17 (1H, m, H-1), 2.20-2.15 (1H, m, H-4), 2.10-2.06 (1H, 
m, H-1), 2.09-2.04 (1H, m, H-8), 2.08-2.03 (1H, m, H-5), 2.02-1.96 (1H, m, H-10), 1.94-
1.87 (1H, m, J = 12.4, 5.3 Hz, H-4), 1.78 (1.2H, s, H-18), 1.75 (1.8H, s, H-18), 1.72-1.63 
(2H, m, H-9), 1.59-1.55 (1.2H, br s, H-16), 1.54 (1.8H, s, H-16), 1.53-1.47 (1.8H, br s, H-
17), 1.41 (1.2H, s, H-17), 1.29 (6H, s, H-19, H-20). 13C NMR (150 MHz, CD3OD) į 
147.9 (C, C-11), 138.9 (C, C-7), 137.1 (CH, C-14), 132.6 (CH, C-2), 131.2 (C, C-3), 
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127.6 (CH, C-13), 127.5 (CH, C-6), 122.9 (CH, C-12), 76.8 (C, C-15), 54.8 (CH, C-10), 
50.6, (CH3, 15-OCH3), 42.8 (CH2, C-8), 40.6 (CH2, C-4), 35.8 (CH2, C-1), 34.8 (CH2, C-
9), 27.6 (CH2, C-5), 26.4 (CH3, C-19, C-20), 17.0 (CH3, C-16), 16.6 (CH3, C-17), 14.7 
(CH3, C-18). HRESIMS m/z 325.2499 [M + Na]+ (calcd for C21H34ONa, 325.2502). 
 
3.4.5 Synthesis and characterization of truncated pseudopterosin mimics 
 
2,6-Dimethoxyphenolic-2,3,4,6-tetra-O-benzoyl-ȕ-D-galactopyranoside (90). The 2,6-
dimethoxyphenol (86, 30.0 mg, 0.195 mmol) and benzoylated glycosyl 
trichloroacetimidate (88, 151.0 mg, 0.229 mmol) were dissolved in anhydrous CH2Cl2 (8 
mL) and stirred with 3Å molecular sieves (~0.5 g) under an N2 atmosphere for 20 min. 
Afterwards, the mixture was cooled to -78 °C and BF3·Et2O (0.206 mmol) was added. 
After stirring for 2.5 h at -78 °C, the glycosyl donor had completely reacted, as indicated 
by TLC analysis (hexanes:TBME 1:1). The reaction was quenched with Et31ȝ/
excess), diluted with EtOAc, and partitioned with DI H2O. The EtOAc phase was 
recovered and subjected to the standard work up procedure to provide the crude product, 
which was purified by MPLC (silica, KH[DQHVĺTBME) to give the desired glycoside 
(90, 101.9 mg, 0.139 mmol, 71%). 90: (white solid); >Į@25D +67.4 (c 0.1917, CH2Cl2); IR 
ȣmax 3065, 2962, 2939, 2838, 1726, 1601, 1479, 1258, 1109, 1069, 709 cmí1. 1H NMR 
(C6D60+]į2H, d, J = 7.8 Hz), 8.10 (2H, d, J = 7.8 Hz), 8.07 (2H, d, J = 7.8 
Hz), 8.00 (2H, d, J = 7.8 Hz), 7.10 (1H, t, J = 7.5 Hz), 7.06 (1H, t, J = 7.5 Hz), 7.03 (2H, 
t, J = 7.7 Hz), 7.01 (1H, t, J = 7.5 Hz), 6.92 (2H, t, J = 7.6 Hz), 6.91 (2H, t, J = 7.6 Hz), 
6.85 (1H, t, J = 7.5 Hz), 6.78 (1H, t, J = 8.4 Hz, H-4), 6.73 (2H, t, J = 7.7 Hz), 6.60 (1H, 
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dd, J = 10.4, 7.9 Hz, H-ƍ2H, d, J = 8.4 Hz, H-3), 6.14 (1H, dd, J = 3.6, 1.2 Hz, 
H-ƍ1H, dd, J = 10.4, 3.6 Hz, H-ƍ1H, d, J = 7.9 Hz, H-ƍ1H, dd, 
J = 11.3, 6.6 Hz, H-ƍ1H, dd, J = 11.3, 6.6 Hz, H-ƍ1H, app. ddd, J = 6.6, 
1.2 Hz, H-ƍ6H, s, 2-OCH3, 6-OCH3). 13C NMR (C6D60+]į&
165.8 (C), 165.7 (C), 165.4 (C), 153.9 (C, C-2), 136.1 (C, C-1), 133.2 (CH), 133.1 (CH), 
133.0 (CH), 132.7 (CH), 130.8 (CH), 130.5 (CH), 130.3 (CH), 130.1 (CH), 130.1 (C), 
130.0 (C), 129.7 (C), 129.6 (C), 128.8 (CH), 128.6 (CH), 128.4 (CH), 128.3 (CH), 124.6 
(CH, C-4), 106.1 (CH, C-3), 103.1 (CH, C-ƍ&+&-ƍ&+&-ƍ
(CH, C-ƍ&+&-ƍ&+2, C-ƍ&+3, 2-OCH3, 6-OCH3). HRESIMS 
m/z 755.2088 [M + Na]+ (calcd for C42H36O12Na, 755.2099). 
 
2,6-Dimethoxyphenolic-ȕ-D-galactopyranoside (92). The benzoylated glycoside (90, 
PJȝPROZDVVWLUUHGZLWK.2CO3 (38.8 mg, 0.281 mmol) in MeOH:TBME 
(5:1, 3 mL) for 20 h. After the deprotection was completed, as indicated by TLC analysis 
(hexanes:TBME 1:1), the reaction mixture was diluted with H2O and desalted by solid 
phase extraction (C18, 19:1 H2O:CH3OH). The product was then eluted with CH3OH and 
purified by RP-MPLC (C18, H2O ĺ CH3OH) to provide 90 PJȝPRO
90: (colorless solid)>Į@25D íc 0.8333, CH2Cl2); ,5ȣmax 3388, 3008, 2940, 2841, 
1599, 1480, 1256, 1108, 1072 cmí1. 1H NMR (DMSO-d60+]į+ t, J = 
8.4 Hz, H-4), 6.66 (2H, d, J = 8.4 Hz, H-3), 4.83 (1H, d, J = 7.6 Hz, H-ƍ±4.74 
(2H, Pƍ-OH, ƍ-OH), 4.50-4.44 (2H, Pƍ-OH, ƍ-OH), 3.74 (6H, s, 2-OCH3), 3.67 
(1H, app. t, J = 3.3 Hz, H-ƍ±3.52 (1H, m, H-ƍ±3.52 (1H, m, H-ƍ±
3.33 (1H, m, H-ƍ±3.32 (1H, m, H-ƍ+DSSWJ = 6.3 Hz, H-ƍ13C 
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NMR (DMSO-d60+]į&&-2), 134.9 (C, C-1), 123.7 (CH, C-4), 106.6 
(CH, C-3), 103.5 (CH, C-ƍ&+&-ƍ&+&-ƍ&+&-ƍ
(CH, C-ƍ&+2, C-ƍ&+3, 2-OCH3). HRESIMS m/z 339.1043 [M + Na]+ 
(calcd for C14H20O8Na, 339.1050). 
 
2,6-Dimethoxy-3-(3-methylbut-2-enyl)phenolic-2,3,4,6-tetra-O-benzoyl-ȕ-D-
galactopyranoside (91). The glycosylation procedure that was described for the 
synthesis of 90 was repeated using 3-prenyl-2,6-dimethoxyphenol (89, 44.6 mg, 0.201 
mmol) as the glycosyl accepting substrate and the benzoylated glycosyl 
trichloroacetimidate (88, 175.6 mg, 0.266 mmol) and. The crude product was separated 
by MPLC (silica, hexanes ĺ TBME) to purify the desired glycoside (91, 149.1 mg, 
0.186 mmol, 93%). 91: (pale yellow solid)>Į@25D +75.9 (c 0.225, CH2Cl2); ,5ȣmax 3063, 
2966, 2936, 1726, 1602, 1493, 1451, 1094, 1069, 709 cmí1. 1H NMR (CD3OD, 600 
0+]į2H, d, J =  7.7 Hz), 7.90 (4H, d, J =  7.8 Hz), 7.75 (2H, d, J =  7.8 Hz), 7.67 
(1H, t, J =  7.7 Hz), 7.57 (1H, t, J =  7.7 Hz), 7.54 (2H, t, J =  7.7 Hz), 7.51 (1H, t, J =  7.7 
Hz), 7.45 (1H, t, J =  7.6 Hz), 7.40 (2H, t, J =  7.7 Hz), 7.36 (2H, t, J =  7.7 Hz), 7.25 (2H, 
t, J =  7.7 Hz), 6.80 (1H, d, J = 8.6 Hz, H-4), 6.54 (1H, d, J = 8.6 Hz, H-5), 6.03 (1H, dd, 
J = 10.3, 8.0 Hz, H-ƍ1H, app. d, J = 3.4 Hz, H-ƍ1H, dd, J = 10.3, 3.4 
Hz, H-ƍ1H, d, J = 8.0 Hz, H-ƍ1H, app. t, J = 7.4 Hz, H-8), 4.58 (1H, dd, 
J = 10.8, 7.0 Hz, H-ƍ1H, app. dd, J = 7.0, 4.9 Hz, H-ƍ1H, dd, J = 10.8, 
4.9 Hz, H-ƍ3H, s, 2-OCH3), 3.53 (3H, s, 6-OCH3), 3.17-3.09 (2H, m, H-7), 1.67 
(3H, s, H-11), 1.64 (3H, s, H-10). 13C NMR (CD32'0+]į (C), 167.3 (C), 
167.1 (C), 166.8 (C), 152.7 (C, C-2), 152.6 (C, C-6), 139.9 (C, C-1), 134.9 (CH), 134.6 
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(CH), 134.5 (CH), 134.4 (CH), 134.3 (C), 132.9 (C), 131.0 (C), 131.0 (C), 130.9 (CH), 
130.7 (CH), 130.6 (CH), 130.5 (CH), 130.2 (C, C-9), 129.9 (CH), 129.6 (CH), 129.1 
(CH, C-3), 129.0 (CH), 128.7 (CH), 125.9 (CH, C-4), 124.4 (CH, C-8), 109.0 (CH, C-5), 
103.2 (CH, C-ƍCH, C-ƍCH, C-ƍ.3 (CH, C-ƍCH, C-ƍ
63.7 (CH2, C-ƍ7 (CH3, 2-OCH3), 56.6 (CH3, 6-OCH3), 29.0 (CH2, C-7), 25.9 (CH3, 
C-11), 17.9 (CH3, C-10). HRESIMS m/z 823.2754 [M + Na]+ (calcd for C47H44O12Na, 
823.2725). 
 
2,6-Dimethoxy-3-(3-methylbut-2-enyl)phenolic-ȕ-D-galactopyranoside (93). The 
deprotection procedure that was described for the synthesis of 92 was repeated for 91 
PJȝPRODQG.2CO3 (33.4 mg, 0.242 mmol). The product was purified using 
the method described for 92 to yield the desired glycoside (93, PJȝPRO
75%). 93: (colorless solid)>Į@25D íc 0.6917, CH3OH); ,5ȣmax 3392, 2967, 2914, 
1602, 1494, 1463, 1442, 1090 cmí1. 1H NMR (DMSO-d60+]į1H, d, J = 
8.5 Hz, H-4), 6.70 (1H, d, J = 8.5 Hz, H-5), 5.20 (1H, app. t, J = 7.3 Hz, H-8), 4.96 (1H, 
d, J  +]ƍ-OH), 4.92 (1H, d, J = 7.6 Hz, H-ƍ1H, d, J  +]ƍ-OH), 
4.49 (1H, Pƍ-OH), 4.47 (1H, Pƍ-OH), 3.76 (3H, s, 6-OCH3), 3.72 (3H, s, 2-OCH3), 
3.68 (1H, app. dd, J = 3.5 Hz, H-ƍ±3.55 (1H, m, H-ƍ±3.52 (1H, m, H-ƍ
3.39±3.36 (1H, m, H-ƍ±3.32 (2H, m, H-ƍ1H, app. t, J = 6.2 Hz, H-ƍ
3.24±3.15 (2H, m, H-7), 1.68 (3H, s, H-11), 1.67 (3H, s, H-10). 13C NMR (DMSO-d6, 
150 0+]į(C, C-2), 151.1 (C, C-6), 138.8 (C, C-1), 131.3 (C, C-9), 127.4 (C, C-
3), 123.6 (CH, C-4), 123.4 (CH, C-8), 108.9 (CH, C-5), 103.2 (CH, C-ƍ&+&-
ƍ&+&-ƍ&+&-ƍ&+&-ƍ&+3, 6-OCH3), 60.1 (CH2, 
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C-ƍ&H3, 2-OCH3), 27.7 (CH2, C-7), 25.5 (CH3, C-11), 17.6 (CH3, C-10). 
HRESIMS m/z 407.1687 [M + Na]+ (calcd for C19H28O8Na, 407.1676). 
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CHAPTER 4 
 
IDENTIFICATION OF PUTATIVE PROTEIN TARGETS OF 
PSEUDOPTEROXAZOLE: A CHEMICAL  
PROTEOMICS APPROACH 
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4.1 Introduction 
 
Mycobacterium tuberculosis, the etiologic agent of tuberculosis (TB), causes 
nearly one and a half million deaths annually, and is thus one of the leading causes of 
infectious disease-related mortality.174a Primarily affecting impoverished regions around 
the globe, M. tuberculosis has established a latent infection in one third of the human 
population.175 Although TB may be cured with a six- to nine-month antibiotic treatment, 
low rates of patient compliance and the emergence of multidrug-resistant strains of M. 
tuberculosis pose a tremendous challenge for the management of TB.190, 193 The 
requirement of such prolonged treatments is largely attributed to a physiological state of 
non-replicating persistence (NRP), a dormant phenotype of M. tuberculosis that exhibits 
antibiotic tolerance.189 Shortening the duration of antitubercular chemotherapy by 
targeting NRP mycobacteria and combatting drug resistance are among the major goals 
of current TB research.  
Bedaquiline (SirturoTM) was recently approved by the FDA for the treatment of 
drug resistant TB infections, representing the first new antitubercular drug class in 
approximately 40 years.288 This diarylquinoline inhibits adenosine triphosphate (ATP) 
biosynthesis by interacting with ATP synthase subunit c, as demonstrated by affinity 
chromatography198 and analysis of bedaquiline-resistant strains of M. tuberculosis.289 
Owing to its unique mechanism of action, bedaquiline underwent accelerated FDA 
approval to provide an alternative therapeutic option for patients with multi-drug resistant 
(MDR)- and extensively-drug resistant (XDR)-TB, despite serious concerns over the 
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GUXJ¶VVDIHW\290 Therefore, a strong demand still exists for novel antitubercular drugs, 
particularly those exhibiting a unique mechanism of action and low toxicity. 
Pseudopteroxazole (30, Figure 4.1) is an amphilectane diterpene first isolated by 
Rodríguez et al. from the alcyonacean coral Pseudopterogorgia elisabethae.154 This 
natural product shows strong inhibitory activity against M. tuberculosis H37Rv [minimum 
inhibitory concentration (MIC): ȝJP/@([SORLWLQJWKHVWUXFWXUDOUHVHPEODQFH
between 30 and the aglycone of pseudopterosins G-J (33-36), a semisynthesis of 30 and a 
library of novel analogues was accomplished.160 These synthetic efforts provided 
structure-activity relationships (SAR) and led to the discovery of a histidine-derived 
analogue, 21-((1H-imidazol-5-yl)methyl)-pseudopteroxazole (PtxHis, 37).161  
The activity of PtxHis (37) against NRP M. tuberculosis (MIC: ȝJP/LV
significantly greater than 30 (MIC: ȝJP/\HWRQSDUZLWKLWVSRWHQF\DJDLQVWM. 
tuberculosis H37Rv (MIC: ȝJP/161 The selectivity index [the ratio between the 
Vero cell half-maximal inhibitory concentration (IC50) and M. tuberculosis MIC values] 
of 37, like that of 30 and 33-36, is highly appealing as no cytotoxicity was observed in 
the Vero cell assay (IC50: >128 ȝJP/). Although the activity of 37 against M. 
tuberculosis H37Rv was modest (MIC: ȝJP/, 34 ȝ0LQFRPSDULVRQWRisoniazid and 
rifampin, its activity compared favorably to ethambutol (4.6±ȝ0kanamycin (2.5±
ȝ0FDSUHRP\FLQ±ȝ0 and cycloserine (122±ȝ0291 
In collaboration with Dr. Malcolm McCulloch, the MIC of 30 against a panel of 
isogenic mono-resistant M. tuberculosis H37Rv strains was determined (Table 4.1).161 
These strains were resistant to one of the following antitubercular drugs: rifampin, 
isoniazid, streptomycin, kanamycin, cycloserine, and moxifloxacin. Any cross-resistance  
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Figure 4.1. Chemical structures of pseudopteroxazole (30) and pseudopterosins G-J (33-
36), antitubercular diterpenes isolated from Pseudopterogorgia elisabethae. Also shown 
is the structure of PtxHis (37), a semisynthetic analogue with significant activity in the 
low-oxygen-recovery assay (LORA). 
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Table 4.1. Susceptibility of isogenic mono-resistant M. tuberculosis H37Rv strains to 
pseudopteroxazole (30), rifampin, and isoniazid.161 
 0,&ȝJP/a 
Compound H37Rv RMPr INHr SMr KMr CSr MOXr 
30 7 8 8 14 16 14 8 
Rifampin 0.03 >3.3 0.02 0.08 0.02 0.01 0.02 
Isoniazid 0.03 0.12 >1.10 0.13 0.13 0.12 0.03 
 
a
 Microplate Alamar blue assay (MABA) against wild-type M. tuberculosis H37Rv 
(H37Rv) and M. tuberculosis H37Rv isogenic strains resistant to rifampin (RMPr), 
isoniazid (INHr), streptomycin (SMr), kanamycin (KMr), cycloserine (CSr) and 
moxifloxacin (MOXr). 
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between 30 and the above clinical drugs would therefore indicate a shared mode of 
action. Although 30 was significantly less potent than rifampin and isoniazid, no cross-
resistance was observed, suggesting that it may exert its antitubercular activity through a 
distinct mechanism of action. 
The aim of this research is to identify putative protein targets of 
pseudopteroxazole (30) by means of chemical proteomics using one of two 
complementary approaches: affinity chromatography and photoaffinity labeling. Given 
the unique structure and antitubercular properties of 30, this chemical proteomics 
approach may lead to the discovery of a novel therapeutic target for TB treatment. To 
achieve this aim, a collection of small molecule probes was prepared through a 
semisynthetic approach beginning with pseudopterosins G-J (33-36), a mixture of 
diterpene glycosides isolated from P. elisabethae. The molecular design of these probes 
was directed by SAR in order to maintain the high binding affinity of these ligands to 
their protein targets. The antimicrobial spectrum of 30 was also further characterized to 
investigate its antimicrobial properties. 
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4.2 Results and discussion 
 
4.2.1 Determination of the antimicrobial spectrum of pseudopteroxazole 
 In addition to their activity against mycobacterial species, pseudopteroxazole (30) 
and pseudopterosins G-J (33-36) are known to inhibit the growth of methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) with IC50 
values as low as 1-ȝJP/160 The pseudopterosins also show activity against 
Streptococcus pyogenes, Staphylococcus aureus, and Enterococcus faecalis.292 These 
results suggest that 30 may have clinical applications in addition to antitubercular 
chemotherapy. Therefore, the antimicrobial spectrum of 30 and 33 was further 
characterized against a taxonomically diverse panel of 22 Gram-positive and 10 Gram-
negative clinical isolates using the agar disk diffusion method.293 On account of the 
interesting activity of PtxHis (37) against NRP M. tuberculosis, this semisynthetic 
analogue was also evaluated in these assays.  
 The microbial collection included a variety of bacteria that cause human illness, 
including Streptococcus pneumoniaea, Pseudomonas aeruginosa, S. aureus, a number of 
common foodborne pathogens (Clostridium perfringens, Campylobacter jejuni, and 
Listeria monocytogenes), as well as Streptococcus equi subsp. equi, Rhodococcus equi, 
Bordetella bronchiseptica, and several other bacteria that are significant pathogens in 
domesticated animals and commonly encountered in veterinary medicine. Other 
organisms, such as Micrococcus luteus and B. bronchiseptica, are relatively innocuous or 
rarely infect humans. The panel of control antibiotics, which included penicillin G, 
vancomycin, rifampin, gentamicin, ciprofloxacin, and polymyxin, was carefully selected 
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so as to encompass a variety of antimicrobial mechanisms of action. Cross-resistance 
between pseudopteroxazole (30) and one of the antibiotic controls might indicate a 
common mechanism and aid the identification of its cellular target. 
At a FRQFHQWUDWLRQRIȝJGLVNditerpenes 30, 33, and 37 were active against 
Gram-positive bacteria and largely inactive against Gram-negative strains (Tables 4.2-
4.3), presumably attributable to the low permeability of the lipopolysaccharide layer. 
Obstruction of peptidoglycan biosynthesis was conceivable, however, the observed 
activity against NRP M. tuberculosis suggested otherwise. Notably, the NRP phenotype 
is known to tolerate antimycobacterial drugs targeting cell wall biosynthesis, including 
isoniazid, cycloserine, and ethambutol.294 Unlike penicillin G and vancomycin, the 
activity against MRSA and VRE was comparable to the activity against S. aureus and E. 
faecalis respectively, indicating their different antimicrobial mechanisms of action. 
Among the Gram-positive bacteria, no growth inhibition of Erysipelothrix rhusiopathiae 
and S. pneumoniaea was observed after administrating a ȝJGLVN concentration of each 
diterpene. Pseudopterosin G (33) typically induced larger zones of growth inhibition, 
presumably due to the greater aqueous solubility compared to pseudopteroxazole (30) and 
PtxHis (37). 
The greater susceptibility of Escherichia coli imp to the antibiotic controls is due 
to the higher permeability of its lipopolysaccharide layer. Polymyxin B, a cationic 
detergent that disrupts cell membrane integrity, was an exception as the zone of growth 
inhibition remained unchanged. Diterpenes 30, 33, and 37, however, were inactive 
against both E. coli strains, suggesting their low permeability across the  
153 
 
Table 4.2. Spectrum of antimicrobial activity of pseudopteroxazole (30), pseudopterosin G (33), and PtxHis (37) using the disk 
diffusion susceptibility method [zones of inhibition measured in mm (n = 2)].a 
 
Compound DMSO 30 33 37 Pen. Van. Rif. Gen. Cip. Poly. 
Concentration ȝJGLVN - 50 50 50 2 5 2 10 0.5 300b 
Gram-negative           
Escherichia coli imp 10 9 8 9 19 17 32 31 36 22 
Gram-positive           
Arcanobacterium pyogenes 10 10 11 15 50 21 48 27 9 - 
Clostridium perfringens 10 12 18 9 36 21 35 13 18 14 
Corynebacterium 
pseudotuberculosis - 12 18 14 26 16 38 18 26 7 
Erysipelothrix rhusiopathiae - - - - 35 - - - 28 - 
Listeria monocytogenes - 10c 20 11 27 15 25 26 10 11 
Micrococcus luteus 8 10 21 14 38 22 43 34 10 19 
Rhodococcus equi 7 11 17 9 19c 24 25 21 15c 11 
Staphylococcus aureus - 9 16 10 47 16 29 25 20 11 
Staphylococcus warneri - 9 15 9 37 16 36 33 22 21 
Streptococcus agalactiae 8 12 22 10 37 17 32 10 14 16 
Streptococcus canis 8 11 30 11 45 20 36 12 12 16 
Streptococcus equi subsp. equi 8 11 26 13 54 20 45 34 13 21 
Streptococcus equi subsp. 
zooepidemicus - 12 19 12 50 21 38 28 14 23 
Streptococcus pneumoniae - - - - 38 20 29 12 - - 
Streptococcus suis - 10 19 10 32 17 24 13c 14 7 
MRSA - 11 16 8 - 15 38 20 15 7 
Mycobacterium smegmatis 9 14 29 14 8 25 21 38 17 25 
Mycobacterium diernhoferi 10 12 31 16 11 22 21 32 42 28 
 
a
 The disk diffusions assays were completed with the assistance of Dr. Malcolm McCulloch and Nick McCarville. b Units/disk. c Zone 
of partial growth inhibition. 
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Table 4.3. Spectrum of antimicrobial activity of pseudopteroxazole (30), pseudopterosin G (33), and PtxHis (37) using the disk 
diffusion susceptibility method [zone of growth inhibition measured in mm (n = 2)].a 
Compound DMSO 30 33 37 Pen. Van. Rif. Gen. Cip. Poly. 
Concentration ȝJGLVN - 50 50 50 20 20 20 10 0.5 300b 
Gram-negatived           
Actinobacillus equuli 7 9 9 - 15 - 23 17 34 21 
Campylobacter jejuni - - - - - - - 26 18 16 
Escherichia coli - - 7 - 10 - 15 23 18 18 
Mannheimia haemolytica - - - - 42 - 31 15 32 23 
Proteus mirabilis - 10c 28c 20c 16 - 18c 22 35 23c 
Pseudomonas aeruginosa - - - - - - 10 19 22 20 
Gram-positive           
Bacillus cereus - 8 15 8 14c 20 21 28 20 12 
Enterococcus faecalis - 10 17 9 28 20 14 9 12 - 
VRE - 10 16 8 14 - 18 15 - - 
 
a
 The disk diffusions assays were completed with the assistance of Dr. Malcolm McCulloch and Nick McCarville. b Units/disk. c Zone 
of partial growth inhibition. d The diterpenes showed no activity against the following Gram-negative bacteria: Bordetella bronchiseptica, 
Klebsiella pneumoniae, and Salmonella enterica serovar Typhimurium.   
 
Overall, no growth inhibition was observed for the remaining vehicle controls, with the following exceptions: H2O and 20% CH3OH 
inhibited the growth of M. diernhoferi (8 mm), while 0.3% HCO2H inhibited the growth of A. equuli (7 mm), S. canis (7 mm), S. equi subsp. 
equi (8 mm), S. equi subsp. zooepidemicus (7 mm), and M. diernhoferi (10 mm). An analogue of elisabatin B, 14,15-dihydro-elisabatin B, 
was also tested and showed no activity. 
 
Abbreviations for control antibiotics: penicillin G (Pen.), vancomycin (Van.), rifampin (Rif.), gentamicin (Gen.), ciprofloxacin (Cip.), 
polymyxin B (Poly.).  
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lipopolysaccharide layer may not be responsible for their inactivity against this Gram-
negative bacterium. Application of these diterpenes onto the surface of the blood agar, a 
media used to support the growth of fastidious organisms, resulted in clear zones under 
the surface of the agar. This observation suggests that these diterpenes may induce 
hemolysis. Regardless, no cross-resistance to pseudopteroxazole (30) was observed for 
any of the control antibiotics, and as a result, there were no indications of a potential 
mechanism of action. 
 
4.2.2 Designing the affinity-based pseudopteroxazole probes 
The basic design of a pseudopteroxazole probe is primarily determined by the 
requirements of the following affinity-based techniques: affinity chromatography and 
photoaffinity labeling. To identify putative targets by affinity chromatography, an 
immobilized probe must consist of the diterpene scaffold as well as an appropriate spacer 
(Figure 4.2). The pseudopteroxazole scaffold enables the biochemical isolation of the 
target protein(s), by virtue of specific binding interactions, while the spacer improves 
binding affinity by reducing steric interactions with the stationary support.231 Considering 
the hydrophobic nature of pseudopteroxazole (30), ethylene glycol (EG)-based spacers 
were chosen over their polymethylene-based counterparts in order to impart greater water 
solubility to the chemical probe. The 4,7,10-trioxa-1,13-tridecanediamine (94) was 
chosen as a hydrophilic spacer due to its prevalence in the affinity chromatography 
literature and commercial availability.237 Owing to the remarkable binding affinity 
between biotin and streptavidin (dissociation constant, Kd = 10-15 M),228 biotinylation of 
small molecule probes is a common strategy for enabling their immobilization to  
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Figure 4.2. Chemical anatomy of the affinity-based pseudopteroxazole probes for the 
identification of protein target candidates by affinity chromatography or photoaffinity 
labeling approaches. Method A: Non-covalent immobilization of a biotinylated probe 
onto a streptavidin resin. Method B: Covalent immobilization of an amino-functionalized 
probe onto NHS-activated agarose. Method C: Photoaffinity labeling of a protein target 
by irradiation of benzophenone, followed by the attachment of a biotin reporter tag using 
click chemistry. Photolabeled targets may subsequently be enriched over a streptavidin 
resin and/or visualized by Western blotting analysis with a biotin reporter. 
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streptavidin resins.227a, 229 Covalent immobilization of small molecules to an NHS-
activated agarose support may otherwise be pursued.237 
The photoaffinity probe consists of three essential features: the diterpene scaffold, 
a benzophenone photoreactive group, and an alkyne handle (Figure 4.2). The reversible 
binding interaction between the pseudopteroxazole scaffold and the protein target(s) 
maintains their close association while the benzophenone moiety, under exposure to long-
wave UV light, becomes activated as a diradical and reacts with C-H bonds of amino 
acids to form a covalent adduct.295 Benzophenone was selected as the photoreactive 
moiety for its excellent stability under ambient light, high labeling efficiency, and the 
lower energy required for photoexcitation.242 After labeling the protein target(s), the 
alkyne moiety serves as a synthetic handle for the purpose of introducing a reporter tag 
via Cu(I)-catalyzed azide-alkyne [3 + 2] cycloaddition.249  
Composed of biotin or tetramethylrhodamine moieties, the reporter tag facilitates 
the visualization of photolabeled proteins through Western blotting analysis or 
fluorescence scanning.246, 252 The alkyne handle, unlike a reporter tag, is sterically 
inconspicuous and has a relatively minor impact on cellular uptake. As a result, the 
ELRRUWKRJRQDO³FOLFNFKHPLVWU\´LVDPHQDEOHWRLQVLWXSURWHLQODEHOLQJLHLGHQWLI\LQJ
specific binding interactions within the context of a living cell.249 This strategy is 
advantageous in consideration of the limitations of cell lysate preparation, which may fail 
to extract the protein target(s) of interest or cause denaturation.221, 224  The positions of 
the azide and alkyne moieties may be reversed, however, the directionality of the click 
reaction has a significant impact on the signal-to-noise ratio. Azido-functionalized 
reporter tags provide lower background labeling than their alkyne counterparts,249 hence 
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the azide-alkyne arrangement in Figure 4.2. Although an EG-based spacer may not be 
necessary, higher photolabeling efficiency may be achieved by increasing the 
conformational flexibility of the benzophenone moiety.241  
The challenge of synthesizing a pseudopteroxazole probe is the retention of the 
desired antimycobacterial activity, which serves as an indication of binding activity. As a 
result, SAR must be examined to identify positions on the diterpene scaffold that are 
suitable for synthetic modification. Unfortunately, only two positions on the scaffold of 
pseudopteroxazole (30) were amenable to chemical synthesis, the oxazole ring and the 
double bond. If the antimicrobial activity prohibits modification of these functionalities, 
the fucose moiety of pseudopterosin G (33) or the phenolic hydroxyl group of its 
aglycone methyl ether (95) could provide alternative sites for attaching the EG spacer. 
Although there is greater interest in 30 as an antitubercular agent, 33 and 95 are similar 
with regards to their structure and antimicrobial activity, suggesting they have a common 
mechanism of action. 
 
4.2.3 Synthesizing the pseudopteroxazole chemical probes 
The pseudopteroxazole probes were prepared using a semisynthetic approach 
beginning with a mixture of pseudopterosins G-J (33-36, Figure 4.3), which was 
extracted from P. elisabethae.296 The fucose moiety of 33-36 was cleaved by acid 
hydrolysis to provide the pseudopterosin G-J aglycone ortho-quinone (96), an 
intermediate required for introducing the oxazole ring. The ortho-quinone (96) was 
condensed with 4,7,10-trioxa-1,13-tridecanediamine (94) to attach the EG spacer, which 
occurred with concomitant ring closure to install the oxazole ring, providing  
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Figure 4.3. TKHVHPLV\QWKHWLFURXWHWRWKHSVHXGRSWHUR[D]ROHSUREHV5HDJHQWVDQGFRQGLWLRQVD+&Oǻ&+3OH:H2O (19:1), ~59%. (b) 
Ag2O (4.4 eq), 4,7,10-trioxa-1,13-tridecanediamine (94HTǻ&+3OH, 14% (unoptimized). (c) biotin-NHS (102), Et3N, DMF, 18%. 
(d) BPA-NHS (110), Et3N, CH2Cl2, 39%. (e) Ag2O (5.5 eq), L-glutamic acid 5-methyl ester (98, HTǻ&+3OH, 46%. (f) LiOH, 
acetone:H2O (10:1), 93%. (g) (i) NHS, DCC, CH2Cl2. (ii) 4-aminobenzophenone, 24% over two steps. (h) (i) NHS, DCC, CH2Cl2. (ii) 94 
(excess), 53% over two steps. (j) 102, Et3N, DMF, 53%. (k) 110, Et3N, CH2Cl2, 49%. (l) K2CO3, CH3OH, ~62%. (m) Ag2O (2.8 eq), glycine 
(13.5 eq), 16%. The synthesis of 102 and 110 is outlined in Figure C.2.
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Ptx-EG3-NH2 (97). This one-pot synthesis, however, was low yielding and resulted in the 
formation of multiple side products, including a significant amount of the oxazole 
regioisomer (5:1 ratio), which complicated the purification and characterization of 97. 
As an alternative approach, the ortho-quinone (96) was condensed with L-
glutamic acid 5-methyl ester (98) to furnish PtxGlu-CO2CH3 (99) in 46% yield (Figure 
4.3). The methyl ester functionality of 99 was removed by base hydrolysis to provide 
PtxGlu-CO2H (100) in high yields (93%). In a one-pot reaction, the carboxylic acid (100) 
was subsequently activated as an NHS ester and immediately reacted with 4,7,10-trioxa-
1,13-tridecanediamine (94) to introduce the EG spacer of PtxGlu-EG3-NH2 (101). For 
this reaction, 94 was added in excess to prevent the formation of dimers. After activating 
biotin as an NHS ester (102, Figure C.2), the primary amino groups of 97 and 101 were 
biotinylated to provide chemical probes Ptx-EG3-Biotin (103) and PtxGlu-EG3-Biotin 
(104), respectively. 
For the preparation of photoaffinity probes, a divergent strategy was envisaged. 
The amino-functionalized Ptx-EG3-NH2 (97) and PtxGlu-EG3-NH2 (101) could serve as 
synthetic precursors to the photoaffinity probes because of the synthetic accessibility of 
their primary amino groups. To generate an amino-specific benzophenone-alkyne (BPA) 
attachment, commercially available ¶-dihydroxybenzophenone (105) was O-alkylated 
with propargyl bromide to introduce the alkyne handle (106, Figure C.2), a reaction that 
also provided ¶-dipropargyloxy-benzophenone (107) as a side product. The product of 
this reaction underwent an additional O-alkylation using tert-butyl bromoacetate to 
synthesize the tert-butyl ester (108), which was immediately subjected to acid hydrolysis 
using trifluoroacetic acid to provide the carboxylic acid (109) in 93% overall yield.  
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The carboxylic acid (109) was then activated with NHS in the presence of DIC to 
provide an NHS ester intermediate (110, Figure C.2), which was cross-linked with Ptx-
EG3-NH2 (97) and PtxGlu-EG3-NH2 (101) to furnish the two photoaffinity probes, Ptx-
EG3-BPA (111) and PtxGlu-EG3-BPA (112, Figure 4.3). To determine if the EG spacer 
was necessary, a photoaffinity probe lacking the spacer was synthesized. For this 
synthesis, PtxGlu-CO2H (100) was activated as an NHS ester, as described previously, 
and then reacted with 4-aminobenzophenone to attach the photoreactive moiety. This 
reaction provided PtxGlu-BP (113) with a low yield of 24%. 
 
4.2.4 Synthesizing the pseudopterosin-derived chemical probes 
The pseudopterosin G-J aglycone methyl ether (95), a compound that is 
structurally similar to pseudopteroxazole (30), provided an opportunity to attach the EG 
spacer to the phenolic hydroxyl group. The aglycone methyl ether (95) was prepared 
using a known procedure, beginning with a methylation using iodomethane followed by 
the removal of the fucose moiety by acid hydrolysis (Figure 4.4).161, 280a Afterwards, 95 
underwent phenolic O-alkylation using tert-butyl bromoacetate to provide Ps-CO2t-Bu 
(114), a synthetic intermediate containing a site for spacer attachment. The tert-butyl 
ester (114) was then subjected to base hydrolysis to generate Ps-CO2H (115) in high 
yields. During the purification of 115 by RP-MPLC, the methyl ester (116, Ps-CO2CH3) 
was obtained as a solvent-derived artifact. Upon activation of 115 as an NHS ester, using 
a previously described procedure, the 4,7,10-trioxa-1,13-tridecanediamine (94) was 
added in excess to provide Ps-EG3-NH2 (117). A product of dimerization, Ps-EG3-Ps 
(118), was also isolated from this reaction and kept for antimicrobial evaluation. After 
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Figure 4.4. The semisynthetic route to the pseudopterosin-derived probes. Reagents and conditions: (a) (i) CH3I, K2CO3, acetone. (ii) HCl, 
ǻ&+3OH:H2O (19:1), ~62% over two steps. (b) tert-butyl bromoacetate (4.2 equiv.), K2CO3, acetone, 50%. (c) LiOH, THF, 95%. (d) 115, 
CH3OH, HCO2H (0.1%). (e) (i) 115, NHS, DIC, CH2Cl2. (ii) 4,7,10-trioxa-1,13-tridecanediamine (94, excess), 66% over two steps. (f) 
biotin-NHS (102), 14% over three steps. (g) H2, Pd/C, EtOAc, 96%. (h) (i) O3, CH3OH:pyridine (1:1), -78°C. (ii) (CH3)2S, 69% over two 
steps. (j) CH3OH:pyridine (1:1). (k) (i) 94 (excess), CH2Cl2. (ii) NaBH4, 48% over two steps. (l) 33, TsOH (0.03 eq), acetone, 87%. (m) 
Dess-Martin periodinane (1.2 eq), CH2Cl2, 23%. Compound 118 was obtained as a side product from reaction (e).
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attaching the EG spacer, a biotin moiety was introduced to the primary amino group of 
117 using biotin-NHS (102) to provide Ps-EG3-Biotin (119) as an additional chemical 
probe for antimicrobial evaluation. 
Previous SAR data for the oxazole position has indicated that the antimicrobial 
activity may tolerate structural variations at this position,160-161 however, the biological 
significance of the double bond was unknown. To expedite the interrogation of SAR 
around this position, the pseudopterosin G-J aglycone methyl ether (95) was selected for 
derivatization instead of pseudopteroxazole (30). The aglycone methyl ether (95) was 
more readily available in large quantities, whereas 30 was synthesized as a mixture of 
regioisomers in lower yields (16%). Therefore, the double bond of 95 was oxidatively 
cleaved by ozonolysis and reduced with dimethyl sulfide to generate the aldehyde, CHO-
PsOH (120), in 69% yield (Figure 4.4). During this synthesis, nucleophilic addition of 
CH3OH to 120 also occurred, resulting in the formation of an acetal (121, CH(OCH3)2-
PsOH). This side reaction was mitigated by shortening the duration of ozone treatment.  
The carbonyl functionality of 120 provided a handle for attaching the EG spacer 
by way of a reductive amination. Similar to the preparation of PtxGlu-EG3-NH2 (101) 
and Ps-EG3-NH2 (117), this reaction was carried out with an excess of 4,7,10-trioxa-1,13-
tridecanediamine (94) to avoid dimerization. The secondary aldimine intermediate was 
subsequently reduced by NaBH4 to provide H2N-EG3-PsOH (122), as well as its 
epimerized analogue (123, epi-H2N-EG3-PsOH). These two products were separated by 
semi-preparative RP-HPLC and the configuration at C-1 was determined by examining 
NOESY correlations. To provide additional SAR data, the aglycone methyl ether (95) 
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was hydrogenated to form compound 124 by vigorously stirring a solution of 95 and 
Pd/C under a H2 atmosphere. 
The carbohydrate moiety of pseudopterosin G (33) served as an additional site for 
attaching the EG-based spacer. Initially, all acetate functionalities of 34-36 were removed 
through base hydrolysis, which facilitated the purification of the desired glycoside (33, 
Figure 4.4). To achieve regioselectivity for spacer attachment, the fucose moiety 
underwent acetonide protection by adding a substoichiometric amount of TsOH to an 
acetone solution of 33. Preferential ketalization of WKH¶¶-diol was anticipated because 
of their favorable cis orientation. Indeed, NMR spectroscopic analysis of the 
pseudopterosin G acetonide (125) confirmed that the acetonide moiety was located at this 
position. 
Oxidation of the remaining secondary hydroxyl group with Dess-Martin 
periodinane was then attempted to provide the ketone (126), a synthetic intermediate 
poised for the attachment of an EG spacer via reductive amination (i.e. 127, Figure 4.4). 
Unfortunately, the pseudopterosin G diketal (128) was obtained as an unanticipated 
product, whose structure was confirmed by NMR spectroscopy and comparison to the 
literature on pseudopterosins and their redox properties.297 Although other synthetic 
strategies could have been pursued, no further efforts toward a glycosidic probe were 
made as other chemical probes were available for antimicrobial evaluation. Unlike the 
ortho-quinone (96), however, the diketal (128) possesses a single carbonyl group at C-9 
and may therefore be exploited as an intermediate for synthesizing novel 
pseudopteroxazole analogues without simultaneous formation of regioisomer side 
products.  
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4.2.5 Antimicrobial evaluation of chemical probes and analysis of structure-activity 
relationships 
To identify the protein target(s) of pseudopteroxazole (30) by chemical 
proteomics, an assessment of SAR must be carried out to determine the biological 
relevance of probe candidates. Previous work showed that the antimycobacterial activity 
had tolerated a variety of unnatural substituents at the oxazole position of 30.160 The 
antitubercular activities exhibited by 30, PtxHis (37), pseudopterosins G-J (33-36), and 
the aglycone methyl ether (95) were also comparable,161 further indicating that the 
oxazole ring is a suitable position for synthetic modification. All semisynthetic 
compounds were evaluated for antimicrobial activity against MRSA, VRE, S. warneri, 
M. smegmatis, and M. diernhoferi using the microbroth dilution method (Table 4.4). The 
SAR data from this study has again demonstrated that substituents at the oxazole position 
are well-tolerated. A preliminary insight into the biological significance of the double 
bond position has also been provided for the first time. 
The PtxGlu-CO2CH3 (99) and PtxGlu-CO2H (100) analogues were also 
synthesized and evaluated for antimicrobial activity by Dr. Malcolm McCulloch in a 
previous study.160-161 The relative inactivity of the methyl ester (99) compared to the 
carboxylic acid (100) suggested that the attachment of an EG spacer would be 
detrimental for the antimicrobial activity. By contrast, PtxGlu-EG3-NH2 (101) was 
significantly more potent than 99 and comparable to 100. The structurally related Ptx-
EG3-NH2 (97) showed even greater activity. Although Ptx-EG3-Biotin (103) and PtxGlu-
EG3-Biotin (104) were mostly inactive against MRSA, VRE, and S. warneri, these 
biotinylated probes inhibited the growth of the mycobacterial species with MICs as low  
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Table 4.4. Antimicrobial activity of pseudopteroxazole and pseudopterosin-derived 
probes as well as other synthetic intermediates, as determined by the microbroth dilution 
method (n = 3). 
 IC50 (ȝJP/) 0,&ȝJP/ 
Compound MRSAa VREa S. warneria M. smegmatis M. diernhoferi 
30 26 3.4 >128 2 4 
33 2.6 2.9 4.0 2 4 
36 2.5 4.6 5.7 4 2 
95 5.4 5.9 >128 4 4 
96 >128 >128 >128 128 64 
97 5.2 2.7 3.1 2 2 
99 >128 >128 >128 >128 >128 
100 7.6 11 16 4 4 
101 9.7 9.2 12 8 8 
103 >128 >128 >128 8 64 
104 >128 68 >128 8 16 
111 >128 >128 >128 >128 >128 
112 >128 >128 >128 >128 >128 
113 >128 >128 >128 >128 >128 
114 >128 >128 >128 >128 >128 
115 21 14 48 16 16 
116 >128 >128 >128 >128 >128 
117 8.9 6.7 6.4 4 4 
118 >128 >128 >128 >128 >128 
119 >128 128 (65%)a >128 8 16 
120 52 59 49 64 64 
121 >128 52 >128 32 32 
122 >128 >128 96 128 128 
123 77 52 19 64 64 
124 4.2 3.6 >128 4 4 
125 >128 >128 >128 >128 >128 
128 >128 >128 >128 >128 >128 
129 >128 >128 >128 >128 >128 
130 >128 >128 >128 >128 >128 
Vancomycin 0.8 - 0.8 - - 
Rifampin - 0.4 - 2 4 
Isoniazid - - - 2 0.5 
 
a
 Assay was completed by Martine Lanteigne. b Percent growth inhibition at the indicated 
concentration. 
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DVȝJP/On the basis of their antimycobacterial activity, these biotinylated probes 
became promising tools for identifying putative protein targets of pseudopteroxazole (30) 
by affinity chromatography.  
Attaching substituents to the phenolic hydroxyl group of the aglycone methyl 
ether (95) has previously been shown to diminish the antimicrobial activity.161 For 
instance, the dimethyl ether, carbamate, and triflate analogues of 95 were largely inactive  
against M. tuberculosis and nonpathogenic mycobacterial species.161 While the Ps-CO2t-
Bu (114) and Ps-CO2CH3 (116) analogues were consistent with this SAR data, Ps-CO2H 
(115) showed moderate antimicrobial activity. Meanwhile, the attachment of the EG 
spacer to synthesize Ps-EG3-NH2 (117) further improved the activity. Similar to Ptx-EG3-
Biotin (103) and PtxGlu-EG3-Biotin (104), the biotinylated probe Ps-EG3-Biotin (119) 
was unable to inhibit the growth of MRSA, VRE, and S. warneri. However, the 
antimycobacterial activity of 119 was nearly identical to that of 103 and 104. As a result, 
this biotinylated probe was selected for affinity chromatography. 
In consideration of the antimycobacterial activities of Ptx-EG3-Biotin (103), 
PtxGlu-EG3-Biotin (104), and Ps-EG3-Biotin (119), the photoaffinity probes Ptx-EG3-
BPA (111) and PtxGlu-EG3-BPA (112) were anticipated to have activity as well. 
Unfortunately, these chemical probes were inactive, even against the mycobacterial 
species. According to the observed SAR trends, the binding activity of 111 and 112 to the 
cell target may be attained in the context of a cell lysate. An in vitro photolabeling 
experiment may therefore provide valuable information. The inactivity of these 
compounds may instead be due to their greater hydrophobicity, which may prohibit their 
uptake and ability to interact with the cell target(s). For instance, the Ps-EG3-Ps (118), a 
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product of dimerization, and PtxGlu-BP (113) showed no activity as well. In addition, 
hydrophobic oxazole substituents were previously shown to weaken the antimicrobial 
activity of pseudopteroxazole (30).160-161  
The importance of the double bond region of pseudopteroxazole (30) was 
indicated by the weak antimicrobial activity of CHO-PsOH (120) and CH(OCH3)2-PsOH 
(121). The H2N-EG3-PsOH (122) and epi-H2N-EG3-PsOH (123) were associated with a 
decrease in the activity, although the latter showed modest activity, hinting at the 
importance of the configuration at C-1. Regardless, the observed SAR indicated that 122 
was best suited as an inactive control probe for identifying non-specific binding (NSB). 
The unsaturation at the double bond position did not appear to be necessary as the 
antimicrobial activity of the aglycone methyl ether (95) was nearly identical to its 
hydrogenated analogue (124). Considering that 124 showed marginal improvements 
against MRSA and VRE, further investigation of the SAR around the double bond 
position could lead to the discovery of novel analogues with greater potency. 
 
4.2.6 Interpreting the structure-activity relationships for pseudopteroxazole analogues 
The observed antimicrobial activity of the chemical probes served as a qualitative 
assessment of their relative binding affinity to the cell target(s). Although antimicrobial 
assays were necessary for examining SAR, variations in solubility and cell permeability 
must be taken into consideration as these are factors that may significantly impact the 
antimicrobial activity and confound the interpretation of SAR.217 In a number of cases, 
the SAR data emanating from this study demonstrated the importance of polarity and 
relative aqueous solubility, particularly for the oxazole substituents of pseudopteroxazole 
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analogues. These results also complement previous efforts aiming to further understand 
the SAR of this class of natural products.160-161 
Among the most active compounds in these antimicrobial assays, despite their 
long EG-based appendages, were Ptx-EG3-NH2 (97), PtxGlu-EG3-NH2 (101), and Ps-
EG3-NH2 (117). Their strong activity may be due to a significant increase in polarity and 
aqueous solubility with the incorporation of the EG spacers. Although the methyl esters, 
PtxGlu-CO2CH3 (99) and Ps-CO2CH3 (116), were inactive, their carboxylic acid 
counterparts exhibited greater aqueous solubility and showed moderate antimicrobial 
activity. Biotinylation of 97 and 101 minimally impacted the antimycobacterial activity, 
whereas the attachment of hydrophobic benzophenone moieties, to provide the 
photoaffinity probes, resulted in a loss of activity. Similar SAR trends were also observed 
for Ps-EG3-NH2 (117) and Ps-EG3-Biotin (119) which, unlike other analogues of the 
aglycone methyl ether (95), displayed good antimycobacterial activity.161 
 
4.2.7 The inactive pseudopteroxazole probe: A control for non-specific binding 
 Identifying cell targets by chemical proteomics is often complicated by the 
presence of NSB.223 The high background generated by NSB confuses the analysis and 
may obscure targets of low abundance. Proteins of high abundance may exhibit low 
binding affinity to the resin, often as a result of generic hydrophobic or electrostatic 
interactions.223 Although a competitive elution may expedite the process of target 
deconvolution by separating the protein target(s) from NSB, the limited aqueous 
solubility of pseudopteroxazole (30) and pseudopterosin G (33) may hinder their 
application as competitive ligands.217 To differentiate between NSB and specific binding 
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interactions, an inactive control probe may be employed instead. The NSB profiles 
exhibited by active and inactive probes are often indistinguishable, owing to their 
structural similarity. As a result, preferential binding to the active probe is indicative of a 
target protein candidate. 
Three basic designs exist for an inactive probe: chiral isomers,233 structurally 
related analogues,234 or analogues with differential spacer attachment.235 An inactive 
chiral isomer is generally the most effective control,233 however, the biological 
significance of the chiral centers of pseudopteroxazole (30) is unknown. Modifying the 
stereochemical configuration of the diterpene skeleton also poses a formidable synthetic 
obstacle. As described earlier, previous SAR data indicated that an inactive structurally 
related probe could be obtained by attaching the EG spacer to the phenolic hydroxyl 
group of the aglycone methyl ether (95). Regrettably, this SAR trend was inconsistent 
with Ps-EG3-NH2 (117) and Ps-EG3-Biotin (119), whose antimicrobial activity prohibited 
their application as inactive control probes. Attaching the spacer to the double bond 
position of 95 abolished the activity, as shown by H2N-EG3-PsOH (122). This data 
suggested that 122 may serve as an inactive control considering that the specific binding 
interaction with the protein target(s) appears to be disrupted by differential placement of 
the spacer.  
In addition to the H2N-EG3-PsOH (122), a set of generic control probes was also 
synthesized. Unlike 122, the generic controls contained all features of the probe except 
for the diterpene scaffold. As a result, any potential hydrophobic-type NSB with the 
scaffold may be unaccounted for. Nonetheless, the supplementary generic control probes 
were synthesized by reacting NHS esters 102 and 110 with an excess of 4,7,10-trioxa-
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1,13-tridecanediamine (94) to provide Biotin-EG3-NH2 (129) and BPA-EG3-NH2 (130) 
(Figure C.2). As expected, control probe 129 showed no antimicrobial activity (Table 
4.4), verifying that the spacer and biotin moieties were not contributing to the growth 
inhibitory properties of biotinylated probes. 
 
4.2.8 Investigating the protein binding interactions of pseudopteroxazole probes by 
affinity chromatography 
A preliminary assessment of protein binding interactions was carried out using the 
two biotinylated pseudopteroxazole probes, Ptx-EG3-Biotin (103) and PtxGlu-EG3-Biotin 
(104). Owing to its fast growth rate and few biosafety restrictions, M. smegmatis 
commonly serves as a surrogate for M. tuberculosis.298 Considering that both 
mycobacterial species are susceptible to pseudopteroxazole (30), cell lysates of M. 
smegmatis were suitable for these affinity chromatography experiments. Preparation of 
mycobacterial lysates by sonication provided satisfactory protein extraction with minimal 
degradation, as indicated by the large amount of high molecular weight protein observed 
during gel electrophoretic analysis (data not shown). The general experimental protocol 
for conducting the affinity chromatography was adapted from the work of Yamamoto et 
al.236 Unless specified otherwise, binding proteins were eluted from the affinity resins 
under denaturing conditions by heating in Laemmli buffer, as described in Section 4.4.3. 
Protein samples were then separated by SDS-PAGE and stained with Coomassie to 
visualize the binding proteins (Figure 4.5). 
Attempts to identify protein target candidates by competitive displacement were 
carried out by pre-incubating the lysate with pseudopteroxazole (30) or pseudopterosin G  
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Figure 4.5. Gel electrophoretic analysis of Mycobacterium smegmatis proteins bound to 
the biotinylated probes, Ptx-EG3-Biotin (103) and PtxGlu-EG3-Biotin (104). Notes and 
conditions: The eluted proteins were resolved over a 4-12% polyacrylamide gel. Both 
competitive displacements represent a pre-incubation of the M. smegmatis lysate with 
either pseudopteroxazole (30) or pseudopterosin G (33). Description of gel lanes: Lane 1, 
M. smegmatis lysate; lane 2, affinity capture of proteins with 104; lane 3, heat-denatured 
control; lane 4, affinity capture of proteins with unblocked streptavidin resin; lane 5, 
affinity capture of proteins with Biotin-EG3-NH2 (129); lane 6, competitive displacement 
control; lane 7, competitive displacement control; lane 8, affinity capture of proteins with 
103; lane 9, heat-denatured control. 
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(33). Unfortunately, these experiments were unsuccessful as no gel bands disappeared 
(Figure 4.5), a result that may be attributed to the low aqueous solubility of 30 and 33. In 
addition, a considerable amount of NSB was observed, particularly for PtxGlu-EG3-
Biotin (104). The diterpene scaffold may have been subjected to generic hydrophobic 
interactions, given the distinct protein profiles exhibited by 104 and Biotin-EG3-NH2 
(129). As a result, no putative targets were identified in this experiment. Efforts to lower 
the NSB background by varying the concentration of polysorbate 20 (P20) in the 
phosphate buffer were unsuccessful. The streptavidin resin, after immobilizing the 
biotinylated probe, was also pre-incubated with bovine serum albumin to block NSB, 
however, no effect on NSB was observed. Washing the affinity resin additional times 
with buffer also failed to lower the background.  
 
4.2.9 Examining an arylsulfonamide model of the affinity chromatography system 
Preliminary experimentation with Ptx-EG3-Biotin (103) and PtxGlu-EG3-Biotin 
(104) in the affinity chromatography experiment presented a number of potential issues. 
For instance, the technical aspects of the protocol, especially the pH and ionic strength of 
the phosphate buffer, may have a tremendous impact on protein stability and overall 
binding affinity. Although a comprehensive analysis of various buffer conditions may be 
pursued, such efforts may be futile if the probe is unable to support a specific binding 
interaction due to improper design. Notably, the length of the EG-based spacer may have 
been insufficient, resulting in steric clashing and reduced binding affinity of potential 
targets.231 Therefore, the probe design was evaluated by simulating the affinity 
chromatography system using a model probe. 
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Carbonic anhydrase (CA) is a mammalian enzyme that catalyzes the 
interconversion of carbon dioxide and water to bicarbonate.299 The clinical relevance of 
CA inhibition, particularly for the treatment of glaucoma, has long been recognized, thus 
a wide range of inhibitors are commercially available.300 Arylsulfonamides (ASAs) are a 
family of CA inhibitors that bind to the zinc prosthetic group of the enzyme as an anion 
(SO2NH±).301 The binding interaction between CA and ASAs is well characterized and 
known to tolerate a wide variety of substituents at the para position of the aromatic 
ring,302 including EG-based moieties.303 The specific binding of CA to an ASA probe of 
the same molecular design as PtxGlu-EG3-Biotin (104) and Ps-EG3-Biotin (119) could 
serve as a model to ensure proper functioning of the affinity chromatography system. 
To synthesize the ASA model probe, an EG-based spacer was attached to 4-
carboxybenzene sulfonamide (131), utilizing synthetic methodology described earlier for 
PtxGlu-EG3-NH2 (101) and Ps-EG3-NH2 (117). The product of this reaction was purified 
by RP-MPLC, providing ASA-EG3-NH2 (132) in 57% yield over two steps (Figure 4.6). 
The subsequent biotinylation of 132 using biotin-NHS (102) provided the ASA-EG3-
Biotin (133) probe in 78% yield. Biochemical isolation of CA by affinity 
chromatography was then attempted by immobilizing 133 onto a streptavidin resin and 
repeating the experimental protocol that was previously described for Ptx-EG3-Biotin 
(103) and PtxGlu-EG3-Biotin (104). 
Regrettably, attempts to isolate CA onto the ASA-EG3-Biotin (133)-immobilized 
streptavidin resin were unsuccessful (Figure C.3). Indeed, no decrease in the CA band 
intensity was observed for the heat-denatured control, indicating a non-specific 
interaction. Pre-incubating CA with acetazolamide (AAZ), a known CA inhibitor,   
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Figure 4.6. Synthesis of a biotinylated arylsulfonamide probe (133, ASA-EG3-Biotin) as 
a simulation of the pseudopteroxazole and pseudopterosin-derived probes. Reagents and 
conditions: (a) (i) NHS, DIC, THF. (ii) 4,7,10-trioxa-1,13-tridecanediamine (94, excess), 
57% over two steps. (b) biotin-NHS (102), DMF, 78%. 
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showed no decrease in band intensity either. Competitive elution of CA with AAZ was 
also attempted, but to no avail. The apparent lack of specific CA binding may be due to 
the EG spacer, whose short length may have been insufficient for minimizing the steric 
repulsions between CA and streptavidin. As a result, biotinylated probes ASA-EG23-
Biotin (134) and PtxGlu-EG23-Biotin (135), whose spacers contained 20 additional EG 
units, were synthesized (Figure 4.7). The commercial availability of Biotin-EG23-NH2 
(136) expedited the preparation of these biotinylated probes. Upon repeating the affinity 
chromatography experiment, no specific binding interaction between CA and the 134-
immobilized streptavidin resin was observed, despite the increased length of the EG 
spacer (Figure C.4). 
 
4.2.10 Covalent immobilization of small molecules onto activated agarose supports 
The specific binding of CA to either ASA-EG3-Biotin (133) or ASA-EG23-Biotin (134) 
was unsuccessful using the biotin-streptavidin system for reasons that were not clear. As 
a result, an alternative set of affinity resins was prepared by covalent immobilization of 
small molecules onto a stationary support. Although having served as synthetic 
precursors to biotinylated probes, PtxGlu-EG3-NH2 (101) and Ps-EG3-NH2 (117) were 
also poised for immobilization onto NHS-activated agarose. Immobilization of H2N-EG3-
PsOH (122), an analogue showing no antimycobacterial activity, may also provide an 
inactive control. Furthermore, by exploiting the availability of ASA-EG3-NH2 (132), a 
model of the affinity chromatography system could be developed rapidly to validate the 
technical aspects of the experiment. Ptx-EG3-NH2 (97) and epi-H2N-EG3-PsOH (123),  
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Figure 4.7. Synthesis of biotinylated arylsulfonamide (134, ASA-EG23-Biotin) and 
pseudopteroxazole (135, PtxGlu-EG23-Biotin) probes with increased EG spacer lengths. 
Reagents and conditions: (a) (i) PtxGlu-CO2H (100, 3.2 eq), NHS (4.6 eq), DIC (13 eq), 
DMF. (ii) Biotin-EG23-NH2 (136), Et3N (4.4 eq), 58% over two steps. (b) (i) 4-
carboxybenzene sulfonamide (131, 2.6 eq) NHS (3.2 eq), DIC (10 eq), DMF. (ii) 136, 
Et3N (4.8 eq), 59% over two steps.  
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close analogues of 101 and 122, respectively, were not available in sufficient quantities 
for generating additional affinity resins. 
To immobilize PtxGlu-EG3-NH2 (101), Ps-EG3-NH2 (117), H2N-EG3-PsOH 
(122), and ASA-EG3-NH2 (132) onto a stationary support, these small molecule ligands 
were incubated with NHS-activated agarose in anhydrous DMSO following a literature 
protocol (Figure 4.8).304 Although the secondary amino group of 122 remained 
unprotected, slower acylation at this position was anticipitated due to steric influences. 
Regardless, an excess of 122 was added to the activated resin to avoid potential acylation 
at both positions. The reaction yield and overall density of the immobilized small 
molecules were estimated by LC-HRESIMS quantification of unreacted primary amine 
(Figures C.5-C.6). Standard curves for each primary amine were generated and their 
concentrations within the reaction media were calculated. Greater than 95% of 101, 117, 
and 132 were immobilized to generate PtxGlu-EG3-Agarose (137), Ps-EG3-Agarose 
(138), and ASA-EG3-Agarose (139), respectively. Meanwhile, approximately 4% of 122 
had reacted to provide Agarose-EG3-PsOH (140), indicating a saturation of the NHS 
esters. The molar density of the immobilized ligands was calculated using these reaction 
yields. A generic control resin (141) was also prepared by deactivating the NHS esters 
with 2-(2-aminoethoxy)ethanol (142), a shorter mimic of the EG spacer.  
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Figure 4.8. Preparation of PtxGlu-EG3-Agarose (137), Ps-EG3-Agarose (138), the 
generic control resin (141), ASA-EG3-Agarose (139), and Agarose-EG3-PsOH (140) by 
covalent immobilization of small molecules onto NHS-activated agarose (143). Reagents 
and conditions: (a) PtxGlu-EG3-NH2 (101), 2% Et3N, DMSO, >95%. (b) Ps-EG3-NH2 
(117), 2% Et3N, DMSO, >95%. (c) 2-(2-aminoethoxy)ethanol (142), 2% Et3N, DMSO. 
(d) ASA-EG3-NH2 (132), 2% Et3N, DMSO, >95%. (e) H2N-EG3-PsOH (122) (excess), 
2% pyridine, DMSO, 4.1%. Immobilization yields were estimated by LC-HRESIMS 
quantitation of unreacted amines, as shown in Figures C.5-C.6. 
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4.2.11 Validating the specific binding of carbonic anhydrase to the arylsulfonamide-
agarose resin 
The binding interaction between CA and ASA-EG3-Agarose (139) was evaluated 
to determine the utility of the affinity resins generated by covalent immobilization of 
small molecule ligands. The binding experiments were performed using purified CA as 
well as a M. smegmatis lysate spiked with CA. By adding CA to the lysis buffer for the 
latter, overall enzyme stability throughout sonication could be assessed. The protocol was 
otherwise identical to previous experiments using biotinylated probes. The results of this 
model experiment demonstrated the formation of a specific CA binding interaction with 
the immobilized ASA ligand. 
Competitive displacement and heat-denatured controls clearly demonstrated a 
specific binding interaction (Figure 4.9). For instance, the binding was disrupted by heat-
denaturation or pre-incubation with AAZ, a competitive ligand that intercepted CA. 
Competitive elution of CA, after immobilization onto ASA-EG3-Agarose (139), was also 
achieved using a buffer solution of AAZ. A vehicle control was also implemented to 
ensure solvent effects were not responsible for the elution. Owing to slow dissociation, a 
considerable amount of CA remained bound to the affinity resin after the competitive 
elution. Increasing the length of AAZ exposure may therefore maximize the elution of 
CA. As anticipated, the generic control resin (141) was incapable of binding CA, 
although a small band was observed due to NSB. Similar trends were observed for CA 
binding within the context of a M. smegmatis lysate (Figure 4.10). 
 The M. smegmatis lysate containing CA was also subjected to serial affinity 
chromatography (SAC), an experiment whose interpretation required the presence of  
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Figure 4.9. Gel electrophoretic analysis of the specific binding interaction between ASA-
EG3-Agarose (139) and CA. Notes and conditions: The affinity resins were incubated 
wLWKDȝJP/&$VROXWLRQ7KH CA was eluted under denaturing conditions, with the 
exception of lanes 9-10, and resolved over a 4-12% polyacrylamide gel. Both types of 
competitive displacements were performed: pre-incubation of CA with AAZ and elution 
of CA from 139 with AAZ. Description of gel lanes: Lane 1, CA standard; lane 2, 
affinity capture of CA with 139; lane 3, heat-denatured control; lane 4, affinity capture of 
CA with the generic control resin (141); lane 5, remaining CA after competitive 
displacement by pre-incubation of CA with AAZ; lane 6, remaining CA after competitive 
elution with AAZ; lane 7, remaining CA after DMSO control of competitive elution; lane 
8, affinity capture of CA with 139 after DMSO control of competitive displacement; lane 
9, competitively eluted CA from 139 in lane 6; lane 10, DMSO control of competitive 
elution from lane 7. 
  
182 
 
 
 
Figure 4.10. Gel electrophoretic analysis of the specific binding interaction between 
ASA-EG3-Agarose (139) and CA within the context of a Mycobacterium smegmatis 
lysate. Notes and conditions: The CA was added to the lysis buffer to a total 
concentration RIȝJP/ The proteins were eluted from the resin under denaturing 
conditions and resolved over a 4-12%% polyacrylamide gel. To complete the SAC 
experiment, the lysate was incubated three times with different batches of 139 (lanes 2-4 
in that order). Description of gel lanes: Lane 1, heat-denatured control; lane 2, affinity 
capture of CA with 139 and 1st SAC sequence; lane 3, affinity capture of CA with 139 
after 2nd SAC sequence; lane 4, affinity capture of CA with 139 after 3rd SAC sequence; 
lane 5, competitively eluted CA from 139; lane 6, DMSO control of competitive elution. 
Serial depletion trend: The intensity of the CA band (~29 kDa) decreases across lanes 2-
4 relative to a NSB protein (~78 kDa). 
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NSB. The SAC experiment served as an alternative to a competitive displacement, which 
may not occur for hydrophobic ligands such as pseudopteroxazole (30) and 
pseudopterosin G (33).217 As described in a preceding chapter (Section 1.9.2), SAC 
entails the transfer of a cell lysate from one batch of affinity resin to another, a process 
that may be repeated several times. During this sequence, the relative abundance of NSB 
remains largely unchanged because of the high abundance and low binding affinity of 
these proteins.236 Protein target candidates are typically of low abundance and exhibit 
high binding affinity, a combination of attributes resulting in their depletion from the 
lysate. Indeed, the CA band intensity underwent serial depletion, meanwhile a single 
NSB protein (78 kDa) remained consistent throughout (Figure 4.10). These experiments 
confirmed the specific binding interaction of CA with ASA-EG3-Agarose (139), and thus 
validated the affinity chromatography system. 
 
4.2.12 Investigation of putative targets by affinity chromatography 
After verifying the specific binding interaction between CA and ASA-EG3-
Agarose (139), the protein binding interactions of PtxGlu-EG3-Agarose (137), Ps-EG3-
Agarose (138), and Agarose-EG3-PsOH (140) were investigated. The latter was 
employed as an inactive control, while the deactivated resin 141 served as a generic 
control, due to the absence of the diterpene scaffold. Both 137 and 140 were utilized in 
the SAC experiment to identify specific binding interactions that may require the EG 
spacer at the double bond position of the diterpene scaffold. Both types of competitive 
displacements were carried out using pseudopteroxazole (30) or pseudopterosin G (33). 
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The ligands were either pre-incubated with the M. smegmatis lysate to intercept the target 
protein(s) or incubated with the affinity resin to achieve a competitive elution. 
Attributable to their structural similarity, PtxGlu-EG3-Agarose (137) and Ps-EG3-
Agarose (138) showed similar protein profiles (Figure 4.11), with the exception of a 
single protein with an apparent molecular weight of 29 kDa that interacted with 137 only. 
Unfortunately, the extent of NSB was significant for both affinity resins, especially 
within the higher molecular weight region (40-260 kDa). The interactome of Agarose-
EG3-PsOH (140) was quite distinct from 137 and 138, presumably due to the cationic 
nature of 140 conferred by the secondary amino group (Figure 4.12). As a result, 140 
was not a suitable inactive control for identifying NSB. Deconvolution of protein targets 
by competitive displacement was also unsuccessful (data not shown), likely owing to the 
limited aqueous solubility of the competitive ligands. 
To identify protein target candidates, the SAC technique was employed to assess 
the relative depletion of protein band intensities, trends that are indicative of a specific 
binding interaction. Indeed, several protein bands of lower molecular weight underwent 
relative serial depletion in experiments using PtxGlu-EG3-Agarose (137) and Agarose-
EG3-PsOH (140, Figure 4.12). The serial depletion profiles for 137 and 140 were quite 
distinct, with the exception of a single protein with an apparent molecular weight of 17.5 
kDa. Although 140 has been designated as an inactive control, the formation of specific 
binding interactions with the immobilized ligand is conceivable. Notably, these 
interactions may not be identified by 137 if the attachment of an EG spacer to the oxazole 
ring disrupts the binding activity. 
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Figure 4.11. Gel electrophoretic analysis of Mycobacterium smegmatis proteins bound to 
PtxGlu-EG3-Agarose (137). Notes and conditions: The proteins were eluted from the 
resin under denaturing conditions and resolved over a 12% polyacrylamide gel. To 
complete the SAC experiment, the M. smegmatis lysate was incubated four times with 
different batches of 137 (lanes 3-6 in that order). Description of gel lanes: Lane 1, 
affinity capture with generic control resin (141); lane 2, heat-denatured control; lane 3, 
affinity capture with 137 in 1st SAC sequence; lane 4, affinity capture with 137 in 2nd 
SAC sequence; lane 5, affinity capture with 137 in 3rd SAC sequence; lane 6, affinity 
capture with 137 in 4th SAC sequence. Serial depletion trends: The relative intensity of 
gel bands at 20, 18.5, 17.5, and 12 kDa decreases across lanes 3-6, as indicated by the 
markings on the right side of the gel image. The red marking indicates the band analyzed 
by tandem mass spectrometry. 
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Figure 4.12. Gel electrophoretic analysis of Mycobacterium smegmatis proteins bound to 
Ps-EG3-Agarose (138) and Agarose-EG3-PsOH (140). Notes and conditions: The proteins 
were eluted from the resin under denaturing conditions and resolved over a 12% 
polyacrylamide gel. To complete the SAC experiment, the M. smegmatis lysate was 
incubated four times with different batches of 140 (lanes 3-6 in that order). Description of 
gel lanes: Lane 1, affinity capture with Ps-EG3-Agarose (138); lane 2, heat-denatured 
control; lane 3, affinity capture with 140 in 1st SAC sequence; lane 4, affinity capture 
with 140 in 2nd SAC sequence; lane 5, affinity capture with 140 in 3rd SAC sequence; 
lane 6, affinity capture with 140 in 4th SAC sequence. Serial depletion trends: The 
relative intensity of gel bands at 31, 18, 17.5, and 15.5 kDa decreases across lanes 3-6, as 
indicated by the markings on the right side of the gel image. 
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The band intensities of nearly all higher molecular weight proteins (40-260 kDa) 
were constant, signifying the non-specificity of these binding interactions. The large 
number of NSB observed within this region, however, may have overlapped with and 
obscured the bands of putative targets. Nonetheless, protein target candidates displaying 
the serial depletion trend were selected for identification by tandem mass spectrometry. 
The gel bands were excised from the gel, as specified in Figure 4.12. Other bands were 
prioritized on the basis of differential binding to PtxGlu-EG3-Agarose (137) and 
Agarose-EG3-PsOH (140), although a serial depletion pattern was not apparent. 
 
4.2.13 Identification of (3R)-hydroxyacyl-ACP dehydratase subunit HadC as a putative 
protein target 
 Mycolic acids are a major component of the mycobacterial cell wall, which is a 
lipid-rich layer known for its complexity and relative impermeability to hydrophilic 
antibiotics.305 Located beyond the cell membrane and peptidoglycan layer, mycolic acids 
are either esterified to an underlying arabinogalactan layer or exist as free trehalose 
dimycolates.306 Mycolic acids consist of long-FKDLQĮ-EUDQFKHGȕ-hydroxylated fatty 
acids (Figure 4.13), and require both fatty acid synthase (FAS)-I and FAS-II pathways 
for their biosynthesis.307 The latter is unable to carry out de novo fatty acid biosynthesis 
in mycobacteria, but is instead devoted to the elongation of intermediate length (C16) fatty 
acids from the FAS-I pathway to generate long-chain (C48-C56) meromycolic acids.308 
The meromycolate chain may subsequently undergo cyclopropanation or oxygenation, 
and is then condensed with a carboxylated C26 fatty acid to provide the branched mycolic 
acid structure.308  
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Figure 4.13. The structure of mycolic acids and their biosynthesis through the FAS-I and 
FAS-II pathways. The polymethylene chain length of the meromycolate and acyl 
moieties are as follows: n1 = 13, n2 = 7, n3 = 15.307, 308b 
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The iterative process of elongating fatty acid chains in the FAS-II pathway is 
initiated by the condensation of a C16 acyl-coenzyme A (CoA) with malonyl-acyl carrier 
SURWHLQ$&3DUHDFWLRQFDWDO\]HGE\ȕ-ketoacyl-ACP synthase (mtFabH, Figure 
4.13).309 7KHȕ-ketoacyl-$&3LQWHUPHGLDWHVXEVHTXHQWO\XQGHUJRHVUHGXFWLRQE\ȕ-
ketoacyl-ACP reductase (MabA) and then dehydration by (3R)-hydroxyacyl-ACP 
dehydratases (HadAB and HadBC).310 The trans-2-enoyl-ACP reductase (InhA) 
catalyzes the reduction of the unsaturated intermediate to provide an acyl chain, which 
PD\XQGHUJRDQRWKHUF\FOHRIHORQJDWLRQYLDWKHȕ-ketoacyl-ACP synthase (KasA and 
KasB).311 The reductive process repeats until the full length of the meromycolate chain 
has been completed. A functioning FAS-II pathway is known to be essential for 
mycobacterial viability;312 therefore the discovery of drugs that arrest mycolic acid 
biosynthesis is an active area of TB research.313 Isoniazid, one of the first-line 
antitubercular drugs, inhibits InhA of the FAS-II pathway.314 
A protein with an apparent molecular weight of 18.5 kDa was selected for further 
analysis as it exhibited a serial depletion pattern in the SAC experiment (Figure 4.11), 
indicating a specific binding interaction. Moreover, the band was not present for the 
inactive control, Agarose-EG3-PsOH (140), suggesting that the interaction was of 
antimycobacterial significance. Mass spectrometric analysis of the tryptic peptides of this 
protein revealed a polypeptide fragment, whose sequence (FGADIVVTR) served as a 
query for protein database analysis using the basic local alignment search tool (BLAST). 
This analysis revealed (3R)-hydroxyacyl-ACP dehydratase subunit HadC as the most 
probable identity of the protein. Complete sequence alignment was observed for M. 
tuberculosis H37Rv and M. smegmatis mc2155 HadC from residues 116 to 124. 
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Importantly, the approximated molecular weight of the gel band was also consistent with 
the expected 18.9 kDa reported for HadC.307 Although no other mycobacterial proteins 
exhibited complete alignment with this polypeptide sequence, additional sequencing 
information must be acquired in the future to further substantiate the HadC identification. 
The affinity chromatography data suggests that subunit HadC binds specifically to 
PtxGlu-EG3-Agarose (137) and Ps-EG3-Agarose (138) and is thus a protein target 
candidate of pseudopteroxazole (30). The HadAB and HadBC heterodimers are 
responsible for the dehydratase function of the FAS-II pathway in mycobacteria (Figure 
4.13).310b HadAB interacts with KasA and appears to be responsible for the formation of 
meromycolates of intermediate length, whereas HadBC and KasB are necessary for the 
later stages of meromycolate biosynthesis.315 This observation is consistent with the 
absence of HadC and KasB orthologs in genera containing mycolic acids of intermediate 
length only.310b Although earlier studies predicted that the hadC gene was not essential 
for M. tuberculosis growth in vitro,310b, 316 overexpression of hadBC conferred high-level 
resistance to isoxyl and thiacetazone in vitro.317 Notably, overexpression of either hadA, 
hadB, or hadC alone had a minimum impact on the MIC of these two antibiotics. 
The deletion of kasB significantly diminished the virulence of M. tuberculosis 
H37Rv in immunocompetent mice, wherein the mycobacteria persisted for more than 600 
days without causing disease.308b, 318 Undoubtedly, further studies of HadC are necessary 
to determine its importance in mycobacterial persistence and survival in the host. The 
Rv0635-Rv0637 gene cluster, which encodes HadABC, is required for M. tuberculosis 
growth in vitro.310b The functional equivalent of HadB in M. smegmatis, MSMEG1341, 
has also been shown to be essential.308a Inhibition of HadBC by pseudopteroxazole (30) 
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by binding to subunit HadC may therefore arrest the growth of M. smegmatis and M. 
tuberculosis, although further studies are required to determine the precise role of HadC 
in vitro.  
The importance of HadC for mycobacterial persistence under hypoxic conditions, 
as is the case for the LORA, is also unknown. Given the role of HadBC in generating 
full-length meromycolates, a HadC binding interaction alone does not explain the 
antimicrobial activity against other Gram-positive bacteria, as observed in the disk 
diffusion assay. It remains to be determined whether affinity chromatography using Ptx-
EG3-Agarose (137) will identify FAS-II dehydratases in other Gram-positive organisms. 
Affinity resin 137 may also interact with subunit HadA, representing an additional target 
of pseudopteroxazole (30) in the mycobacterial FAS-II pathway. Notably, the SAC also 
demonstrated the serial depletion of a protein with a molecular weight of approximately 
17.5 kDa (Figure 4.11), a close match to the anticipated 17.4 kDa of HadA (17.4 kDa, M. 
tuberculosis H37Rv). 
Quantification of thermodynamic parameters, particularly the dissociation 
constant (Kd), isothermal titration caloritmetry or surface plasmon resonance may provide 
formal proof of the HadC binding interaction.221, 319 The antimycobacterial significance 
of the HadC interaction may also be examined through its overexpression in M. 
smegmatis. An increase in HadC expression may compensate for the inhibitory effects of 
pseudopteroxazole (30), resulting in partial restoration of normal dehydratase function 
and higher MIC values. The affinity chromatography approach pursued in this study has 
also revealed several other protein target candidates, whose identification may point the 
direction to an as yet unrecognized antitubercular treatment.  
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4.3 Conclusions 
 
In addition to their antimycobacterial activity, diterpenes of the amphilectane 
class, pseudopteroxazole (30) and pseudopterosin G (33), showed antimicrobial activity 
against a variety of Gram-positive clinical isolates, but were largely inactive against 
Gram-negative strains. The results of this assay suggest that 30 may have clinical 
applications in addition to the treatment of TB, especially considering its activity against 
foodborne pathogens (e.g. Clostridium perfringens and Listeria monocytogenes) and 
other bacteria of relevance in veterinary medicine (e.g. Streptococcus equi subsp. equi). 
During a preliminary study, in collaboration with Dr. Malcolm McCulloch, the activity of 
30 against a panel of isogenic mono-resistant M. tuberculosis H37Rv strains was 
evaluated. Although the MIC of 30 was greater than rifampin or isoniazid, no cross-
resistance with any of the clinical antitubercular drugs was observed, suggesting that 30 
may exert its activity through a unique mechanism of action. 
The antitubercular mechanism of action of pseudopteroxazole (30) was 
investigated by affinity chromatography using a collection of semisynthetic natural 
product-based probes. In an effort to retain the binding activity of the diterpene scaffold, 
both pseudopteroxazole and pseudopterosin-derived probes were designed by attaching 
the EG spacer to the oxazole ring, the phenolic hydroxyl group, and double bond 
positions. Antimicrobial testing of the chemical probes, and other semisynthetic 
intermediates, indicated that the binding activity was maintained by attaching the spacer 
to either the oxazole ring of 30 or the phenolic hydroxyl group of the aglycone methyl 
ether (95). According to the observed SAR trends, modifying the double bond appeared 
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to disrupt this binding activity, while the inactivity of Ptx-EG3-BPA (111) and PtxGlu-
EG3-BPA (112) was attributed to their greater hydrophobicity and poor aqueous 
solubility. Nonetheless, these photoaffinity probes may retain their binding activity 
within the context of a cell lysate and have applications in future investigations of protein 
binding interactions.  
The molecular design of these biotinylated probes was simulated by the ASA 
model probes, which were utilized to ensure the specific binding of CA to the affinity 
resin. Although the interaction was not observed for the biotin-streptavidin approach, a 
covalently immobilized ASA ligand proved successful. As a result, the technical aspects 
of the affinity chromatography experiment were validated, and therefore covalent 
immobilization of pseudopteroxazole and pseudopterosin-derived probes ensued. Protein 
target candidates were then investigated by probing the binding interactions of the M. 
smegmatis proteome with the affinity resins. Despite the large extent of NSB, promising 
protein target candidates were identified by implementing the SAC technique.  
Analysis of gel bands by gel electrophoresis revealed the serial depletion of a 
~18.5 kDa protein, indicative of a specific binding interaction with the PtxGlu-EG3-
Agarose (137) resin. Analysis of the tryptic digest by tandem mass spectrometry 
identified (3R)-hydroxyacyl-ACP dehydratase subunit HadC as a protein target candidate 
of pseudopteroxazole (30). As discussed earlier, the heterodimer HadBC is responsible 
for the dehydratase step in the FAS-II pathway, a process that is essential for 
mycobacterial viability.312a Although the biological relevance of the observed HadC 
binding interaction must be validated by an independent molecular- or cellular-based 
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assay, 30 appears to exert its antitubercular activity, at least in part, by inhibiting mycolic 
acid biosynthesis. 
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4.4 Experimental 
 
General experimental methods as well as procedures for the mouse ear edema assay and 
the microbroth dilution assay are described in Appendix B. Also see Appendix B for a 
GHVFULSWLRQRIWKH³VWDQGDUGZRUNXSSURFHGXUH´ 
 
4.4.1 Reagents and general experimental methods 
 
Manufacturer procedures were followed for performing SDS-PAGE analysis, gel 
staining, and the Bradford protein quantification assay. The following reagents and 
buffers were purchased from Invitrogen Life Technologies for SDS-PAGE analysis: 
NuPAGE® LDS sample buffer (cat. number: NP0007), NuPAGE® sample reducing 
agent (cat. number: NP0004), NuPAGE® 4-12% bis-tris gradient gels (1.0 mm, cat. 
number: NP0322BOX), NuPAGE® 12% bis-tris gels (1.0 mm, cat. number: 
NP0342BOX), NuPAGE® MOPS SDS running buffer (cat. number: NP0001), 
NuPAGE® antioxidant (cat. number: NP0005), Novex® pre-stained protein marker (cat. 
number: LC5800), and SimplyBlueTM SafeStain (Colloidal Coomassie® G-250 staining 
solution, cat. number: LC6060). The silver staining kit (ProteosilverTM staining kit, cat. 
number: PROTSIL1-1KT), Bradford reagent (cat. number: B6916-500ML), and CA 
(CAS number: 9001-03-0) were purchased from Sigma-Aldrich. For the Bradford assay, 
a standard curve of bovine serum albumin (Thermo Scientific: HyClone BSA, cat. 
number: SH30574.01) was used to estimate protein quantity. The magnetic streptavidin 
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particles were purchased from EMD Millipore (MagPrep® P-25 streptavidin particles 
and PureProteomeTM streptavidin magnetic beads).  
 
4.4.2 Determination of antimicrobial activity by the disk diffusion susceptibility method 
 
The antimicrobial disk diffusion susceptibility assay was completed following the 
Kirby-Bauer protocol.320 Each agar plate was prepared with 25 mL of liquid agar to 
establish a consistent depth of approximately 4 mm. The panel of clinical isolates was 
generously donated by Dr. Jeff Lewis and Beatrice Despres. All bacteria were grown on 
cation-adjusted Mueller-Hinton agar with the following exceptions: M. haemolytica, S. 
agalactiae, S. canis, S. equi subsp. equi, and S. equi subsp. zooepidemicus were grown on 
brain-heart infusion (BHI) agar, while A. equuli, A. pyogenes, E. rhusiopathiae, and S. 
pneumoniae ZHUHJURZQRQEORRGDJDU7KHLQGLFDWHGFRQFHQWUDWLRQȝJGLVNof each 
DQWLPLFURELDOFRPSRXQGZDVGHOLYHUHGXVLQJȝ/RIDVWRFNVROXWLRQ
Pseudopteroxazole (30) and pseudopterosin G (33) were delivered in DMSO, PtxHis (37) in 
20% CH3OH, ciprofloxacin in H2O with 0.3% HCO2H, and all other antibiotic controls in 
H2O. All disks were 6 mm in diameter and made from filter paper using a hole punch. 
The inocula were standardized by adjusting the turbidity of the bacterial suspensions to a 
0.5 McFarland standard and were spread onto agar plates use sterile cotton swabs. After 
incubating the plates at 37ºC for 24-72 h, the zones of growth inhibition were measured 
using a caliper. The assay was completed in duplicate, and as such, the reported 
antimicrobial activity is a consensus of two measurements. Samples of PtxHis (37) and 
14,15-dihydro-elisabatin B were provided by Dr. Malcolm McCulloch.  
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4.4.3 Investigation of protein binding interactions by affinity chromatography 
  
After streaking for purity on Middlebrook 7H10 agar, M. smegmatis was grown to 
stationary phase in BHI broth at 30ºC with shaking at 200 rpm. The culture was 
examined for purity by streaking on BHI agar. The cells were pelleted by centrifugation, 
washed three times with phosphate buffered saline (PBS, adjusted to pH 7.4), and stored 
at -80ºC until required for affinity chromatography experiments. Proteome samples were 
prepared by sonication of thawed M. smegmatis cells in PBS (0.01% P20), pulsing at 
30% maximum power (5s pulse, 20s rest) while maintaining the temperature below 5ºC. 
The lysates underwent centrifugation to remove cellular debris, and the supernatants were 
collected for affinity chromatography.  
The procedure for conducting the affinity chromatography experiment was 
adapted from the work of Yamamoto et al.236 For the biotin-streptavidin system, the 
ELRWLQ\ODWHGSUREHVZHUHLPPRELOL]HGRQWRPDJQHWLFVWUHSWDYLGLQEHDGVȝ/YLD
overnight incubation at 4ºC with gentle agitation (end-over-end rotation). The biotin 
binding sites were saturated by adding the biotinylated probes in excess. To remove all 
unbound small molecules, the streptavidin resins were subsequently washed 3-4 times 
with PBS (1.5 mL total volume). For experiments conducted with covalently 
LPPRELOL]HGVPDOOPROHFXOHVWKHDJDURVHUHVLQVȝ/RI 50% slurry) were washed 
twice with PBS (1 mL total volume) to remove the 10% EtOH storage buffer. 
The affinity resins were incubated with the M. smegmatis lysate for 30 min at 4ºC 
under gentle agitation after implementing any necessary controls. For the heat-denatured 
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control, the lysate was heated to 95ºC for 10 min followed by centrifugation to remove 
precipitated protein. Meanwhile, the competitive displacement controls were performed 
by pre-incubating the lysate with either 1.0 mM pseudopteroxazole (30) or 
pseudopterosin G (33) ligands for 30 min at 4ºC. The affinity resins were then washed 
three times with ice-cold PBS (1.5 mL total volume) to remove all non-binding proteins. 
Competitive elutions were carried out at this stage by incubating the affinity resin with 1 
mM 30 or 33 for 20 min at 4ºC. Proteins were eluted from the affinity resins under 
denaturing conditions by heating to 95ºC in Laemmli sample buffer and then resolved by 
SDS-PAGE using manufacturer procedures. 
 
4.4.4 Protein identification by tandem mass spectrometry 
 
Gel bands were manually excised with a clean blade and transferred to 1.5 mL 
microcentrifuge tubes under laminar flow to avoid contamination of the samples. The 
preparation of the tryptic digests (in-gel procedure), as well as the LC-MS/MS analysis of 
tryptic peptides, was completed by Dr. Alejandro Cohen of the Life Sciences Research 
Institute at Dalhousie University according to an existing protocol.321 
 
4.4.5 Isolation of pseudopterosins from Pseudopterogorgia elisabethae 
 
The mixture of pseudopterosins G-J (33-36) was provided by Nautilus 
Biosciences Canada Inc. The pseudopterosins were extracted from samples of P. 
elisabethae obtained from Victory Reef, The Bahamas and purified by a combination of 
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liquid-liquid partitioning and chromatography. The major pseudopterosin constituents in 
the sample possessed the aglycone skeleton of 33-36. 
 
4.4.6 Preparation of pseudopteroxazole and pseudopterosins G and J 
 
Pseudopterosin G-J aglycone ortho-quinone (96). Following an existing protocol, a 
mixture of pseudopterosins G-J (33-36) underwent acid hydrolysis to provide the ortho-
quinone (96).160, 279 To a solution of 33-36 (13.19 g) dissolved in H2O:CH3OH (1:19, 150 
mL) were added three drops of HCl. The mixture was heated to reflux for 48 h, at which 
point TLC analysis (hexanes:TBME 1:1) indicated hydrolysis of the reactants. The 
mixture was diluted with EtOAc and partitioned between NaHCO3(aq) and DI H2O. The 
organic layer was then subjected to the standard work up procedure and separated by 
MPLC (silica, hexanes ĺEtOAc), yielding the ortho-quinone (96, 7.738 g, ~59%). All 
1H and 13C NMR spectroscopic data for 96 were consistent with the literature.161, 322 
 
Pseudopteroxazole (30). An existing protocol was utilized to prepare pseudopteroxazole 
(30) from the pseudopterosin G-J aglycone ortho-quinone (96).160 To a solution of ortho-
quinone (96, 226.5 mg, 0.7539 mmol) dissolved in CH3OH (30 mL) was added Ag2O 
(141.5 mg, 0.6106 mmol). The reaction mixture was then heated to reflux for 2 h, and. 
afterwards, glycine (200.4 mg, 2.670 mmol) was transferred to the reaction along with an 
additional portion of Ag2O (176.0 mg, 0.7595 mmol). The reaction was heated at reflux 
for an additional 2 h before adding another portion of glycine (282.1 mg, 3.758 mmol) 
and Ag2O (175.5 mg, 0.7573 mmol). Additional glycine (279.9 mg, 3.729 mmol) was 
200 
 
added 2 h later and the reaction was heated at reflux overnight. The mixture was then 
filtered through Celite® and partitioned between EtOAc and DI H2O. The EtOAc layer 
was subjected to the standard work up procedure and separated by MPLC (silica, hexanes 
ĺEtOAc). Fractions containing the desired product were combined and separated by 
semi-preparative RP-HPLC (phenylhexyl, 92% CH3OH, 0.1% HCO2H), yielding 
pseudopteroxazole (30, 37.7 mg, 0.122 mmol, 16%). All 1H and 13C NMR spectroscopic 
data for 30 were in agreement with the literature.154, 160 
 
Pseudopterosins G (33) and J (36). The mixture of pseudopterosins G-J (33-36, 545.3 
mg) was dissolved in CH3OH (10 mL) and stirred with K2CO3 (102.3 mg, 740.2 mmol) at 
room temperature for 55 h. The reaction mixture was then diluted with EtOAc and 
washed successively with DI H2O. The EtOAc layer was recovered, subjected to the 
standard work up procedure, and separated by flash chromatography (C18, H22ĺ
CH3OH, 0.1% HCO2H) to provide pseudopterosin G (33, 331.1 mg, 0.7414 mmol, 
~61%). The mixture of 33-36 was also separated by semi-preparative RP-HPLC 
(phenylhexyl, 86% CH3OH, 0.1% HCO2H), providing a sample of pseudopterosin J (36) 
in addition to 33. All 1H and 13C NMR spectroscopic data for 33 and 36 were in 
agreement with the literature.280a 
 
4.4.7 Synthesis and characterization pseudopteroxazole probes 
 
The regioisomeric ratios of all pseudopteroxazole probes, and other synthetic 
intermediates containing oxazole rings, were determined by comparing the 1H NMR 
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integrals for the region containing the benzylic methyl groups (2.40-2.25 ppm). The 
location of the nitrogen atom for all major regioisomers was at the C-10 position. 
 
Ptx-EG3-NH2 (97). Method 1: A solution of the pseudopterosin G-J aglycone ortho-
quinone (96, 109.5 mg, 0.3645 mmol) and Ag2O (93.8 mg, 0.4048 mmol) in CH3OH (25 
mL) was heated to reflux for 30 min. Afterwards, 4,7,10-trioxa-1,13-tridecanediamine 
(94, ȝ/PPROZDVDGGHG$J2O (96.4 mg, 0.4160 mmol) and 94 ȝ/
mmol) were then added after 1 h and the reaction was heated at reflux overnight. Two 
more portions of Ag2O (91.4 mg, 0.394 mmol; 92.6 mg, 0.400 mmol) were added at 16 
and 20 h and the reaction was kept at reflux for an additional 9 hr. The reaction mixture 
was then filtered through Celite® and partitioned between EtOAc and DI H2O. The 
EtOAc layer was subjected to the standard work up procedure and separated by size 
exclusion chromatography (Sephadex® LH-20, CH3OH 0.05% HCO2H) to provide 97 
PJȝPRO, 7%).  
Method 2: A solution of ortho-quinone (96, 170.6 mg, 0.5678 mmol) and Ag2O (150.3 
mg, 0.6486 mmol) in CH3OH (20 mL) was heated to reflux and kept at that temperature 
for 30 min. Afterwards, the reaction was cooled to room temperature, transferred to a 
buret, and added dropwise to a solution of 94 ȝ/PPRO LQ&+3OH (5 mL). 
The slow addition continued overnight and was completed after approximately 16 hr. The 
reaction mixture was then subjected to the same work up procedure as in Method 1 and 
separated by size exclusion chromatography (Sephadex® LH-20, CH3OH 0.05% 
HCO2H) to yield the desired primary amine (97, 38.0 mg, 76.2 ȝPRO, 13%) as a 
regioisomeric mixture with a ratio of approximately 5:1. 97: orange oil; [Į]25D +74.2 (c 
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0.1025, CHCl3); IR ȣmax 3374, 2920, 2869, 1578, 1375, 1348, 1114 cm-1. 1H NMR 
(CDCl30+]į4.95 (1H, d, J = 9.3 Hz, H-14), 3.94-3.88 (1H, m, H-1), 3.93 (2H, t, 
J = 6.7 Hz, H-23), 3.64-3.62 (2H, m, H-27), 3.62-3.58 (4H, m, H-24, H-28), 3.58-3.53 
(4H, m, H-25, H-26), 3.22-3.17 (1H, m, H-7), 3.21 (2H, t, J = 6.7 Hz, H-22), 3.07 (2H, 
m, H-30), 2.37 (3H, s, H-20), 2.22 (1H, m, H-4), 2.20-2.14 (1H, m, H-6a), 2.17-2.12 (1H, 
m, H-5a), 2.11 (1H, m, H-2a), 1.91 (2H, p, J = 5.6 Hz, H-29), 1.76 (3H, s, H-17), 1.66 
(3H, s, H-16), 1.42 (3H, d, J = 6.7 Hz, H-19), 1.42-1.35 (1H, m, H-6b), 1.30-1.23 (1H, m, 
H-2b), 1.27-1.21 (1H, m, H-3), 1.08-1.01 (1H, m, H-5b), 1.03 (3H, d, J = 5.9 Hz, H-18). 
13C NMR (CDCl30+]į163.2 (C, C-21), 148.0 (C, C-9), 139.1 (C, C-10), 135.9 
(C, C-13), 134.4 (C, C-12), 130.9 (CH, C-14), 128.9 (C, C-15), 125.7 (C, C-11), 122.0 
(C, C-8), 70.4, 70.4 (CH2, C-24, C-27), 70.2 (CH2, C-26), 69.9, 69.9 (CH2, C-25, C-28), 
68.2 (CH2, C-23), 44.8 (CH, C-4), 40.2 (CH2, C-2), 39.1 (CH2, C-30), 36.5 (CH, C-1), 
34.7 (CH, C-3), 32.3 (CH2, C-6), 30.4 (CH, C-7), 29.8 (CH2, C-22), 28.2 (CH2, C-5), 
27.7 (CH2, C-29), 25.6 (CH3, C-16), 22.4 (CH3, C-19), 19.9 (CH3, C-18), 17.8 (CH3, C-
17), 13.7 (CH3, C-20). HRESIMS m/z 499.3530 [M + H]+ (calcd for C30H48N2O4, 
499.3530). 
 
Biotin N-succinimidyl ester (102). The Biotin-NHS ester (102) was synthesized 
following a known procedure.323 Biotin (279.2 mg, 1.143 mmol) and NHS (157.7 mg, 
1.370 mmol) were dissolved in DMF (12 mL) and stirred with 3Å molecular sieves (~0.8 
g) under a N2 atmosphere. After stirring for 30 min, DCC (484.4 mg, 2.348 mmol) was 
added and the reaction was stirred for 40 h, during which a white precipitate formed. The 
mixture was filtered, concentrated in vacuo, and diluted with Et2O to precipitate the 
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product. The precipitate was then collected by vacuum filtration, yielding the desired 
biotin-NHS (102, 349.7 mg, 1.024 mmol, 90%). All 1H and 13C NMR spectroscopic data 
for 102 were consistent with the literature.324 
 
Ptx-EG3-Biotin (103): A solution of 97 (5.64 mg, 11.3 ȝPRO) in anhydrous DMF (2 mL) 
was stirred with 3Å molecular sieves (~30 mg) for 20 min before adding biotin-NHS 
(102, 15.7 mg, 46.0 ȝPRO). Et31ȝ/ȝPRO) was then added and the reaction was 
stirred overnight at room temperature. After removing the solvent in vacuo, the crude 
product was separated by semi-preparative RP-HPLC (phenylhexyl, 88% CH3OH, 0.1% 
HCO2H) to provide 103 (1.45 mg, 2.00 ȝPRO, 18%) as a regioisomeric mixture with a 
ratio of approximately 4:1. 103: yellow oil; [Į]25D +46.1 (c 0.1985, CHCl3); IR ȣmax 3283, 
2922, 2861, 1703, 1644, 1550, 1452, 1115, 756 cm-1. 1H NMR (CDCl30+]į
(1H, t, J = 5.1 Hz, 30-NH+EUV¶-NH+EUV¶-NH), 4.95 (1H, d, J 
= 9.3 Hz, H-14), 4.47 (1H, dd, J = 7.5, 5.0 Hz, H-¶+GGJ = 7.5, 4.7 Hz, H-
¶  + W J = 6.9 Hz, H-23), 3.95-3.88 (1H, m, H-1), 3.68-3.64 (2H, m, H-27), 
3.64-3.61 (2H, m, H-26), 3.61-3.58 (2H, m, H-24), 3.55-3.51 (4H, m, H-25, H-28), 3.33 
(2H, q, J = 6.0 Hz, H-30), 3.24-3.17 (1H, m, H-7), 3.19 (2H, t, J = 6.9 Hz, H-22), 3.12 
(1H, td, J = 7.3, 4.7 Hz, H-¶8 (1H, dd, J = 12.8, 5.0 Hz, H-¶+GJ = 
12.8, H-¶+V+-20), 2.23 (1H, m, H-4), 2.22-2.14 (1H, m, H-6a), 2.18-2.12 
(1H, m, H-5a), 2.17 (2H, t, J = 7.4 Hz, 2, H-¶+P+-2a), 1.77-1.72 (2H, m, 
H-29), 1.76 (3H, s, H-17), 1.74-1.69 (1H, m, H-¶D-1.60 (2H, m, H-¶-1.61 
(1H, m, H-¶E+V+-16), 1.46-1.38 (2H, m, H-¶-1.34 (1H, m, H-6b), 
1.42 (3H, d, J = 6.8 Hz, H-19), 1.31-1.23 (1H, m, H-2b), 1.28-1.20 (1H, m, H-3), 1.09-
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1.00 (1H, m, H-5b), 1.04 (3H, d, J = 6.0 Hz, H-18). 13C NMR (CDCl30+]į
(C, C-¶&&-21), 164.1 (C, C-¶&&-9), 139.3 (C, C-10), 135.8 (C, 
C-13), 134.3 (C, C-12), 130.9 (CH, C-14), 128.8 (C, C-15), 125.8 (C, C-11), 121.9 (C, C-
8), 70.6 (CH2, C-24), 70.5, 70.5 (CH2, C-26, C-27), 70.1, 70.1 (CH2, C-25, C-28), 68.3 
(CH2, C-23), 61.9 (CH, C-¶ &+&-¶ &+&-¶ &+&-4), 40.6 
(CH2, C-¶&+2, C-2), 37.9 (CH2, C-30), 36.5 (CH, C-1), 36.1 (CH2, C-¶
(CH, C-3), 32.3 (CH2, C-6), 30.3 (CH, C-7), 29.8 (CH2, C-22), 29.0 (CH2, C-29), 28.4 
(CH2, C-¶&+2, C-5), 28.2 (CH2, C-¶&+2, C-¶&+3, C-16), 22.3 
(CH3, C-19), 19.9 (CH3, C-18), 17.7 (CH3, C-17), 13.6 (CH3, C-20). HRESIMS m/z 
725.4302 [M + H]+ (calcd for C40H61N4O6S, 725.4306).  
 
PtxGlu-CO2CH3 (99). A solution of pseudopterosin G-J aglycone ortho-quinone (96, 
222.7 mg, 0.7413 mmol) and Ag2O (189.6 mg, 0.8182 mmol) in CH3OH (25 mL) were 
heated to reflux for 30 min before adding L-glutamic acid 5-methyl ester (98, 133.9 mg, 
0.8309 mmol). The resulting mixture was kept at reflux for 4 h prior to adding additional 
Ag2O (192.4 mg, 0.8303 mmol) and 98 (136.8 mg, 0.8489 mmol). After maintaining the 
reaction at reflux overnight, two portions of Ag2O (380.4 mg, 1.642 mmol; 188.4 mg, 
0.8130 mmol) and 98 (139.1 mg, 0.8631 mmol; 132.4 mg, 0.8216 mmol) were added 3 h 
apart. The reaction mixture was heated at reflux for an additional 3 h and subsequently 
filtered through Celite® and partitioned between EtOAc and DI H2O. The EtOAc phase 
was recovered, subjected to the standard work up procedure, and separated by MPLC 
VLOLFDKH[DQHVĺ(W2$FWRyield PtxGlu-CO2CH3 (99, 133.5 mg, 0.3375 mmol, 46%). 
All 1H and 13C NMR spectroscopic data for 99 were in agreement with the literature.160  
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PtxGlu-CO2H (100). The methyl ester (99, 133.5 mg, 0.338 mmol) and LiOH (61.8 mg, 
2.58 mmol) were dissolved in acetone:H2O (10:1, 11 mL) and stirred for 48 hr. To 
quench the reaction, HCO2+ȝ/PPROZDVDGGHGDQGWKHVROYHQWZDVUHPRYHG
in vacuo before separating the crude product by RP-MPLC (C18, H22ĺ&+3OH, 0.1% 
HCO2H) to purify PtxGlu-CO2H (100, 119.9 mg, 0.314 mmol, 93%). All 1H and 13C 
NMR spectroscopic data for 100 were in agreement with the literature.160 
 
PtxGlu-EG3-NH2 (101). The carboxylic acid (100, 40.7 mg, 0.107 mmol), NHS (18.7 
mg, 0.162 mmol), and 3Å MS (~100 mg) were stirred in anhydrous CH2Cl2 (4 mL) under 
a N2 atmosphere for 20 min prior to adding DCC (35.2 mg, 0.171 mmol). The reaction 
was stirred overnight at room temperature and filtered through Celite®. The filtrate was 
evaporated in vacuo, resuspended in CH2Cl2 (4 mL), and 4,7,10-trioxa-1,13-
tridecanediamine (94, ȝ/PPROZDVDGGHG$IWHUVWLUULQJWKHUHDFWLRQDWURRP
temperature for 40 min, the reaction mixture was partitioned between EtOAc and DI 
H2O. The EtOAc layer was subjected to the standard work up procedure and separated by 
RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to yield 101 (33.1 mg, 56.7 ȝPRO, 53%) 
as a regioisomeric mixture with a ratio of approximately 14:1. 101: yellow oil; [Į]25D 
+65.0 (c 0.1108, CHCl3); IR ȣmax 3299, 2921, 2867, 1656, 1549, 1445, 1376, 1110 cm-1. 
1H NMR (CDCl30+]į+GJ = 9.3 Hz, H-14), 3.91 (1H, app. q, J = 8.7 
Hz, H-1), 3.63-3.59 (4H, m, H-29, H-30), 3.59-3.55 (2H, m, H-31), 3.58-3.54 (2H, m, H-
32), 3.55-3.52 (2H, m, H-28), 3.39 (2H, q, J = 6.2 Hz, H-34), 3.35 (2H, app. q, J = 6.1 
Hz, H-25), 3.22-3.16 (1H, m, H-7), 3.21 (2H, t, J = 7.5 Hz, H-22), 2.73 (2H, t, J = 7.5 
Hz, H-23), 2.36 (3H, s, H-20), 2.25-2.19 (1H, m, H-4), 2.19-2.13 (1H, m, H-6a), 2.17-
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2.11 (1H, m, H-5a), 2.14-2.07 (1H, m, H-2a), 1.79-1.73 (4H, m, H-26, H-33), 1.76 (3H, s, 
H-17), 1.66 (3H, s, H-16), 1.41 (3H, d, J = 6.8 Hz, H-19), 1.41-1.34 (1H, m, H-6b), 1.28-
1.22 (1H, m, H-2b), 1.26-1.20 (1H, m, H-3), 1.08-1.00 (1H, m, H-5b), 1.03 (3H, d, J = 
5.9 Hz, H-18). 13C NMR (CDCl30+]į&&-24), 164.5 (C, C-21), 148.0 
(C, C-9), 139.2 (C, C-10), 135.8 (C, C-13), 134.4 (C, C-12), 131.0 (CH, C-14), 128.8 (C, 
C-15), 125.7 (C, C-11), 122.0 (C, C-8), 70.6 (CH2, C-30), 70.5 (CH2, C-29), 70.2, 70.2 
(CH2, C-28, C-32), 69.9 (CH2, C-31), 69.7 (CH2, C-27), 44.8 (CH, C-4), 40.2 (CH2, C-2), 
37.8 (CH2, C-25), 36.8 (CH2, C-34), 36.5 (CH, C-1), 34.7 (CH, C-3), 33.3 (CH2, C-23), 
32.3 (CH2, C-6), 30.3 (CH, C-7), 29.1 (CH2, C-26), 28.6 (CH2, C-33), 28.2 (CH2, C-5), 
25.6 (CH3, C-16), 24.7 (CH2, C-22), 22.4 (CH3, C-19), 19.9 (CH3, C-18), 17.7 (CH3, C-
17), 13.6 (CH3, C-20). HRESIMS m/z 584.4059 [M + H]+ (calcd for C34H54N3O5, 
584.4058). 
 
PtxGlu-EG3-Biotin (104). To a stirred solution of 101 (5.86 mg, 10.0 ȝPRO) and 3Å 
molecular sieves (~30 mg) in anhydrous DMF (2 mL) was added biotin-NHS (102, 16.0 
mg, 46.9 ȝPRO) and Et31ȝ/ȝPRO). After stirring the reaction mixture overnight 
at room temperature, the solvent was removed in vacuo. The crude product was then 
separated by semi-preparative RP-HPLC (phenylhexyl, 88% CH3OH, 0.1% HCO2H) to 
provide 104 (3.35 mg, 4.14 ȝPRO, 41%). No regioisomer side product was observed in 
the purified product. 104: colorless oil; [Į]25D +45.2 (c 0.3723, CHCl3); IR ȣmax 3286, 
3083, 2922, 2861, 1701, 1649, 1551, 1446, 1118, 754 cm-1. 1H NMR (CDCl3, 600 MHz) 
į+WJ = 5.2 Hz, 25-NH), 6.66 (1H, t, J = 5.2 Hz, 34-NH+EUV¶-
NH+EUV¶-NH), 4.94 (1H, d, J = 9.3 Hz, H-14), 4.47 (1H, dd, J = 7.5, 5.0 
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Hz, H-¶+GGJ = 7.5, 4.8 Hz, H-¶+DSSTJ = 8.6 Hz, H-1), 3.65-
3.60 (4H, m, H-29, H-30), 3.59-3.55 (4H, m, H-28, H-31), 3.53 (2H, app. dd, J = 5.7, 3.4 
Hz, H-32), 3.52 (2H, app. dd, J = 5.9, 3.8 Hz, H-27), 3.35 (2H, app. q, J = 6.2 Hz, H-25), 
3.32 (2H, app. q, J = 6.1 Hz, H-34), 3.24 (2H, t, J = 7.6 Hz, H-22), 3.23-3.15 (1H, m, H-
7), 3.12 (1H, td, J = 7.3, 4.8 Hz, H-¶+GGJ = 12.8, 5.0 Hz, H-¶D+
t, J = 7.6 Hz, H-23), 2.71 (1H, d, J = 12.8 Hz, H-¶E+V+-20), 2.22 (1H, app. 
ddd, J = 3.7 Hz, H-4), 2.19-2.13 (1H, m, H-6a), 2.17 (2H, t, J = 7.3 Hz, H-¶-2.12 
(1H, m, H-5a), 2.13-2.08 (1H, m, H-2a), 1.80-1.74 (2H, m, H-26), 1.76 (3H, s, H-17), 
1.76-1.71 (2H, m, H-33), 1.74-1.69 (1H, m, H-¶D-1.63 (2H, m, H-¶+V
H-16), 1.66-1.60 (1H, m, H-¶E-1.40 (2H, m, H-¶-1.34 (1H, m, H-6b), 1.41 
(3H, d, J = 6.8 Hz, H-19), 1.30-1.23 (1H, m, J = 11.8, 8.2 Hz, H-2b), 1.27-1.20 (1H, m, 
H-3), 1.08-1.00 (1H, m, H-5b), 1.03 (3H, d, J = 5.9 Hz, H-18). 13C NMR (CDCl3, 150 
0+]į&&-¶&&-24), 164.5 (C, C-21), 164.1 (C, C-¶&&-
9), 139.1 (C, C-10), 135.8 (C, C-13), 134.3 (C, C-12), 130.9 (CH, C-14), 128.7 (C, C-15), 
125.6 (C, C-11), 122.0 (C, C-8), 70.5, 70.5 (CH2, C-29, C-30), 70.1, 70.1 (CH2, C-28, C-
32), 69.9 (CH2, C-31), 69.7 (CH2, C-27), 61.9 (CH, C-¶&+&-¶ (CH, C-
¶  &+ &-4), 40.6 (CH2, C-¶  &+2, C-2), 37.7, 37.7 (CH2, C-25, C-34), 
36.5 (CH, C-1), 36.1 (CH2, C-¶ &+&-3), 33.3 (CH2, C-23), 32.3 (CH2, C-6), 
30.3 (CH, C-7), 29.1, 29.1 (CH2, C-26, C-33), 28.3 (CH2, C-¶&+2, C-5), 28.1 
(CH2, C-¶  &+2, C-¶  &+3, C-16), 24.8 (CH2, C-22), 22.3 (CH3, C-19), 
19.9 (CH3, C-18), 17.7 (CH3, C-17), 13.6 (CH3, C-20). HRESIMS m/z 810.4832 [M + 
H]+ (calcd for C40H61N4O6S, 810.4834). 
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PtxGlu-EG23-Biotin (135). To a stirred solution of PtxGlu-CO2H (100, 19.8 mg, 51.9 
ȝPRODQG1+6PJȝPROLQDQK\GURXV'0)P/ZDVDGGHG',&ȝ/
0.22 mmol). After stirring the reaction overnight at room temperature, Biotin-EG23-NH2 
(136PJȝPRODQG(W31ȝ/ȝPROZHUHDGGHG7KHUHDFWLRQZDVOHIW
to stir for 24 h, at which point analysis of the mixture by LC-HRESIMS indicated product 
formation. Upon removing the solvent by rotary evaporation, the crude product was 
resuspended in CH3OH and eluted through a plug of C18. The eluate was subsequently 
evaporated in vacuo, and separated by semi-preparative RP-HPLC (phenylhexyl, 94% 
CH3OH, 0.1% HCO2H) to yield PtxGlu-EG23-Biotin (135PJȝPRO
135: clear oil; [Į]25D +35.2 (c 0.5725, CH2Cl2) IR ȣmax 3325, 3081, 2905, 2867, 1704, 
1671, 1544, 1454, 1349, 1298, 1251, 1106, 950, 844 cm-1. 1H NMR (CDCl30+]į
4.92 (1H, d, J = 8.2 Hz, H-14), 4.48-4.44 (1H, br m, H-¶-4.25 (1H, br m, H-¶
3.88 (1H, app. q, J = 8.2 Hz, H-1), 3.74-3.47 (92H, H-26, H-«+-70, H-71), 3.44-
3.39 (2H, m, H-24), 3.41-3.36 (2H, m, H-72), 3.21 (2H, t, J = 7.2 Hz, H-21), 3.20-3.12 
(1H, m, H-7), 3.12-3.07 (1H, m, H-¶+P+-¶D-2.69 (2H, m, H-22), 
2.70 (1H, m, H-¶E), 2.33 (3H, s, H-20), 2.22-2.14 (1H, m, H-4), 2.16-2.09 (1H, m, H-
6a), 2.14-2.09 (1H, m, H-5a), 2.10-2.04 (2H, m, H-¶-2.04 (1H, m, H-2a), 1.73 
(3H, s, H-17), 1.73-1.68 (1H, m, H-¶D-1.62 (2H, m, H-¶-1.59 (1H, m, H-
¶E+V H-16), 1.43-1.37 (2H, m, H-¶+GJ = 8.2 Hz, H-19), 1.38-
1.30 (1H, m, H-6b), 1.25-1.19 (1H, m, H-2b), 1.23-1.17 (1H, m, H-3), 1.04-0.97 (1H, m, 
H-5b), 1.00 (3H, br d, H-18). 13C NMR (CDCl30+]į&&-¶&
C-24), 164.3 (C, C-21), 164.0 (C, C-¶&&-9), 139.2 (C, C-10), 135.6 (C, C-
13), 134.2 (C, C-12), 130.9 (C, C-14), 128.6 (C, C-15), 125.7 (C, C-11), 121.9 (C, C-8), 
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70.6, 70.5, 70.4, 70.3, 70.1, 70.0, 69.9 (CH2, C-26, C-«&-70, C-71), 61.8 (CH, C-
¶&+&-¶&+&-¶&+&-4), 40.5 (CH2, C-¶&+2, C-2), 
39.4 (CH2, C-25), 39.2 (CH2, C-72), 36.4 (CH, C-1), 35.9 (CH2, C-¶&+&-3), 
33.1 (CH2, C-23), 32.3 (CH2, C-6), 30.2 (CH, C-7), 28.2 (CH2, C-¶&+2, C-¶
28.1 (CH2, C-5), 25.6 (CH2, C-¶&+3, C-16), 24.6 (CH2, C-22), 22.3 (CH3, C-
19), 19.8 (CH3, C-18), 17.7 (CH3, C-17), 13.5 (CH3, C-20). HRESIMS m/z 1662.9840 [M 
+ H]+ (calcd for C82H144N5O27S, 1662.9764). 
 
4.4.8 Synthesis and characterization of pseudopteroxazole photoaffinity probes 
 
PtxGlu-BP (113). The carboxylic acid (100PJȝPRO 4-aminobenzophenone 
(19.3 mg, 97.9 ȝPRO), and 3Å molecular sieves (~100 mg) were stirred in anhydrous 
CH2Cl2 (6 mL) under a N2 atmosphere for 30 min prior to adding DCC (42.8 mg, 0.207 
mmol). The reaction was stirred overnight at room temperature and was then partitioned 
between EtOAc and DI H2O. The EtOAc phase was recovered, subjected to the standard 
work up procedure, and separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to 
yield 113 (10.5 mg, 18.7 mmol, 24%). 113: white solid; [Į]25D +61.4 (c 0.1392, CHCl3); 
IR ȣmax 3326, 2922, 2855, 1703, 1656, 1596, 1528, 1446, 1408, 1374, 1312, 1280, 1175, 
1603, 938, 924, 854, 743, 700 cm-1. 1H NMR (CDCl30+]į+V1H), 7.80 
(2H, app. d, J = 8.6 Hz, H-¶), 7.75 (2H, app. d, J = 7.5 Hz, H-¶), 7.68 (2H, app. d, J = 
8.6 Hz, H-¶), 7.56 (1H, tt, J = 7.5, 1.3 Hz, H-¶), 7.46 (2H, app. t, J = 7.5 Hz, H-¶), 
4.96 (1H, app. d, J = 9.3 Hz, H-14), 3.94 (1H, app. q, J = 8.8 Hz, H-1), 3.34 (2H, app. 
ddd, J = 7.3, 5.7, 2.6 Hz, H-22), 3.24-3.16 (1H, m, H-7), 3.06-2.95 (2H, m, H-23), 2.45 
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(3H, s, H-20), 2.27-2.20 (1H, m, H-4), 2.20-2.14 (1H, m, H-6a), 2.18-2.13 (1H, m, H-5a), 
2.14-2.10 (1H, m, H-2a), 1.78 (3H, s, H-17), 1.68 (3H, s, H-16), 1.41 (3H, d, J = 6.8 Hz, 
H-19), 1.41-1.35 (1H, m, H-6b), 1.29-1.24 (1H, m, H-2b), 1.27-1.21 (1H, m, H-3), 1.07-
1.01 (1H, m, H-5b), 1.04 (3H, d, J = 6.0 Hz, H-18). 13C NMR (CDCl30+]į
(C, C-¶), 170.5 (C, C-24), 164.7 (C, C-21), 148.1 (C, C-9), 142.4 (C, C-¶), 138.6 (C, C-
10), 138.1 (C, C-¶), 136.4 (C, C-13), 134.9 (C, C-12), 132.9 (C, C-¶), 132.3 (CH, C-¶), 
131.7 (CH, C-¶), 130.8 (C, C-14), 130.0 (CH, C-¶), 129.1 (C, C-15), 128.4 (CH, C-¶), 
125.6 (C, C-11), 122.3 (C, C-8), 118.8 (CH, C-¶), 44.9 (CH, C-4), 40.1 (CH2, C-2), 36.6 
(CH, C-1), 34.7 (CH, C-3), 34.5 (CH2, C-23), 32.3 (CH2, C-6), 30.3 (CH, C-7), 28.2 
(CH2, C-5), 25.6 (CH3, C-16), 24.7 (CH2, C-22), 22.4 (CH3, C-19), 19.9 (CH3, C-18), 
17.8 (CH3, C-17), 13.8 (CH3, C-20). HRESIMS m/z 561.3087 [M + Na]+ (calcd for 
C37H41N2O3, 561.3112). 
 
4-Hydroxy-¶-propargyloxy-benzophenone (106). A VWLUUHGVROXWLRQRI¶-
dihydroxybenzophenone (105, 1.0358 g, 4.8352 mmol) and K2CO3 (333.0 mg, 2.41 
mmol) in anhydrous DMF (30 mL) under an argon atmosphere was heated to 100°C prior 
to adding propargyl bromide (80% (w/vLQWROXHQHȝ/PPRO After stirring 
overnight at 80°C, the reaction mixture was diluted with EtOAc and washed successively 
with DI H2O. The EtOAc phase was then subjected to the standard work up procedure 
and separated by MPLC VLOLFDKH[DQHVĺ(W2$FWR\LHOGFRPSRXQGV106 (447.1 mg, 
1.772 mmol, 73%) and ¶-dipropargyloxy-benzophenone (107, 167.9 mg, 0.5783 
mmol, 24%). The starting material 105 (470.0 mg, 2.194 mmol, 45% recovery) was also 
obtained. 106: white solid; IR ȣmax 3288, 1634, 1598, 1506, 1309, 1283, 1226, 1165, 
211 
 
1021, 929, 852, 770 cm-1. 1H NMR (CDCl30+]į+DSSGJ = 8.7, H-¶
7.73 (2H, app. d, J = 8.5, H-¶+DSSGJ = 8.7, H-¶+DSSGJ = 
8.5, H-¶+GJ = 2.3, H-¶+WJ = 2.3 Hz, H-¶13C NMR 
(CDCl30+]į&&-¶&&-¶&&-¶&+&-
¶&+&-¶&&-¶&&-¶&+&-¶&+&-
¶&&-¶&+&-¶&+2, C-¶+5(6,06m/z 253.0857 [M 
+ H]+ (calcd for C16H13O3, 253.0859). 107: white solid; IR ȣmax 3289, 1644, 1597, 1504, 
1418, 1305, 1284, 1220, 1166, 1018, 926, 849, 767 cm-1. 1H NMR (CDCl30+]į
7.75 (2H, app. d, J = 8.7 Hz, H-¶+DSSGJ = 8.7 Hz, H-¶+GJ = 
2.3 Hz, H-¶+WJ = 2.3 Hz, H-¶13C NMR (CDCl30+]į&
C-¶&&-¶&+&-¶&&-¶&+&-¶&&-
¶&+&-¶&+2, C-¶+5(6IMS m/z 291.1013 [M + H]+ (calcd for 
C19H15O3, 291.1016). 
 
tert-Butyl 2-¶-propargyloxy-4-benzophenonoxy)acetate (108). To a stirred solution 
of 106 (323.7 mg, 1.283 mmol) and K2CO3 (425.7 mg, 3.080 mmol) in anhydrous 
acetone (10 mL) under a N2 atmosphere was added tert-EXW\OEURPRDFHWDWHȝ/
mmol). After stirring overnight at room temperature, the reaction mixture was partitioned 
between EtOAc and DI H2O. The organic layer was recovered and subjected to the 
standard work up procedure to provide the desired tert-butyl ester (108, 746.0 mg). 108: 
white solid; [Į]25D +54.7 (c 0.3033, CHCl3); IR ȣmax 3288, 2979, 1749, 1647, 1601, 1508, 
1369, 1307, 1222, 1168, 1152, 1076, 1023, 928, 850, 769 cm-1. 1H NMR (CDCl3, 600 
0+]į+DSSGJ = 8.7 Hz, H-¶+-¶+DSSGJ = 8.7 Hz, H-¶
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6.94 (2H, app. d, J = 8.7 Hz, H-¶+GJ = 2.3 Hz, H-¶+V+-¶
2.56 (1H, t, J = 2.3 Hz, H-¶+V&&H3)3). 13C NMR (CDCl30+]į
194.3 (C, C-¶&&-¶&&-¶&&-¶&+&-¶
132.2 (CH, C-¶&&-¶&-¶&+&-¶&+&-¶
82.8 (C, C(CH3)3), 78.0 (C, C-¶&+&-¶&+2, C-¶ 56.0 (CH2, C-
¶&+3, C(CH3)3). HRESIMS m/z 367.1523 [M + H]+ (calcd for C22H23O5, 
367.1540).  
 
2-¶-Propargyloxy-4-benzophenonoxy)acetic acid (109). The tert-butyl ester (108, 
746.0 mg) was dissolved in CH2Cl2 (10 mL) and CF3CO2H (2.61 mL, 34.1 mmol) was 
added. After stirring the reaction overnight at room temperature, the mixture was 
partitioned between EtOAc and NaHCO3(aq). The EtOAc phase was recovered and 
subjected to the standard work up procedure to provide the crude product, which was 
separated by RP-MPLC (C18, H2O ĺ CH3OH, 0.1% HCO2H) to yield 109 (398.1 mg, 
1.283 mmol, 93% over two steps). 109: white solid; [Į]25D +32.3 (c 1.9169, CHCl3); IR 
ȣmax 3287, 1741, 1643, 1600, 1508, 1308, 1226, 1170, 1021, 929, 851, 769 cm-1. 1H NMR 
(CDCl30+]į+DSSGJ = 8.8 Hz, H-¶+-¶+DSSGJ = 8.8 
Hz, H-¶+DSSGJ = 8.8 Hz, H-¶+V+-¶+GJ = 2.4 
Hz, H-¶+WJ = 2.4 Hz, H-¶13C NMR (CDCl30+]į93.9 (C, C-
¶&&-¶&&-¶&&-¶&+&-¶&+&-
¶&&-¶&&-¶&+&-¶&+&-¶&&-
¶&+&-¶&+2, C-¶&+2, C-¶HRESIMS m/z 311.0907 [M 
+ H]+ (calcd for C18H15O5, 311.0914).  
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N-Succinimidyl 2-¶-propargyloxy-4-benzophenonoxy)acetate (110). A solution of 
109 (491.9 mg) and NHS (401.2 mg, 3.486 mmol) in THF (25 mL) were stirred in the 
presence of 3Å molecular sieves (~500 mg) under a N2 atmosphere. After stirring for 30 
min, DIC (ȝ/, 3.929 mmol) was added and the reaction mixture was stirred 
overnight at room temperature. The mixture was then partitioned between EtOAc and DI 
H2O. The EtOAc phase was recovered and subjected to the standard work up procedure 
to provide a crude sample of NHS ester 110 (783.5 mg), which was utilized without 
purification. 
 
Ptx-EG3-BPA (111). A solution of 97 (16.PJȝPRO) in anhydrous CH2Cl2 (5 mL) 
was stirred with 3Å molecular sieves (~100 mg) for 20 min before adding the crude 
sample of NHS ester 110 (33.8 mg). Afterwards, Et3N ȝ/ȝPRO was added and 
the reaction was stirred overnight at room temperature. After removing the solvent in 
vacuo, the crude product was separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% 
HCO2H) to provide 111 PJȝPRO39%) as a regioisomeric mixture with a 
ratio of approximately 5:1. 111: clear oil; [Į]25D +54.7 (c 0.3033, CHCl3); IR ȣmax 3292, 
2920, 2868, 1674, 1649, 1601, 1537, 1508, 1445, 1248, 1169, 1116, 928, 769 cm-1. 1H 
NMR (CDCl30+]į+DSSGJ = 8.7 Hz, H-¶+DSSGJ = 8.8 
Hz, H-¶+WJ = 5.4 Hz, 30-NH), 7.03 (2H, app. d, J = 8.8 Hz, H-¶
(2H, app. d, J = 8.7 Hz, H-¶+GJ = 9.3 Hz, H-14), 4.76 (2H, d, J = 2.4 Hz, H-
¶+V+-¶-3.88 (1H, m, H-1), 3.93 (2H, t, J = 6.9 Hz, H-23), 3.65-3.62 
(2H, m, H-27), 3.60-3.57 (4H, m, H-25, H-26), 3.53 (2H, t, J = 6.1 Hz, H-28), 3.54-3.51 
(2H, m, H-24), 3.47 (2H, q, J = 6.1 Hz, H-30), 3.23-3.16 (1H, m, H-7), 3.17 (2H, t, J = 
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6.9 Hz, H-22), 2.56 (1H, t, J = 2.4 Hz, H-¶ (3H, s, H-20), 2.22 (1H, app. ddd, J = 
9.4, 3.6 Hz, H-4), 2.20-2.13 (1H, m, H-6a), 2.17-2.11 (1H, m, H-5a), 2.13-2.08 (1H, m, 
H-2a), 1.81 (2H, p, J = 6.1 Hz, H-29), 1.76 (3H, s, H-17), 1.65 (3H, s, H-16), 1.43-1.34 
(1H, m, H-6b), 1.41 (3H, d, J = 6.8 Hz, H-19), 1.29-1.23 (1H, m, H-2b), 1.27-1.20 (1H, 
m, H-3), 1.09-1.00 (1H, m, H-5b), 1.03 (3H, d, J = 5.9 Hz, H-18). 13C NMR (CDCl3, 150 
0+]į&&-¶&&-¶&&-21), 160.9 (C, C-¶&&-
¶&&-9), 139.3 (C, C-10), 135.7 (C, C-13), 134.3 (C, C-12), 132.4 (CH, C-¶
132.3 (CH, C-¶&&-¶&&-¶&+&-14), 128.8 (C, C-15), 
125.9 (C, C-11), 121.9 (C, C-8), 114.6 (CH, C-¶&+&-¶&&-¶
76.3 (CH, C-¶6, 70.6 (CH2, C-25, C-26, C-27), 70.4 (CH2, C-24), 70.0 (CH2, 
C-28), 68.3 (CH2, C-23), 67.6 (CH2, C-¶&+2, C-¶&+&-4), 40.2 
(CH2, C-2), 37.7 (CH2, C-30), 36.5 (CH, C-1), 34.7 (CH, C-3), 32.3 (CH2, C-6), 30.3 
(CH, C-7), 29.8 (CH2, C-22), 29.1 (CH2, C-29), 28.2 (CH2, C-5), 25.5 (CH3, C-16), 22.3 
(CH3, C-19), 19.9 (CH3, C-18), 17.7 (CH3, C-17), 13.6 (CH3, C-20). HRESIMS m/z 
791.4261 [M + H]+ (calcd for C48H59N2O8, 791.4266).  
 
PtxGlu-EG3-BPA (112). Method 1: A solution of 100 (45.4 mg, 0.119 mmol) and NHS 
(17.8 mg, 0.155 mmol) in CH2Cl2 (5 mL) was stirred with 3Å molecular sieves (~500 
mg) under an argon atmosphere. The 4,7,10-trioxa-1,13-tridecanediamine (94, ȝ/
1.18 mmol) was then added and the reaction was stirred for 48 h at room temperature, at 
which point the reaction mixture was partitioned between EtOAc and DI H2O. The 
EtOAc phase was then subjected to the standard work up procedure, providing a crude 
sample of PtxGlu-EG3-NH2 (101, 86.6 mg). This intermediate was dissolved in CH2Cl2 
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(5 mL) and a crude sample of NHS ester 110 (118.8 mg) was then added. After stirring 
the reaction for 48 h at room temperature, the reaction mixture was worked up, as 
described above, and separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to 
yield the desired product 112 PJȝPRO over three steps). Method 2: To 
a stirred solution of PtxGlu-EG3-NH2 (101, PJȝPROLQ&+2Cl2 (5 mL) was 
added a crude sample of NHS ester 110 (39.1 mg). After stirring the reaction was left to 
stir for 48 h at room temperature, the mixture was worked up, as described above, and 
separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to yield 112 (7.67 mg, 8.75 
ȝPROThe products of both reactions were isolated as a regioisomeric mixture with 
a ratio of approximately 27:1. 112: yellow oil; [Į]25D +52.3 (c 0.9883, CHCl3); IR ȣmax 
3302, 2921, 2867, 1651, 1601, 1542, 1444, 1305, 1248, 1226, 1169, 1116, 928, 851, 769  
cm-1. 1H NMR (CDCl30+]į+DSSGJ = 8.7 Hz, H-¶+-¶+
t, J = 5.5 Hz, 34-NH), 7.00 (2H, app. d, J = 8.7 Hz, H-¶+DSSGJ = 8.7 Hz, 
H-¶+WJ = 5.4 Hz, 25-NH), 4.91 (1H, d, J = 9.3 Hz, H-14), 4.73 (2H, d, J = 
2.4 Hz, H-¶+V+-¶+DSSTJ = 8.8 Hz, H-1), 3.60-3.58 (2H, m, 
H-29), 3.57-3.55 (2H, m, H-30), 3.55-3.52 (2H, m, H-31), 3.52-3.48 (2H, m, H-28), 3.50 
(2H, t, J = 6.2 Hz, H-32), 3.48 (2H, t, J = 5.9 Hz, H-27), 3.43 (2H, q, J = 6.2 Hz, H-34), 
3.32 (2H, app. q, J = 6.2 Hz, H-25), 3.21 (2H, t, J = 7.6 Hz, H-22), 3.18-3.12 (1H, m, H-
7), 2.71 (2H, t, J = 7.6 Hz, H-23), 2.33 (3H, s, H-20), 2.56 (1H, t, J = 2.4 Hz, H-¶
2.19 (1H, app. ddd, J = 10.4, 3.5 Hz, H-4), 2.16-2.10 (1H, m, H-6a), 2.14-2.08 (1H, m, 
H-5a), 2.10-2.04 (1H, m, H-2a), 1.77 (2H, p, J = 6.2 Hz, H-33), 1.75-1.70 (2H, m, H-26), 
1.73 (3H, s, H-17), 1.63 (3H, s, H-16), 1.39-1.31 (1H, m, H-6b), 1.38 (3H, d, J = 6.8 Hz, 
H-19), 1.27-1.20 (1H, m, H-2b), 1.23-1.17 (1H, m, H-3), 1.05-0.96 (1H, m, H-5b), 1.00 
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(3H, d, J = 6.0 Hz, H-18). 13C NMR (CDCl30+]į&&-¶&&-
24), 167.4 (C, C-¶&&-¶&&-¶&&-21), 147.9 (C, C-9), 
139.1 (C, C-10), 135.6 (C, C-13), 134.2 (C, C-12), 132.3 (CH, C-¶&+&-¶
131.8 (C, C-¶&&-¶&+&-14), 128.6 (C, C-15), 125.6 (C, C-11), 
121.8 (C, C-8), 114.4 (CH, C-¶&+&-¶&&-¶&+&-¶
70.5, 70.5 (CH2, C-29, C-30), 70.3 (CH2, C-31), 70.1 (CH2, C-28), 69.8, 69.8 (CH2, C-27, 
C-32), 67.4 (CH2, C-¶&+2, C-¶&+&-4), 40.0 (CH2, C-2), 37.8 (CH2, 
C-25), 37.5 (CH2, C-34), 36.4 (CH, C-1), 34.5 (CH, C-3), 33.2 (CH2, C-23), 32.2 (CH2, 
C-6), 30.2 (CH, C-7), 29.0, 29.0 (CH2, C-26, C-33), 28.1 (CH2, C-5), 25.4 (CH3, C-16), 
24.7 (CH2, C-22), 22.2 (CH3, C-19), 19.8 (CH3, C-18), 17.6 (CH3, C-17), 13.5 (CH3, C-
20). HRESIMS m/z 876.4785 [M + H]+ (calcd for C52H66N3O9, 876.4794). 
 
4.4.9 Synthesis and characterization pseudopterosin-derived probes 
 
Pseudopterosin G-J aglycone methyl ether (95). The methyl ether (95) was prepared 
following a known procedure.280a To a stirred solution of pseudopterosins G-J (33-36) 
(10.079 g) and K2CO3 (15.82 g, 114.5 mmol) in freshly distilled acetone (125 mL) was 
added CH3I (20 mL, 320 mmol). The reaction was heated to reflux overnight and then 
partitioned between EtOAc and DI H2O. The EtOAc layer was evaporated in vacuo to 
provide the crude product, which was immediately dissolved in CH3OH:H2O (95:5, 100 
mL), adjusted to pH 1 with HCl, and heated under reflux overnight. After removing 
approximately 90 mL of the reaction solvent in vacuo, the reaction mixture was diluted 
with EtOAc and washed successively with NaHCO3(aq). The EtOAc phase was recovered, 
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subjected to the standard work up procedure, and then separated by MPLC (silica, 
KH[DQHVĺ7%0( to yield 95 (4.238 g, 13.48 mmol, ~62%). All 1H and 13C NMR 
spectroscopic data for 95 were in agreement with the literature.280a 
 
Ps-CO2t-Bu (114). A solution of aglycone methyl ether (95, 442.5 mg, 1.407 mmol) in 
anhydrous DMF (15 mL) was stirred under a N2 atmosphere at 0 ºC. Afterwards, NaH 
(69.8 mg, 2.91 mmol) was slowly added and the mixture was stirred for 3 h. During this 
time, the reaction slowly warmed to room temperature and tert-butyl bromoacetate (415 
ȝ/PPROZDVDGGHG7KHUHDFWLRQZDVOHIt to stir for 72 h, after which TLC 
analysis (hexanes:EtOAc 7:3) showed the formation of the desired product. The reaction 
mixture was diluted with EtOAc and washed successively with DI H2O. The recovered 
EtOAc layer was then subjected to the standard work up procedure, providing a crude 
product that was separated by MPLC (silica, KH[DQHVĺ7%0( to yield 114 (321.3 mg, 
0.7496 mmol, 50%). 114: white solid; [Į]25D +32.3 (c 1.9169, CHCl3); IR ȣmax 2925, 
2861, 1758, 1730, 1456, 1413, 1368, 1321, 1223, 1160, 1098, 845 cm-1. 1H NMR 
(CDCl30+]į+GJ = 9.2 Hz, H-14), 4.53 (1H, d, J = 15.7 Hz, H-21a), 
4.46 (1H, d, J = 15.7 Hz, H-21b), 3.74 (3H, s, 10-OCH3), 3.72-3.66 (1H, m, H-1), 3.39 
(1H, app. sextet, J = 7.2 Hz, H-7), 2.14-2.07 (1H, m, H-6a), 2.10-2.04 (1H, m, H-5a), 
2.08-2.03 (1H, m, H-4), 2.07 (3H, s, H-20), 1.96 (1H, app. ddd, J = 10.3, 8.0, 1.5 Hz, H-
2a), 1.73 (3H, s, H-17), 1.69 (3H, s, H-16), 1.52 (9H, s, C(CH3)3), 1.39-1.31 (1H, m, H-
6b), 1.27-1.21 (1H, m, H-3), 1.26 (3H, d, J = 6.9 Hz, H-19), 1.25-1.20 (1H, m, H-2b), 
1.03 (3H, d, J = 5.8 Hz, H-18), 0.97-0.89 (1H, m, H-5b). 13C NMR (CDCl30+]į
169.1 (C, C-22), 149.0 (C, C-10), 148.0 (C, C-9), 135.6 (C, C-13), 134.6 (C, C-12), 133.3 
218 
 
(C, C-8), 131.0 (CH, C-14), 128.8 (C, C-15), 128.5 (C, C-11), 81.4 (C, C(CH3)3), 70.6 
(CH2, C-21), 60.4 (CH3, 10-OCH3), 44.1 (CH, C-4), 40.2 (CH2, C-2), 37.4 (CH, C-1), 
34.2 (CH, C-3), 31.3 (CH2, C-6), 28.3 (CH, C-7), 28.3 (CH3, C(CH3)3), 27.7 (CH2, C-5), 
25.6 (CH3, C-16), 24.6 (CH3, C-19), 20.2 (CH3, C-18), 17.7 (CH3, C-17), 12.2 (CH3, C-
20). HRESIMS m/z 451.2809 [M + Na]+ (calcd for C27H40O4Na, 451.2819).  
 
Ps-CO2H (115). To a solution of the tert-butyl ester (114, 308.6 mg, 0.7200 mmol) in 
THF (10 mL) was added LiOH (338.0 mg, 14.11 mmol). The mixture was stirred at room 
temperature for 96 h, at which point TLC analysis (hexanes:EtOAc 7:3) showed product 
formation. The reaction mixture was then diluted with EtOAc and partitioned with DI 
H2O. The EtOAc layer was recovered, subjected to the standard work up procedure, and 
separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to provide the desired 
carboxylic acid (115, 254.3 mg, 0.6827 mmol, 95%). 115: yellow oil; [Į]25D +59.3 (c 
1.3600, CHCl3); IR ȣmax 2923, 2861, 1736, 1448, 1413, 1375, 1319, 1220, 1098, 1044, 
1009, 756 cm-1.1H NMR (CDCl30+]į-8.10 (1H, br s, CO2H), 4.96 (1H, d, 
J = 9.2 Hz, H-14), 4.73 (1H, d, J = 16.5 Hz, H-21a), 4.53 (1H, d, J = 16.5 Hz, H-21b), 
3.79 (3H, s, 10-OCH3), 3.71 (1H, app. q, J = 8.7 Hz, H-1), 3.24 (1H, app. sextet, J = 7.2 
Hz, H-7), 2.16-2.08 (1H, m, H-6a), 2.12-2.05 (1H, m, H-5a), 2.10-2.05 (1H, m, H-4), 
2.09 (3H, s, H-20), 2.00 (1H, app. dd, J = 10.0, 8.2 Hz, H-2a), 1.75 (3H, s, H-17), 1.70 
(3H, s, H-16), 1.41-1.32 (1H, m, H-6b), 1.26 (3H, d, J = 6.9 Hz, H-19), 1.26-1.21 (1H, m, 
H-3), 1.26-1.20 (1H, m, H-2b), 1.04 (3H, d, J = 5.7 Hz, H-18), 0.98-0.90 (1H, m, H-5b). 
13C NMR (CDCl30+]į3.3 (C, C-22), 148.5 (C, C-10), 147.7 (C, C-9), 136.6 
(C, C-13), 135.8 (C, C-12), 130.6 (CH, C-14), 129.1 (C, C-15), 128.6 (C, C-11), 132.9 
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(C, C-8), 70.4 (CH2, C-21), 61.0 (CH3, 10-OCH3), 44.1 (CH, C-4), 40.1 (CH2, C-2), 37.3 
(CH, C-1), 34.2 (CH, C-3), 31.3 (CH2, C-6), 28.8 (CH, C-7), 27.5 (CH2, C-5), 25.5 (CH3, 
C-16), 23.9 (CH3, C-19), 20.0 (CH3, C-18), 17.7 (CH3, C-17), 12.3 (CH3, C-20). 
HRESIMS m/z 373.2356 [M + H]+ (calcd for C23H33O4, 373.2373). 
 
Ps-CO2CH3 (116). The methyl ester (116) was obtained as a solvent-derived artifact 
during the RP-MPLC purification of the carboxylic acid (115). 116: yellow oil; [Į]25D 
+42.0 (c 0.5517, CHCl3); IR ȣmax 2923, 2857, 1767, 1743, 1448, 1413, 1320, 1205, 1100, 
1072, 1044, 839 cm-1. 1H NMR (CDCl30+]į+GJ = 9.2 Hz, H-14), 4.63 
(2H, s, H-21), 3.81 (3H, s, 22-OCH3), 3.73 (3H, s, 10-OCH3), 3.69 (1H, app. q, J = 8.8 
Hz, H-1), 3.35 (1H, app. sextet, J = 7.2 Hz, H-7), 2.13-2.07 (1H, m, H-6a), 2.09-2.03 
(1H, m, H-5a), 2.08-2.02 (1H, m, H-4), 2.06 (3H, s, H-20), 1.96 (1H, app. ddd, J = 10.3, 
8.1, 1.5 Hz, H-2a), 1.73 (3H, s, H-17), 1.68 (3H, s, H-16), 1.37-1.31 (1H, m, H-6b), 1.25 
(3H, d, J = 6.9 Hz, H-19), 1.25-1.20 (1H, m, H-3), 1.24-1.18 (1H, m, H-2b), 1.03 (3H, d, 
J = 5.9 Hz, H-18), 0.95-0.89 (1H, m, H-5b). 13C NMR (CDCl30+]į&&-
22), 149.0 (C, C-10), 147.6 (C, C-9), 135.8 (C, C-13), 134.9 (C, C-12), 133.3 (C, C-8), 
130.9 (CH, C-14), 128.9 (C, C-15), 128.6 (C, C-11), 69.7 (CH2, C-21), 60.4 (CH3, 10-
OCH3), 51.9 (CH3, 22-OCH3), 44.1 (CH, C-4), 40.1 (CH2, C-2), 37.5 (CH, C-1), 34.2 
(CH, C-3), 31.3 (CH2, C-6), 28.3 (CH, C-7), 27.7 (CH2, C-5), 25.6 (CH3, C-16), 24.6 
(CH3, C-19), 20.2 (CH3, C-18), 17.7 (CH3, C-17), 12.2 (CH3, C-20). HRESIMS m/z 
387.2529 [M + H]+ (calcd for C24H35O4, 387.2530).  
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Ps-EG3-NH2 (117). The carboxylic acid (115, 17.9 mg, ȝPRO) and NHS (8.2 mg, 71 
ȝPROZHUHGLVVROYHGLQDQK\GURXV&+2Cl2 (5 mL) and stirred under a N2 atmosphere. 
DCC (28.2 mg, 0.137 mmol) was then added and the reaction was stirred overnight at 
room temperature. An excess of 4,7,10-trioxa-1,13-tridecanediamine (94ȝ/
mmol) was then added and the reaction was left to stir for 7 h, at which point the mixture 
was diluted with EtOAc and washed successively with DI H2O. After recovery of the 
EtOAc layer, the standard work up procedure was completed, and the crude product was 
separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to provide the desired 
product (117, 18.3 mg, 31.8 ȝPRO, 66% over two steps). 117: yellow oil; [Į]25D -32.9 (c 
0.1950, CHCl3); IR ȣmax 3332, 2923, 2867, 1660, 1587, 1538, 1456, 1413, 1375, 1348, 
1319, 1109, 1072, 766 cm-1.1H NMR (CDCl30+]į+WJ = 5.5 Hz, 24-
NH), 4.93 (1H, d, J = 9.2 Hz, H-14), 4.43 (2H, s, H-21), 3.68 (1H, app. q, J = 8.7 Hz, H-
1), 3.70 (3H, s, 10-OCH3), 3.64-3.60 (2H, m, H-30), 3.62-3.55 (8H, m, H-26, H-27, H-
28, H-29), 3.57 (2H, t, J = 6.0 Hz, H-25), 3.46 (2H, q, J = 6.9 Hz, H-23), 3.32 (2H, q, J = 
6.1 Hz, H-32), 3.14 (1H, sextet, J = 7.2 Hz, H-7), 2.12-2.05 (1H, m, H-6a), 2.08-2.02 
(1H, m, H-5a), 2.06-1.99 (1H, m, H-4), 2.05 (3H, s, H-20), 1.95 (1H, app. q, J = 10.2, 8.1 
Hz, H-2a), 1.94-1.88 (2H, m, H-31), 1.86 (2H, p, J = 6.5 Hz, H-24), 1.72 (3H, s, H-17), 
1.67 (3H, s, H-16), 1.37-1.29 (1H, m, H-6b), 1.24-1.18 (1H, m, H-3), 1.23 (3H, d, J = 6.8 
Hz, H-19), 1.22-1.17 (1H, m, H-2b), 1.01 (3H, d, J = 5.8 Hz, H-18), 0.95-0.87 (1H, m, H-
5b). 13C NMR (CDCl30+]į&&-22), 149.1 (C, C-10), 147.2 (C, C-9), 
136.1 (C, C-13), 135.5 (C, C-12), 132.6 (C, C-8), 130.7 (CH, C-14), 129.1 (C, C-15), 
128.9 (C, C-11), 72.0 (CH2, C-21), 70.6, 70.3, 70.3, 70.1 (CH2, C-26, C-27, C-28, C-29), 
69.9 (CH2, C-30), 69.1 (CH2, C-25), 60.6 (CH3, 10-OCH3), 44.1 (CH, C-4), 40.1 (CH2, 
221 
 
C-2), 39.0 (CH2, C-32), 37.4 (CH, C-1), 36.7 (CH2, C-23), 34.2 (CH, C-3), 31.3 (CH2, C-
6), 29.7 (CH2, C-24), 28.7 (CH, C-7), 27.9 (CH2, C-31), 27.5 (CH2, C-5), 25.6 (CH3, C-
16), 24.3 (CH3, C-19), 20.1 (CH3, C-18), 17.7 (CH3, C-17), 12.3 (CH3, C-20). HRESIMS 
m/z 575.4056 [M + H]+ (calcd for C33H55N2O6, 575.4055). 
 
Ps-EG3-Biotin (119). The above procedure for synthesizing Ps-EG3-NH2 (117) was 
carried out using the carboxylic acid (115, 28.7 mg, 76.9 ȝPRO), NHS (13.7 mg, 0.119 
mmol), DCC (41.6 mg, 0.202 mmol), 4,7,10-trioxa-1,13-tridecanediamine (94ȝ/
0.775 mmol), and anhydrous CH2Cl2 (6 mL). Without further purification, the crude 
product of 117 was dissolved in anhydrous CH2Cl2 and added to biotin-NHS (102, 54.9 
mg, 0.1608 mmol). The reaction was stirred for 2 h, at which point LC-HRESIMS 
analysis indicated the formation of the desired product. The mixture was then diluted 
with EtOAc and partitioned between DI H2O. The organic layer was recovered, subjected 
to the standard work up procedure, and separated by RP-MPLC (C18, H22ĺ&+3OH, 
0.1% HCO2H). The biotinylated Ps-EG3-Biotin (119PJȝPRORYHU
three steps) was then purified by semi-preparative RP-HPLC (C18, 90% CH3OH, 
HCO2H). 119: yellow oil; [Į]25D +75.5 (c 0.1508, CHCl3); IR ȣmax 3298, 2922, 2866, 
1699, 1657, 1542, 1452, 1093, 1071, 712 cm-1. 1H NMR (CDCl30+]į+
t, J = 5.6 Hz, 24-NH), 6.64 (1H, t, J = 5.4 Hz, 33-NH), 6.27 (1H, br s, ¶-NH), 5.48 (1H, 
EUV¶-NH), 4.93 (1H, d, J = 9.2 Hz, H-14), 4.48 (1H, dd, J = 7.5, 4.9 Hz, H-¶
(2H, s, H-21), 4.28 (1H, dd, J = 7.5, 4.8 Hz, H-¶+V-OCH3), 3.68 (1H, app. 
q, J = 8.7 Hz, H-1), 3.64-3.55 (8H, m, H-26, H-27, H-28, H-29), 3.60-3.56 (2H, m, H-
25), 3.54 (2H, t, J = 6.0 Hz, H-30), 3.47 (2H, q, J = 6.5 Hz, H-23), 3.32 (2H, q, J = 6.0 
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Hz, H-32), 3.18-3.12 (1H, m, H-7), 3.12 (1H, td, J = 7.3, 4.8 Hz, H-¶+GGJ = 
12.8, 4.9 Hz, H-¶D+GJ = 12.8 Hz, H-¶E+WJ = 7.5 Hz, H-¶
2.13-2.05 (1H, m, H-6a), 2.09-2.03 (1H, m, H-5a), 2.07-2.01 (1H, m, H-4), 2.05 (3H, s, 
H-20), 1.96 (1H, app. q, J = 10.1, 8.2 Hz, H-2a), 1.87 (2H, p, J = 6.5 Hz, H-24), 1.76 
(2H, p, J = 6.0 Hz, H-31), 1.76-1.70 (1H, m, H-¶D+V+-17), 1.69-1.61 (2H, 
m, H-¶-1.62 (1H, m, H-¶E+V+-16), 1.43 (2H, p, J = 7.5 Hz, H-¶
1.38-1.30 (1H, m, H-6b), 1.24-1.19 (1H, m, H-3), 1.24-1.17 (1H, m, H-2b), 1.23 (3H, d, J 
= 6.9 Hz, H-19), 1.01 (3H, d, J = 5.7 Hz, H-18), 0.96-0.88 (1H, m, H-5b). 13C NMR 
(CDCl30+]į&&-¶&&-22), 163.9 (C, C-¶&&-10), 
147.2 (C, C-9), 136.1 (C, C-13), 135.5 (C, C-12), 132.6 (C, C-8), 130.6 (CH, C-14), 
129.1 (C, C-15), 128.9 (C, C-11), 72.0 (CH2, C-21), 70.6, 70.6, 70.4, 70.1 (CH2, C-26, C-
27, C-28, C-29), 70.1 (CH2, C-30), 69.4 (CH2, C-25), 61.9 (CH, C-¶&+3, 10-
OCH3), 60.3 (CH, C-¶&+&-¶&+&-4), 40.7 (CH2, C-¶&+2, 
C-2), 37.8 (CH2, C-32), 37.4 (CH, C-1), 36.8 (CH2, C-23), 36.1 (CH2, C-¶&+
C-3), 31.3 (CH2, C-6), 29.7 (CH2, C-24), 29.1 (CH2, C-31), 28.7 (CH, C-7), 28.3 (CH2, 
C-¶&+2, C-¶&+2, C-5), 25.8 (CH2, C-¶&+3, C-16), 24.3 (CH3, 
C-19), 20.1 (CH3, C-18), 17.7 (CH3, C-17), 12.3 (CH3, C-20). HRESIMS m/z 801.4827 
[M + H]+ (calcd for C43H69N4O8S, 801.4831). 
 
Ps-EG3-Ps (118). Compound 118 was obtained from the synthesis of Ps-EG3-NH2 (117) 
and Ps-EG3-Biotin (119) during RP-MPLC separation. 118: orange oil; [Į]25D +30.6 (c 
1.5707, CHCl3); IR ȣmax 3326, 2919, 2851, 1667, 1534, 1456, 1413, 1318, 1222, 1071, 
838, 721 cm-1. 1H NMR (CDCl30+]į+W- +]-NH), 4.93 (2H, 
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app. d, J = 9.2 Hz, H-14), 4.44 (4H, s, H-21), 3.71 (6H, s, 10-OCH3), 3.68 (2H, app. q, J 
= 8.7 Hz, H-1), 3.58-3.54 (12H, m, H-25, H-26, H-27), 3.47 (4H, q, J = 6.4 Hz, H-23), 
3.15 (2H, sextet, J = 7.3 Hz, H-7), 2.13-2.06 (2H, m, H-6a), 2.09-2.04 (2H, m, H-5a), 
2.07-2.02 (2H, m, H-4), 2.05 (6H, s, H-20), 1.97 (2H, app. q, J = 10.2, 8.0 Hz, H-2a), 
1.87 (4H, p, J = 6.4 Hz, H-24), 1.73 (6H, s, H-17), 1.68 (6H, s, H-16), 1.38-1.31 (2H, m, 
H-6b), 1.24-1.19 (2H, m, H-3), 1.24-1.18 (2H, m, H-2b), 1.23 (6H, d, J = 6.9 Hz, H-19), 
1.02 (6H, d, J = 5.8 Hz, H-18), 0.95-0.88 (2H, m, H-5b). 13C NMR (CDCl30+]į
169.7 (C, C-22), 149.2 (C, C-10), 147.2 (C, C-9), 136.1 (C, C-13), 135.5 (C, C-12), 132.6 
(C, C-8), 130.7 (CH, C-14), 129.1 (C, C-15), 128.9 (C, C-11), 72.0 (CH2, C-21), 70.7 
(CH2, C-27), 70.5 (CH2, C-26), 69.5 (CH2, C-25), 60.6 (CH3, 10-OCH3), 44.1 (CH, C-4), 
40.1 (CH2, C-2), 37.4 (CH, C-1), 36.9 (CH2, C-23), 34.2 (CH, C-3), 31.4 (CH2, C-6), 
29.6 (CH2, C-24), 28.7 (CH, C-7), 27.5 (CH2, C-5), 25.6 (CH3, C-16), 24.3 (CH3, C-19), 
20.1 (CH3, C-18), 17.7 (CH3, C-17), 12.3 (CH3, C-20). HRESIMS m/z 929.6248 [M + 
H]+ (calcd for C56H85N2O9, 929.6250). 
 
CHO-PsOH (120). The aldehyde (120) was synthesized by ozonolysis using two 
different methods.  
Method 1: The aglycone methyl ether (95, 423.6 mg, 1.347 mmol) dissolved in 
CH2Cl2:CH3OH (5:1, 15 mL) was cooled to -78°C and ozone was bubbled through the 
solution for 10 min. The solution was then purged with N2 and cooled to 0°C before 
adding dimethyl sulfide (3 mL, 40.8 mmol). The reaction was left to stir overnight at 
room temperature before removing the solvent in vacuo and separating the mixture by 
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MPLC VLOLFDKH[DQHVĺ(W2$FWR\LHOGCHO-PsOH (120, 268.7 mg, 0.9317 mmol, 
69%).  
Method 2: The ozonolysis reaction above was repeated with the aglycone methyl ether 
(95, 388.1 mg, 1.234 mmol), except the ozone was bubbled through the solution for 1 hr. 
After separating the reaction mixture by MPLC VLOLFDKH[DQHVĺ(W2$FERWKCHO-
PsOH (120PJȝPRO, 32%) and an acetal side product (121) were obtained. 
120: yellow oil; [Į]25D +67.8 (c 1.1262, CHCl3); IR ȣmax 3450, 2942, 2865, 1718, 1599, 
1458, 1418, 1300, 1230, 1202, 1059, 1019, 891, 799 cm-1. 1H NMR (CDCl30+]į
9.28 (1H, d, J = 3.9 Hz, H-14), 5.95 (1H, s, 9-OH), 3.79 (1H, app. td, J = 8.8, 3.9 Hz, H-
1), 3.74 (3H, s, 10-OCH3), 3.16 (1H, app. sextet, J = 7.3 Hz, H-7), 2.17-2.11 (1H, m, H-
6a), 2.11 (3H, s, H-17), 2.10-2.04 (1H, m, H-5a), 2.03-1.97 (1H, m, H-4), 2.01-1.95 (1H, 
m, H-2a), 1.57-1.50 (1H, m, H-2b), 1.38-1.30 (1H, m, H-6b), 1.32-1.26 (1H, m, H-3), 
1.29 (3H, d, J = 6.8 Hz, H-16), 1.10 (3H, d, J = 6.5 Hz, H-15), 1.05-0.96 (1H, m, H-5b). 
13C NMR (CDCl30+]į&+&-14), 146.3 (C, C-9), 143.9 (C, C-10), 136.9 
(C, C-13), 127.0 (C, C-11), 126.9 (C, C-8), 120.8 (C, C-12), 60.9 (CH3, 10-OCH3), 51.0 
(CH, C-1), 43.8 (CH, C-4), 33.1 (CH, C-3), 31.7 (CH2, C-2), 31.6 (CH2, C-6), 28.8 (CH, 
C-7), 27.3 (CH2, C-5), 22.6 (CH3, C-16), 19.9 (CH3, C-15), 12.9 (CH3, C-17). HRESIMS 
m/z 311.1607 [M + Na]+ (calcd for C20H24O3Na, 311.1612). 
 
CH(OCH3)2-PsOH (121). During the synthesis and purification of CHO-PsOH (120), 
using method 2, as described above, the acetal (121, PJȝPRO) was 
obtained as a side product. 121: orange oil; [Į]25D +72.0 (c 0.7069, CHCl3); IR ȣmax 3424, 
2942, 2868, 2829, 1457, 1417, 1205, 1180, 1108, 1075, 1054, 883, 800, 775 cm-1. 1H 
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NMR (CDCl30+]į+V-OH), 4.12 (1H, d, J = 5.3 Hz, H-14), 3.74 (3H, 
s, 10-OCH3), 3.42 (1H, app. p, J = 4.9 Hz, H-1), 3.21 (3H, s, 14-OCH3), 3.16 (6H, s, 14-
OCH3), 3.09-3.02 (1H, m, H-7), 2.27 (3H, s, H-17), 2.13-2.08 (1H, m, H-4), 2.12-2.05 
(1H, m, H-6a), 2.05-1.99 (1H, m, H-5a), 1.92 (1H, ddd, J = 14.0, 10.0, 6.1 Hz, H-2a), 
1.63 (1H, ddd, J = 14.0, 11.0, 4.4 Hz, H-2b), 1.33-1.25 (1H, m, H-6b), 1.28 (3H, d, J = 
6.7 Hz, H-16), 1.13-1.06 (1H, m, H-3), 1.06-0.99 (1H, m, H-5b), 1.02 (3H, d, J = 6.4 Hz, 
H-15). 13C NMR (CDCl30+]į&&-9), 143.5 (C, C-10), 138.0 (C, C-13), 
126.7 (C, C-12), 126.6 (C, C-11), 125.9 (C, C-8), 110.0 (CH, C-14), 60.9 (CH3, 10-
OCH3), 56.3 (CH3, 14-OCH3), 55.8 (CH3, 14-OCH3), 42.5 (CH, C-4), 39.2 (CH, C-1), 
35.1 (CH, C-3), 31.9 (CH2, C-6), 31.3 (CH2, C-2), 29.6 (CH, C-7), 27.0 (CH2, C-5), 22.3 
(CH3, C-16), 19.9 (CH3, C-15), 12.5 (CH3, C-17). HRESIMS m/z 357.2026 [M + Na]+ 
(calcd for C20H30O4Na, 357.2036).  
 
H2N-EG3-PsOH (122). A solution of CHO-PsOH (120PJȝPROLQ&+3OH 
(1 mL) was slowly added to 4,7,10-trioxa-1,13-tridecanediamine (94, 1.00 mL, 4.56 
mmol) in CH3OH (2 mL). After the addition was complete, the mixture was stirred 
overnight at room temperature before adding NaBH4 (118.6 mg, 3.135 mmol). The 
reaction was stirred for an additional 3 h, diluted with CHCl3, and partitioned between DI 
H2O. The CHCl3 layer was recovered, subjected to the standard work up procedure, and 
then separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to provide a mixture 
of H2N-EG3-PsOH (122) and epi-H2N-EG3-PsOH (123) (33.8 mg, ȝPRO
overall yield). These two compounds were separated by semi-preparative RP-HPLC 
(phenylhexyl, 5 min at 5% CH3OH increasing linearly to 50% CH3OH at 30 min, 0.1% 
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HCO2H). 122: colorless oil; [Į]25D +16.5 (c 0.0983, CHCl3); IR ȣmax 2928, 2866, 1582, 
1460, 1421, 1347, 1132, 764 cm-1. 1H NMR (CDCl3, 600 0+]į-3.68 (2H, m, H-
¶+V-OCH3), 3.67-3.55 (10H, m, H-¶+-¶+-¶+-¶+-¶6-3.40 
(1H, m, H-1), 3.29 (1H, app. sextet, J = 7.0 Hz, H-7), 3.17 (2H, br t, J = 5.0 Hz, H-¶
3.11-3.00 (2H, m, H-¶+DSSWJ = 12.2 Hz, H-14a), 2.76 (1H, app. d, J = 
12.2 Hz, H-14b), 2.28 (3H, s, H-17), 2.19-2.12 (1H, m, H-5a), 2.17-2.13 (1H, m, H-2a), 
2.12-2.04 (2H, m, H-¶-2.05 (1H, m, H-6a), 2.06-1.98 (1H, m, H-4), 2.05-1.96 
(2H, m, H-¶-1.55 (1H, m, H-3), 1.53 (1H, app. td, J = 13.1, 3.7 Hz, H-2b), 1.50-
1.41 (1H, m, H-6b), 1.20 (3H, d, J = 7.0 Hz, H-16), 1.15-1.06 (1H, m, H-5b), 1.10 (3H, d, 
J = 6.0 Hz, H-15). 13C NMR (CDCl30+]į&&-9), 144.0 (C, C-10), 135.1 
(C, C-13), 127.2 (C, C-8), 125.6 (C, C-11), 125.4 (C, C-12), 70.7 (CH2, C-¶
70.0, 69.7 (CH2, C-¶&-¶&-¶&-¶&+2, C-¶&+3, 10-OCH3), 50.8 
(CH2, C-14), 45.9 (CH2, C-¶&+&-4), 39.9 (CH2, C-¶&+&-1), 32.3 
(CH2, C-2), 30.5 (CH2, C-6), 28.9 (CH, C-3), 28.2 (CH2, C-5), 27.3 (CH, C-7), 26.8 
(CH2, C-¶&+2, C-¶&+3, C-16), 20.6 (CH3, C-15), 11.7 (CH3, C-17). 
HRESIMS m/z 493.3636 [M + H]+ (calcd for C28H49N2O5, 493.3647). 
 
epi-H2N-EG3-PsOH (123). The epimerized analogue (123) was obtained as a side 
product during the synthesis and purification of H2N-EG3-PsOH (122) by semi-
preparative RP-HPLC. 123: colorless oil; [Į]25D +12.4 (c 0.4808, CHCl3); IR ȣmax 2927, 
2868, 1582, 1459, 1419, 1347, 1120, 764 cm-1. 1H NMR (CDCl30+]į+
s, 10-OCH3), 3.68-3.62 (2H, m, H-¶-3.54 (8H, m, H-¶+-¶+-¶+-¶-
3.52 (2H, m, H-¶-3.51 (1H, m, H-1), 3.12 (2H, br t, J = 5.8 Hz, H-¶-3.00 
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(2H, m, H-¶-2.98 (1H, m, H-7), 2.92 (1H, app. d, J = 11.3 Hz, H-14a), 2.72 (1H, 
app. t, J = 11.3 Hz, H-14b), 2.25-2.19 (1H, m, H-2a), 2.22 (3H, s, H-17), 2.04-1.98 (2H, 
m, H-¶-2.04 (1H, m, H-6a), 2.04-1.97 (1H, m, H-4), 2.02-1.96 (1H, m, H-5a), 
1.97-1.92 (2H, m, H-¶-1.34 (1H, m, H-2b), 1.27-1.19 (1H, m, H-6b), 1.24 (3H, d, 
J = 6.5 Hz, H-16), 1.15-1.07 (1H, m, H-3), 0.99 (3H, d, J = 6.0 Hz, H-15), 0.95-0.87 (1H, 
m, H-5b). 13C NMR (CDCl30+]į&&-9), 144.0 (C, C-10), 137.0 (C, C-
13), 126.7 (C, C-8), 125.8 (C, C-11), 125.6 (C, C-12), 70.4, 70.0, 70.0, 69.8 (CH2, C-¶
C-¶&-¶&-¶&+2, C-¶&+2, C-¶&+3, 10-OCH3), 54.9 (CH2, 
C-14), 46.1 (CH2, C-¶&+&-4), 39.2 (CH2, C-¶&+2, C-2), 35.0 (CH, 
C-3), 32.8 (CH, C-1), 31.9 (CH2, C-6), 29.5 (CH, C-7), 27.2 (CH2, C-5), 26.6 (CH2, C-
¶&+2, C-¶&+3, C-16), 19.6 (CH3, C-15), 12.1 (CH3, C-17). HRESIMS 
m/z 493.3642 [M + H]+ (calcd for C28H49N2O5, 493.3647). 
 
14,15-Dihydro-pseudopterosin G-J aglycone methyl ether (124). A mixture of the 
aglycone methyl ether (95PJȝPRO) and Pd/C (29.5 mg) in EtOAc (5 mL) 
were stirred with vigorous agitation overnight under a H2 atmosphere. The reaction 
mixture was then filWHUHGWKURXJK&HOLWHDQGVHSDUDWHGE\03/&VLOLFDKH[DQHVĺ
EtOAc), yielding the hydrogenated product (124PJȝPRO124: yellow 
oil; [Į]25D +29.8 (c 1.1262, CHCl3); IR ȣmax 3529, 2950, 2924, 2866, 1457, 1416, 1298, 
1227, 1202, 1181, 1050, 1013, 961, 799, 770 cm-1. 1H NMR (CDCl30+]į
(1H, s, 9-OH), 3.77 (3H, s, 10-OCH3), 3.13-3.08 (1H, m, H-1), 3.12-3.07 (1H, m, H-7), 
2.24 (3H, s, H-20), 2.16-2.09 (1H, m, H-6a), 2.13-2.09 (1H, m, H-2a), 2.09-2.05 (1H, m, 
H-4), 2.07-2.03 (1H, m, H-5a), 1.88-1.78 (1H, m, H-15), 1.36-1.30 (1H, m, H-6b), 1.33 
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(3H, d, J = 6.7 Hz, H-19), 1.31-1.25 (2H, m, H-14), 1.23-1.18 (1H, m, H-2b), 1.20-1.14 
(1H, m, H-3), 1.04 (3H, d, J = 6.1 Hz, H-18), 1.04-1.01 (1H, m, H-5b),  1.02 (3H, d, J = 
6.6 Hz, H-17), 0.92 (3H, d, J = 6.6 Hz, H-16). 13C NMR (CDCl30+]į&
C-9), 143.8 (C, C-10), 136.2 (C, C-13), 132.5 (C, C-12), 125.9 (C, C-8), 124.8 (C, C-11), 
60.7 (CH3, 10-OCH3), 48.9 (CH2, C-14), 43.4 (CH, C-4), 38.5 (CH2, C-2), 35.4 (CH, C-
3), 32.9 (CH, C-1), 32.1 (CH2, C-6), 29.7 (CH, C-7), 27.4 (CH2, C-5), 25.3 (CH, C-15), 
24.5 (CH3, C-16), 22.4 (CH3, C-19), 20.9 (CH3, C-17), 20.3 (CH3, C-18), 12.2 (CH3, C-
20). HRESIMS m/z 317.2468 [M + H]+ (calcd for C20H32O2, 317.2475). 
 
Pseudopterosin G acetonide (125). A solution of pseudopterosin G (33, 331.1 mg, 
0.7414 mmol) dissolved in acetone (10 mL) was stirred with TsOH (3.7 PJȝPRODW
room temperature for 40 h. The reaction mixture was then diluted with EtOAc and 
partitioned between DI H2O. The EtOAc layer was recovered, subjected to the standard 
work up procedure, and separated MPLC VLOLFDKH[DQHVĺ7%0(to furnish the 
desired acetonide (125, 315.5 mg, 0.6483 mmol, 87%). 125: white solid; [Į]25D -58.7 (c 
1.8585, CHCl3); IR ȣmax 3328, 2923, 2863, 1445, 1375, 1320, 1245, 1219, 1085, 1031, 
980, 868, 758 cm-1. 1H NMR (CDCl30+]į+GJ = 3.8 Hz, H-¶
(1H, d, J = 9.2 Hz, H-14), 4.62 (1H, qd, J = 6.7, 2.2 Hz, H-¶+WJ = 6.1 Hz, H-
¶(1H, dd, J = 6.1, 2.2 Hz, H-¶-3.98 (1H, m, H-¶+DSSTJ = 
8.8 Hz, H-1), 3.36 (1H, sextet, J = 7.6, 7.2, 6.9 Hz, H-7), 2.13 (1H, m, H-6a), 2.09-2.03 
(1H, m, H-5a), 2.05 (3H, s, H-20), 2.02 (1H, app. ddd, J = 10.0, 3.7 Hz, H-4), 2.00-1.95 
(1H, m, H-2a), 1.73 (3H, s, H-17), 1.67 (3H, s, H-16), 1.52 (3H, s, C(CH3)2), 1.41 (3H, d, 
J = 6.7 Hz, H-¶+V&&H3)2), 1.33 (1H, tdd, J = 12.8, 6.8, 4.9 Hz, H-6b), 
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1.25-1.19 (1H, m, H-2b), 1.27-1.21 (1H, m, H-3), 1.20 (3H, d, J = 6.9 Hz, H-19), 1.03 
(3H, d, J = 5.9 Hz, H-18), 0.96 (1H, app. ddd, J = 12.5, 11.4, 4.9 Hz, H-5b). 13C NMR 
(CDCl30+]į&&-10), 142.4 (C, C-9), 135.8 (C, C-12), 132.6 (C, C-8), 
131.3 (CH, C-14), 130.5 (C, C-13), 128.6 (C, C-15), 122.3 (C, C-11), 109.9 (C, 
C(CH3)2), 102.5 (CH, C-¶&+&-¶&+&-¶&+&-¶
(CH, C-¶&+&-4), 40.2 (CH2, C-2), 37.3 (CH, C-1), 34.3 (CH, C-3), 31.1 (CH2, 
C-6), 28.1 (CH3, C(CH3)2), 27.9 (CH, C-7), 27.7 (CH2, C-5), 26.1 (CH3, C(CH3)2), 25.6 
(CH3, C-16), 24.9 (CH3, C-19), 20.2 (CH3, C-18), 17.7 (CH3, C-17), 16.6 (CH3, C-¶
12.4 (CH3, C-20). HRESIMS m/z 487.3052 [M + H]+ (calcd for C29H43O6, 487.3054). 
 
Pseudopterosin G diketal (128).  To a stirred solution of 125 (311.9 mg, 0.6409 mmol) 
in CH2Cl2 (8 mL) was added Dess-Martin periodinane (336.3 mg, 0.7929 mmol). The 
reaction mixture became red upon adding the oxidant. After stirring overnight at room 
temperature, TLC analysis (hexanes:TBME 7:3) showed the disappearance of starting 
material. The mixture was then partitioned between EtOAc and DI H2O before carrying 
out the standard work up procedure. The crude product was then separated by MPLC 
(VLOLFDKH[DQHVĺ7%0(\LHOGLQJ the diketal (128, 72.7 mg, 0.150 mmol, 23%) and 
ortho-quinone (96, 70.5 mg, 0.236 mmol, 37%). 128: yellow solid; IR ȣmax 2930, 2870, 
1733, 1664, 1455, 1378, 1247, 1213, 1044, 1010, 965, 756 cm-1.1H NMR (CDCl3, 600 
0+]į+GJ = 5.8 Hz, H-¶+GJ = 9.1 Hz, H-14), 4.54 (1H, dd, J = 
8.0, 1.4 Hz, H-¶+GGJ = 5.8, 1.4 Hz, H-¶+TGJ = 6.5, 1.9 Hz, H-
¶+GGJ = 8.0, 1.9 Hz, H-¶+DSSTJ = 8.0 Hz, H-1), 2.98-2.91 
(1H, m, H-7), 2.02-1.94 (1H, m, H-5a), 1.90-1.83 (1H, m, H-4), 1.89-1.82 (1H, m, H-2a), 
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1.85-1.79 (1H, m, H-6a), 1.69 (3H, s, H-20), 1.69 (3H, s, H-16), 1.67 (3H, s, H-17), 1.44 
(3H, s, C(CH3)2), 1.42-1.36 (1H, m, H-6b), 1.41 (3H, d, J = 6.5 Hz, H-¶-1.26 (1H, 
m, H-3), 1.32 (3H, s, C(CH3)2), 1.24-1.17 (1H, m, H-2b), 1.21-1.14 (1H, m, H-5b), 1.13 
(3H, d, J = 7.1 Hz, H-19), 0.99 (3H, d, J = 6.5 Hz, H-18). 13C NMR (CDCl30+]į
197.6 (C, C-10), 152.2 (C, C-12), 139.2 (C, C-13), 139.0 (C, C-8), 131.6 (C, C-11), 126.7 
(CH, C-14), 126.2 (C, C-15), 108.8 (C, C(CH3)2), 99.4 (C, C-9), 98.4 (CH, C-¶
(CH, C-¶&+&-¶&+&-¶&+&-¶&+&-4), 37.8 
(CH, C-1), 37.6 (CH2, C-2), 32.6 (CH, C-3), 28.5 (CH2, C-6), 26.8 (CH, C-7), 26.2 (CH3, 
C(CH3)2), 25.7 (CH3, C-16), 24.7 (CH2, C-5), 24.5 (CH3, C(CH3)2), 22.0 (CH3, C-19), 
21.0 (CH3, C-18), 17.8 (CH3, C-17), 16.0 (CH3, C-¶&+3, C-20). HRESIMS m/z 
485.2884 [M + H]+ (calcd for C29H41O6, 485.2898). 
 
4.4.10 Synthesis and characterization of arylsulfonamide probes 
 
ASA-EG3-NH2 (132). To a stirred solution of 4-carboxybenzene sulfonamide (100.0 mg, 
0.4970 mmol) and NHS (115.9 mg, 1.007 mmol) in anhydrous THF (8 mL) was added 
',&ȝ/PPRO$IWHUVWLUULQJWKHUHDFWLRQPL[WXUHRYHUQLJKWDWURRP
temperature, 4,7,10-trioxa-1,13-tridecanediamine (94, 1.10 mL, 5.02 mmol) was added 
and the reaction was stirred for an additional 8 h, at which point the mixture was 
concentrated in vacuo and separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) 
to provide ASA-EG3-NH2 (132, 115.2 mg, 0.2855 mmol, 57%). 132: clear oil; IR ȣmax 
3270, 3079, 2934, 2873, 1641, 1569, 1345, 1167, 1098, 762 cm-1. 1H NMR (CD3OD, 600 
0+]į-8.40 (1H, br m, 6-NH), 8.00-7.96 (2H, m, H-2), 7.99-7.95 (2H, m, H-3), 
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3.67-3.58 (8H, m, H-9, H-10, H-11, H-12), 3.65-3.60 (2H, m, H-13), 3.61-3.57 (2H, m, 
H-8), 3.49 (2H, t, J = 7.0 Hz, H-6), 3.15-3.04 (2H, br m, H-15), 1.96-1.90 (2H, m, H-14), 
1.93-1.86 (2H, m, H-7). 13C NMR (CD32'0+]į&&-5), 147.6 (C, C-1), 
139.0 (C, C-4), 129.0 (CH, C-3), 127.3 (CH, C-2), 71.4, 71.1, 71.1, 71.0 (CH2, C-9, C-10, 
C-11, C-12), 70.2 (CH2, C-13), 70.0 (CH2, C-8), 39.8 (CH2, C-15), 38.7 (CH2, C-6), 30.3 
(CH2, C-7), 28.2 (CH2, C-14). HRESIMS m/z 404.1851 [M + H]+ (calcd for 
C17H30N3O6S, 404.1850).  
 
ASA-EG3-Biotin (133). To a stirred solution of ASA-EG3-NH2 (132, 33.6 mg, 83.3 
ȝPROLQanhydrous DMF (3 mL) under a N2 atmosphere was added biotin-NHS (102, 
45.7 mg, 0.187 mmol). The reaction was stirred overnight at room temperature, at which 
point LC-HRESIMS indicated the formation of the desired product. The mixture was 
evaporated in vacuo and separated by RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H), 
yielding the biotinylated probe ASA-EG3-Biotin (133, PJȝPRO133: 
white solid; [Į]25D +23.1 (c 0.6383, DMF) IR ȣmax 3284, 3085, 2929, 2869, 1691, 1638, 
1548, 1459, 1332, 1166, 1097, 858, 762 cm-1. 1H NMR (DMF-d7, 0+]į8.62 (1H, 
t, J = 5.4 Hz, 6-NH), 8.06 (2H, app. d, J = 8.4 Hz, H-2), 7.96 (2H, app. d, J = 8.4 Hz, H-
3), 7.73 (1H, t, J = 5.5 Hz, 15-NH+EUV¶-NH+EUV¶-NH), 4.43 
(1H, dd, J = 7.5, 5.0 Hz, H-¶+GGJ = 7.5, 4.4 Hz, H-¶-3.47 (8H, m, H-
9, H-10, H-11, H-12), 3.45-3.40 (2H, m, H-13), 3.53-3.48 (2H, m, H-8), 3.45-3.40 (2H, 
m, H-6), 3.19-3.14 (1H, m, H-¶-3.14 (2H, m, H-15), 2.89 (1H, dd, J = 12.4, 5.0 
Hz, H-¶D+GJ = 12.4 Hz, H-¶E+WJ = 7.5 Hz, H-¶+S
J = 6.6 Hz, H-14), 1.82 (2H, p, J = 6.6 Hz, H-7), 1.74-1.68 (1H, m, H-5¶D-1.53 
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(2H, m, H-¶-1.50 (1H, m, H-¶E-1.30 (2H, m, H-¶ 13C NMR (DMF-d7, 
0+]į&&-¶&&-5), 164.2 (C, C-¶&&-1), 139.1 (C, 
C-4), 128.9 (CH, C-3), 126.9 (CH, C-2), 71.3, 71.1, 71.1, 71.0 (CH2, C-9, C-10, C-11, C-
12), 69.7 (CH2, C-8), 69.6 (CH2, C-13), 62.6 (CH, C-¶&+&-¶&+&-
¶&+2, C-¶&+2, C-6), 37.2 (CH2, C-15), 36.6 (CH2, C-¶&+2, C-
14), 30.6 (CH2, C-7), 29.6 (CH2, C-¶&+2, C-¶(CH2, C-¶+5(6,06
m/z 630.2655 [M + H]+ (calcd for C27H44N5O8S2, 630.2626). 
 
ASA-EG23-Biotin (134). The above procedure for synthesizing PtxGlu-EG23-Biotin 
(135) was carried out using 4-carboxybenzene VXOIRQDPLGHPJȝPRO, NHS (5.8 
PJȝPRO, ',&ȝ/0.16 mmol), Biotin-EG23-NH2 (136, PJȝPRO, 
Et31ȝ/ȝPRO, and anhydrous DMF (3 mL). The crude product was separated by 
semi-preparative RP-HPLC (C18, 72% CH3OH, 0.1% HCO2H) to yield ASA-EG23-Biotin 
(134PJȝPRO, 59%). 134: clear oil; [Į]25D +21.9 (c 0.8775, DMF) IR ȣmax 
3303, 3083, 2869, 1700, 1654, 1545, 1456, 1347, 1300, 1250, 1100, 949, 857 cm-1. 1H 
NMR (DMF-d7, 600 0+]į8.79-8.70 (1H, br m, 6-NH), 8.12 (2H, br d, J = 6.6 Hz, H-
3), 8.00 (2H, br d, J = 6.6 Hz, H-2), 7.88-7.77 (1H, br m, 53-NH+EUV¶-NH), 
+EUV¶-NH), 4.51-4.43 (1H, br m, H-¶-4.26 (1H, br m, H-¶-3.51 
(2H, br m, H-6), 3.37-3.27 (2H, br m, H-53), 3.23-3.17 (1H, br m, H-¶-2.90 (1H, 
br m, H-¶D+G- +]+-¶E+EUWJ = 7.2 Hz, H-¶-
1.71 (1H, br m, H-¶D-1.57 (2H, br m, H-¶-1.53 (1H, br m, H-¶E-
1.35 (2H, br m, H-¶ 13C NMR (DMF-d70+]į73.5 (C, C-¶&&-5), 
164.2 (CH2, C-¶&&-1), 138.8 (C, C-4), 129.0 (CH, C-3), 127.0 (CH, C-2), 
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71.3, 71.3, 71.1, 71.1, 70.6, 70.3 (CH2, C-7, C-«&-51, C-52), 62.6 (CH2, C-¶
(CH2, C-¶&+2, C-¶&+2, C-¶&+2, C-6), 39.9 (CH2, C-53), 36.5 
(CH2, C-¶&+2, C-¶&+2, C-¶&+2, C-¶HRESIMS m/z 
1482.7609 [M + H]+ (calcd for C65H120N5O28S2, 1482.7556). 
 
4.4.11 Synthesis and characterization of generic control probes 
 
Biotin-EG3-NH2 (129). To a stirred solution of biotin-NHS (102PJȝPROLQ
anhydrous DMF (3 mL) was added 4,7,10-trioxa-1,13-tridecanediamine (94, ȝ/
1.60 mmol). After stirring the reaction mixture at room temperature for 8 h, the solvent 
was evaporated in vacuo and the crude product separated by solid phase extraction (C18, 
H2O:CH3OH stepwise gradient, 0.1% HCO2H) to yield 129 PJȝPRO
129: white solid; [Į]25D +18.2 (c 0.7742, CHCl3); IR ȣmax 3267, 3085, 2928, 2870, 1684, 
1643, 1582, 1463, 1347, 1101 cm-1. 1H NMR (CDCl30+]įGGJ = 7.8, 5.0 
Hz, H-¶GGJ = 7.8, 4.5 Hz, H-¶-3.57 (8H, m, H-4, H-5, H-6, H-7), 3.66 
(2H, t, J = 6.1 Hz, H-3), 3.52 (2H, t, J = 6.5 Hz, H-8), 3.25 (2H, t, J = 6.5 Hz, H-10), 
3.24-3.18 (m, H-¶+WJ = 6.1 Hz, H-1), 2.93 (dd, J = 12.8, 5.0 Hz, H-¶D
(d, J = 12.8 Hz, H-¶EWJ = 7.4 Hz, H-¶+SJ = 6.1 Hz, H-2), 1.79-
1.70 (m, H-¶D+SJ = 6.5 Hz, H-9), 1.72-1.59 (m, H-¶-1.55 (m, H-¶E
1.44 (p, J = 7.7 Hz, H-¶13C NMR (CDCl30+]į&&-¶&&-
¶&+2, C-4, C-5, C-6, C-7), 70.2 (CH2, C-3), 69.7 (CH2, C-8), 
63.4 (CH, C-¶&+&-¶&+&-¶&+2, C-¶&+2, C-1), 
37.7 (CH2, C-10), 36.8 (CH2, C-¶&+2, C-9), 29.8 (CH2, C-¶&+2, C-¶
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28.2 (CH2, C-2), 26.9 (CH2, C-¶+5(6,06m/z 447.2616 [M + H]+ (calcd for 
C20H39N4O5S, 447.2636). 
 
BPA-EG3-NH2 (130). To a stirred solution of NHS ester 110 (34.3 mg, 84.2 ȝPROLQ
anhydrous THF (7 mL) was added 4,7,10-trioxa-1,13-tridecanediamine (94, ȝ/
mmol). After stirring the reaction at room temperature for 8 h, the mixture was then 
partitioned between EtOAc and DI H2O. The EtOAc phase was recovered and subjected 
to the standard work up procedure providing the crude product, which was separated by 
RP-MPLC (C18, H22ĺ&+3OH, 0.1% HCO2H) to yield BPA-EG3-NH2 (130, 32.5 mg, 
ȝPRO130: clear oil; IR ȣmax 3238, 3070, 2924, 2873, 1646, 1600, 1508, 1307, 
1285, 1250, 1170, 1115, 1020, 928, 853, 770 cm-1.1H NMR (CD32'0+]į
(2H, app. d, J = 8.8 Hz, H-¶+DSSGJ = 8.8 Hz, H-¶+DSSGJ = 
8.8 Hz, H-¶+DSSGJ = 8.8 Hz, H-¶+GJ = 2.3 Hz, H-¶
(2H, s, H-¶-3.55 (8H, m, H-4, H-5, H-6, H-7), 3.63 (2H, t, J = 6.1 Hz, H-3), 3.50 
(2H, t, J = 6.5 Hz, H-8), 3.38 (2H, t, J = 6.5 Hz, H-10), 3.08 (2H, t, J = 6.1 Hz, H-1), 3.04 
(1H, t, J = 2.3 Hz, H-¶+SJ = 6.1 Hz, H-2), 1.80 (2H, p, J = 6.5 Hz, H-9). 
13C NMR (CD32'0+]į&&-¶&&-¶&&-¶
(C, C-¶&+&-¶&+&-¶&&-¶&&-¶
(CH, C-¶&+&-¶&&-¶&+&-¶
(CH2, C-4, C-5, C-6, C-7), 70.2 (CH2, C-3), 69.9 (CH2, C-8), 68.2 (CH2, C-¶
(CH2, C-¶&+2, C-1), 37.7 (CH2, C-10), 30.4 (CH2, C-9), 28.2 (CH2, C-2). 
HRESIMS m/z 513.2575 [M + H]+ (calcd for C28H37N2O7, 513.2595). 
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4.4.12 Preparation of affinity resins by covalent immobilization of amino-functionalized 
pseudopteroxazole and pseudopterosin-derived probes 
 
PtxGlu-EG3-Agarose (137). To a solution of PtxGlu-EG3-NH2 (101, 1.07 mg, 1.84 
ȝPRO) dissolved in DMSO (1 mL) with 2% Et3N was added NHS-activated agarose 
(107.8 mg). After incubating with gentle agitation (end-over-end rotation) at room 
temperature for 72-96 h, the agarose resin was pelleted by centrifugation. The supernatant 
was collected for LC-HRESIMS quantitation of unreacted 101, which indicated an 
immobilization yield of >95% and a ligand density of 2.16-2.70 µmol/mL. After washing 
the resin three times with DMSO, 1M ethanolamine in DMSO (0.5 mL) was added and 
the resin was incubated for 24 h. The affinity resin was subsequently washed with PBS to 
remove the DMSO and any unreacted ethanolamine. The resin was stored as a ~50% 
slurry at 4 ºC in PBS containing 10% EtOH.  
 
Ps-EG3-Agarose (138). The procedure described for the preparation of PtxGlu-EG3-
Agarose (137) was repeated using Ps-EG3-NH2 (117PJȝPRODQGNHS-
activated agarose (104.4 mg). The immobilization yield (>95%) and ligand density (2.42-
3.02 µmol/mL) were calculated according to LC-HRESIMS quantitation, as described for 
PtxGlu-EG3-Agarose (137). 
  
ASA-EG3-Agarose (139). The procedure described for the preparation of PtxGlu-EG3-
Agarose (137) was repeated using ASA-EG3-NH2 (132, 1.05 mg, 2.59 ȝPRO and NHS-
activated agarose (101.5 mg). The immobilization yield (>95%) and ligand density (3.41-
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4.26 µmol/mL) were calculated according to LC-HRESIMS, as described for PtxGlu-
EG3-Agarose (137). 
 
Agarose-EG3-PsOH (140). To prepare the inactive control resin (140), H2N-EG3-PsOH 
(122, 2.63 mg, 5.33 ȝPRO) was dissolved in a 2% pyridine solution in DMSO (0.5 mL) 
and added to NHS-activated agarose (29.4 mg). The immobilization yield (0.22 µmol, 
4.1%) and ligand density (4.10-5.13 µmol/mL) were calculated according to LC-
HRESIMS, as described for PtxGlu-EG3-Agarose (137). 
 
Generic control agarose (141). The procedure described for the preparation of PtxGlu-
EG3-Agarose (137) was repeated using 2-(2-aminoethoxy)ethanol (142, ȝ/ and 
NHS-activated agarose (51.0 mg).  
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CONCLUSIONS AND FUTURE DIRECTIONS 
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5.1 Marine Diterpenes: An Opportunity for Novel Drug Development 
 
Marine corals belonging to the phylogenetic order of Alcyonacea are a rich source 
of structurally diverse diterpenes, such as the fuscosides and pseudopteroxazole, with 
promising therapeutic applications. The fuscosides are a class of anti-inflammatory 
diterpene arabinosides isolated from the Caribbean alcyonacean Eunicea fusca.74-75 
Fuscoside B (11) is known for its selective inhibition of 5-LO,76,77 an enzyme committed 
to LT biosynthesis.89 On the basis of its unique structure, 11 may exert its activity as a 
competitive substrate and thus belong to a novel class of 5-LO inhibitors.77 Therefore, 11 
provides a tremendous opportunity for the development of novel anti-inflammatory 
drugs. Pseudopteroxazole (30) is an amphilectane diterpene isolated from 
Pseudopterogorgia elisabethae with activity against M. tuberculosis,154 the etiologic 
agent of TB. The inhibitory activity of 30 in the LORA, an in vitro model of the NRP 
phenotype, is highly intriguing. Furthermore, no cross-resistance to 30 by isogenic mono-
resistant M. tuberculosis H37Rv strains was observed (Table 4.1), suggesting the 
antitubercular mechanism of 30 could represent a novel strategy for TB treatment.  
 
5.2 A New Anti-inflammatory Diterpene Isolated from Eunicea fusca  
 
 The structure of eunicidiol (49), a novel anti-inflammatory diterpene isolated 
from E. fusca, was elucidated by 1D and 2D NMR spectroscopic analysis after 
purification by extensive RP-HPLC separation. The absolute configuration of 49 was 
assigned by the Mosher method, an analysis involving the derivatization of the secondary 
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hydroxyl group with (R)- and (S)-MPA. In addition, the absolute configuration of eunicol 
(16), a structurally related diterpene, was unambiguously determined as 10S via 
stereospecific Cope rearrangement of the cyclodecadiene moiety to generate fuscol (15), 
whose configuration is known.82,83 Fuscosides A (10) and B (11) as well as other 
diterpenes belonging to this class (17 and 45-48) are proposed to have a 10S 
configuration based on the established biosynthetic pathway.85 
This study represents the first in vivo anti-inflammatory evaluation of fuscol (15), 
eunicol (16), and eunicidiol (49). Topical administration of diterpenes 15-16 and 49 at a 
100 ȝJHDU dose significantly reduced PMA-induced edema in the mouse ear assay. The 
observed anti-inflammatory activity was superior to indomethacin, a benchmark anti-
inflammatory drug that required a 3 mg/ear dose to achieve a similar reduction of PMA-
induced edema. It remains to be determined whether diterpenes 15-16 and 49 exert their 
anti-inflammatory activity via selective 5-LO inhibition. Although 15 is known to inhibit 
LTB4 biosynthesis in adherent human polymorphonuclear leukocytes,77 the effect on 5-
LO inhibition was not measured directly. In the future, enzymatic 5-LO and COX assays 
may be pursued in an effort to determine the anti-inflammatory mechanism of action of 
15-16 and 49. 
An assessment of SAR has suggested that the eight-carbon side chain, consisting 
of the tertiary hydroxyl group and conjugated diene moieties, may be important for the 
anti-inflammatory activity of these diterpenes as it is the most common structural feature. 
To confirm the significance of this side chain, further assessment of the SAR may be 
pursued by isolating other structurally related diterpenes. In fact, several potentially novel 
diterpenes were collected during the RP-HPLC purification of 49, as observed in the 
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chromatogram in Section 2.2.1. A preliminary analysis of their 1H NMR spectra showed 
the presence of the conjugated diene moieties found in 15-16 and 49. Similarities in their 
LC-APCIMS fragmentation suggested the presence of hydroxylated analogues of 
eunicidiol (49), but unfortunately the diterpenes were not available in sufficient quantities 
for complete structural elucidation. Alternatively, one may pursue the synthesis of 
truncated diterpene mimics containing the aforementioned eight-carbon side chain. These 
compounds may be prepared with commercially available building blocks, such as 2-
methyl-3-buten-2-ol (55) or sorbic acid. 
 
5.3 A Chemical Glycosylation of Fuscol Yields Novel Fuscoside B Analogues 
 
The glycosylation of fuscol (15) and eunicol (16) has been accomplished for the 
first time using a modification of the Koenigs-Knorr method. A novel structural class of 
diterpene glycosides, called the eunicosides, has also been synthesized. Initially, the 
glycosylation methodology was established using 2-methyl-3-buten-2-ol (55) as a 
glycosyl acceptor model of 15 and 16. The use of strong Lewis acids for glycosyl donor 
activation was strictly prohibited due to the instability of 15 and 16, which also degraded 
in the presence of milder Lewis acids such as AgOTf. However, a combination of AgOTf 
and Ag2CO3 were capable of activating glycosyl bromides without degradation of 15 and 
16 when DIEA was employed as an acid scavenger. The glycosylation yields were 
significantly improved by protecting the glycosyl bromides as benzoate esters, 
presumably due to resonance stabilization of the acyloxonium intermediate. The acid 
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lability of 15 and 16 was also exploited to introduce EG3 and EG4 substituents as mimics 
of the arabinose moiety.  
The inhibition of LTB4 biosynthesis by fuscol (15)77 and its lower in vivo anti-
inflammatory activity, relative to fuscoside B (11),78 suggested that the arabinose moiety 
was insignificant with regards to 5-LO inhibition but instead has an overall impact on the 
bioavailability of fuscoside B (11). The results of the current study, however, have 
indicated otherwise. In fact, the anomer of 11 showed no anti-inflammatory activity, 
GHPRQVWUDWLQJWKHLPSRUWDQFHRIDJO\FRVLGLFOLQNDJHZLWKWKH¶¶-cis configuration. 
Replacing the arabinose moiety with galactose or an EG-based substituent also failed to 
emulate the anti-inflammatory activity of 11. As a result, the significance of the arabinose 
moiety is much greater than originally anticipitated, although its precise role in the 
inhibition of 5-LO remains to be determined. The mouse ear edema assay does not serve 
as a direct indication of 5-LO inhibition, therefore enzymatic 5-LO assays should be 
carried out with future analogues of 11.  
A limitation of the modified Koenigs-Knorr approach was the inability to install 
¶¶-cis glycosidic linkages. Future glycosylation efforts should therefore focus on 
applying this methodology to glycosyl donors protected with non-participating functional 
groups. Although acetonide functionalities PD\GLUHFWWKHIRUPDWLRQRI¶¶-cis 
glycosidic linkages, the fuscoside may not tolerate acidic conditions required for their 
removal; therefore base-sensitive protecting groups are preferred. Furthermore, the 
SURSRVHGDJO\FRQHDFFHSWRUPHWKRGPD\RQO\SURYLGH¶¶-trans glycoside products, 
considering that the axially-oriented hydroxyl group would be the weaker nucleophile. 
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Regardless, tKHV\QWKHVLVRI¶¶-cis glycoside analogues of fuscoside B (11) should be 
pursued to understand the biological significance of anomeric configuration. 
 
5.4 Affinity Chromatography Identifies Putative Targets of Pseudopteroxazole 
 
A collection of semisynthetic pseudopteroxazole- and pseudopterosin-type probes 
were prepared from a pseudopterosin G-J (33-36) mixture that was isolated from P. 
elisabethae. To retain the antimicrobial activity of pseudopteroxazole (30), the EG spacer 
was attached to different positions on the diterpene scaffold, thus providing a collection 
of natural product-based probes. On the basis of their antimicrobial activity, the target 
binding interaction was maintained by attaching the EG spacer to either the oxazole ring 
of 30 or the phenolic hydroxyl group of the aglycone methyl ether (95). However, 
modification of the double bond appeared to disrupt the desired binding activity, as 
indicated by inactivity of H2N-EG3-PsOH (122). The biotinylated probes showed 
moderate antimycobacterial activity, while the corresponding photoaffinity probes were 
inactive. This result advised against the in situ labeling experiment, which would have 
been the primary advantage of the photolabeling approach. The observed SAR, however, 
suggests that the photoaffinity probes may exhibit binding activity within the context of a 
cell lysate. 
The wealth of SAR data obtained during the antimicrobial evaluation of the 
natural product-based probes may be exploited for the future development of novel 
pseudopteroxazole analogues. As mentioned previously, the oxazole region of the 
diterpene scaffold can be modified without major repercussions on the antimicrobial 
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activity. However, there is a preference for polar substituents at this position, suggesting 
the importance of increasing the aqueous solubility. A preliminary investigation of SAR 
around the double bond indicates that this position is more significant for specific binding 
to the cell target(s). All synthetic modifications to this position, with the exception of a 
hydrogenation, were detrimental for the antimycobacterial activity. Further modification 
of the double bond, as well as the configuration at C-1, should be investigated in the 
future in an effort to identify novel pseudopteroxazole analogues with improved 
bioactivity. 
The molecular design of the natural product-based probes was simulated in an 
ASA model of the affinity chromatography experiment. The results of this preliminary 
study demonstrated the specific binding of CA to a covalently immobilized ASA ligand, 
thus validating the approach. Therefore, covalent immobilization of pseudopteroxazole- 
and pseudopterosin-type probes onto NHS-activated agarose was pursued to identify 
protein target candidates. Despite the large extent of NSB and ineffectiveness of 
competitive displacement controls, specific binding interactions were detected by the 
SAC technique, according to the serial depletion of several gel bands. As a result, one of 
the proteins was excised and analyzed by tandem mass spectrometry for identification. 
Analysis of the tryptic digest identified (3R)-hydroxyacyl-ACP dehydratase 
subunit HadC as a protein target candidate of pseudopteroxazole (30). Constituting a 
portion of the heterodimer HadBC, subunit HadC is responsible for carrying out the 
dehydratase step during mycolic acid biosynthesis in the FAS-II pathway,310 a process 
that is known to be essential for mycobacterial viability.312a The binding interaction 
between HadC and 30, as well as its antimycobacterial significance, shall be validated in 
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future studies to unequivocally determine whether or not 30 is arresting mycolic acid 
biosynthesis. In addition, the affinity chromatography has indicated several other protein 
target candidates, whose identification may lead to the discovery of novel targets for 
antitubercular drug development. 
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Figure A.1. The 1H and 13C NMR spectra (600 and 150 MHz, respectively, C6D6) of eunicol (16>įLQSSPUHODWLYHWRUHVLGXDOVROYHQW
signal]. 
 
267 
 
 
 
Figure A.2. The COSY spectrum of eunicidiol (49>įLQSSPUHODWLYHWR residual solvent signal].  
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Figure A.3. The upfield region of the COSY spectrum of eunicidiol (49>įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@ 
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Figure A.4. The HSQC spectrum of eunicidiol (49>įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@ 
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Figure A.5. The HMBC spectrum of eunicidiol (49>įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@ 
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Figure A.6. The TOCSY spectrum of eunicidiol (49>įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@ 
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Figure A.7. The NOESY spectrum of eunicidiol (49>įLQ ppm relative to residual solvent signal]. 
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Figure A.8. The stack plot of 1H NMR spectra (600 MHz, C6D6) of (R)- and (S)-MPA esters of eunicidiol [50 (above) and 51 (below), 
respectively, įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@ 
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Figure A.9. Enlarged regions within the 1H NMR spectra (600 MHz, C6D6) of (R)- and (S)-MPA esters of eunicidiol [50 (above) and 
51 (below), respectively, įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@  
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Figure A.10. The stack plot of 1H NMR spectra (600 MHz, C6D6) of semisynthetic fuscol (above) and fuscol (15) isolated from 
Eunicea fusca EHORZ>įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@ 
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Figure A.11. The stack plot of 13C NMR spectra (150 MHz, C6D6) of semisynthetic fuscol (15, above) and 15 isolated from Eunicea 
fusca EHORZ>įLQSSPUHODWLYHWRUHVLGXDOVROYHQWVLJQDO@ 
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B.1 General experimental information 
Medium pressure liquid chromatography (MPLC) was performed using pre-
packaged RediSep® Rf columns and a CombiFlash® Rf system (Teledyne Isco) with 
UV-triggered fraction collection. All flash chromatography was carried out on silica gel 
(230-400 mesh, Fisher), while TLC was performed using aluminum-backed silica plates 
(Whatman®, cat. number: 4420 222). Separation of products by RP-HPLC was 
performed using Phenomenex Luna Phenyl-+H[\OîPPȝPRU3KHQRPHQH[
Gemini C18 îPPȝPVHPL-preparative columns. Analysis of samples by LC-
APCIMS and LC-HRESIMS with hyphenated ELSD-UV detection was performed with 
FinniganTM LXQTM linear ion trap and Thermo Scientific ExactiveTM mass spectrometers, 
respectively, using a Kinetex C18 (50 × 2.1 mm, 1.7 ȝP) analytical column. The Thermo 
Scientific ExactiveTM instrument was operated by Patricia Boland. Optical rotations were 
measured on a Rudolph Autopol III Polarimeter. Infrared spectra were acquired using 
attenuated total reflectance on a Thermo Scientific Nicolet 6700 FT-IR spectrometer 
(Smart iTRTM).  
All 1H and 13C NMR spectra were acquired by Dr. Chris Kirby or Lloyd Kerry on 
a Bruker Avance III 600 MHz NMR spectrometer operating at 600 and 150 MHz for 1H 
and 13C, respectively. Chemical shifts are reported in ppm and were relative to residual 
solvent signals: CDCl3 (1H: 7.26 ppm, 13C: 77.16 ppm), CD3OD (1H: 3.31 ppm, 13C: 
49.05 ppm), C6D6 (1H: 7.15 ppm, 13C: 128.02 ppm), DMSO-d6 (1H: 2.50 ppm, 13C: 39.52 
ppm), DMF-d7 (1H: 2.75 ppm, 13C: 163.15 ppm). All 1H and 13C NMR spectral 
assignments were made on the basis of 2D NMR techniques, primarily COSY, HSQC, 
and HMBC. Coupling constants are reported along with their multiplicity: singlet (s), 
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doublet (d), triplet (t), quartet (q), pentet (p), multiplet (m), broad (br), apparent (app.). 
All deuterated solvents were purchased from Sigma-Aldrich.  
All commercially available anhydrous solvents and reagents were obtained from 
VWR, Sigma-Aldrich, or Fisher Scientific and utilized without further purification. 
Molecular sieves (3Å pore size) were activated by microwave heating, and all anhydrous 
reactions were carried out with oven-dried glassware. All reactions were performed at 
room temperature unless otherwise specified. Rotary evaporation of all solutions was 
performed in vacuo at 30 °C, except for DMF solutions which were heated to 55 °C. 
Glycosyl bromides were utilized within one month, during which they were stored under 
high vacuum over anhydrous CaSO4 to prevent hydrolytic degradation. The model 
glycosyl acceptor, 2-methyl-3-buten-2-ol (55) was dried in the presence of 3Å molecular 
sieves to remove traces of water. On the basis of BF3 content, the BF3Et2O (Sigma-
Aldrich) was between 46.5 and 53.5%. 
 
B.2 Determination of anti-inflammatory activity by the mouse ear edema assay 
The mouse ear edema assay was completed by Amplia PharmaTek Inc. according 
to a protocol adapted from Martinez et al.325 The 6-7 week-old female CD-1 mice 
(Charles River Canada Inc.) were provided with food and water ad libitum and 
acclimatized for at least 5 days. Indomethacin (150 mg/mL) and the test samples (5 
mg/mL) were formulated in DMSO, while PMA (ȝJP/) was prepared as an acetone 
solution. Initially, the right ears were treated with 20 ȝ/ DMSO (vehicle control group, n 
= 6), indomethacin (20 ȝ/, 3 mg total, n = 6), or test sample (20 ȝ/, ȝJtotal, n = 3). 
All left ears received 20 ȝ/ DMSO as a vehicle control. One hour later, the phlogistic 
280 
 
agent, PMA (20 ȝ/, ȝJ total), was administered by topical application to the right ears 
of each mouse, while the left ears received 20 ȝ/acetone as a vehicle control. Edema 
was measured at 6 and 24 hr post-PMA treatment using a digital caliper and calculated by 
subtracting the thickness of the left ear from the right ear. The data is represented as the 
mean ± SEM in terms of percent reduction of edema, relative to the vehicle control 
group. The statistical significance of the comparison between test groups and the vehicle 
FRQWUROZDVDVVHVVHGE\6WXGHQW¶VXQSDLUHGt-test. A p value <0.05 was considered to 
indicate statistical significance. 
 
B.3 Determination of antimicrobial activity by the microbroth dilution method 
The determination of antimicrobial activity against MRSA (ATCC 33591), VRE 
(Enterococcus faecium, VREF Ef 379), S. warneri (ATCC 17917), M. smegmatis (ATCC 
12051), and M. diernhoferi (ATCC 19340) was conducted in accordance with the testing 
standards of the Clinical Laboratory Standards Institute.326 The antimicrobial assays 
against the former three organisms were carried out by Martin Lanteigne. Eight 
concentrations of each compound were prepared by serial two-fold dilutions in 20% 
DMSO so as to achieve testing concentrations of 1-ȝJP/LQWKHDVVD\ZHOOV$OO
bacteria were grown in cation-adjusted Mueller-Hinton broth under static conditions. The 
IC50 values were determined by measuring the optical density of the plates at 600 nm 
before and after incubation at 37ºC for 22 h, as described previously.160 For the 
mycobacterial species only, the MIC values were determined by visually inspecting the 
plates after incubation at 30ºC for 96 h, as described previously.160 All antimicrobial 
testing against M. tuberculosis H37Rv (ATCC 27294) was conducted by the Institute for 
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Tuberculosis Research using the microplate Alamar blue assay (MABA).327 Activities in 
the low-oxygen-recovery assay (LORA)294 and against the Vero cell line were also 
determined by the Institute for Tuberculosis Research.  
 
B.4 Standard procedure for reaction workup 
 The following protocol is referred to as the ³VWDQGDUGZRUNXSSURFHGXUH´ 
throughout the experimental sections of each chapter: The organic layer from the 
liquid/liquid partition was recovered, dried with anhydrous MgSO4, filtered, and 
evaporated in vacuo to provide the crude product. 
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Figure C.1. Synthesis of the arabinosyl (80), glucosyl (81), and mannosyl (82) bromides. 
Reagents and conditions: (a) (i) BzCl, pyridine. (ii) AcBr (3.0 eq), CH3OH (3.3 eq), 50% 
(80), 13% (81), and 35% (82) over two steps. 
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Figure C.2. Preparation of activated NHS esters (102 and 110) and generic control probes (129 and 130) of biotin and the 
benzophenone-alkyne (BPA) conjugate. Reagents and conditions: (a) biotin, NHS (1.2 eq), DCC (2.1 eq), DMF, 90%. (b) 4,7,10-
trioxa-1,13-tridecanediamine (94, excess), DMF, 84%. (c) propargyl bromide (0.7 eq), K2CO3, DMF, 73% (106) and 24% (107). (d) 
106, tert-butyl bromoacetate (4.2 eq), K2CO3, DMF. (e) CF3COOH (excess), CH2Cl2, 92% over two steps. (f) NHS, DCC, CH2Cl2. (g) 
94 (excess), CH2Cl2, 75% over two steps.
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Figure C.3. Gel electrophoretic analysis of the specific binding interaction between 
ASA-EG3-Biotin (133) and CA. Notes and conditions: The affinity resins were incubated 
with a 1 mg/mL CA solution. The CA was eluted under denaturing conditions, with the 
exception of lanes 7-8, and resolved over a 4-12% polyacrylamide gel. Both types of 
competitive displacements were performed: pre-incubation of CA with AAZ and elution 
of CA from 133 with AAZ. Description of gel lanes: Lane 1, CA standard; lane 2, 
affinity capture of CA with 133; lane 3, heat-denatured control; lane 4, affinity capture of 
CA with the generic control Biotin-EG3-NH2 (129); lane 5, remaining CA after 
competitive displacement by pre-incubation of CA with AAZ; lane 6, remaining CA after 
competitive elution with AAZ; lane 7, 1st fraction of competitively eluted CA from 133 in 
lane 6; lane 8, 2nd fraction of competitively eluted CA from 133 in lane 6. 
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Figure C.4. Gel electrophoretic analysis of the specific binding interaction between 
ASA-EG23-Biotin (134) and CA. Notes and conditions: The affinity resins were 
incubated wLWKDȝJP/&$VROXWLRQ7KH CA was eluted under denaturing 
conditions, with the exception of lanes 9-10, and resolved over a 4-12% polyacrylamide 
gel. Both types of competitive displacements were performed: pre-incubation of CA with 
AAZ and elution of CA from 134 with AAZ. Description of gel lanes: Lane 1, CA 
standard; lane 2, affinity capture of CA with 134; lane 3, heat-denatured control; lane 4, 
affinity capture of CA with the generic control Biotin-EG23-NH2 (136); lane 5, remaining 
CA after competitive displacement by pre-incubation of CA with AAZ; lane 6, remaining 
CA after competitive elution with AAZ; lane 7, remaining CA after DMSO control of 
competitive elution; lane 8, affinity capture of CA with 134 after DMSO control of 
competitive displacement; lane 9, competitively eluted CA from 134 in lane 6; lane 10, 
DMSO control of competitive elution from lane 7.  
287 
 
 
 
 
 
 
 
Figure C.5. Characterization of reaction yields for the preparation of PtxGlu-EG3-
Agarose (137, above) and Ps-EG3-Agarose (138, above) by LC-HRESIMS. 
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Figure C.6. Characterization of reaction yields for the preparation of ASA-EG3-Agarose 
(139, above) and Agarose -EG3-PsOH (140, above) by LC-HRESIMS.  
 
 
 
 
